kidney

INTERNATIONAL

Volume 37, 1990

Editor Emeritus
Roscoe R. Robinson, Nashville

Editor
Thomas E. Andreoli, Little Rock

Associate Editors
Claude Amiel, Paris
Harry Jacobson, Nashville
James P. Knochel, Dallas
Jan J. Weening, Groningen

Consulting Editors
J. S. Cameron, London
Ramzi Cotran, Boston
William G. Couser, Seattle
Gerhard Giebisch, New Haven
Nishio Honda, Hamamatsu
Wilhelm Kriz, Heidelberg
François Morel, Paris
Pierre Verroust, Paris

Editorial Board
Robert J. Alpern, Dallas
Robert C. Atkins, Melbourne
Knut Aukland, Bergen
Peter Bàlint, Budapest
Rashad Barsoum, Guiza
Laurent Baud, Paris
Jonas Bergstrom, Stockholm
Ori S. Better, Haifa
Roland C. Blantz, San Diego
Jean-Philippe Bonjour, Geneva
Vittorio Bonomini, Bologna
Barry M. Brenner, Boston
Victoria Cattell, London
Anthony R. Clarkson, North Terrace
Jack W. Coburn, Los Angeles
Giuseppe D'Amico, Milan
Vincent W. Dennis, Durham
Evert J. Dorhout Mees, Utrecht
Ratislav Dzúrik, Bratislava
Jesus Egido, Madrid
Marilyn G. Farquhar, New Haven
Thomas F. Ferris, Minneapolis
Richard J. Glassock, Torrance
Jared J. Grantham, Kansas City
Rainer Greger, Freiburg
J. P. Grünfeld, Paris
Renée Habib, Paris
Raymond M. Hakim, Nashville
Steven C. Hebert, Boston
Jaime Herrera-Acosta, Mexico City
Klaus Hierholzer, Berlin
Malcolm A. Holliday, San Francisco
H. David Humes, Ann Arbor
Rex L. Jamison, Rochester, NY
Colin I. Johnston, Melbourne
Horst Klinkmann, Rostock
Franciszek Kokot, Katowice
Rajiv Kumar, Rochester, MN
Kiyoshi Kurokawa, Tokyo
Neil A. Kurtzman, Lubbock
Guy Lemieux, Montreal
David Z. Levine, Ottawa
Francisco Llach, Los Angeles
Robert G. Luke, Cincinnati
Manuel Martinez-Maldonado, San Juan
Alfred F. Michael, Minneapolis
Paul Michielsen, Louvain
William E. Mitch, Atlanta
John F. Moorhead, London
T. J. Neale, Wellington
Karl D. Nolph, Columbia
D. Keith Peters, Cambridge
Mordecai M. Popovtzer, Jerusalem
Jaime Borrero Ramirez, Medellin
Guiseppe Remuzzi, Bergamo
Eberhard Ritz, Heidelberg
Jose L. Rodicio, Madrid
Claudio Ronco, Vincenza
Anthony Sebastian, San Francisco
Jay H. Stein, San Antonio
Liliane Striker, Bethesda
Nobuhiro Sugino, Tokyo
Wadi N. Suki, Houston
Richard L. Tannen, Los Angeles
Gilbert Thiel, Basel
C. Craig Tisher, Gainesville
Heinz Valtin, Hanover
Edward J. Weinman, Houston
Clark D. West, Cincinnati
Guillermo Whittembury, Caracas
Christopher S. Wilcox, Gainesville

Manuscript Editor
Shellie Newell, Little Rock

Editorial Assistant
Joni Owens, Little Rock

Springer International

The exclusive copyright for all languages and for all countries, including the right for photomechanical and any other reproductions, also in microform, is transferred to the publisher.

The use of registered names, trademarks, etc. in this publication does not imply, even in the absence of a specific statement, that such names are exempt from the relevant protective laws and regulations and therefore free for general use.

Printed in the United States of America by The William Byrd Press Inc., Richmond, Virginia

© 1990 by International Society of Nephrology

Author Index For Volume 37

Aarhus LL (abst) 375
Aarseth HP (abst) 1384
Abad E (abst) 1597
Abaigar P (abst) 1598
Abboud HE (abst) 205, 414
Abdella P (abst) 387, 389, 457
Abdelnoor M (abst) 1384
Abe Y (abst) 556, 582
Abel H-H (abst) 1182
Abels RI (abst) 240
Abels RT *See* Lim VS et al 131
Abitbol C (abst) 262, 463, 466
Abitzsch D (abst) 1178
Abraham AA (abst) 523
Abraham MI (abst) 452
Abraham NG (abst) 309, 344, 600
Abraham NG *See* Schwartzman ML et al 94
Abraham P (abst) 304
Abraham PA (abst) 352, 358
Abraham WT (abst) 269, 275
Abrahamson DR (abst) 217
Abramovici M (abst) 269
Abramowicz D (abst) 406, 414
Abramowitz J (abst) 584
Abramson RG (abst) 559
Abreo K (abst) 286, 472
Abreo K, Glass J, Sella M: Aluminum inhibits hemoglobin synthesis but enhances iron uptake in Friend erythroleukemia cells 677
Abu-Hamdan D (abst) 276, 473
Abuelo JG (abst) 294
Abumrad NN (abst) 515
Acara M (abst) 585
Acchiardo SR (abst) 286, 311
Acebal R (abst) 1594, 1613
Acerbo S *See* Candiano G et al 1002
Adamson JW (abst) 235, 237, 237, 240, 507
Addo FEK (abst) 289
Adelberg E (abst) 233
Adler AJ (abst) 471
Adler S (abst) 191, 192
Adler S, Chen X, Eng B: Control of rat glomerular epithelial cell growth in vitro 1048
Adler SG (abst) 508, 511, 598
Affres H (abst) 363
Agardh C-D (abst) 1381, 1388
Agodoa LY *See* MacKay K et al 741
Aguirre B (abst) 1597
Agulian S (abst) 548
Ahijado F (abst) 1596, 1596, 1610, 1615
Ahlstrom NG (abst) 270
Ahmad MF (abst) 444
Ahmad S (abst) 237
Ahmed A (abst) 286
Ahmed G (abst) 542
Ahonen J (abst) 1384, 1389
Ahrens E (abst) 335
Airaghi C *See* Colussi G et al 28:S-63
Aizawa S (abst) 330, 432
Akcicek F (abst) 358
Åkerström I (abst) 1379
Akerstrom V (abst) 367
Aki Y (abst) 556
Akiba T (abst) 450, 463
Akmal M (abst) 244, 270, 466
Akmal M, Kasim SE, Soliman AR, Massry SG: Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure 854
Akrawi A (abst) 558, 589
Akusjärvi G (abst) 561
Al-Awqati Q (abst) 231, 234
Al-Bander HA (abst) 469
Al-Dahwi A (abst) 270
Alarabi A (abst) 286
Alati G (abst) 315
Alaupovic P (abst) 1382
Albarracin C (abst) 1610, 1610
Albers C (abst) 1170
Albers FJ (abst) 453, 456
Albert FW (abst) 1179, 1180
Albert S (abst) 266
Albertazzi A (abst) 293
Alberti D (abst) 235
Albrechtsen D (abst) 605
Albrightson-Winslow CR (abst) 210, 406
Alcazar JM (abst) 403, 403, 1587, 1604
Alcázar JM (abst) 1606, 1606
Alcazar JM (abst) 1606
Aldins Z (abst) 583
Alegre M-L (abst) 414
Aleo MD (abst) 525
Alexander EA (abst) 546
Alexander S (abst) 614
Alexander SR (abst) 270
Alexiewicz JM *See* Klinger M et al 1543
Alexopoulos E, Seron D, Hartley RB, Cameron JS: Lupus nephritis: Correlation of interstitial cells with glomerular function 100
Alfrey AC (abst) 248, 452, 498
Alfrey AC, Hammond WS: Renal iron handling in the nephrotic syndrome 1409
Alfrey AC *See* Durr JA et al 28:S-58
Algarra G (abst) 1591
Algarra GR (abst) 1591
Ali AA (abst) 498
Ali ACY (abst) 601
Ali M (abst) 293
Alkan M *See* Levy D et al 1310
Allee S (abst) 343
Allen HM (abst) 262
Allende MT (abst) 1612
Allende V (abst) 334
Allon M (abst) 257, 259, 260, 262, 263, 271
Alion M, Rodriguez M, Llach F: Insulin in the acute renal adaptation to dietary phosphate restriction in the rat 14

Almaraz M (abst) 1598
Almeida A (abst) 453
Almirall J (abst) 1602, 1615, 1616
Alonso A (abst) 1604, 1605
Alonso M (abst) 1604
Alper SL (abst) 230
Alpern R (abst) 539
Alpern RJ (abst) 538, 543
Alpers C (abst) 406, 412, 417
Alpert H (abst) 475, 478, 496
Alsina J (abst) 1591, 1600, 1600, 1600, 1600, 1601, 1601, 1601, 1601, 1601
Altman JJ (abst) 279
Altmann P (abst) 313, 455, 602
Altomonte M (abst) 406, 506
Alvarado JA (abst) 498
Alvarez de Lara MA (abst) 1590, 1590
Alvarez MJ (abst) 1590
Alvarez RJ (abst) 224
Alvarez U (abst) 468
Alvarez V (abst) 1588, 1609, 1609
Amair P (abst) 334
Amarantes B (abst) 294
Amato D (abst) 498
Amenabar JJ (abst) 1587, 1588
Amenta F (abst) 341
Amiel C (abst) 190, 208, 209, 231, 363
Aminalai A (abst) 1174
Amir-Moazami A (abst) 1187
Ammann H (abst) 525
Ammon A (abst) 1181
Amore A (abst) 273, 407, 444
Amoroso L (abst) 293
Amraoui Z (abst) 406
Anagnostopoulos T (abst) 559
Anastasio P (abst) 235, 503
Ancri D (abst) 242
Anderson M (abst) 268
Anderson NG (abst) 601
Anderson P (abst) 511
Anderson PS (abst) 508, 598
Anderson RJ (abst) 207, 360, 364
Anderson RL (abst) 352
Anderson S (abst) 356, 371, 498, 511
Anderson WR (abst) 611
Ando A (abst) 515
Ando K (abst) 282, 596
Ando R (abst) 463
Ando Y (abst) 576
Andrade A (abst) 1602
Andrassy K (abst) 1167, 1167, 1168, 1169
Andreoli SP (abst) 475
Andreoli TE (abst) 570
Andres A (abst) 261, 403, 610, 1587, 1587, 1604
Andrés A (abst) 1606
Andres A (abst) 1606, 1607, 1607
Andrés A (abst) 1607
Andres A (abst) 1608, 1608
Andrés E (abst) 1591, 1600, 1600, 1601
Andres E (abst) 1601, 1601
Andrés E (abst) 1601, 1601
Andres G (abst) 410, 410, 427
Andres GA (abst) 252
Andreu J (abst) 1615, 1615, 1615
Andreucci VE (abst) 338, 599
Andrews PM (abst) 549
Andrianarison I *See* Drüeke T et al 1438
Anelli A (abst) 287, 289
Ang KS (abst) 247
Angelakos ET (abst) 381
Anger MS, Shanley P, Mansour J, Berl T: Effects of lithium on cAMP generation in cultured rat inner medullary collecting tubule cells 1211
Ansell J (abst) 306
Ansorge G (abst) 1170
Antiga L (abst) 404
Antignani A (abst) 287
Aoyagi K (abst) 514, 515, 522
Aperia A (abst) 197, 199, 217, 368, 368, 512, 560, 561
Appel G (abst) 476
Appel RG (abst) 335
Apperl A (abst) 602
Appiani AC (abst) 549
Appling DR (abst) 220
Aquiling T (abst) 237
Arai J (abst) 527
Arakawa M (abst) 221, 491, 519
Arant BS Jr. (abst) 271, 359, 555
Aranzabal J (abst) 1605
Arbeit LA (abst) 190
Arcas R (abst) 1596
Arcocha V (abst) 1596
Ardaillou N (abst) 344
Ardaillou R (abst) 335, 337, 344, 363
Ardito T (abst) 584
Arduino M (abst) 298
Arenas J (abst) 1609, 1609
Arendshorst WJ (abst) 550
Arge B (abst) 1379
Argyle JC (abst) 257
Arieff AI (abst) 262, 267
Arimura Y (abst) 281
Arisz L (abst) 186, 253, 258
Armada E (abst) 1586, 1586, 1586, 1587
Armandola E (abst) 406
Armstrong WM (abst) 566
Arn E (abst) 250
Arnaiz A (abst) 1608
Arnaout MA (abst) 444
Aronoff GR (abst) 336
Aronson PS (abst) 233, 539, 571
Arranz B (abst) 1603
Arribas I (abst) 316
Arrieta J (abst) 1605
Arrizabalaga P (abst) 1588
Arruda JAL (abst) 371, 544
Arthus M-F (abst) 250
Arthus MF (abst) 246, 361
Asano Y (abst) 306, 568, 573, 592
Ascencio C (abst) 1591
Ash RC (abst) 438
Askenase A (abst) 340
Asplin J (abst) 471, 472
Assael BM (abst) 549
Assia E (abst) 265
Assmann KJM (abst) 187, 429, 445
Aten J (abst) 407
Atherton JC, Green R, Higgins A, Large A, McNicholas C, Parker D, Pempkowiak L, Rajani K, Smith J: Lithium clearance in healthy humans: Effects of sodium intake and diuretics 28:S-36
Atkin C (abst) 248

Atkins J (abst) 476
Atkins RC *See* Li H-L et al 1552
Atkins RC *See* Saito T 1076
Attman P-O (abst) 1382
Aubia J (abst) 1603, 1603
Audrain J (abst) 324
Augenbraun E (abst) 227
August P (abst) 401
Ault KA (abst) 287, 301
Aurell M (abst) 236, 399, 1379, 1380, 1380
Ausiello D (abst) 215, 217
Ausiello DA (abst) 213, 226
Austin HA (abst) 216, 275
Austin J (abst) 476
Avanzini G (abst) 289
Aventaggiato L (abst) 445
Avilla JM (abst) 1604
Avison MJ (abst) 476
Avner E (abst) 578
Avner ED (abst) 190
Avram MM (abst) 287
Awad J *See* Moore RH et al 991
Awazu M (abst) 360, 382
Awni WM (abst) 608
Axelsen RA *See* Emmerson BT et al 36
Aynedjian HS (abst) 263, 371
Ayo SH (abst) 220
Ayus JC (abst) 263, 305, 331
Azar S *See* Mauer SM et al 909
Azemoto R *See* Yoshida H et al 1286
Baamonde E (abst) 1586, 1586, 1587
Bab I (abst) 451
Babcock S (abst) 298
Bacallao R (abst) 224, 228
Bach D (abst) 1187, 1188
Bach FH (abst) 599, 601
Bach JF (abst) 483
Bachmann S (abst) 1161
Bäcker A (abst) 342, 372, 1172
Bacskai BJ (abst) 205
Badger A (abst) 406
Badr KF (abst) 203, 217, 347, 348, 351, 352, 362, 375, 375, 385, 484, 493, 515
Bae H-R (abst) 559
Baelde JJ (abst) 409
Bagby SP (abst) 516
Baglioni C (abst) 410
Baig F (abst) 273
Bailie G (abst) 331
Bailly C (abst) 363
Bain J (abst) 540
Baines AD (abst) 559, 601
Baio MA (abst) 1594
Baird BM (abst) 453
Bakaletz AP *See* Cosio FG et al 1429
Baker F (abst) 597
Baker MS (abst) 479
Baker P (abst) 412, 417
Bakker MJ (abst) 445
Bakker WW (abst) 407, 427
Bakker WW *See* Poelstra K et al 1500
Bakris GL (abst) 190, 367, 612
Balcke P (abst) 235, 298, 300, 379, 384, 400, 602, 613, 613
Balcke P *See* Stockenhuber F et al 150
Balcke P *See* Sunder-Plassmann G et al 1350
Balda I (abst) 1599
Baldamus CA (abst) 271, 396, 1178, 1178
Baldi E (abst) 363
Balfour R (abst) 250
Ballard J (abst) 383, 553
Ballardie FW (abst) 438
Ballarin JA (abst) 1589
Ballarín JA (abst) 1590
Baller JFW (abst) 407, 427
Ballermann BJ (abst) 346, 361, 373, 374
Ballesta AM (abst) 1605
Balsells M (abst) 1606
Baluarte HJ (abst) 602, 611
Baluarte J (abst) 329
Bambauer R (abst) 1180
Bander S (abst) 303
Bandyk M (abst) 476
Bang NU (abst) 254
Bank N (abst) 263, 371
Bankir L (abst) 462, 499, 528
Banner B (abst) 384
Bannett A (abst) 609
Bantle JP (abst) 610
Bar-Khayim Y *See* Kagan A et al 971
Bar-Khayim Y *See* Kagan A et al 980
Barac-Nieto M (abst) 453, 455, 553
Barach P (abst) 470
Barajas L (abst) 508, 511
Baranowski RL (abst) 336, 343, 477
Barany P (abst) 1383
Barba GV (abst) 235
Barber W (abst) 609
Barbosa JA (abst) 382, 394
Barcelli U (abst) 345
Barceló P (abst) 1589, 1590, 1590
Barcelon FS (abst) 212
Bargman JM (abst) 254
Baricos WH (abst) 407
Barker D (abst) 248
Barker PB (abst) 461
Barlee V (abst) 287
Barndt I (abst) 307
Barnes JL (abst) 408
Barnett R (abst) 205, 213
Barney MH (abst) 316, 318
Barocci S (abst) 594
Barr JG (abst) 238, 281
Barré P (abst) 288
Barrett KJ (abst) 435
Barrett PQ (abst) 205
Barria MS (abst) 607
Barrientos A (abst) 1590, 1595, 1616
Barril G (abst) 1609, 1609
Barron WM (abst) 395
Barry J (abst) 247
Barry JM (abst) 604, 610
Barth C (abst) 436, 601
Barth HP (abst) 289
Barth RH (abst) 288, 325
Barthelmebs M, Caillette A, Ehrhardt J-D, Velly J, Imbs J-L: Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney 1414
Bartlett RR (abst) 1184
Bartocci A (abst) 424
Barton M (abst) 192, 345
Barton R (abst) 432
Bartosh S (abst) 329, 602

Bartsch A (abst) 320
Bas J (abst) 1601
Bashore TM (abst) 484
Bass AS (abst) 363
Bassett AH (abst) 504
Basta-Jovanovic G (abst) 246
Bastani B (abst) 532
Bastl CP (abst) 353
Bastos MG (abst) 593
Bataille P (abst) 271
Bathe OF (abst) 594
Batlle DC (abst) 391, 393, 544, 544, 1597, 1598
Batlle DC, Gutterman C, Keilani T, Peces R, LaPointe M: Effect of cyclosporin A on renal function and kidney growth in the uninephrectomized rat 21
Batlle DC *See* Godinich MJ 28:S-52
Batsford S (abst) 423, 434
Battaglia C (abst) 377, 518, 519
Batz C (abst) 1167
Baud L (abst) 363
Baudouin B (abst) 201
Bauer C (abst) 1164
Bauer JH (abst) 402
Bauernschmitt HG (abst) 1164
Baum M (abst) 530, 533
Baumelou B (abst) 480
Bayati A *See* Hellberg POA et al 1240
Baylis C (abst) 347, 382, 392, 517, 550, 555, 558, 571
Bazzato G (abst) 326, 327, 403
Béa M-L (abst) 335
Bea M-L (abst) 354
Beals T (abst) 192
Bear JC (abst) 250, 251
Bear R (abst) 266
Beasley D (abst) 364
Beaufils H (abst) 480
Beaugrand M (abst) 279
Beaumont K (abst) 561, 566, 566
Beaumont P (abst) 610
Beck F-X, Dörge A, Giebisch G, Thurau K: Effect of diuretics on cell potassium transport: An electron microprobe study 1423
Beck J (abst) 576
Beck JC (abst) 559
Beck M (abst) 215
Becket B (abst) 471
Beckman B (abst) 240
Bedell A (abst) 201
Bedi GS (abst) 500
Bedogna V (abst) 235, 404
Beesley M (abst) 516
Behar M (abst) 408, 589
Beierwaltes WH (abst) 345
Belda J (abst) 1585, 1585
Béliveau R (abst) 230, 462
Bell JL (abst) 268
Bell MR (abst) 553
Bell PD (abst) 561, 565
Bell RD (abst) 488
Bellas C (abst) 1594
Bello-Reuss E (abst) 533
Belloni A *See* Zoja C et al 934
Bellorin-Font E (abst) 334, 463
Bellotti G (abst) 237
Bellucci A (abst) 254, 309
Ben-Ari J (abst) 344
Ben-Bassat M *See* Yussim A et al 812
Benabe JE (abst) 528
Benalia H (abst) 607
Benavides B (abst) 1598
Benazzi E *See* Colussi G et al 28:S-63
Benfield MR (abst) 408
Bengel D (abst) 1180
Benigni A (abst) 339, 345, 377
Benigni A *See* Zoja C et al 927
Bennett W (abst) 247
Bennett WM (abst) 477, 495, 604, 610
Bennhold I (abst) 1182
Bens M (abst) 335
Benson B *See* Logan JL et al 57
Benstein JA (abst) 511
Bentley MD (abst) 553
Berden JHM (abst) 185, 187, 445
Berg JA (abst) 565
Berg KJ (abst) 239, 605, 607, 1380
Berg T (abst) 369
Berg U (abst) 1381
Berg W (abst) 1186
Bergamelli A *See* Zoja C et al 934
Bergamo R (abst) 245
Berger B (abst) 416, 431
Berger B *See* Torbohm I et al 1098
Berger I (abst) 1182
Bergeron M (abst) 578
Berglund J (abst) 1381
Bergman JA (abst) 533, 546
Bergmann L (abst) 1166
Bergmann P (abst) 293, 324
Bergofsky E (abst) 323
Bergot C (abst) 271
Bergstein JM (abst) 254
Bergstralh EJ (abst) 255
Bergstrand A (abst) 1380, 1388
Bergström J (abst) 1383, 1384
Berl T (abst) 298, 576
Berl T: Treating hyponatremia: Damned if we do and damned if we don't (Nephrology Forum) 1006
Berl T *See* Anger MS et al 1211
Berlyne G (abst) 292, 567
Berlyne GM (abst) 288, 325, 471
Bernabeu F (abst) 1603
Bernard DB (abst) 322
Bernardini J (abst) 326, 328, 329, 333
Bernat A (abst) 1585, 1585, 1586, 1586
Berndt TJ (abst) 454, 458
Bernheim J (abst) 392, 392, 451, 569
Bernheim J *See* Rosen S et al 1067
Bernieh B (abst) 290
Bernis C (abst) 1588, 1609, 1609
Bernstein K (abst) 359
Bernstein KE (abst) 355
Bernstein KN (abst) 310
Berry C (abst) 563
Berry PL (abst) 242
Bertani T (abst) 424, 428, 485, 518
Bertani T *See* Zoja C et al 934
Berthet L *See* Drüeke T et al 1438
Bertolatus JA (abst) 408
Bertorello A (abst) 217, 368, 560
Bertrand W (abst) 233
Besarab A (abst) 236, 237, 311
Beshensky AM (abst) 462

Besley M (abst) 321
Best CF (abst) 501
Bettcher KB (abst) 327
Bettoni S (abst) 205
Betts CR (abst) 463
Betz M (abst) 303
Beukhof JR (abst) 499
Beutler JJ (abst) 335, 577, 577
Bevan C (abst) 577, 1164
Beyer KH Jr. (abst) 399
Beyer M (abst) 259
Beyer WEP (abst) 446
Bhatt G (abst) 541
Bia M (abst) 450
Bia MJ *See* Castellino P et al 793
Bianchetti MG (abst) 1169
Bianchi G (abst) 383
Bianchi G *See* Salvati P et al 1084
Bianco P (abst) 220
Bichara M (abst) 464, 537, 541
Bichet DG (abst) 246, 250, 266, 361
Bidani AK (abst) 241, 431
Biersack K (abst) 473
Bijlsma JA (abst) 335, 577
Bijlsma JA *See* Rabelink TJ et al 996
Bijvoet OLM *See* Kok DJ et al 51
Bills T (abst) 419
Bilo HJG (abst) 499, 614
Bindels RJM (abst) 454
Bindi P (abst) 290
Binswanger U (abst) 1177
Biondi ML (abst) 364
Bircks W (abst) 1183
Bird JE (abst) 382, 477
Birmingham DJ (abst) 409
Birzgalis A (abst) 388
Bitker MO (abst) 607
Bittner K (abst) 1186
Björck S (abst) 236
Björk S (abst) 1388
Black AJ *See* Cohen JJ et al 1219
Black JL (abst) 275
Blagg CR (abst) 239, 240
Blake P (abst) 321
Blake PG (abst) 326
Bläker F (abst) 1176
Blanche S (abst) 445
Bland L (abst) 298
Bland LA *See* Gordon SM et al 110
Blantz R (abst) 370
Blantz RC (abst) 382, 477, 501, 517, 522, 551, 555, 557
Blazer-Yost B (abst) 233
Blazer-Yost BL (abst) 380
Bleackley C (abst) 598
Blech M (abst) 1174
Blecher SR *See* McDonald ATJ et al 901
Bleich M (abst) 562, 571, 1162, 1162
Blendis L (abst) 553
Blendis LM (abst) 341
Blexrud MD (abst) 306
Blobel G (abst) 216
Bloch RD (abst) 353
Bluestone P (abst) 309
Blum G (abst) 1594, 1613
Blumenfeld J (abst) 383
Blumenstein M *See* Ward RA et al 776
Blumenthal S (abst) 477
Blumenthal SS (abst) 462
Bobadilla N (abst) 498
Boberg U (abst) 549
Boccardo P (abst) 339
Bocchicchio T (abst) 314
Bochicchio T (abst) 397
Bock GH (abst) 615
Bock HA (abst) 353, 1165, 1184
Bock TA (abst) 1182
Böcker R III (abst) 1180
Böcker W (abst) 1186
Boer P (abst) 577, 592
Boer WH (abst) 577, 577, 577
Boer WH, Koomans HA, Dorhout Mees EJ: Lithium clearance in healthy humans suggesting lithium reabsorption beyond the proximal tubules 28:S-39
Boeschoten EW (abst) 186
Bögeholz J (abst) 1186
Bogenschütz O (abst) 1167
Bognetti E (abst) 510
Bohle A (abst) 518, 1167, 1168, 1168
Böhler J (abst) 288, 1167, 1171
Bohnert G (abst) 1180
Boitard C (abst) 483
Boitard C *See* Hannedouche TP et al 1126
Bolaños L (abst) 1612, 1613
Bollinger RR (abst) 319
Bolton WK (abst) 191
Bommer G (abst) 289
Bommer J (abst) 289, 289
Bommer J *See* Deppisch R et al 696
Bonal J (abst) 1597
Bonar SL (abst) 375
Boneh A, Tennenhouse HS: Protein kinase C in mouse kidney: Effect of the *Hyp* mutation and phosphate deprivation 682
Boner G (abst) 266, 312, 349
Bonet J (abst) 1597
Bönner G (abst) 369
Bonsib SM (abst) 224
Bonventre JV (abst) 350, 488
Booker BB (abst) 494
Borcherding S (abst) 305
Border W (abst) 221, 222
Border WA, Okuda S, Languino LR, Ruoslahti E: Transforming growth factor-β regulates production of proteoglycans by mesangial cells 689
Border WA *See* Marinides GN et al 749
Bordes J (abst) 397
Borensztein P (abst) 464
Borke JL (abst) 454
Borneff M (abst) 289
Boron WF (abst) 191, 535, 537, 563
Borrego F (abst) 1593, 1593, 1593, 1594, 1614
Borsatti A (abst) 503
Borzecki JS *See* Peterson LN 1492
Bos HJ (abst) 184
Bosch J (abst) 1592, 1595, 1603
Bosch JP (abst) 272, 287, 297, 307, 330, 523
Bosch R (abst) 1594, 1613
Bossaller C (abst) 1185
Bosse A (abst) 1186
Botella J (abst) 1586, 1586, 1586, 1587
Bouby N (abst) 499
Boudaillez B (abst) 452

Boudreau RJ (abst) 610
Bouhtiauy I (abst) 458, 464
Bouillon R (abst) 271, 470
Boulanger Y (abst) 525
Bouman AA (abst) 185
Bourdeau J (abst) 302, 458, 470
Bourdeau JE (abst) 464
Bourgoignie J (abst) 303, 466
Bourgoignie JJ (abst) 194, 314, 398
Bourgoignie JJ: Renal complications of human immunodeficiency virus type 1 (Nephrology Forum) 1571
Bowen PA II (abst) 602
Bower J (abst) 333, 448
Bowersox L (abst) 473
Bowie EJW (abst) 303
Boyarsky G (abst) 191
Boyce N (abst) 409
Boyd GJ (abst) 502
Braden G (abst) 263
Bradley ME *See* Hensley CB et al 707
Brady HR (abst) 281, 346, 483, 556
Braendle E (abst) 1161
Braidotti P (abst) 287
Brancaccio D (abst) 287, 289
Branch RA (abst) 493
Brand K (abst) 202, 336, 364
Brand R (abst) 345
Brandi L (abst) 451
Brango C (abst) 550
Branton M (abst) 336
Braslavsky D *See* Yussim A et al 812
Braun WE: Long-term complications of renal transplantation (Nephrology Forum) 1363
Bravo E (abst) 340, 400
Bravo EL (abst) 397
Bray SH (abst) 272
Brazy PC, Fitzwilliam JF: Progressive renal disease: Role of race and antihypertensive medications 1113
Brecht M (abst) 378
Breckenridge WC (abst) 502
Breckon R (abst) 207, 360, 364
Bredl C (abst) 496
Brem AS (abst) 353
Brenchley PEC (abst) 437, 438
Brennan DC (abst) 409
Brenner BM (abst) 346, 356, 361, 371, 373, 374, 511, 582
Brentjens J (abst) 410, 410, 427, 440
Bresnahan BA (abst) 346, 421
Breton S (abst) 576
Bretschneider HJ (abst) 1174
Breuer W (abst) 365
Brewer ED (abst) 603
Breyer J (abst) 374
Breyer M (abst) 348
Breyer MD (abst) 206, 576, 582, 589
Brezis M (abst) 493
Brezis M *See* Rosen S et al 1067
Bricio T (abst) 1594
Brickson BB (abst) 406
Bridges JM (abst) 526
Brier ME (abst) 336
Briggs JP (abst) 357, 381, 494, 556, 560
Brines ML (abst) 380
Brinker KR (abst) 311
Brion LP (abst) 533
Briscoe D (abst) 603
Brissenden J (abst) 251
Brissenden JE (abst) 247
Broadley C (abst) 508
Brock J (abst) 1612
Brockmöller S (abst) 1186
Brodsky WA (abst) 534
Brooks DP (abst) 499
Brookshire CA (abst) 365
Brosius FC III (abst) 230
Brothis J (abst) 291
Broughton MC (abst) 575
Brouhard BH (abst) 256
Brown A (abst) 464, 465, 469
Brown CD (abst) 506, 603
Brown D (abst) 226, 415, 588
Brown DM (abst) 220, 421
Brown DM *See* Mauer SM et al 909
Brown E (abst) 460
Brown GP (abst) 346
Brown J (abst) 603
Brown J: Osmotic diuresis and proximal tubular lithium reabsorption in the dog 28:S-67
Brown JH (abst) 526
Brown ML (abst) 252, 404, 405
Brown NL (abst) 560
Brown O (abst) 222
Brown RS (abst) 264
Brown WS (abst) 313
Browne JK (abst) 237
Brownlee A (abst) 440, 443
Brownlee M (abst) 218
Brownley R (abst) 336
Broyer M (abst) 260
Bru C (abst) 1588, 1588
Brú C (abst) 1615
Bruggeman CA (abst) 187
Bruggeman LA (abst) 218
Bruijn JA (abst) 409
Brunda M (abst) 427
Bründermann H (abst) 1186
Brunette MG (abst) 458, 460, 461, 464
Brunkhorst R (abst) 1170, 1177
Brunner FP (abst) 184, 353, 1165, 1184
Brunner HR (abst) 337
Brunner R (abst) 271, 396, 1178, 1178
Bruyn JA (abst) 429
Brynda E (abst) 291
Brynger H (abst) 1383
Buchholz B (abst) 1177
Bucht H (abst) 1380, 1388
Buckalew V (abst) 236, 239
Buckalew VM (abst) 551
Budde K (abst) 410
Buddemeyer EU (abst) 277
Budisavlievic M (abst) 354
Budreau A (abst) 578, 593
Bugiani O (abst) 289
Buhl R (abst) 1183
Bühring H-J (abst) 424
Bukoski RD (abst) 388
Buku A (abst) 191
Bullock ML (abst) 478
Bunchman TE (abst) 365
Bunnachak D (abst) 478, 486
Buonaventura E (abst) 293
Burbelo PD (abst) 218

Burchert W (abst) 296
Burdick JF (abst) 495
Burg MB (abst) 580, 584, 586
Burger H-U (abst) 1177
Burgwitz K (abst) 1185
Burhop KE (abst) 334
Burk L (abst) 286
Burk SE (abst) 232
Burkart J (abst) 236, 239
Burke TJ (abst) 453, 478, 486, 494
Burlingame R (abst) 410
Burnett J (abst) 403
Burnett JC (abst) 343
Burnett JC Jr. (abst) 267, 337, 338, 342, 373, 375, 489
Burnier M (abst) 337
Burns KD (abst) 560
Burr IM (abst) 419
Burritt MF (abst) 310
Burstein IR (abst) 265
Bursten SL (abst) 227
Burtin M (abst) 510
Burzminski D (abst) 609
Busch R (abst) 1165
Bushinsky D (abst) 454
Bushinsky DA (abst) 448, 452
Buss WC (abst) 477
Busse J (abst) 478
Bussolino F (abst) 410
Bustamante J (abst) 1597
Bustamante R (abst) 1597
Butkowski R (abst) 249
Buttyan R (abst) 476, 479
Buxbaum M (abst) 311, 397
Cabell-Kluch L (abst) 533
Cabello M (abst) 1614
Cachero S (abst) 236, 385, 395
Cacho CP (abst) 289
Caflisch CR (abst) 535
Caglioti A (abst) 338, 579
Cahan DH (abst) 254
Cai H (abst) 389
Caillette A *See* Barthelmebs M et al 1414
Cajias J (abst) 315
Calero F (abst) 1590, 1590
Califano JR (abst) 474
Callard P (abst) 279
Calleja C (abst) 498
Calò L (abst) 503
Cam G (abst) 247
Camargo MJF (abst) 383
Cameron JS *See* Alexopoulos E et al 100
Camp MA (abst) 263
Campbell HT (abst) 290
Campbell JA (abst) 281
Campbell L (abst) 431
Campbell RA (abst) 224
Campbell S (abst) 361
Campbell WG Jr. (abst) 383
Campese VM (abst) 383, 553
Campistol JM (abst) 1588, 1588, 1615, 1615, 1615, 1616
Campos SP (abst) 376
Camps J (abst) 1605
Camussi G (abst) 410
Canavaggio M (abst) 314
Candiano G, Ginevri F, Acerbo S, Garberi A, Gusmano R, Ghiggeri GM: Analysis of albumin charge by direct immunofixation in ultrathin gels (Technical Note) 1002
Cannata JB (abst) 1611, 1611, 1611, 1611, 1612, 1612
Cannon JK (abst) 229
Cannon JK *See* Olbricht CJ et al 918
Cantaluppi A (abst) 290
Cantiello HF (abst) 213, 383
Cantley LC (abst) 203
Canzanello VJ (abst) 604
Cao M (abst) 1616
Caparros G (abst) 1593, 1613, 1614
Capasso G (abst) 235, 503, 534, 548
Capdevila J (abst) 348
Caplan M (abst) 575
Caplan MJ (abst) 535, 568
Capparelli AW (abst) 196, 499, 526
Cappelli G (abst) 308, 309
Capraro FE (abst) 270
Caralps A (abst) 1597
Caramelo C (abst) 337, 1611
Cardella CJ (abst) 446, 500
Cardinal J (abst) 565
Carey RM (abst) 354
Caride AJ (abst) 454
Carlisle EF (abst) 306
Carlson K (abst) 333
Carmines PK (abst) 552
Caro J (abst) 236, 237
Caron MG (abst) 202, 567
Carosi SL (abst) 570
Carozzi S (abst) 290, 594
Carpenter CB (abst) 599
Carpenter HA (abst) 615
Carrasco ML (abst) 1598
Carrascosa T (abst) 1608, 1608
Carrera M (abst) 1588, 1600, 1600
Carreras J (abst) 1591
Carreras L (abst) 1600, 1600
Carreras M (abst) 1601
Carretero O (abst) 356
Carretero P (abst) 1587
Carriazo A (abst) 1591, 1591, 1591
Carroll HJ (abst) 282
Cartwright K (abst) 506
Caruana RJ (abst) 290, 465
Caruso DE (abst) 488
Carvounis CP (abst) 365
Casadei D (abst) 313, 313
Casadevall N (abst) 308
Casado S (abst) 1592
Casagrande P (abst) 404
Casal M (abst) 1599
Casale P (abst) 319, 422
Casali P (abst) 601
Casanueva FF (abst) 1602
Casares M (abst) 1594, 1613
Case G (abst) 333
Casellas D (abst) 554
Casellas D *See* Moore LC 1402
Cases A (abst) 1605, 1605
Casiere D (abst) 500
Casper JT (abst) 438
Cassals M (abst) 534
Cassingena R (abst) 201

Castelao AM (abst) 1591, 1600, 1600, 1601, 1601, 1601, 1601, 1601, 1603
Castell J (abst) 1602
Castellino P (abst) 500, 521
Castellino P, Bia MJ, DeFronzo RA: Adrenergic modulation of potassium metabolism in uremia 793
Castello G (abst) 406
Castenfors J (abst) 1381
Castillo R (abst) 1605
Casto RL (abst) 394
Castro A (abst) 1598
Catafau A (abst) 1615
Catalano C (abst) 272
Cattell V (abst) 411
Cattran D (abst) 255
Catucci G (abst) 293
Cavalli G (abst) 444
Cavallo T (abst) 410, 414
Cavallotti D (abst) 485
Cavalot F (abst) 410
Cavanagh HD (abst) 549
Cavanna G (abst) 549
Cavero PG (abst) 337, 338, 375
Caviglia P (abst) 290, 594
Cecchin E, De Marchi S, Querin F, Marin MG, Fiorentino R, Tesio F: Efficacy of hepatic computed tomography to detect iron overload in chronic hemodialysis 943
Cederholm B (abst) 1388
Celsi G (abst) 217, 561
Cerami A (abst) 600
Cerezo S (abst) 1591
Cerney M (abst) 314
Cerutti JA (abst) 1181
Cervera J (abst) 355
Cerveró A (abst) 1585
Chabala JM (abst) 448
Chaillet R (abst) 582
Chaimovitz C *See* Levy D et al 1310
Challoner-Hue L (abst) 393
Chan L (abst) 280, 461, 509, 525, 528, 545, 585
Chan M (abst) 461
Chan W (abst) 451
Chanard J (abst) 290
Chander P (abst) 394, 411
Chandra M (abst) 272
Chang D (abst) 389
Chang JK (abst) 389
Chang P-N (abst) 605
Chang TT (abst) 1174
Chang Y-S (abst) 561
Chansel D (abst) 337
Chapman AB (abst) 248, 249, 251, 397
Charboneau JW (abst) 450
Charles LA (abst) 441
Charney D (abst) 290
Charney P (abst) 290
Charron MJ (abst) 230
Chastain J (abst) 505
Chatelain C (abst) 607
Chaudhari A (abst) 365, 371
Chavers B (abst) 612
Chavers BM (abst) 604
Chaves C (abst) 383
Chazan JA (abst) 291, 294
Chedid K *See* London GM et al 137
Cheek PL (abst) 465
Cheigh J (abst) 449
Chen A (abst) 500
Chen CK (abst) 259
Chen L (abst) 366, 588
Chen N (abst) 442, 444
Chen PY (abst) 396
Chen S (abst) 240
Chen T (abst) 469
Chen X (abst) 191
Chen X *See* Adler S et al 1048
Chen Y-DI *See* Fuh MMT et al 1295
Chen YC (abst) 196, 500
Chen ZF (abst) 561
Chen-Gal B (abst) 349
Cheng J (abst) 353
Cheng L (abst) 455, 552
Chesney R (abst) 593
Chesney RW (abst) 578, 583
Cheung A (abst) 291, 293
Cheung AK, Parker CJ, Wilcox LA, Janatova J: Activation of complement by hemodialysis membranes: Polyacrylonitrile binds more C3a than cuprophan 1055
Cheung JY (abst) 213, 213
Chevalier RL (abst) 338, 354
Chiarmonte S (abst) 316
Chida Y (abst) 321, 463
Chintala MS (abst) 485
Chlebowski H (abst) 1182
Cho CR (abst) 411
Chobanian MC (abst) 526
Chonko A (abst) 285
Choo QL (abst) 303
Chou C (abst) 471
Chou C-L (abst) 578
Chou S-Y, Porush JG, Faubert PF: Renal medullary circulation: Hormonal control (Editorial Review) 1
Chou SY (abst) 366
Choyke PL (abst) 275
Chrisp JS *See* Seow F et al 818
Christensen S: Furosemide effect during volume expansion: Evidence against lithium transport in the loop 28:S-45
Christenson M (abst) 594
Christie LG (abst) 333
Chu M (abst) 326
Chua A (abst) 478
Chuncharunee A (abst) 374
Churchill DN (abst) 250, 251, 291
Churg J (abst) 246, 252
Cieslinski DA (abst) 192, 478, 485, 492
Cimadevila A (abst) 1596
Cinotti GA (abst) 201, 210, 366
Cirillo D (abst) 500
Clark BA (abst) 264
Clark ML (abst) 262
Clark WT III (abst) 273
Clarke D (abst) 206
Clarkson T (abst) 292
Claus H (abst) 1170
Clausen C (abst) 544
Clayberger C (abst) 596
Clayman P (abst) 214
Clegg K (abst) 389
Clemens MR *See* Gröne H-J et al 1449
Clement J (abst) 1169

Clement JP (abst) 186
Clerch AR (abst) 267
Cleveland MvB (abst) 449
Clore J (abst) 357
Clyne N (abst) 1382
Coburn JW (abst) 314, 328, 451
Cockfield SM (abst) 411
Cody R (abst) 319
Coe FL (abst) 439, 443, 471, 472, 474, 474
Coffey AK (abst) 362
Coffman TM (abst) 346, 351, 434, 501, 501, 604
Cogan M (abst) 541
Cogan MG: Atrial natriuretic peptide (Nephrology Forum) 1148
Coggi G (abst) 287
Cohan A (abst) 284
Cohen AH (abst) 606
Cohen AH *See* Marinides GN et al 749
Cohen D (abst) 1163
Cohen EP (abst) 438, 505
Cohen JJ, Black AJ, Wertheim SJ: Direct effects of endotoxin on the function of the isolated perfused rat kidney 1219
Cohen L (abst) 398
Cohen MAH (abst) 255
Cohen RE (abst) 500
Cohen Solal M (abst) 296, 452
Coimbra T (abst) 478
Colantonio G (abst) 289
Cole DEC *See* McDonald ATJ et al 901
Cole EH, Glynn MFX, Laskin CA, Sweet J, Mason N, Levy GA: Ancrod improves survival in murine systemic lupus erythematosus 29
Cole M (abst) 398
Coleman DL (abst) 410
Coleman RA (abst) 401
Coles GA (abst) 261, 366, 381
Coles GA *See* Mackenzie RK et al 1316
Coles GA *See* Stylianou E et al 1563
Colina F (abst) 1604
Colla R (abst) 402, 557
Collart F (abst) 293, 324
Collins A (abst) 304
Collins DM (abst) 346, 501, 501
Collins RC (abst) 501, 522
Colman J *See* Sebastian A et al 1341
Colussi G, Rombolà G, Surian M, De Ferrari ME, Airaghi C, Benazzi E, Malberti F, Minetti L: Lithium clearance in humans: Effects of acute administration of acetazolamide and furosemide 28:S-63
Comp PC (abst) 595
Comper WD (abst) 479, 593
Conger JD (abst) 479, 481, 493
Conley SB (abst) 603
Connor JP (abst) 479
Connors B (abst) 412
Consul N (abst) 378
Conte G (abst) 338, 579
Contiguglia R (abst) 298
Contino LC (abst) 499
Cook AK (abst) 552
Cook ME (abst) 605
Cook T (abst) 411
Cook WJ (abst) 232
Cooke R (abst) 443
Cooley AJ (abst) 415
Cooper A (abst) 347
Cooper P (abst) 594, 1184
Copley J (abst) 305
Copley JB (abst) 448
Coppens PJW (abst) 326
Coppo R (abst) 273, 407, 444
Coppola S (abst) 235, 500, 503
Corbin AL (abst) 526
Corbin J (abst) 199
Cordy PE (abst) 301
Corey H (abst) 455
Coritsidis G (abst) 501, 502
Corna D (abst) 428, 516, 523
Corona M (abst) 264, 315
Coronel F (abst) 1590, 1594, 1613, 1616
Correa-Rotter R (abst) 358
Corry D (abst) 395
Corry DB (abst) 499, 502
Cortell S (abst) 279
Cortes P (abst) 502, 615
Cortez SL (abst) 407
Corteza Q (abst) 522, 595
Coruzzi P (abst) 402, 557
Coscarella G (abst) 235, 503
Cosio FG (abst) 218, 221, 409, 422, 432, 433
Cosio FG, Bakaletz AP, Mahan JD: Role of precipitating and nonprecipitating antibodies in glomerular immune complex formation 1429
Costello J (abst) 291
Costerton JW (abst) 327
Cotterell LW (abst) 555, 603, 604
Coudrier E *See* Drüeke T et al 1438
Coulson R (abst) 367
Coupes BM (abst) 438
Courel MA (abst) 1602
Couroucé A-M (abst) 320
Courteau M (abst) 438
Couser W (abst) 406
Couser WG (abst) 412, 417, 430
Couser WG *See* Johnson RJ 663
Cowart RG (abst) 247
Cowgill LD (abst) 455
Cox M (abst) 233
Cox P (abst) 420
Coyne D (abst) 192
Coyne DW (abst) 345
Crabos M (abst) 383
Craelius W (abst) 192
Cragoe EJ (abst) 538
Cragoe EJ Jr. (abst) 196, 547, 581
Craig W (abst) 335
Cramer BC (abst) 250, 251
Craven PA (abst) 347
Creech EA (abst) 604
Criado R (abst) 1596
Croatt AJ (abst) 376
Crocker JFS (abst) 425, 502
Crocker JFS *See* McDonald ATJ et al 901
Croker BC (abst) 606
Cronin C (abst) 321
Cronin RE (abst) 487
Cross M *See* Emmerson BT et al 36
Crowley S (abst) 218
Crusius JBS (abst) 590
Cruz A (abst) 1594, 1613
Cruz C (abst) 334

Cruz IA (abst) 289
Cucuzzella A (abst) 277
Cuesta MV (abst) 1614
Cuesta V (abst) 1604
Culpepper RM (abst) 206
Cunningham EE (abst) 292
Cunningham J (abst) 313, 455, 602
Cunningham J *See* Moore RH et al 991
Cunningham JA (abst) 488
Curatola A (abst) 405
Curtis J (abst) 609
Curtis JJ (abst) 606
Cushner H (abst) 305
Cutler J (abst) 285
Cuzzola F (abst) 405
Cybulsky AV (abst) 206, 410
Dabbagh S (abst) 326, 578
Daccordi H (abst) 274
Dadan J (abst) 339, 345, 377, 424, 479
Dadan J *See* Zoja C et al 934
D'Agati V (abst) 412
Daha MR (abst) 186, 187, 446
Dahhan A (abst) 366
Dai L-J (abst) 460
Dal Canton A (abst) 338, 506, 579, 599
Dalal SP (abst) 292
Dalecki T (abst) 218, 418
Dalmasso AP (abst) 599
Dalquen P (abst) 1186
Danechi K (abst) 578
Dang P *See* Drüeke T et al 1438
Daniel TO (abst) 192, 199, 484
Daniels BS (abst) 503, 507
Daniels F *See* Kasiske BL et al 880
Daniels F *See* O'Donnell MP et al 1263
Daniels FH (abst) 550
Danielson BG (abst) 274, 286, 373, 468
Danovitch G (abst) 616
Danovitch GM (abst) 606, 610
Dantzler WH (abst) 1163
Daphnis E (abst) 534
Darnell A (abst) 1602
Dasgupta MK (abst) 327
Dass PD (abst) 264
Daudon M (abst) 462
Daugaard H (abst) 451
Daugirdas JT (abst) 267, 292
Davidson CJ (abst) 484
Davidson RC (abst) 237
Davies M (abst) 255, 261, 366
Davies M *See* Horton JK et al 717
Davies M *See* Stylianou E et al 1563
Davies ME (abst) 381
Davies RW (abst) 503
Davis G (abst) 448
Davis ID (abst) 605
Davis J (abst) 494
Davis JA (abst) 556
Davis UC (abst) 503
de Arriba G (abst) 1608, 1608, 1608, 1615
De Biase V (abst) 243
De Broe ME (abst) 186, 187, 187, 292, 496
de Chambrier L (abst) 316
de Cotret PR (abst) 266
de Diego F (abst) 1596
De Ferrari ME *See* Colussi G et al 28:S-63
de Fijter CWH (abst) 327
de Heer E (abst) 407
De Heer E (abst) 429
de Jong PE (abst) 184, 340, 503, 508
de Lima JJG (abst) 237
De Marchi S *See* Cecchin E et al 943
de Medina M (abst) 303, 314
de Mello Aires M *See* MacLaughlin M 28:S-75
de Moor EAM (abst) 253
De Nicola L (abst) 338, 599
de Nobel E (abst) 185
De Oleo P (abst) 1616
de Paula A (abst) 1592, 1592
de Pont JJHHM (abst) 185
de Rouffignac C (abst) 207
De Santo NG (abst) 235
de Vinuesa SG (abst) 1596, 1615
de Vries PJMJ (abst) 186
de Weck AL (abst) 439
de Zeeuw D (abst) 184, 187, 340, 503, 508, 527
Dean D (abst) 315
Dean J (abst) 245
DeBoer DK (abst) 347, 351
DeBoer DK *See* Lipman JJ et al 892
Deck LV (abst) 262
Decker R (abst) 259, 259
Decker-Ihle D (abst) 291
DeFronzo R (abst) 261
DeFronzo RA (abst) 521
DeFronzo RA *See* Castellino P et al 793
DeFronzo RA *See* Groop L et al 1120
DeGanello S (abst) 471, 472
DeGowin RL *See* Lim VS et al 131
Deierhoi M (abst) 609
Deierhoi MH (abst) 606
Dekant W (abst) 1161
Del Prete M (abst) 287
del Río G (abst) 1589
Delaney NB (abst) 337
Delaney V (abst) 506, 605, 613
Delano BG (abst) 292
Delarue F (abst) 195, 219
Delgado AG *See* Hannedouche TP et al 1126
Delin K (abst) 1379, 1380
Delisle M-C (abst) 462
Delmez J (abst) 303, 324, 465
DeLuca L (abst) 446, 500
DeMeester CA (abst) 220
Demeule M (abst) 230
Demura H (abst) 491
Dengler K (abst) 1169
Denker BM (abst) 214
Denneberg T (abst) 1379, 1389
Denneberg T *See* Mårtensson J et al 143
Dennis VW (abst) 202, 453, 456, 567
Deppisch R, Schmitt V, Bommer J, Hänsch GM, Ritz E, Rauterberg EW: Fluid phase generation of terminal complement complex as a novel index of bioincompatibility 696
Deray G (abst) 480
Derby L (abst) 404
Derfler K (abst) 235, 300, 384, 613
Deridder L (abst) 183
Dern K (abst) 288
DeRubertis FR (abst) 347
DeSanto NG (abst) 503

Descamps-Latscha B *See* Herbelin A et al 116
DeSpain M (abst) 291, 293
Dessau RB (abst) 1385
Dettmer R (abst) 490
Deuber HJ (abst) 1170, 1180, 1182
Deulofeu R (abst) 1588
Deuter G (abst) 268
Devine P (abst) 538
DeVita MV (abst) 264, 405
DeWolf R (abst) 579
DeYoung DR (abst) 558
D'Haese PC (abst) 186, 292
Dhakal M (abst) 273
Dhiman JK (abst) 526
Di Paolo B (abst) 293
Dia H (abst) 1594, 1613
Diamond JR (abst) 504
Diaz A (abst) 1609
Díaz C (abst) 1600, 1600, 1601, 1603
Diaz D (abst) 1601
Díaz Gallo C (abst) 1601
Díaz López B (abst) 1611
Diaz López B (abst) 1612
Díaz-Gallo C (abst) 1591
Diaz-Gallo C (abst) 1601
Díaz-Tejeiro R (abst) 1612, 1613
DiBona GF (abst) 384
Dicarlo RM (abst) 407
DiCillo M (abst) 445
Dickman KG (abst) 535
Dickson R (abst) 403
Diederich A (abst) 387, 550
Diederich D (abst) 387, 550
Diethelm A (abst) 609
Diethelm AG (abst) 606
Dietl P (abst) 216
Díez-Marqués ML (abst) 316, 378
Digout SC *See* McDonald ATJ et al 901
Dikman S (abst) 246
Dillingham MA (abst) 579
DiMari SJ (abst) 195, 221
Dinarello CA (abst) 319, 328, 334
Dinarello CA *See* Schindler R et al 85
Ding G (abst) 225
Ding Z (abst) 613
DiNola M (abst) 595
DiPaola J (abst) 535
DiPietro S (abst) 582
Dippold WG (abst) 1181
DiScala V (abst) 583
DiScala VA (abst) 589
Diskin CJ (abst) 473
Distler A (abst) 209, 393, 393, 1172, 1172, 1172, 1187, 1187
Dittmar A (abst) 1181
Dixon BS (abst) 207, 360, 364
Dixon TE (abst) 544
Djaldetti M (abst) 436
Dobos GJ (abst) 1167
Doctor RB (abst) 480
Dodds R (abst) 510
Dodhia N (abst) 605
Doi T (abst) 504
Dominguez JH (abst) 207, 216, 456, 458, 533
Don BR (abst) 465
Donadio JV Jr. (abst) 255
Doñate T (abst) 1590
Donatsch P (abst) 594
Donauer J (abst) 288
Donker AJM (abst) 185, 186, 275, 327, 499, 557, 590, 591, 614
Donnay S (abst) 1608
Donnelly S (abst) 293
Donohoue PA (abst) 615
Dooley K (abst) 502
Dörfler A (abst) 1176, 1180
Dorfman DM (abst) 373
Dörge A *See* Beck F-X et al 1423
Dorhout Mees EJ (abst) 184, 283, 577, 577, 577, 592
Dorhout Mees EJ, Koomans HA: Introduction 28:S-1
Dorhout Mees EJ: History of the "lithium concept" 28:S-2
Dorhout Mees EJ *See* Boer WH et al 28:S-39
Dorhout Mees EJ *See* Koomans HA 28:S-78
Dorhout Mees EJ *See* Rabelink TJ et al 996
Douglas FL (abst) 604
Douglas JG (abst) 350, 431
Dousa TP (abst) 343, 362, 377, 457, 459, 460, 465, 481
Doutrelepont J-M (abst) 406
Dowd TL (abst) 453
Dowling C (abst) 583
Dowling JP *See* Li H-L et al 1552
Downes SJ (abst) 371
Downing MR (abst) 237
Drachman J *See* Gordon SM et al 110
Drangova R (abst) 559
Dratwa M (abst) 293, 324
Dreisbach A (abst) 259
Dreischer M (abst) 1183
Dreyling KW (abst) 347
Dreznin S (abst) 256
Drsata J (abst) 367
Drüeke T (abst) 308, 321
Drüeke T, Hennessen U, Nabarra B, Nasr LB, Lucas PA, Dang P, Thomasset M, Lacour B, Coudrier E, McCarron DA, Duchambon P, Berthet L, Andrianarison I, Sacksick T, Eb M: Ultrastructural and functional abnormalities of intestinal and renal epithelium in the SHR 1438
Druet E (abst) 415
Druet P (abst) 435
Druet Ph. (abst) 415
Druml W (abst) 379, 510
Drutarosky MD (abst) 269
Duarte CG (abst) 480
Dubiski S (abst) 410
Dublineau I (abst) 207
DuBois J (abst) 270
Dubois M (abst) 480
DuBose TD Jr. (abst) 535
Dubost C (abst) 321
Duchambon P *See* Drüeke T et al 1438
Dudley C (abst) 384
Duerinckx A (abst) 616
Dumann H (abst) 258, 438, 1179
Dumas A (abst) 398
Dumas SE *See* Wuthrich RP et al 783
Dumbauld SL (abst) 273
Dumler F (abst) 294, 334, 502, 615
Dunbar R (abst) 443
Dunlay R (abst) 294
Dunn MJ (abst) 208, 211, 351, 363
Dunn MJ *See* Menè P 1256
Dunn S (abst) 611

Dupre J (abst) 612
Duque I (abst) 378
Durham JH (abst) 534
Durr J (abst) 269, 274
Durr JA (abst) 275, 284
Durr JA, Miller NL, Alfrey AC: Lithium clearance derived from the natural trace blood and urine lithium levels 28:S-58
Düsing R (abst) 348
Dussaule J-C (abst) 335, 354
Dusso AS (abst) 465
Dworkin LD (abst) 504, 511
Dyreborg U (abst) 1385
Dzau VJ (abst) 356
Eadington DW (abst) 550
Earnest MP (abst) 249
Easterling TR (abst) 237
Eaton DC (abst) 561, 565
Eb M *See* Drüeke T et al 1438
Ebben J (abst) 304
Ebel H (abst) 1181
Ebert J (abst) 347, 375, 484
Ebihara I (abst) 219
Eby BK (abst) 464
Ecija JL (abst) 1616
Ecija Peiró JL (abst) 1616
Eckardt K-U (abst) 321, 1164, 1164, 1177
Eckardt KU (abst) 1164
Eddy A (abst) 412
Edelstein D (abst) 218
Edward A (abst) 1181
Edwards BS (abst) 595
Edwards JC (abst) 231
Egfjord M (abst) 451
Eggena MP (abst) 389
Eggena P (abst) 191, 389
Eggers PW (abst) 239, 270
Egrie JC (abst) 235, 237
Ehlenz K (abst) 1181
Ehmer B (abst) 299, 331
Ehrhardt J-D *See* Barthelmebs M et al 1414
Eide I (abst) 362
Eiffert H (abst) 1181
Eigler J (abst) 1182
Einstein M (abst) 463
Eisele G (abst) 331
Eisen TD (abst) 535
Eisenhauer T (abst) 1170
Eiser AR (abst) 256
Eissele R (abst) 1185
Ekberg G (abst) 1381
Ekeberg Ø (abst) 1384
Ekholm J (abst) 1382
Eklöf O (abst) 276, 279
Ekstrand A (abst) 1384, 1389
El Esper N (abst) 354
El Gammal T (abst) 274
El Nahas AM (abst) 504
El Yandouzi EH (abst) 207
El-Bedewi M (abst) 1172
El-Dahr SS (abst) 354
El-Sherif N (abst) 192
Elalouf JM (abst) 207
Elder GE (abst) 526
Elema JD *See* Tervaert JWC et al 799
Ellery CA (abst) 554
Elliott WC (abst) 505
Ellis B (abst) 228
Ellis C (abst) 489
Ellis CL (abst) 499, 502
Ellis D (abst) 193, 326, 384, 578
Ellis EN (abst) 505
Ellis S (abst) 480
Ellison DH (abst) 562
Ellman C (abst) 302
Elnour M (abst) 294
Elseviers MM (abst) 186
Eltahir M (abst) 435
Elving LD (abst) 185
Elzinga L (abst) 247, 555
Elzinga LE (abst) 477
Emancipator SN (abst) 407, 414, 428
Emanuelli G (abst) 410
Emmerson BT, Cross M, Osborne JM, Axelsen RA: Reaction of MDCK cells to crystals of monosodium urate monohydrate and uric acid 36
Emmett M (abst) 449
Emmons CL (abst) 536
Endlich K *See* Fretschner M et al 1227
Endou H (abst) 531
Eneström S (abst) 1379
Eng B (abst) 191
Eng B *See* Adler S et al 1048
Engels K (abst) 550
Engen DE (abst) 615
Enger E (abst) 1384
Engeseth S (abst) 335
England BK (abst) 505, 510
English D (abst) 216
Engström L (abst) 1381
Enia G (abst) 456
Enriquez JL (abst) 256
Eppler S (abst) 398
Epstein FH (abst) 336, 364, 480
Epstein M (abst) 367, 373, 386
Epstein Y (abst) 265
Erat V (abst) 274
Erb A (abst) 1167, 1167, 1168
Erbsloeh-Moeller B (abst) 398
Ercolani L (abst) 215
Eres A (abst) 582
Ergie JC (abst) 292
Erickson A (abst) 328
Ericsson F (abst) 304, 314, 1380
Eriksson C-G (abst) 279
Eriksson CG (abst) 314, 1380
Erkelens DW (abst) 185
Erley CM (abst) 294, 1187
Erley CMM (abst) 1172
Erman A (abst) 266, 349
Ernst S (abst) 564
Errasti P (abst) 1612, 1613
Erythropoietin Study Group Canadian (abst) 278, 278
Esbensen K (abst) 1386
Esbrit P (abst) 1606
Escandon C (abst) 1591
Escandón C (abst) 1591
Eschbach JW (abst) 235, 237, 237, 240, 507
Escobedo JM (abst) 1585, 1585, 1585
Escolar G (abst) 1605
Escoubet B (abst) 190, 231
Esparza A (abst) 429

Esparza N (abst) 1612, 1613
Espinoza R (abst) 268
Esposito C (abst) 579
Espósito H (abst) 313
Estrade S (abst) 201
Ethier J (abst) 265, 266, 562
Ethier JH (abst) 539
Eto S (abst) 257, 258, 276
Ettenger RB (abst) 610, 616
Evan A (abst) 412
Evan AP (abst) 533, 566
Evans DB (abst) 440
Evans R (abst) 295, 301
Evers-Schouten JH (abst) 446
Faber LM (abst) 186
Fabrizi F (abst) 272
Faccenda F (abst) 295
Fadda GZ (abst) 462, 466, 470, 505
Fadda GZ *See* Klinger M et al 1543
Fagan T (abst) 265
Fainaru M *See* Kagan A et al 971
Fainaru M *See* Kagan A et al 980
Fairbanks R (abst) 367
Falardeau P (abst) 348
Falck J (abst) 348
Falk RJ (abst) 256, 440, 441
Falk SA (abst) 481
Falkner B (abst) 381, 386, 398
Falsetti G (abst) 578
Fambrough D (abst) 231
Fan R (abst) 193, 200, 530
Fan WW (abst) 441
Fanestil DD (abst) 561, 566, 566
Fangman J (abst) 279, 295, 296
Fangman J *See* Lim VS et al 131
Fangman J *See* Lim VS et al 1557
Fanti P (abst) 466
Fantone J (abst) 413
Fargin A (abst) 202, 567
Farias J (abst) 1607, 1607, 1608
Farjam A (abst) 1166, 1166
Farquet C (abst) 611
Farrow N (abst) 529
Fasoli E (abst) 402
Fassbinder W (abst) 184
Faubert PF *See* Chou S-Y et al 1
Fauchald P (abst) 239, 605, 607, 1384
Faugere M-C (abst) 309
Fauler J (abst) 1166
Faulkner M (abst) 269
Favaro S (abst) 503
Favero M (abst) 298
Favero M *See* Gordon SM et al 110
Favre H (abst) 442, 574
Favus M (abst) 454
Fdez Soto I (abst) 1611
Fdez Vega F (abst) 1603
Federico S (abst) 295
Feehally J (abst) 531, 597
Fees H (abst) 202
Feig PU (abst) 384, 385
Feiner HD (abst) 504
Feingold R (abst) 320
Feinstin EI (abst) 302
Fejes-Toth G (abst) 216, 360, 536
Feld L (abst) 395
Feld LG (abst) 236, 385
Felder RA (abst) 388
Feldman GM (abst) 269, 546, 579
Felipe C (abst) 1613, 1614
Feliz T (abst) 1605
Fellström B (abst) 274, 468
Felsenfeld A (abst) 294, 295, 473, 518
Fen Z (abst) 192
Fenner R (abst) 365
Ferder L (abst) 274
Ferguson CW (abst) 324
Ferguson E (abst) 272
Feriani M (abst) 317
Fernandez A (abst) 1594
Fernández A (abst) 1599
Fernandez A (abst) 1599
Fernández A (abst) 1599, 1600
Fernández C (abst) 1589, 1590, 1590
Fernández Daza J (abst) 1602, 1605
Fernández F (abst) 1616
Fernández García J (abst) 1611
Fernández JL (abst) 1612
Fernandez Martin JL (abst) 1611
Fernández Martin JL (abst) 1611
Fernández MJ (abst) 1612
Fernández Montero F (abst) 1591
Fernandez PC (abst) 269
Fernández Rivera C (abst) 1602
Fernández Soto I (abst) 1612, 1612
Fernandez Zamorano A (abst) 1614
Fernandez-Cruz L (abst) 1587
Fernandez-Fernandez J (abst) 1586, 1586, 1586, 1587
Fernandez-Gallego J (abst) 1598
Fernandez-Giron F (abst) 1586, 1586, 1587
Fernando N (abst) 409
Fernando ON (abst) 612
Ferraras I (abst) 1590
Ferrari P (abst) 1170, 1172, 1173, 1173
Ferrario RG *See* Salvati P et al 1084
Ferreras I (abst) 1590
Ferrier C (abst) 1170
Ferrier JP (abst) 279
Ferris TF (abst) 610
Ferrone S (abst) 406, 506
Festenstein H *See* Moore RH et al 991
Fester C *See* Fretschner M et al 1227
Fett D (abst) 338
Fidalgo A (abst) 1594, 1613
Fidler A *See* Moore RH et al 991
Fiedler G (abst) 299
Field MJ *See* Seow F et al 818
Fiellin D (abst) 469
Fiers W (abst) 414
Fievet P (abst) 354
Fiksen-Olsen MJ (abst) 552
Filburn C (abst) 211
Filburn CR (abst) 202
Filella X (abst) 1605
Fillastre JP (abst) 260
Finch J (abst) 464, 465, 466
Fine A (abst) 527
Fine LG (abst) 193, 193, 198, 201
Fine LG: Henry Bence Jones (1813–1873): On the influence of diet on urine composition 1019
Fine RN (abst) 240, 329, 513, 616

Finn WF: Prevention of ischemic injury in renal transplantation (Nephrology Forum) 171
Fiorentino R *See* Cecchin E et al 943
Fioretto P (abst) 394
Firanek C (abst) 330
Fireman B (abst) 243
First M (abst) 249
Fischel RJ (abst) 601
Fischer JA (abst) 1177
Fisher J (abst) 612
Fisher JW (abst) 240
Fisher K (abst) 334
Fisher KA (abst) 353
Fishman P (abst) 436
Fitz AE (abst) 401
FitzSimmons SC (abst) 239, 241, 270, 283
Fitzwilliam JF *See* Brazy PC 1113
Fivush B (abst) 517, 594
Fivush BA (abst) 615
Flaharty K (abst) 236, 237
Flament V (abst) 414
Flamion B (abst) 580
Flanders D (abst) 310
Flanigan M (abst) 279, 295
Flanigan MJ (abst) 296
Flanigan MJ *See* Lim VS et al 131
Flanigan MJ *See* Lim VS et al 1557
Flasterstein B (abst) 266
Flatmark A (abst) 605, 1384
Flessner MF (abst) 536
Floege J (abst) 204, 296, 320
Floege J, Topley N, Wessel K, Kaever V, Radeke H, Hoppe J, Kishimoto T, Resch K: Monokines and platelet-derived growth factor modulate prostanoid production in growth arrested, human mesangial cells 859
Flöge J *See* Radeke HH et al 767
Floras J (abst) 341, 553
Floriano J (abst) 414
Fobbe F (abst) 1172
Foellmer HG (abst) 201
Fogo A (abst) 242, 332, 413, 419, 486, 494, 508, 551
Foidart J-M (abst) 409
Foley J (abst) 328, 451
Fong IW (abst) 307
Fontán MP (abst) 1605
Fontoura BMA (abst) 354
Ford DM (abst) 255
Ford KK (abst) 468
Forgo J (abst) 586, 587
Forman D (abst) 361
Fornasieri A (abst) 413
Forrest JN Jr. (abst) 380
Forsberg L (abst) 1388
Forslund T (abst) 1387
Forsman E (abst) 1387
Forsström J (abst) 1382, 1387
Fort J (abst) 1605
Foster MH (abst) 435
Foster R (abst) 575
Fouad-Tarazi F (abst) 340, 400
Fouad-Tarazi FM (abst) 397
Fournier A (abst) 271, 296, 354, 452
Fowler J (abst) 439
Fowler N (abst) 467
Foxwell B (abst) 1184
Fracasso A (abst) 326, 327, 403
Fradin M (abst) 489
Fraile M (abst) 1602
Franceschetti S (abst) 289
Francis CW (abst) 280
Franco E (abst) 1601
Franco M (abst) 498
Francoeur R (abst) 321
Frank JA (abst) 275
Frankamp P (abst) 301
Frankenschmidt A (abst) 347
Franki N (abst) 225
Franssen EJF (abst) 187, 527
Frantz P (abst) 607
Franz HE (abst) 1163
Franz M (abst) 245, 1178
Frate D (abst) 400, 400
Frazer M (abst) 385
Frederickson ED (abst) 606
Fredholm B (abst) 217
Fredin D (abst) 206
Freedlender AE (abst) 338
Freestone A (abst) 612
Frei U (abst) 1173, 1177
Freigberg M (abst) 263
Frenken LAM (abst) 183, 326, 551
Fretschner M, Endlich K, Fester C, Parekh N, Steinhausen M: A narrow segment of the efferent arteriole controls efferent resistance in the hydronephrotic rat kidney 1227
Freudiger H (abst) 1176, 1181
Freundlich M (abst) 466
Frey BM (abst) 439
Frey FJ (abst) 439
Freyschuss U (abst) 1383
Fried V (abst) 234
Friedlaender MM (abst) 296
Friedlander G (abst) 208, 209
Friedler RM (abst) 466
Friedman A (abst) 285
Friedman E (abst) 446, 500
Friedman EA (abst) 259, 292, 398, 401, 506, 603
Friedman J (abst) 420
Friedman PA (abst) 205, 427
Friedman R (abst) 536
Friedrich F (abst) 209, 377, 1165
Frier BM (abst) 550
Fries D (abst) 611
Friess D (abst) 1180
Frifelt JJ (abst) 1385, 1385, 1386, 1387
Frisbie DD (abst) 415
Frischauf A-M (abst) 248
Frischmuth N (abst) 302
Fritschka E (abst) 368
Frohnert PP (abst) 615
Froissart M (abst) 537
Frölich JC (abst) 1166
Frömter E (abst) 1161
Frosch U (abst) 472
Fröseth B (abst) 1387
Frost L (abst) 1389
Frutos MA (abst) 1614
Fryckstedt J (abst) 368
Fuchs E (abst) 372
Fueyo A (abst) 1603

Fuh MMT, Lee C-M, Jeng C-Y, Shen D-C, Shieh S-M, Reaven GM, Chen Y-DI: Effect of chronic renal failure on high-density lipoprotein kinetics 1295
Fuiano G (abst) 506
Fujihara CK (abst) 506
Fujimi S (abst) 285, 300, 302
Fujishima M (abst) 285, 300, 302
Fujita T (abst) 243
Fujiwara Y (abst) 193, 376
Fukagawa M (abst) 467, 468
Fukami K (abst) 208
Fukatsu A (abst) 413, 426, 440
Fukuda Y (abst) 368, 561
Fukuhara Y (abst) 193, 481, 524, 532
Fukui K (abst) 556
Fukunaga M (abst) 193, 376
Funari C (abst) 549
Funke AJ (abst) 492
Furayh O (abst) 298
Furuya H (abst) 568, 573
Fusco MJ (abst) 338
Fushimi K (abst) 225
Futterweit S (abst) 591
Fyhrquist F (abst) 1382, 1383
Gabanelli M (abst) 339
Gabbai FB (abst) 551, 557
Gaber O (abst) 612
Gabl F (abst) 1168
Gabow P (abst) 380
Gabow PA (abst) 248, 249, 249, 249, 251, 397
Gabow PA *See* Granot Y et al 1301
GaCaton C (abst) 1588, 1609
Gaciong Z *See* Klinger M et al 1543
Gadallah M (abst) 244
Gadallah M SG Massry, (abst) 399
Gafter U (abst) 420, 475, 600, 606, 608
Gaggai FB (abst) 382
Gagnon RF (abst) 212, 327, 333
Gahl G (abst) 329
Gaillard CA (abst) 339
Gal RA (abst) 297
Galan A (abst) 1596, 1596
Galán A (abst) 1610
Galbusera M (abst) 339
Galfayan V (abst) 462
Galicia M (abst) 1599
Gall A (abst) 253
Gall M-A (abst) 243
Galla JH (abst) 548
Gallego A (abst) 1592, 1592
Gallego E (abst) 1596, 1596, 1610, 1610, 1610
Gallieni M (abst) 287, 289
Gallotta G (abst) 295
Galonsky R (abst) 506
Galun E (abst) 265
Gamba G (abst) 355
Ganousis L (abst) 275, 284
Gans ROB (abst) 275, 499
Ganz M (abst) 358
Ganz MB (abst) 191, 214, 563
Ganz MD *See* Unwin RJ et al 1031
Garabedian M (abst) 452
Garattini S (abst) 516
Garb J (abst) 263
Garberi A *See* Candiano G et al 1002
Garces L (abst) 1585, 1585, 1586
Garcés L (abst) 1586
Garcia Aznar A (abst) 1598
García G (abst) 313, 313
García García M (abst) 1588, 1588, 1588
Garcia J (abst) 463
Garcia JR (abst) 239, 270, 283
García Martín F (abst) 1592, 1608, 1608, 1608
Garcia R (abst) 417
Garcia Robles R (abst) 1606
García RVG (abst) 1602
Garcia S (abst) 512
Garcia-Alonso D (abst) 481
García-Erauzkin G (abst) 1587, 1588
García-Escribano MC (abst) 378
García-Estañ J (abst) 358
Garcia-Maldonado M (abst) 595
García-Martín F (abst) 1615
García-Masdevall D (abst) 1588
Garcia-Perez A (abst) 580, 584, 586
García-Porrero JA *See* Ojeda JL et al 1270
Garcia-Robles R (abst) 403, 403
Gardenswartz MH (abst) 405
Garev L (abst) 483
Garg LC (abst) 206, 580
Garoni JA (abst) 220
Garrick R (abst) 368, 411
Garrido M (abst) 1605
Garrod S (abst) 382
Gärtner HV (abst) 1167
Gassner D (abst) 1186
Gaston RS (abst) 606
Gaudio KM (abst) 481
Gault H (abst) 297
Gault MH (abst) 250, 251
Gausch A (abst) 445
Gavellas G (abst) 466
Gayner R (abst) 506
Gazit D (abst) 451
Gea E (abst) 1601
Geberth St. (abst) 253
Geering K (abst) 560
Geerlings W (abst) 184
Gege E (abst) 1186
Geibel J (abst) 537, 584
Geiran O (abst) 607
Geissler K *See* Stockenhuber F et al 150
Gelardi R (abst) 369
Gelardin RT (abst) 399
Gellai M (abst) 369, 579
Genard J (abst) 552
Gendler S (abst) 279
Genest AF *See* London GM et al 137
Geniteau M (abst) 201
Gennari FJ (abst) 518, 542, 545
Gentil MA (abst) 1591, 1591, 1591
Gerber S (abst) 422
Gerhardt RE (abst) 297
Germain M (abst) 263
Germino GG (abst) 248, 521
Gesek FA (abst) 206, 537
Gesualdo L (abst) 414
Geyer JJ (abst) 227
Ghadishah E (abst) 530
Ghiggeri GM *See* Candiano G et al 1002
Ghoshroy KB (abst) 226
Giachino D (abst) 1172

Gianoglio B (abst) 273
Gibel L (abst) 595
Gibson SM (abst) 297
Gicquaud C (abst) 462
Giebisch G (abst) 483, 534, 537, 548, 568, 571, 574, 575, 576, 581, 584
Giebisch G *See* Beck F-X et al 1423
Gielow P (abst) 296
Gignac M (abst) 338
Gil J (abst) 246
Gil-Vernet S (abst) 1591, 1601, 1601, 1601, 1601
Gilabert R (abst) 1615
Gilbert N (abst) 216, 456
Giliberti A (abst) 295
Gill BM (abst) 382
Gillespie GAJ (abst) 248, 521
Gillum D (abst) 482
GilVernet S (abst) 1600, 1600, 1601
Ginevri F *See* Candiano G et al 1002
Ginn HE (abst) 298
Giocondi M-C (abst) 580
Giorato C (abst) 394
Giordano C (abst) 500
Giralt SA (abst) 273
Girardi S (abst) 571
Girton ME (abst) 275
Giuffra L (abst) 384
Given BD (abst) 337
Gladziwa U (abst) 1180
Glasgow EF (abst) 479
Glass J (abst) 286, 472
Glass J *See* Abreo K et al 677
Glassock R (abst) 511
Glassock RJ (abst) 508
Gleim GW (abst) 405
Glick AD (abst) 242, 507
Glimcher LH (abst) 417, 437
Glimcher LH *See* Wuthrich RP et al 783
Glöckner WM (abst) 1180
Glotz D (abst) 415
Gluck S (abst) 225, 232, 532
Glück Z (abst) 1176, 1181
Glynn MFX *See* Cole EH et al 29
Gmur DJ (abst) 482, 496, 497
Gnionsahe DA *See* Hannedouche TP et al 1126
Göbel BO (abst) 348
Godinich MJ, Batlle DC: Renal tubular effects of lithium 28:S-52
Goicolea J (abst) 1600
Golchini K (abst) 457, 530
Goldberg C (abst) 268, 298
Goldberg H (abst) 234
Goldberg HJ (abst) 194
Goldblat M (abst) 315, 439
Goldfarb S (abst) 224, 521
Goldgar D (abst) 248
Goldinger J *See* Zamlauski-Tucker MJ et al 1536
Goldinger JM (abst) 581
Goldman M (abst) 406, 414
Goldschmeding R (abst) 275
Goldschmeding R *See* Tervaert JWC et al 799
Goldstein J (abst) 292
Goldstein MB (abst) 306, 307
Goldwasser P (abst) 287
Goligorsky MS (abst) 205, 385, 387, 490
Golub MS (abst) 395
Gómez Alonso C (abst) 1611, 1611, 1612
Gomez Campdera F (abst) 1596
Gómez E (abst) 1603
Gomez RA (abst) 354
Gómez-Fernández P (abst) 1598
Gómez-Ullate P (abst) 1587, 1588
Gomi H (abst) 432
Gomolka D (abst) 421
Gong QY (abst) 389
Gonzales S (abst) 616
Gonzalez C (abst) 1591
González C (abst) 1600, 1601
Gonzalez C (abst) 1601, 1601
González C (abst) 1603
González Clemente M (abst) 1602
Gonzalez E (abst) 471
Gonzalez L (abst) 1596
González MT (abst) 1600
Gonzalez OF (abst) 212
Gonzalez R (abst) 256
Gonzalez S (abst) 606
Gonzalez-Molina M (abst) 1614
Gonzalo A (abst) 1597, 1597
Good DW (abst) 535, 537
Goodman A (abst) 309, 344, 411, 600
Goodman AI *See* Schwartzman ML et al 94
Goodman WG (abst) 328, 449, 449, 451
Goodship THJ *See* Moore RH et al 991
Gordon P (abst) 223
Gordon SM (abst) 298
Gordon SM, Drachman J, Bland LA, Reid MH, Favero M, Jarvis WR: Epidemic hypotension in a dialysis center caused by sodium azide 110
Gorfien PC (abst) 582
Gorlen T (abst) 138
Gosele A (abst) 302
Gosh L (abst) 439, 443
Götze O (abst) 1179
Gotzen R (abst) 1172
Gouge S (abst) 290
Gouge SF (abst) 238
Gougoux A (abst) 525, 529
Gower P (abst) 447
Grabensee B (abst) 1167, 1174, 1174, 1182, 1183, 1187, 1187, 1188, 1188
Graber M (abst) 211, 535, 538
Gràcia S (abst) 1603
Graeber C (abst) 398
Graf H (abst) 238
Graf S (abst) 1173
Graff J (abst) 202
Granados R (abst) 414
Granbom L (abst) 1385
Granerus G (abst) 1379, 1380
Granholm NA (abst) 410, 414
Granner DK (abst) 197
Granot Y (abst) 194, 380
Granot Y, Van Putten V, Przekwas J, Gabow PA, Schrier RW: Intra- and extracellular proteins in human normal and polycystic kidney epithelial cells 1301
Grant E (abst) 616
Grant J (abst) 292
Grant ME (abst) 581
Grantham J (abst) 573
Grantham JJ (abst) 581
Grauer GF (abst) 415

Graves K (abst) 428
Gray MS (abst) 354
Gray RW (abst) 459
Green DF (abst) 194
Green J (abst) 467
Green R (abst) 581
Green R *See* Atherton JC et al 28:S-36
Greenberg A (abst) 482
Greenberg H (abst) 323
Greene HL (abst) 360, 532
Greenes RA (abst) 283
Greenfeld Z (abst) 493
Greenfeld Z *See* Rosen S et al 1067
Greengard P (abst) 368
Greenwald JE (abst) 339
Greenwood C (abst) 255, 451
Greer W (abst) 298
Grefberg N (abst) 1381
Greger R (abst) 562, 571, 1162, 1162
Greger R: Possible sites of lithium transport in the nephron 28:S-26
Gregoire I (abst) 354
Gregoire JR (abst) 328
Gregory M (abst) 248
Greizerstein HB (abst) 292
Gretz N (abst) 253
Greven J (abst) 1161, 1166, 1166
Griessner A (abst) 1177
Griffin Z (abst) 302
Griffith BJ (abst) 482
Grillo FG (abst) 356
Grimby G (abst) 1380
Grimm G (abst) 298, 400
Griñó JM (abst) 1591, 1601, 1601, 1603
Griño JM (abst) 1600, 1600, 1601, 1601, 1601
Grishman E (abst) 256
Groene E (abst) 482
Groene H-J (abst) 482
Grogan W (abst) 360
Groggel GC (abst) 194, 219, 415
Groggel GC *See* Marinides GN et al 749
Gröne E *See* Gröne H-J et al 1449
Gröne H-J (abst) 372, 1185
Gröne H-J, Walli AK, Gröne E, Krämer A, Clemens MR, Seidel D: Receptor mediated uptake of apo B and apo E rich lipoproteins by glomerular epithelial cells 1449
Grönhagen-Riska C (abst) 1379, 1382, 1382, 1383, 1384, 1384, 1385, 1386, 1389
Gronow G (abst) 1183
Groop L (abst) 1384, 1389
Groop L, Mäkipernaa A, Stenman S, DeFronzo RA, Teppo A-M: Urinary excretion of kappa light chains in patients with diabetes mellitus 1120
Gross JB Jr. (abst) 252
Gross P (abst) 369
Grossman E (abst) 369
Grosvenor M (abst) 245
Grote D (abst) 482
Grothe-Pfautsch U (abst) 1180
Grotz W (abst) 1174
Groves B (abst) 275
Grüber A (abst) 1186
Grundy SM: Management of hyperlipidemia of kidney disease (Editorial Review) 847
Grunewald JM (abst) 1163
Grunewald RW (abst) 1163, 1164, 1169
Grünfeld J-P *See* Hannedouche TP et al 1126
Grünfeld JP (abst) 444, 483
Grupp CT (abst) 1163
Gruppi C (abst) 237
Grüssinger A (abst) 475
Grützmacher P (abst) 299
Gstraunthaler G (abst) 1163
Gu Y (abst) 487
Gu Y-M (abst) 487
Guay DRP (abst) 478
Guay-Woodford L (abst) 231
Guber H (abst) 192, 567
Gudat F (abst) 1186
Guelpa G (abst) 316
Guerediaga J (abst) 1611
Guerin AP *See* London GM et al 137
Guerra E (abst) 229
Guerrero A (abst) 1592
Guéry JC (abst) 415
Guggino S (abst) 456
Guggino WB (abst) 566, 567
Guidet B (abst) 432
Guillén E (abst) 1603
Guillermo R (abst) 508, 511
Guire KE (abst) 324
Gulick T (abst) 214
Gullans S (abst) 586, 588
Gullans SR (abst) 281, 483, 556, 582
Gulmi FA (abst) 339
Gümbel W (abst) 1179
Gung A (abst) 494
Gupta A (abst) 214, 468
Gupta D (abst) 292
Gupta S (abst) 365, 371
Gurland H-J (abst) 1182
Gurland HJ *See* Ward RA et al 776
Gurley K (abst) 427
Gusmano R *See* Candiano G et al 1002
Gutierez Millet V (abst) 1608
Gutierrez A (abst) 1386
Gutierrez R (abst) 265, 266, 267
Gutierrez-Millet V (abst) 1607
Gutjahr E (abst) 1185
Gutjahr E *See* Olbricht CJ et al 918
Gutmann EJ (abst) 415
Gutterman C (abst) 544, 1598
Gutterman C *See* Batlle DC et al 21
Guzelian P (abst) 360
Guzman NJ (abst) 229
Guzzi LM (abst) 284
Haag K (abst) 1174
Haag-Weber M (abst) 299, 595
Haakenstad AO (abst) 415
Haapanen E (abst) 1388
Haas JA (abst) 565
Haase G (abst) 1180
Habermehl GG *See* Radeke HH et al 767
Habib R (abst) 260, 445
Hack N (abst) 214
Hadro E (abst) 598
Haffner D (abst) 238, 1171
Hagan EA (abst) 323
Hagège J (abst) 219
Hagemann J (abst) 318
Hain H (abst) 329

Haist K (abst) 424
Hajjar S (abst) 581
Hakim RM (abst) 250, 287, 299, 301, 322, 325, 494
Hakim RM: Assessing the adequacy of dialysis (Nephrology Forum) 822
Haldemann C (abst) 1176
Haley NR (abst) 235, 237, 237, 240, 507
Haley RJ (abst) 299
Hall B (abst) 427
Hall BM (abst) 445
Hall E (abst) 321
Hall JE (abst) 339
Hall PS (abst) 497
Haller H (abst) 209, 385, 1187, 1187
Halligan RD (abst) 386, 388
Halloran BP (abst) 469
Halloran P (abst) 609
Halloran PF (abst) 411, 421
Halls D (abst) 1612
Halma C (abst) 186
Halperin M (abst) 266
Halperin ML (abst) 265, 539, 562
Halstenson CE (abst) 478
Halvorsen S (abst) 1384
Hamberger B (abst) 314, 1380
Hamburger RJ (abst) 564
Hamburger S (abst) 297
Hamed F (abst) 268
Hamm LL (abst) 538, 543, 549
Hammell RL (abst) 225
Hammond TG (abst) 527
Hammond WS (abst) 498
Hammond WS *See* Alfrey AC 1409
Hampel G (abst) 472, 483
Hampl H (abst) 300
Hancock J (abst) 196
Hancock WW *See* Li H-L et al 1552
Handa RK (abst) 551
Handler JS (abst) 584
Handt S (abst) 1180
Hanlon S (abst) 394
Hannedouche T (abst) 483
Hannedouche TP, Delgado AG, Gnionsahe DA, Boitard C, Lacour B, Grünfeld J-P: Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes 1126
Hänsch GM (abst) 303, 416, 431
Hänsch GM *See* Deppisch R et al 696
Hänsch GM *See* Torbohm I et al 1098
Hansen HE (abst) 1389
Hansen K (abst) 439
Hanson G (abst) 304
Hanss BG (abst) 395, 483
Hansson L (abst) 399
Haralson M (abst) 217
Haralson MA (abst) 195, 221, 507
Haramati A (abst) 460
Hardesty RL (abst) 482
Hardie W (abst) 484
Hardonk MJ (abst) 407, 427
Hardonk MJ *See* Poelstra K et al 1500
Hardwick L (abst) 196
Hardwick LL (abst) 457
Hardy DN (abst) 201
Harendza S (abst) 195
Harford AM (abst) 595
Hariharan S (abst) 238
Hariprasad MK (abst) 300, 300
Hariprasad R (abst) 300, 300
Hariprasad SM (abst) 300, 300
Harken A (abst) 284
Harker CT (abst) 509
Harmon W (abst) 277, 603, 607
Harmon WE (abst) 615
Harnandez E (abst) 1587
Harrington R (abst) 211
Harris HW (abst) 231, 583, 593
Harris K (abst) 431, 484, 490
Harris RC (abst) 195, 195, 196, 217, 348, 360, 370, 374, 508, 560
Harris RC *See* Safirstein R et al 1515
Harrow AS (abst) 257
Hart D (abst) 534, 536, 538, 543
Hartenstein K (abst) 1187
Hartley RB *See* Alexopoulos E et al 100
Hartmann A (abst) 239, 607
Hartog A (abst) 454
Harton P (abst) 550
Harvie BR (abst) 372, 486
Harvie BR *See* Kon V et al 1487
Hashimoto H (abst) 507
Hashimoto O (abst) 257
Hashimoto S (abst) 369
Haskell LP (abst) 338
Hasui K (abst) 582
Hasuo Y (abst) 300
Hatano M (abst) 243, 422
Hattersley J (abst) 531
Hattery RR (abst) 252
Hatton DC (abst) 388
Hattori N, Shimatsu A, Kato Y, Imura H: Growth hormone and growth hormone binding protein in human urine 951
Haubitz M (abst) 307, 1180
Haupert GT Jr. (abst) 386
Haupt DM (abst) 202
Hauser A-C (abst) 235, 300
Hauser AC (abst) 400
Hauser CA (abst) 613
Hauser EB (abst) 507
Hauser K (abst) 1187
Havemann K (abst) 1186
Haverty TP (abst) 224, 380, 416, 521
Hawkins EP (abst) 242
Hayashi K (abst) 367, 373, 386
Hayashi M (abst) 370
Hayde M (abst) 613
Hayes C *See* Sugimoto T et al 1522
Hays RM (abst) 225, 378
Hays SR (abst) 538
Hayslett J (abst) 358
Hdex Jaras J (abst) 1588
Hdz-Jaras J (abst) 1609, 1609
He CJ (abst) 195
Heaton A (abst) 440
Hebert LA (abst) 409, 422, 432, 444
Hebert MM (abst) 444
Hebert RL (abst) 582
Hebert SC (abst) 361, 380, 540, 547, 562, 583
Hed J (abst) 308
Hedberg B (abst) 1385
Hederström E (abst) 1388

Heeg JE (abst) 503, 508
Heering P (abst) 1167, 1187, 1187, 1188, 1188
Heezius ECJM (abst) 184
Hegde SS (abst) 341
Heidland A (abst) 520
Heidland U (abst) 520
Heilig C (abst) 586, 588
Heilig CW (abst) 582
Heim-Duthoy K (abst) 608
Heimbürger O (abst) 1384
Heintz B (abst) 1175
Helanterä A (abst) 1382
Held PJ (abst) 239, 241, 270
Heldermen JH (abst) 614
Helin H (abst) 1379
Hellberg POA, Bayati A, Källskog O, Wolgast M: Red cell trapping after ischemia and long-term kidney damage. Influence of hematocrit 1240
Heller J (abst) 1171
Helmchen U (abst) 378, 1174, 1187
Hemken P (abst) 225, 532
Hempelmann U (abst) 595
Henderson LW (abst) 288
Hendy GN (abst) 246
Hennessen U *See* Drüeke T et al 1438
Henrich W (abst) 355
Hensen J (abst) 269, 274, 275
Hensley CB, Bradley ME, Mircheff AK: Subcellular distribution of Na^+/H^+ antiport activity in rat renal cortex 707
Herbelin A, Nguyen AT, Zingraff J, Ureña P, Descamps-Latscha B: Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α 116
Hercz G (abst) 449, 451
Hering-Smith KS (abst) 538
Herlitz H (abst) 399, 1379
Herman A (abst) 552
Hermans J (abst) 186, 446
Hermle M (abst) 353, 1165
Hermon O (abst) 212
Hermsmeyer K (abst) 388
Hernández C (abst) 1615
Hernández CR (abst) 1599
Hernandez E (abst) 403, 403, 1604
Hernández E (abst) 1606, 1606
Hernandez E (abst) 1607, 1607
Hernández E (abst) 1607, 1608
Hernandez E (abst) 1608
Hernandez Poblete G (abst) 1608
Hernandez RE *See* Sebastian A et al 1341
Hernández-Pando R (abst) 355
Hernando L (abst) 1592
Hernando N (abst) 1592
Hernanz A (abst) 1594
Herndon J (abst) 543
Herrera I (abst) 1593
Herrera J (abst) 1604
Herrera-Acosta J (abst) 314, 397, 498
Herrero E (abst) 1588, 1604
Herrero JA (abst) 1589, 1589, 1595
Herron K (abst) 285
Herschman HR (abst) 198
Hersh WR (abst) 283
Hess S (abst) 431
Heublein DM (abst) 375
Heuner A (abst) 1161
Hevey KA (abst) 408
Hewitt R (abst) 250, 251
Heymanns J (abst) 1186
Heyn H (abst) 1182
Hiatt R (abst) 243
Hiatt W (abst) 251
Higdon M (abst) 561
Higgins A *See* Atherton JC et al 28:S-36
Hildebrandt DA (abst) 339
Hildebrandt F (abst) 233, 539
Hilden SA (abst) 226
Hill J (abst) 443
Hillis AN (abst) 261
Hillman NM (abst) 488
Hillman P (abst) 298
Hilme E (abst) 399
Hilton PJ (abst) 392
Hiltunen U (abst) 1386
Himmelbauer H (abst) 248
Himmelfarb J (abst) 287, 301
Himmelmann G (abst) 1181
Himmelstein SI (abst) 484
Hinds TR (abst) 390
Hines WH (abst) 430
Hingst V (abst) 289
Hinoshita F (abst) 239
Hinterberger W *See* Stockenhuber F et al 150
Hirakata H (abst) 300, 340, 400
Hirasawa Y (abst) 305
Hirata CA (abst) 478
Hirata Y (abst) 282
Hirose S (abst) 344
Hirsch AT (abst) 356
Hirsch DJ (abst) 246
Hirsch F (abst) 415
Hirschberg R (abst) 245, 370
Hirschmann J (abst) 1168
Hirt A (abst) 1169
Hirt D (abst) 348
Hise MK (abst) 522, 526
Hitman GA *See* Moore RH et al 991
Hjemdahl P (abst) 1379
Ho P (abst) 559
Ho PWM *See* Pun KK et al 72
Hobbs B (abst) 456
Hobby P (abst) 438, 447
Hoch BS (abst) 582
Hodsman AB (abst) 301
Hodsman AB *See* Kaye M et al 1142
Hoek FJ (abst) 258
Hoffman A (abst) 369
Hoffman W (abst) 274
Hoffmann G (abst) 348
Hogan SL (abst) 256
Hogg RJ (abst) 257, 603
Hoitsma AJ (abst) 187, 262
Hökfelt T (abst) 368
Holbrook D (abst) 287, 301
Holdaas H (abst) 239, 605, 607, 1380
Holden G *See* Kasiske BL et al 880
Holdsworth S (abst) 409
Hollenbeck M (abst) 1187, 1188
Holley J (abst) 329, 333
Holley JL (abst) 328
Holley KE (abst) 276, 281

Holliday M (abst) 270
Hollis B (abst) 463, 466
Hollomby DJ (abst) 301
Holm G (abst) 1380
Holm S (abst) 1388
Holman RT (abst) 255
Holmes C (abst) 295, 301, 331
Holstein-Rathlou N-H (abst) 558, 1388
Holstein-Rathlou N-H: Lithium transport across biological membranes 28:S-4
Holtbäck U (abst) 217
Holthöfer H (abst) 416, 1388
Holtzman E (abst) 215
Holub BJ (abst) 255
Hölzer H (abst) 1186
Holzman LB (abst) 416
Homan van der Heide JJ (abst) 614
Homma S (abst) 592
Homma T (abst) 196, 370, 508, 560
Hong J (abst) 605
Hong JH (abst) 613
Hong R (abst) 285
Hong SK (abst) 581
Honkanen E (abst) 1379, 1382, 1385, 1386
Honrath U (abst) 562
Hooke DH *See* Li H-L et al 1552
Hoorntje SJ (abst) 275
Hootkins R (abst) 302
Hoover RL (abst) 195, 196, 230, 370, 486, 508
Hoover RL *See* Kon V et al 1487
Hopf G (abst) 1180
Hopfer U (abst) 350
Hoppe A (abst) 454, 457, 458, 460, 465
Hoppe J (abst) 204
Hoppe J *See* Floege J et al 859
Horáček V (abst) 1171
Hori K (abst) 302
Hori MT (abst) 449
Horie S (abst) 539
Horikoshi S (abst) 196, 223
Horisberger J-D (abst) 563
Horl W (abst) 274
Hörl WH (abst) 288, 299
Horl WH (abst) 302
Hörl WH (abst) 323, 492, 595, 1175
Hortal L (abst) 1594, 1599, 1599, 1599, 1600
Horton JK (abst) 255
Horton JK, Davies M, Topley N, Thomas D, Williams JD: Activation of the inflammatory response of neutrophils by Tamm-Horsfall glycoprotein 717
Horton M (abst) 319
Hoshi T: Electrophysiology of *Triturus* nephron: Cable properties and electrogenic transport systems (Robert F. Pitts Memorial Lecture) 157
Hoshino M (abst) 468
Hosselet C (abst) 231, 583
Hostetter TH (abst) 358, 503, 507, 612
Hotter G (abst) 1587
Hou S (abst) 302
Houde I (abst) 266
Houghton M (abst) 303
Houser MT (abst) 423
Housman D (abst) 510
Hovingh P (abst) 194, 219
Howard R (abst) 268
Howard RJ (abst) 606
Howard RL (abst) 248
Howard T (abst) 355
Hoyer J (abst) 416
Hoylaerts MF (abst) 496
Hreniuk D (abst) 229
Hricik DE (abst) 607
Hruby K *See* Sunder-Plassmann G et al 1350
Hruska K (abst) 214, 468
Hsiang F (abst) 535
Hsiao RJ (abst) 382
Hsiao RJ, Mezger MS, O'Connor DT: Chromogranin A in uremia: Progressive retention of immunoreactive fragments 955
Hsu C (abst) 422, 467
Hsu CH, Patel S: Factors influencing calcitriol metabolism in renal failure 44
Hu DCK (abst) 344
Hu J (abst) 302
Hu MS (abst) 196, 387, 389, 457
Huang C-L (abst) 208
Huang H (abst) 411
Huang Z-Q (abst) 196, 232
Hudson S (abst) 609
Huff JL (abst) 191
Huffer W (abst) 452
Huffman W (abst) 361
Hughes R (abst) 588
Huguet J (abst) 1603
Hui R (abst) 348
Hui S (abst) 448
Huitema MG *See* Tervaert JWC et al 799
Hulman S (abst) 381, 386, 398
Hultgardh-Nilsson A (abst) 197
Humes HD (abst) 192, 478, 484, 485, 492
Humphreys MH (abst) 312, 383
Humphreys MH *See* Mazbar SA et al 1325
Huntenburg CC (abst) 328, 334
Hunter JB (abst) 438
Hura CE (abst) 512
Hurley JK (abst) 275
Hurtado J (abst) 1606
Hus-Citharel A (abst) 528
Huser B (abst) 1184
Husserl F (abst) 240
Husted RF (abst) 563
Hutchinson R (abst) 545
Hutchison FM (abst) 503
Hutchison FN (abst) 509
Hutchman J (abst) 406
Huth MM (abst) 392
Hutton RD (abst) 381
Hwang K (abst) 194, 466
Hwang SD (abst) 442
Hylander B (abst) 236, 239, 1386
Hyndman V (abst) 398
Iacovitti M (abst) 541
Iandolo R (abst) 295
Icardo JM *See* Ojeda JL et al 1270
Ichikawa I (abst) 230, 242, 332, 360, 382, 413, 419, 486, 497, 508, 508, 532, 551
Ichikawa I *See* Kon V et al 1487
Ida T (abst) 596
Ideura T (abst) 417
Idicula A (abst) 603
Iesato K *See* Yoshida H et al 1286
Igarashi P (abst) 233, 539

Igarashi T (abst) 467
Ihm C (abst) 511
Ihm CG (abst) 508
Iijima K (abst) 385, 387
Ikeda K (abst) 435, 440, 447
Ikoma M (abst) 332, 413, 508, 551
Ilson BE (abst) 583
Ilstrup DM (abst) 303
Imai E (abst) 197
Imai M (abst) 461, 576
Imai M, Isozaki T, Yasoshima K, Yoshitomi K: Permeability characteristics and probability of lithium transport in the thin limbs of Henle's loop 28:S-31
Imamura M (abst) 397
Imberti O (abst) 485
Imboden J (abst) 208
Imbs J-L *See* Barthelmebs M et al 1414
Imura H *See* Hattori N et al 951
In H (abst) 519
Inada T (abst) 468
Inagami T (abst) 203, 372, 375, 486
Inagami T *See* Iwai N 1460
Inagami T *See* Kon V et al 1487
Ince A (abst) 420
Ing TS (abst) 267, 292, 334
Ingeana A (abst) 355
Ingelfinger JR (abst) 356
Ingmundson P (abst) 305
Ingram P (abst) 487, 495
Ingulli E (abst) 257
Inka I (abst) 1169
Inniger R (abst) 1168, 1168
Inokuchi S (abst) 208
Inoue K (abst) 417
Inscho EW (abst) 552
Inscoe SW (abst) 275
Inserra F (abst) 274
Inskeep EK (abst) 347
Iqbal Z (abst) 292
Irmler H *See* Olbricht CJ et al 918
Isales CM (abst) 205
Iseki K (abst) 285, 302
Ishibashi K (abst) 563
Ishigami M (abst) 485
Ishikawa S, Saito T: Optimal concentration of cellular free calcium for AVP-induced cAMP in collecting tubules 1060
Ishikawa T (abst) 514, 515, 522
Ishimitsu T (abst) 387
Ishimoto F (abst) 432
Ishimura E (abst) 197, 223
Iskandar SS (abst) 440
Islam A (abst) 521
Isozaki T *See* Imai M et al 28:S-31
Italiano per lo Studio della N Gruppo (abst) 437
Ito S (abst) 356
Ito Y (abst) 426, 440
Itoh Y (abst) 436
Ittel TH (abst) 472, 1177, 1182
Ivens K (abst) 1183
Ives HE (abst) 200, 204, 208
Iwai N, Inagami T: Molecular cloning of a complementary DNA to rat cyclophilin-like protein mRNA 1460
Iwamoto H (abst) 239
Iwamoto T, Nakashima Y, Sueishi K: Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells 1466
Iwao H (abst) 556
Izraeli S (abst) 266
Jabs K (abst) 607
Jabs KL (abst) 615
Jäckle-Meyer I (abst) 1169
Jackson BA (abst) 590
Jackson CA (abst) 569
Jackson S (abst) 261
Jacobs C (abst) 480, 607
Jacobson H (abst) 246, 348, 576
Jacobson HR (abst) 507, 515, 582, 589
Jacobson S (abst) 1386
Jacobson SH (abst) 276, 279, 308, 320
Jacoby M (abst) 209
Jaeger J (abst) 328
Jaeger Ph. (abst) 467
Jahn B (abst) 303, 416
Jahn C (abst) 379
Jahn C *See* Stockenhuber F et al 150
Jalanti T (abst) 316
James SH (abst) 399
Jameson M (abst) 387, 550
Jamgotchian N (abst) 387, 389, 457
Jamison RL (abst) 381
Janata O (abst) 300, 1177, 1185
Janatova J (abst) 291
Janatova J *See* Cheung AK et al 1055
Jandhyala BS (abst) 485
Jangula J (abst) 472
Janoshazi A (abst) 593
Janosky JE (abst) 482
Janssen WMT (abst) 184, 340
Jarillo MD (abst) 1609, 1609, 1609, 1610
Jarnot MD (abst) 488
Jarusiripipat C (abst) 509
Jarvis WR (abst) 298
Jarvis WR *See* Gordon SM et al 110
Jayne D (abst) 440, 441, 443
Jayne DRW, Marshall PD, Jones SJ, Martin Lockwood C: Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis 965
Jeanpretre M (abst) 316
Jedicke H (abst) 1178
Jeffers L (abst) 303
Jeffery JR (abst) 600
Jeffries WB (abst) 370
Jen JF (abst) 572
Jendrisak M (abst) 303, 324
Jeng C-Y *See* Fuh MMT et al 1295
Jenner LA *See* Stylianou E et al 1563
Jennette JC (abst) 256, 440, 441
Jennings ML (abst) 227
Jensen G (abst) 1380
Jensik SC (abst) 605
Jenson BM (abst) 303, 310
Jervell J (abst) 239, 1380
Jester JV (abst) 549
Jetté M (abst) 230
Jevnikar AM (abst) 417, 437
Jevnikar AM *See* Wuthrich RP et al 783
Jiménez M (abst) 1594
Jindal KK (abst) 307
Jo OD (abst) 359, 500, 526

Joannidis M (abst) 1162
Jofre R (abst) 1596, 1596, 1610
Jofré R (abst) 1610
Jogestrand T (abst) 1382
Joh K (abst) 432
Johns CA (abst) 547
Johnsen S-A (abst) 236
Johnson AM (abst) 248, 249, 251, 397
Johnson CA (abst) 335
Johnson E (abst) 297
Johnson GC (abst) 494
Johnson HK (abst) 614
Johnson JP (abst) 356, 489
Johnson LB (abst) 192, 485
Johnson M (abst) 245
Johnson R (abst) 273, 406, 412, 417, 490
Johnson RJ (abst) 430
Johnson RJ, Couser WG: Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations (Editorial Review) 663
Johnson WJ (abst) 276, 303
Johnston B (abst) 454
Johnston CC (abst) 448
Johnston J (abst) 333
Johnston JR (abst) 328, 329, 384
Johnston PA (abst) 234
Jokinen S (abst) 1387
Joles JA (abst) 185, 356
Jolesz FA (abst) 281
Jones DP (abst) 583
Jones ER (abst) 272
Jones H Jr. (abst) 509
Jones J (abst) 366
Jones K (abst) 363
Jones RH (abst) 249
Jones SJ (abst) 441
Jones SJ *See* Jayne DRW et al 965
Jones SL (abst) 510
Jones SY (abst) 384
Jonges E (abst) 187
Jorge P (abst) 1589, 1589
Jørgensen F (abst) 243
Jørgensen HE (abst) 243
Jorkasky DK (abst) 583
Jörres A (abst) 329
Joseph J (abst) 478, 486
Joseph N (abst) 401
Josephs W (abst) 1176
Josephson M (abst) 608
Josepovitz C (abst) 350, 486
Joshi N (abst) 276
Jovanovic G (abst) 252
Jugus M (abst) 579
Juhl A (abst) 1383
Julian B (abst) 609
Julian BA (abst) 261, 606
Julien Y (abst) 523
Julin CM (abst) 526
Junco E (abst) 1610, 1615
Juncos LA (abst) 356
Jung KY (abst) 531
Junge W (abst) 260
Jünger E (abst) 251
Jungers P (abst) 462
Jungmann E (abst) 1170
Jungwirth A (abst) 209, 1162
Jungwirth A, Paulmichl M, Lang F: Cadmium enhances potassium conductance in cultured renal epitheloid (MDCK) cells 1477
Jurado M (abst) 1612
Jusko WJ (abst) 614
Jutzler G (abst) 1180
Kachadorian W (abst) 583
Kachadorian WA (abst) 589
Kachel HG (abst) 1185
Kachoris C (abst) 386
Kacinski BM (abst) 201
Kaczmarek RG (abst) 297
Kaehny WD (abst) 248, 249
Kaever V *See* Floege J et al 859
Kaffarnik H (abst) 1181
Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD: I. Different characteristics for low and high molecular weight proteins 971
Kagan A, Bar-Khayim Y, Schafer Z, Fainaru M: Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels 980
Kahf S (abst) 195, 378
Kahn AM (abst) 386, 388
Kahn SB (abst) 378
Kain R (abst) 238
Kaiser B (abst) 329, 611
Kaissling B (abst) 1164, 1164
Kaizu K (abst) 257, 258, 276
Kakihara M (abst) 481
Kala A-R (abst) 1385
Kalaitzis H (abst) 393
Kalechman Y (abst) 600, 606, 608
Kalia A (abst) 256
Kallenberg CGM *See* Tervaert JWC et al 799
Källskog Ö *See* Hellberg POA et al 1240
Kaloyanides GJ (abst) 350, 351, 486
Kamada T (abst) 193, 376, 481, 524, 532
Kamata K (abst) 417, 418
Kamber V (abst) 1184
Kamei N (abst) 436
Kamel K (abst) 265, 266
Kamel KS (abst) 539
Kamil ES (abst) 329, 616
Kamper A (abst) 1388
Kanaka C (abst) 1169
Kanalas JJ (abst) 418
Kanalas JJ *See* Makker SP 64
Kaname S (abst) 197, 467, 468
Kanda S (abst) 198
Kanda S, Nomata K, Saha PK, Nishimura N, Yamada J, Kanetake H, Saito Y: A study of growth regulators of renal cortical tubular cells in the rabbit liver 875
Kanemitsu H (abst) 463
Kanetake H (abst) 198
Kanetake H *See* Kanda S et al 875
Kanfer A (abst) 597, 611
Kang L-L (abst) 342
Kang MS (abst) 304, 315
Kankam M (abst) 297
Kanwar Y (abst) 218
Kanwar YS (abst) 418, 436
Kao J (abst) 340
Kaplan R (abst) 371
Kapoor SC (abst) 268, 277, 357

Kapur KK (abst) 283
Karanja N (abst) 388
Karlén J (abst) 512
Karlsson U-M (abst) 1385
Karniski LP (abst) 227, 539
Karnovsky MJ (abst) 504
Karsenti E (abst) 224
Karsh J (abst) 596
Karubian F (abst) 244
Kasai K (abst) 449
Kashgarian M (abst) 197, 214, 223, 481, 584
Kashihara N (abst) 218, 418
Kashtan C (abst) 249
Kashtan CE (abst) 441
Kasim SE *See* Akmal M et al 854
Kasinath BS (abst) 198
Kasiske BL (abst) 391, 509, 509, 520, 556, 608, 611, 611
Kasiske BL, O'Donnell MP, Schmitz PG, Kim Y, Keane WF, Phillips F, Daniels F, Holden G: Renal injury of diet-induced hypercholesterolemia in rats 880
Kasiske BL *See* O'Donnell MP et al 1263
Kaskel F (abst) 190, 388
Kasner SE (abst) 563
Kato Y *See* Hattori N et al 951
Katz A (abst) 254, 476
Katz AI (abst) 379, 565
Katz LA (abst) 330
Katz SA (abst) 352, 358, 391, 509
Katzberg RW (abst) 282
Katzir Z (abst) 296
Kaufman CE Jr. (abst) 595
Kaufman J (abst) 273
Kaufman JS (abst) 564
Kaufmann B (abst) 331
Kaufmann C (abst) 1168
Kawabe M (abst) 450
Kawachi H (abst) 418
Kawaguchi Y (abst) 330, 568, 590
Kawahara K (abst) 564, 568
Kawai C (abst) 246, 425
Kawamura J *See* Yamakawa K 1105
Kawamura T (abst) 332, 413, 419, 508, 551
Kawasaki K (abst) 230
Kawashima A (abst) 527
Kaye M, Hodsman AB, Malynowsky L: Staining of bone for aluminum: Use of acid solochrome azurine (Technical Note) 1142
Kaysen GA (abst) 503, 509
Kazatchkine M (abst) 441
Keane WF (abst) 391, 478, 509, 509, 520, 556
Keane WF *See* Kasiske BL et al 880
Keane WF *See* O'Donnell MP et al 1263
Kehrer G (abst) 1174
Keilani T *See* Batlle DC et al 21
Keiser HR (abst) 369
Keiser JA (abst) 382
Kelch B (abst) 378
Kelepouris E (abst) 564
Keller E (abst) 1171
Keller F (abst) 258
Keller U (abst) 1170, 1172
Kelley K (abst) 343
Kelley VE (abst) 409, 417, 426, 437, 593
Kelley VE *See* Wuthrich RP et al 783
Kelly C (abst) 419
Kelly CJ (abst) 423, 430
Kelly D (abst) 423
Kelly MR (abst) 240
Kelly P (abst) 272
Kelly RA (abst) 510
Kemmer F (abst) 1174
Kempson S (abst) 412
Kempson SA (abst) 452
Kennedy B *See* Ziegler MG et al 1357
Kentera D (abst) 390
Kenyon JB (abst) 249
Keown PA (abst) 495
Kern S (abst) 367
Kern SR (abst) 190
Kersting U (abst) 228, 1163, 1163
Keshaviah P (abst) 304
Kesteloot D (abst) 183
Kester M (abst) 208, 431
Kettenbaum F (abst) 1180
Keuchel M (abst) 1181
Keusch G (abst) 1177
Key NS (abst) 599
Khanna R (abst) 332
Khoury S (abst) 276
Khraibi AA (abst) 454
Kiberd BA (abst) 419, 419, 608
Kida H (abst) 435, 440, 447
Kierdorf H (abst) 1175
Kierulf P (abst) 1384
Kihara I (abst) 219, 230, 344
Kiil F (abst) 572
Kiil F *See* Stokke ES et al 28:S-71
Kikeri D (abst) 361, 540, 562, 583, 593
Kilian PL (abst) 431
Killebrew E (abst) 243
Killen P (abst) 416
Killen PD (abst) 220, 560
Kim DU (abst) 246, 252
Kim H (abst) 449
Kim JK (abst) 361
Kim KE (abst) 378
Kim KR *See* Lee HY et al 727
Kim M (abst) 277, 603
Kim Y (abst) 220, 408, 509
Kim Y *See* Kasiske BL et al 880
Kim YK *See* Lee HY et al 727
Kimberling WJ (abst) 249
Kimmel PL (abst) 307, 330, 523
Kindler J (abst) 1175
King AJ (abst) 371, 511
Kinkhabwala M (abst) 600
Kinne RKH (abst) 577, 1163, 1164, 1164, 1169
Kinoshita S (abst) 388
Kinsella JL (abst) 216
Kinter LB (abst) 361, 587
Kintziger PN (abst) 457
Kirchner KA (abst) 389
Kirchner KA: Effect of diuretic and antidiuretic agents on lithium clearance as a marker for proximal delivery 28:S-22
Kirk KA (abst) 244, 261
Kirkpatrick WG (abst) 449
Kirmani S (abst) 489
Kirschbaum B (abst) 471, 486
Kirschenbaum MA (abst) 365, 371
Kishimoto T *See* Floege J et al 859

Kisslo K (abst) 484
Kitajima W (abst) 370
Kitaoka M (abst) 468
Kittur DS (abst) 613
Kjellstrand C (abst) 304, 314, 1380
Kjellstrand C-M (abst) 1386
Kjellstrand CM (abst) 320
Klag MJ (abst) 404
Klahr S (abst) 352, 431, 484, 490, 570
Klahr S *See* Yanagisawa H et al 1528
Klassen D (abst) 595
Klassen DK (abst) 277, 497
Klause N (abst) 1183
Kleeman CR (abst) 467
Klein DJ (abst) 220, 421
Klein H (abst) 342
Klein J (abst) 215
Klein J *See* Levy D et al 1310
Klein M (abst) 298
Klein PS (abst) 428
Kleinert H (abst) 1174
Kleinknecht C (abst) 510, 511
Kleinknecht D (abst) 279
Kleinman H (abst) 223
Kleinman HK *See* Taub M et al 1090
Kleinman J (abst) 222, 477, 540
Kleinman KS (abst) 240
Kleinman LI (abst) 542
Kleinzeller A (abst) 579
Kleppel M (abst) 249
KLeppel MM (abst) 441
Kleyman TR (abst) 564
Kliem V (abst) 1170
Klingel R (abst) 1181
Klinger K (abst) 250
Klinger M, Alexiewicz JM, Linker-Israeli M, Pitts TO, Gaciong Z, Fadda GZ, Massry SG: Effect of parathyroid hormone on human T. cell activation 1543
Klöss T (abst) 1180
Klotman P (abst) 223
Klotman PE (abst) 196, 218, 346, 351, 434, 501, 501, 604
Klugerman A (abst) 585
Knauf H (abst) 1174
Knecht A (abst) 198
Knehans A (abst) 475
Knepper MA (abst) 531, 536, 542, 573, 578
Kniaz D (abst) 371
Knibloe KA (abst) 457
Knobel S (abst) 532
Knox FG (abst) 454, 458, 465, 565
Knutson DW (abst) 399
Kobayashi K (abst) 435, 447
Kobayashi Y (abst) 418
Kobrin S (abst) 304
Koch K-M (abst) 319
Koch K-M *See* Schindler R et al 85
Koch KM (abst) 296, 307, 320, 1170, 1173, 1180, 1185
Koch M (abst) 1182
Koch VH (abst) 329, 616
Koda Y (abst) 305
Koderisch J (abst) 1167, 1167, 1168
Koene RAP (abst) 183, 262, 326, 429, 551
Koenig K (abst) 305
Koepchen HP (abst) 1182
Koeppen B (abst) 569
Koeppen-Hagemann I (abst) 369, 420
Kogan B (abst) 270
Koh HI (abst) 512
Kohan DE (abst) 349, 429
Kohan DE *See* Rovin BH et al 1509
Kohl S (abst) 420
Köhler D (abst) 393
Köhler H (abst) 258, 438, 446, 597, 1179, 1181
Koide H (abst) 219, 531
Kok A (abst) 591
Kok DJ, Papapoulos SE, Bijvoet OLM: Crystal agglomeration is a major element in calcium oxalate urinary stone formation 51
Komine N (abst) 257
Kon V (abst) 372, 486, 551
Kon V, Sugiura M, Inagami T, Harvie BR, Ichikawa I, Hoover RL: Role of endothelin in cyclosporine-induced glomerular dysfunction 1487
Kondo S (abst) 420, 448
Kone B (abst) 231
Kone BC (abst) 483
König P (abst) 332
Kontessis P (abst) 510
Kontoghiorghes G (abst) 1611
Koomans HA (abst) 184, 283, 335, 356, 577, 577, 577, 592
Koomans HA, Dorhout Mees EJ: Lithium in renal physiology: Post-conference discussion and consensus 28:S-78
Koomans HA *See* Boer WH et al 28:S-39
Koomans HA *See* Dorhout Mees EJ 28:S-1
Koomans HA *See* Rabelink TJ et al 996
Koomen GCM (abst) 253, 258
Koopman MG (abst) 253, 258
Kopp J (abst) 223
Kopp JB (abst) 220
Köppe B (abst) 1177
Kopple JD (abst) 245, 278, 370
Kopsa H (abst) 1168, 1177, 1185
Korbet S (abst) 330
Korbet SM (abst) 605
Korpela M (abst) 1379
Koshikawa S (abst) 417
Köster W (abst) 288
Kostyniag PJ (abst) 292
Kotchen T (abst) 392
Köttgen E (abst) 329
Koudstaal J *See* Poelstra K et al 1500
Koureta P (abst) 470
Kovach JS (abst) 481
Kovacs G (abst) 240, 513
Kovarik J (abst) 245, 1178, 1184
Kovithavongs T (abst) 609
Kowalewska-Grochowska K (abst) 327
Koyle M (abst) 609
Kozaki M (abst) 447
Kraehenbuhl JP (abst) 564
Krall JF (abst) 387
Krämer A *See* Gröne H-J et al 1449
Kramer HJ (abst) 210, 342, 372, 396, 1172
Kramp RA (abst) 552
Krane NK (abst) 277
Krapf R (abst) 233, 540
Kraus E (abst) 552
Krause R (abst) 1182
Kraut JA (abst) 372, 585
Krediet RT (abst) 186, 253, 258, 326
Kreisberg JI (abst) 220

Kremer S (abst) 215
Kren SM (abst) 503
Krensky AM (abst) 596
Kretzler M (abst) 420
Kreusser W (abst) 1183
Kreuzpaintner G (abst) 1188
Krezoski S (abst) 477
Krian A (abst) 1183
Kribben A (abst) 393, 1172, 1172
Krieger FL (abst) 404
Krishna GG (abst) 268, 277, 357, 514
Kristensen C (abst) 305
Kriz W (abst) 420, 1161
Krolewski A (abst) 241, 404, 510
Kroll H (abst) 439
Krömer G (abst) 331
Kroon A (abst) 187
Krothapalli P (abst) 331
Krothapalli R (abst) 263, 305, 331
Krotkiewski M (abst) 1380
Krupp G (abst) 251
Kubey W (abst) 295, 331
Kubo K (abst) 515
Kubota S (abst) 196
Kubota T (abst) 420, 448
Kucharczyk J (abst) 262
Küchle C (abst) 1184
Kudo LH, van Baak AA, Rocha AS: Effect of furosemide on water and urea transport in cortical and inner medullary collecting duct 1248
Küfner A (abst) 260
Kühl PG *See* Tönshoff B et al 1134
Kuhlbäck B (abst) 1379
Kuhlmann M (abst) 274, 278, 1175
Kühn K (abst) 475
Kühn KW (abst) 1170
Kuizinga MC (abst) 275
Kujubu DA (abst) 198
Kumagai H (abst) 340, 400
Kumano K (abst) 306
Kumar R (abst) 361, 454
Kumar S (abst) 565
Kumjian DA (abst) 199
Kunau R (abst) 261
Kunau RT Jr. (abst) 512
Küntziger HE (abst) 320, 457
Kunz F (abst) 472, 483
Kuo G (abst) 303
Kupin W (abst) 596
Kurihara S (abst) 450
Kuriyama R (abst) 463
Kurnik BRC (abst) 340, 343
Kurnik PB (abst) 340
Kurokawa A (abst) 418
Kurokawa K (abst) 197, 211, 362, 380, 467, 468
Kurts C (abst) 1179
Kurtz A (abst) 321, 1164, 1164, 1175, 1177
Kurtz I (abst) 193, 200, 264, 457, 530, 548
Kurtz SB (abst) 306, 310, 319, 328
Kurtzman NA (abst) 228, 534, 541, 572
Kurtzman NA *See* Sabatini S 79
Kurz RW (abst) 400
Kurz RW *See* Stockenhuber F et al 150
Kusakari S (abst) 306
Kusano E (abst) 306, 592
Kushner D (abst) 240
Kushner H (abst) 381
Kutkuhn B (abst) 1187
Kutschera D (abst) 1187
Kuwahara M (abst) 540
Kwon HM (abst) 581, 584
Kwon O (abst) 581
Kwon S (abst) 207, 216, 458
Kyle RA (abst) 247, 276
Kyo M (abst) 1186
L-Revuelta K (abst) 1594, 1613
La B-Q (abst) 570
La Belle P (abst) 278, 402
La Greca G (abst) 317, 317, 317
Laage C (abst) 1181
Labios M (abst) 1586
Lacave R (abst) 195, 219, 597
Lachaal M (abst) 292
Lacour B (abst) 462
Lacour B *See* Drüeke T et al 1438
Lacour B *See* Hannedouche TP et al 1126
Ladefoged J, Langhoff E: Accessory cell functions in mononuclear cell cultures from uremic patients 126
Laekeman G (abst) 552
Laffel L (abst) 241, 404, 510
Lafferty HM (abst) 511
Lagoda PJL (abst) 1181
Lahera V (abst) 403, 403, 552
Lai KN (abst) 442, 443
Lai L (abst) 528
Laine K (abst) 1387
Lajeunesse D (abst) 456, 458
Lamas S (abst) 316, 378
Lamberts LV (abst) 186, 292
Lameire N (abst) 183
Lamm ME (abst) 407, 414
Lamperi S (abst) 290
Lampreabe I (abst) 1587, 1588
Landmann J (abst) 1184
Landwehr DM (abst) 291
Lane B (abst) 486
Lane JM (abst) 512
Lane PH (abst) 241
Lanese DL (abst) 579
Lang F (abst) 209, 377, 1162, 1162, 1162, 1165
Lang F *See* Jungwirth A et al 1477
Lang R (abst) 1178
Langberg H (abst) 572
Lange H (abst) 1178, 1181, 1186
Langer KH (abst) 1184
Langford HG (abst) 400, 400
Langford K (abst) 355, 359
Langhans S (abst) 1163
Langheinrich M (abst) 1174
Langhoff E *See* Ladefoged J 126
Längle F (abst) 1184
Langman CB (abst) 468
Languino L (abst) 222
Languino LR *See* Border WA et al 689
Lankford S (abst) 476
Laouari D (abst) 510, 511
Lapin A (abst) 1168, 1177, 1185
Laplace JR (abst) 563
Lapointe JY (abst) 565
LaPointe M (abst) 1597, 1598
LaPointe M *See* Batlle DC et al 21
LaPointe MS (abst) 391

Lappin T (abst) 374
Lappin TRJ (abst) 526
Laprade R (abst) 529, 576
Laragh JH (abst) 383, 401
LaRaia JA (abst) 487
Large A *See* Atherton JC et al 28:S-36
Larsen C (abst) 1385
Larsen S (abst) 243
Larson TS (abst) 565
Larsson L-O (abst) 1381
Larsson SH (abst) 197, 199
Lash LH (abst) 525
Laski ME (abst) 541
Laskin CA *See* Cole EH et al 29
Laskow D (abst) 609
Lathon PV (abst) 336
Lau K (abst) 458, 470
Lau P *See* Pun KK et al 72
Laubie M (abst) 354
Lauchart W (abst) 1186
Laue A (abst) 372
Laurie GW *See* Taub M et al 1090
Lauro PN (abst) 193
Lauzurica R (abst) 1597
Lavaud S (abst) 290
Lawrence JR *See* Seow F et al 818
Lawrence PL *See* Lipman JJ et al 892
Lawton WJ (abst) 401
Lax DS (abst) 511
Layward E (abst) 531
Lazarovits AI (abst) 596
Le Carpentier JE (abst) 504
Le Grimellec C (abst) 207, 208, 209, 580
Le Hir M (abst) 1164, 1164
Leadbetter MG (abst) 310
Leaf A (abst) 488
Leanza H (abst) 313, 313
Lechene C (abst) 383, 573
Lechner K *See* Stockenhuber F et al 150
Leclerc M (abst) 458
Lederer ED (abst) 584, 584
Ledingham JGG (abst) 517
Lee C (abst) 473
Lee C-M *See* Fuh MMT et al 1295
Lee DBN (abst) 196, 316, 318, 387, 389, 457
Lee G (abst) 511
Lee GSL (abst) 508
Lee H (abst) 314
Lee HB (abst) 442
Lee HS (abst) 512
Lee HY, Kim KR, Woo JS, Kim YK, Park YS: Transport of organic compounds in renal plasma membrane vesicles of cadmium intoxicated rats 727
Lee JY (abst) 389
Leeber DA (abst) 287, 301
Leehey DJ (abst) 267
Leenaerts P (abst) 427
Leer M (abst) 385
Lefebvre C (abst) 499
Lefevre A (abst) 1169
Leffell MS (abst) 290
Lefkowith J (abst) 431
Lefkowith JB (abst) 352
Lefkowitz RJ (abst) 202, 567
LeFurgey A (abst) 487, 495
Legault L (abst) 341
Leggett J (abst) 335
Leino A (abst) 1382
Leite M Jr. (abst) 584, 584
Leitner T (abst) 585
Leivestad T (abst) 605
Lemann J Jr. (abst) 241, 459
Lemas V (abst) 231
Lemire J (abst) 420
Lemoine R (abst) 442
Lencer WI (abst) 226
Lenga P (abst) 1176
Lens XM (abst) 1606
Lenz T (abst) 401
Leo O (abst) 414
Leonhart K (abst) 221
Lerman A (abst) 373
Lerman LO (abst) 553
Lerman MJ (abst) 302
Lerner T (abst) 250
Lesavre P (abst) 442, 444
Lesnefsky E (abst) 275
Leu N (abst) 291
Leung JM (abst) 267
Levere R (abst) 309
Levere RD (abst) 600
Levere RD *See* Schwartzman ML et al 94
Levi J (abst) 420, 436, 475
Levi M (abst) 453, 487
Levi-Setti R (abst) 448
Leviel F (abst) 537, 541
Levillain O (abst) 528
Levin A (abst) 265, 266, 306, 307
Levin NW (abst) 241, 324
Levine BS (abst) 457
Levine DZ (abst) 541, 548
Levine JS (abst) 437
Levine SD (abst) 209
Levy B (abst) 398
Levy D, Klein J, Rubinek T, Alkan M, Shany S, Chaimovitz C: Diversity in peritoneal macrophage response of CAPD patients to 1,25-dihydroxyvitamin D_3 1310
Levy GA *See* Cole EH et al 29
Lew SQ (abst) 272, 307, 330
Lewand D (abst) 477
Lewicki J (abst) 342
Lewicki JA (abst) 341
Lewis EJ (abst) 241, 431, 444
Leyssac PP (abst) 1388
Leyssac PP: Validity of the lithium clearance concept assessed with micropuncture studies 28:S-17
Li CC (abst) 304
Li H-L, Hancock WW, Hooke DH, Dowling JP, Atkins RC: Mononuclear cell activation and decreased renal function in IgA nephropathy with crescents 1552
Li L (abst) 224
Li LK (abst) 199
Li PP (abst) 307
Li XW (abst) 421
Liang CT (abst) 216
Liaño F (abst) 1592, 1592, 1594, 1594, 1595, 1595
Lianos EA (abst) 346, 421
Lianos EA, Zanglis A: Glomerular platelet-activating factor levels and origin in experimental glomerulonephritis 736
Lie JT (abst) 281

Lieberman D (abst) 234
Lieberthal W (abst) 487, 495
Lien MG (abst) 239, 1380
Lien YH (abst) 528, 585
Lifschitz MD (abst) 512
Light D (abst) 199, 216, 217
Lim I (abst) 232
Lim V (abst) 295
Lim VS (abst) 279, 296
Lim VS, Fangman J, Flanigan MJ, DeGowin RL, Abels RT: Effect of recombinant human erythropoietin on renal function in humans 131
Lim VS, Flanigan MJ, Fangman J: Effect of hematocrit on solute removal during high efficiency hemodialysis 1557
Limongi DMZP (abst) 512
Lin F (abst) 394
Lin J-T (abst) 362, 457, 459, 465, 481
Lin S-Y (abst) 487
Lin SY (abst) 389
Linas S (abst) 268
Linas SL (abst) 359, 476
Lindberg J (abst) 305
Lindberg JS (abst) 459
Linde T (abst) 373
Lindell Å *See* Mårtensson J et al 143
Linden JM (abst) 338
Lindenfeld J (abst) 275
Lindheimer MD (abst) 395
Lindholm B (abst) 1384
Lindman BJ (abst) 421, 599, 601
Lindmeier I (abst) 1185
Lindner A (abst) 390
Lindqvist B (abst) 1385
Lindschau C (abst) 209, 1187, 1187
Lindsjö M (abst) 274, 468
Ling BN (abst) 561, 565
Lingeman J (abst) 412
Linker A (abst) 194, 219
Linker-Israeli M *See* Klinger M et al 1543
Linné T (abst) 512
Lins L-E (abst) 276, 279, 308, 320, 1382, 1386
Linshaw MA (abst) 226
Lipkowitz MS (abst) 559
Lipman JJ, Lawrence PL, DeBoer DK, Shoemaker MO, Sulser D, Tolchard S, Teschan PE: Role of dialysable solutes in the mediation of uremic encephalopathy in the rat 892
Lipner HI (abst) 280, 582
Lipson LG (abst) 466, 505
Lipszyc P (abst) 274
Lison AE (abst) 1168
Litynski J (abst) 331
Liu C (abst) 383, 553
Liu E (abst) 412
Liu F-Y (abst) 541
Liu SM (abst) 553
Liu Z (abst) 218, 418
Liucci L (abst) 263
Liuzzo J (abst) 490
Ljungberg B (abst) 1386
Ljunghall S (abst) 274, 468
Llach F (abst) 294, 295, 473, 518
Llach F *See* Allon M et al 14
Lloveras J (abst) 1603, 1603
Lobel SA (abst) 290
Lockwood CM (abst) 440, 441, 441, 442, 443
Lodish HF (abst) 230
Logan A (abst) 341, 553
Logan AG (abst) 341
Logan JL, Michael UF, Benson B: Effects of dietary fish oil on renal growth and function in uninephrectomized rats 57
Loghman-Adham M (abst) 459
Logue B (abst) 528
Lohr JW (abst) 585
Loibl U (abst) 307, 311, 332, 379, 397, 400
Lokhandwala MF (abst) 341
Lomeña P (abst) 1615
London AM *See* London GM et al 137
London GM, Marchais SJ, Safar ME, Genest AF, Guerin AP, Metivier F, Chedid K, London AM: Aortic and large artery compliance in end-stage renal failure 137
London M (abst) 294
London R (abst) 320
Londowski JM (abst) 361
Lonergan M (abst) 246, 250, 361
Long R (abst) 220
Longerich L (abst) 297
Longhofer SL (abst) 415
Lonnemann G (abst) 307, 319, 1177
Lonnemann G *See* Schindler R et al 85
Look Z (abst) 506
Loomis T (abst) 413
Loon N (abst) 513
Lopes HF (abst) 237
Lopez A (abst) 1609
Lopez C (abst) 463
Lopez Castejon A (abst) 1610
López de Novales E (abst) 1598, 1614
Lopez EJ (abst) 259
López Gómez JM (abst) 1610
Lopez Gomez JM (abst) 1596
López Gomez JM (abst) 1610
López J (abst) 1591
López O (abst) 1589, 1590, 1590
López P (abst) 498
López R (abst) 374
Lopez Revuelta K (abst) 1613
Lopez-Castejon A (abst) 1609
Lopez-Costea J (abst) 1601
López-Farré A (abst) 1603
Lopez-Gomez JM (abst) 1596
Lopez-Hilker S (abst) 464
Lopez-Novoa JM (abst) 1592
López-Novoa JM (abst) 1603
López-Pedret J (abst) 1605, 1605, 1616
Lorch J (abst) 279
Lorenz JM (abst) 542
Lorenz JN (abst) 357, 381, 494
Lorenzo V (abst) 1594
Losekann A (abst) 308, 321
Lösse B (abst) 1183
Louis BM (abst) 280
Loutzenhiser R (abst) 367, 373, 386
Lovell HB (abst) 226
Lovett DH (abst) 227
Lowrie E (abst) 291
Lozano L (abst) 1609, 1609, 1609, 1610
Lu CY (abst) 597
Lu L (abst) 566

Lubrich-Birkner I (abst) 1179
Lucas EY *See* Moore RH et al 991
Lucas PA *See* Drücke T et al 1438
Lucchi L (abst) 308, 309
Luciani J (abst) 607
Lucio FJ (abst) 316, 378
Lufío J (abst) 1596
Luke RG (abst) 244, 548
Lum GM (abst) 255
Lumpkin MD (abst) 460
Lumsden CJ (abst) 411, 488
Lundahl J (abst) 308
Lundberg L (abst) 1386, 1389
Lundblad H (abst) 1386
Luneburg P (abst) 295, 331
Luño J (abst) 1596, 1610, 1615
Luo H (abst) 566
Lüscher T (abst) 387
Lustig S *See* Yussim A et al 812
Lusvarghi E (abst) 308, 309
Lutz WH (abst) 361
Lynch RW (abst) 375
Lyngdal P (abst) 362
Lyon RC (abst) 569
Lytton J (abst) 232
M-Ara J (abst) 1593
Maack T (abst) 341, 342, 354
Macalister T (abst) 226
Macconi D (abst) 367, 376, 428
MacDonald C (abst) 310
MacDonell RC (abst) 614
MacDonnell RC (abst) 242
Macdougall IC (abst) 366, 381
MacDougall M (abst) 285
MacGillivray MH (abst) 376
Macia M (abst) 1590, 1595
Macias WL (abst) 207, 566
Macica C (abst) 524
Maciejewski AR (abst) 566
MacKay K, Striker LJ, Stauffer JW, Agodoa LY, Striker GE: Relationship of glomerular hypertrophy and sclerosis: Studies in SV40 transgenic mice 741
Mackenzie HS (abst) 390
Mackenzie RK, Coles GA, Williams JD: Eicosanoid synthesis in human peritoneal macrophages stimulated with *S. epidermidis* 1316
Mackovic-Basic M (abst) 193, 200
Mackow RC (abst) 284
MacLaughlin M, de Mello Aires M: Impairment of renal tubular acidification by lithium: A microperfusion study in the rat 28:S-75
MacLennan DH (abst) 232
MacManus M (abst) 374
Macnicol AM (abst) 250
Macrae JP (abst) 259
Madaio MP (abst) 435, 604
Maddox DA (abst) 518, 542, 545
Madias NE (abst) 226, 547, 604
Madl C (abst) 298
Madrenas J (abst) 421
Madsen KM (abst) 229, 560
Maduell F (abst) 1612, 1613
Maeda K (abst) 232, 443
Maesaka J (abst) 259, 259
Maggiore Q (abst) 272, 315
Magnusson K-E (abst) 1389
Magnusson M (abst) 340, 400, 1389
Mahajan S (abst) 276, 473
Mahan JD (abst) 422
Mahan JD *See* Cosio FG et al 1429
Mahdiyoun S (abst) 212
Maheut H (abst) 290
Mahiout A (abst) 309, 329
Mahootchi A (abst) 221
Maidenberg M (abst) 607
Mailloux J (abst) 460
Mailloux L (abst) 254, 309
Maini R (abst) 447
Maiwald D (abst) 1176
Mak R (abst) 212
Mak RHK (abst) 513, 513
Makin H (abst) 602
Mäkipernaa A *See* Groop L et al 1120
Makker SP (abst) 418
Makker SP, Kanalas JJ: Renal antigens in mercuric chloride induced, anti-GBM autoantibody glomerular disease 64
Mai F (abst) 279
Malachi T (abst) 420
Malavasi P (abst) 444
Malberti F *See* Colussi G et al 28:S-63
Malhotra D (abst) 268, 280, 298
Malis CD (abst) 386, 488
Mall G (abst) 1165
Mallafré JM (abst) 1606
Mallamaci F (abst) 405
Mallick NP (abst) 437, 438
Mallis L (abst) 192, 567
Malluche HH (abst) 309, 466
Malmusi G (abst) 308, 309
Malynowsky L *See* Kaye M et al 1142
Mampaso F (abst) 1594, 1595
Manahan F (abst) 292, 334
Manahan FJ (abst) 267
Mandal AK (abst) 390, 488, 488
Mandel G (abst) 222
Mandel JL (abst) 246
Mandel LJ (abst) 480, 487, 492, 495, 529, 535
Mandel N (abst) 222
Mandelbrot D (abst) 430
Mandin H (abst) 594
Mangano DT (abst) 267
Mangili R (abst) 513
Maniar S (abst) 511
Maniscalco M (abst) 501
Manker W (abst) 307, 311, 332, 379, 397, 400
Mann H (abst) 1180
Mann RA (abst) 422, 433, 434
Mann T (abst) 314
Manohar NL (abst) 280
Manske CL (abst) 280
Mansour J (abst) 576
Mansour J *See* Anger MS et al 1211
Mantzouris NM (abst) 522
Manuel A (abst) 449, 451
Marcén R (abst) 1589, 1589, 1589, 1592
Marcen R (abst) 1593
Marcén R (abst) 1595, 1595
Marcen R (abst) 1595
Marchais SJ *See* London GM et al 137
Margolis BL (abst) 194, 200
Margolius L (abst) 399

Margulies KB (abst) 337, 489
Mariani S (abst) 406
Marie A (abst) 452
Marin MG *See* Cecchin E et al 943
Marín R (abst) 1603
Marín-Grez M (abst) 1165, 1171
Marinides GN, Groggel GC, Cohen AH, Border WA: Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy 749
Mariñoso L (abst) 1603, 1603
Marion D (abst) 339
Mark NH (abst) 267
Markarian K (abst) 542
Markell M (abst) 506
Markell MS (abst) 401
Marks T (abst) 446
Marquart C (abst) 398
Marquez LP (abst) 483
Marsden PA (abst) 373, 374
Marsh DJ (abst) 558
Marsh F (abst) 455
Marsh FP *See* Moore RH et al 991
Marsh JT (abst) 313
Marshall PD *See* Jayne DRW et al 965
Martasek P (abst) 309, 344, 600
Martasek P *See* Schwartzman ML et al 94
Mårtensson J, Denneberg T, Lindell Å, Textorius O: Sulfur amino acid metabolism in cystinuria; A biochemical and clinical study of patients 143
Martí MS (abst) 374
Martin AS (abst) 390
Martin B (abst) 580
Martin ER (abst) 374
Martín Escobar E (abst) 1608, 1608, 1608
Martín Garcia J (abst) 1590, 1590
Martin GR *See* Taub M et al 1090
Martín Hernández R (abst) 1608, 1608, 1608
Martin K (abst) 214
Martin KJ (abst) 463, 464, 466
Martin LL (abst) 604
Martin Lockwood C *See* Jayne DRW et al 965
Martin MJ (abst) 1585, 1585, 1585, 1586, 1586
Martin V (abst) 509
Martín-Escobar E (abst) 1615
Martín-Hernández R (abst) 1615
Martinelli D (abst) 289
Martínez E (abst) 1604
Martinez F (abst) 480
Martínez J (abst) 1594
Martínez ME (abst) 1616
Martínez MJ (abst) 1604
Martinez MT (abst) 1615
Martínez-Amenós A (abst) 1600
Martínez-Amenòs A (abst) 1600
Martínez-Maldonado M (abst) 374, 528
Martorano C (abst) 315
Martos MR (abst) 316
Martul EV (abst) 1605
Marty E (abst) 537, 541
Marumo F (abst) 282, 321, 343, 379, 450, 463, 540, 545, 547, 586, 587, 596
Maruyama Y (abst) 519
Marver D (abst) 349
Marx M (abst) 597
Masaki T (abst) 380
Masaki Y (abst) 596
Maschio G (abst) 235, 242, 243, 404
Masino S (abst) 487
Mason AJ (abst) 307
Mason J (abst) 594, 598
Mason N *See* Cole EH et al 29
Masood K (abst) 232
Masramón J (abst) 1603, 1603
Massry SG (abst) 244, 270, 302, 318, 462, 466, 470, 505, 521
Massry SG *See* Akmal M et al 854
Massry SG *See* Klinger M et al 1543
Masur S (abst) 191
Masur SK (abst) 227
Masurel N (abst) 446
Matas A (abst) 612
Matesanz R (abst) 316, 1589, 1592
Matheson KL (abst) 353
Mathias RS (abst) 460
Matsuchima M (abst) 246
Matsuda O (abst) 282
Matsui H (abst) 370
Matsui K (abst) 418
Matsumoto K (abst) 422
Matsumoto T (abst) 468
Matsuo S (abst) 413, 426, 436, 440
Matthess A (abst) 1170
Matthias S (abst) 1165
Mauer SM (abst) 241, 612
Mauer SM, Brown DM, Steffes MW, Azar S: Studies of renal autoregulation in pancreatectomized and streptozotocin diabetic rats 909
Mauri JM (abst) 1600
Maurin N (abst) 1175
Maury CPJ (abst) 1386
Mautner M (abst) 200
Maxwell P (abst) 374
May RC (abst) 528
Mayes JT (abst) 607
Maynar M (abst) 1599
Mayor J (abst) 1609, 1609, 1610
Mazbar SA, Schoenfeld PY, Humphreys MH: Renal involvement in patients infected with HIV: Experience at San Francisco General Hospital 1325
Mazzucco G (abst) 444
McAllister C (abst) 422
McAllister E (abst) 355
McAteer J (abst) 412
McAteer JA (abst) 452, 475, 533, 566
McCallum S (abst) 579
McCarron DA (abst) 388, 390, 402, 405
McCarron DA *See* Drüeke T et al 1438
McCarthy JT (abst) 303, 310, 319, 450
McCarthy RT (abst) 205
McCarthy SC (abst) 425
McCarthy SC *See* McDonald ATJ et al 901
McCaughran JA Jr. (abst) 388
McClellan W (abst) 310
McClurkin C (abst) 422
McCluskey RT (abst) 415, 444
McConnell I (abst) 361
McCrindle B (abst) 594
McCulloch L (abst) 412
McCusker C (abst) 592
McDaniel HB (abst) 196, 232
McDonald ATJ, Crocker JFS, Digout SC, McCarthy SC, Blecher SR, Cole DEC: Glucocorticoid-induced polycystic kidney disease—A threshold trait 901

McDonald BR (abst) 489
McDonald F (abst) 473
McDonald JA (abst) 223
McEnroe G (abst) 342
McFarlane M (abst) 603
McGarry BM (abst) 426
McGeown MG (abst) 526
McKanna JA (abst) 374
McKay CP (abst) 210
McKay DB (abst) 597
McKenna BA (abst) 282
McKenna CE (abst) 460
McKenna PJ (abst) 310
McKenna RM (abst) 310
McLeish K (abst) 215
McLeod L (abst) 321
McManamon PJ (abst) 250, 251
McNally PG (abst) 597
McNicholas C *See* Atherton JC et al 28:S-36
McPeak RA (abst) 360
McReynolds J (abst) 585
McVicar M (abst) 272
McWeeny OJ (abst) 570
Mecarelli L (abst) 442
Medcalf R (abst) 219
Medina F (abst) 236
Meggs L (abst) 600
Meggs LG (abst) 411
Meguira S (abst) 398
Mehls O (abst) 238, 240, 513, 1171
Mehrgut FM (abst) 536, 542
Mehring N (abst) 391
Mehta PS (abst) 567
Mehta RL (abst) 280, 323, 489
Meier B *See* Radeke HH et al 767
Meierhenrich R (abst) 1178
Meigs R (abst) 398
Meijer DKF (abst) 187, 527
Meisinger V (abst) 307
Meisl F (abst) 307, 311, 332, 397, 400
Meissl F (abst) 379
Meister B (abst) 368
Mejia R (abst) 542
Melsen F (abst) 1389
Melton LJ (abst) 247
Mendelson W (abst) 323
Mendelssohn D (abst) 585
Mendez AJ (abst) 514
Mendez M (abst) 609
Méndez RE (abst) 374
Mendrick DL (abst) 414, 423, 428
Menè P (abst) 201, 210, 366
Menè P, Dunn MJ: Prostaglandins and rat glomerular mesangial cell proliferation 1256
Menéndez P (abst) 1604
Mennini T (abst) 339
Mento P (abst) 524
Menzel S (abst) 1183
Mercier O (abst) 464
Meric F (abst) 450
Merino J (abst) 1616
Merke J (abst) 391, 1165
Merkel F (abst) 597
Merli C (abst) 543
Merola E (abst) 1588
Merrill G (abst) 290
Mertz A (abst) 423, 430, 434
Messana JM (abst) 489
Messinger D (abst) 299
Metivier F *See* London GM et al 137
Metsärinne K (abst) 1382
Metz JA (abst) 390
Metze V (abst) 1169
Meuer S (abst) 438
Meuer SC (abst) 1179
Meulders Q (abst) 597
Meuwissen SGM (abst) 590, 591
Meydrech EF (abst) 400, 400
Meyer E (abst) 1168
Meyer K (abst) 1181
Meyer TW (abst) 514
Meyer WL (abst) 518
Meyer zum Büschenfelde KH (abst) 438
Meyer-Lehnert H (abst) 210, 342, 372, 396, 1172
Meyers AM (abst) 399
Meyers CM (abst) 423
Meyrier A (abst) 242, 279
Mezger MS *See* Hsiao RJ et al 955
Michael A (abst) 249
Michael AF (abst) 408, 441
Michael H (abst) 311
Michael UF *See* Logan JL et al 57
Michaelis IV OE (abst) 523
Michaels E (abst) 439, 443
Michel C (abst) 260
Michel F (abst) 210, 396
Michelis MF (abst) 264, 405
Middleton JP (abst) 202, 453, 456, 567
Miescher P (abst) 442
Miettinen A (abst) 416, 1388
Mignon F (abst) 260
Miguel A (abst) 1585, 1585
Miguel JL (abst) 1593, 1593, 1593, 1594, 1613, 1614, 1614
Miguélez MC (abst) 1592, 1592
Mihatsch M-J (abst) 442
Mihatsch MJ (abst) 1184, 1184, 1186
Mijares J (abst) 1605
Mikels TM (abst) 489
Milán JA (abst) 1591
Milanes CL (abst) 463
Mildenberger S (abst) 1161
Milford EL (abst) 599
Milgrom F (abst) 410
Millá F (abst) 1597
Millás I (abst) 1603
Miller A (abst) 210
Miller BA (abst) 213, 213
Miller D (abst) 221, 454
Miller E (abst) 362
Miller J (abst) 341, 553
Miller LC (abst) 319
Miller NL *See* Durr JA et al 28:S-58
Miller PL (abst) 514
Miller RP (abst) 352
Miller RT (abst) 215
Miller WL (abst) 375
Millet VG (abst) 1587
Millington D (abst) 492
Mills JW (abst) 427
Milly KA (abst) 473
Milne FJ (abst) 399
Milner LS (abst) 423

Mimran A (abst) 401, 523, 574
Min KW (abst) 259
Minetti L *See* Colussi G et al 28:S-63
Miranda B (abst) 1593, 1613, 1613, 1614, 1614, 1614, 1614
Miranda LR (abst) 528
Miravitlles MR (abst) 1601
Mircheff AK *See* Hensley CB et al 707
Mishell J (abst) 298
Mishler DR (abst) 372, 585
Miskell CA, Simpson DP: Hyperplasia precedes increased glomerular filtration rate in rat remnant kidney 758
Mistry N (abst) 597
Mitch WE (abst) 505, 510, 528
Mitchell J (abst) 287
Mitchell JH (abst) 311
Mitsuhashi T (abst) 200
Mittman N (abst) 287
Miyata M (abst) 410
Miyata T (abst) 232, 443
Miyauchi A (abst) 468
Mizelle HL (abst) 339
Moallem A (abst) 279
Modi K (abst) 490
Mòdol Gort J (abst) 1598
Moe O (abst) 215, 539
Moffa PJ (abst) 237
Mohaupt M (abst) 342, 1172
Mola R (abst) 371
Molina A (abst) 1592, 1592
Molina JJ (abst) 537
Molina R (abst) 1605
Molino A (abst) 273
Molitoris B (abst) 576
Molitoris BA (abst) 490
Moll R (abst) 1585, 1585, 1586, 1586
Möllmann M (abst) 1177
Molony DA (abst) 567
Momper R *See* Tönshoff B et al 1134
Moncada R (abst) 492
Moncada S (abst) 379
Moncalián FJ (abst) 1602
Moncalian J (abst) 1596
Moncalián J (abst) 1616
Montañés I (abst) 1603
Montanari A (abst) 402, 557
Montane B (abst) 262
Montani J-P (abst) 339
Montanya X (abst) 1600
Monteagudo J (abst) 1605
Montenegro J (abst) 1605
Montez AJ (abst) 316, 318
Montinaro V (abst) 424, 429
Montoya C (abst) 1608
Montoyo C (abst) 1587, 1587, 1607, 1607
Montrella M (abst) 357
Montrose-Rafizadeh C (abst) 566, 567
Moolenaar F (abst) 187, 527
Moonen M (abst) 1380
Moore GE (abst) 311
Moore J (abst) 336
Moore L (abst) 190, 388
Moore LC (abst) 554
Moore LC, Casellas D: Tubuloglomerular feedback dependence of autoregulation in rat juxtamedullary afferent arterioles 1402
Moore LW (abst) 286, 311
Moore R (abst) 602
Moore RH, Hitman GA, Lucas EY, Richards NT, Venning MC, Papiha S, Goodship THJ, Fidler A, Awad J, Festenstein H, Cunningham J, Marsh FP: HLA DQ region gene polymorphism associated with primary IgA nephropathy 991
Moore RM (abst) 297
Moore-Jarrett T (abst) 497
Moorhead JF (abst) 498, 524, 612
Morales JM (abst) 261, 610, 1604, 1607, 1607, 1607, 1607, 1608, 1608
Moran M (abst) 398, 421
Morasco K (abst) 361
Mordhorst M (abst) 192
Morduchowicz G (abst) 312, 349
Morel F (abst) 528
Moreno F (abst) 1597, 1604, 1606, 1606, 1607, 1613, 1613, 1614, 1614, 1614
Moretti JL (abst) 242
Morgan J (abst) 250, 251
Morgan M (abst) 490
Morgano P (abst) 362, 481
Mori T (abst) 424, 430
Mori T *See* Yoshida H et al 1286
Mori Y *See* Yoshida H et al 1286
Morigi M (abst) 424
Morigi M *See* Zoja C et al 934
Morimoto C (abst) 429
Moriniere P (abst) 296, 452
Morioka T (abst) 418
Morita E (abst) 258, 276
Moriyama T (abst) 580, 586
Morris CD (abst) 402, 405
Morris DJ (abst) 353, 357
Morris KG (abst) 484
Morris RC Jr. (abst) 200, 469
Morris RC Jr. *See* Sebastian A et al 1341
Morris TW (abst) 282
Morrison A (abst) 352
Morrison AR (abst) 192, 233, 345
Morrison AR *See* Yanagisawa H et al 1528
Morrison R (abst) 586
Morrison RT (abst) 281
Morrissey E *See* Ziegler MG et al 1357
Morrissey J (abst) 352, 464
Morrissey J *See* Sugimoto T et al 1522
Morrissey J *See* Yanagisawa H et al 1528
Morse GD (abst) 614
Morsing P (abst) 549
Morton AR (abst) 251, 312
Moscovitch-Lopatin M (abst) 598
Moses AM (abst) 365
Moskovitz A (abst) 296, 451
Moskowitz DW (abst) 375
Mosquera J (abst) 426
Moss J (abst) 447
Moss NG (abst) 554
Mossey R (abst) 309
Motojima M (abst) 230, 332
Mougenot B (abst) 260
Moulin B (abst) 260
Moullier PM (abst) 413
Moulton LH (abst) 283
Mourad G (abst) 401
Mouri T (abst) 321

Moyer T (abst) 310
Mozzato MG (abst) 394
Muallem S (abst) 467
Muchmore A: Tamm-Horsfall protein—uromodulin (1950–1990) (Editorial Review) 1395
Mueller-Schweinitzer E (abst) 598
Mühlbacher F (abst) 602
Mühlbauer HG (abst) 1170
Muirhead N (abst) 301, 312
Mujais S (abst) 581
Mulcahy WS (abst) 514
Muldowney WP (abst) 312
Mulec H (abst) 236
Muley Alonso R (abst) 1616
Mulkern RV (abst) 281
Müller C (abst) 251, 329
Müller CA (abst) 424
Müller FB (abst) 401
Müller G (abst) 1167
Müller GA (abst) 424, 518, 1186
Müller HJ (abst) 1178
Muller J (abst) 583, 589
Müller R (abst) 396, 1178
Muller S (abst) 430
Mulroney SE (abst) 460
Munaut C (abst) 409
Munck O (abst) 1388
Mündlein E (abst) 1167
Munger K (abst) 571
Munger KA (abst) 362, 375, 375
Munn SR (abst) 615
Muñoz J (abst) 1593, 1593, 1593, 1594, 1613, 1614
Muñoz ML (abst) 1593
Muñoz-Gomez J (abst) 1615
Munson JL (abst) 610
Mur O (abst) 1616
Murakami O (abst) 321
Murakami T (abst) 202
Murayama E (abst) 464
Murer H (abst) 586, 587
Murphy G (abst) 450
Murphy HR (abst) 580
Murphy MB (abst) 363
Murray BM (abst) 355, 376
Musial E (abst) 311
Muso E (abst) 246, 425
Mustonen J (abst) 1379
Muto S (abst) 568, 573
Myers BD (abst) 445, 507, 513
Mytilineos J (abst) 251
Nabarra B *See* Drüeke T et al 1438
Nada AK (abst) 281
Nadler J (abst) 395
Nagami GT (abst) 369, 372, 543, 585
Nagasawa T (abst) 281, 447
Nagase S (abst) 514, 515, 522
Nagorney DM (abst) 252, 252
Nahman NS Jr. (abst) 218, 221, 433
Nair DR (abst) 498, 524
Naito T (abst) 435
Najarian JS (abst) 612
Najún Zarazaga C (abst) 313, 313
Nakabayashi K (abst) 281
Nakagawa Y (abst) 439, 443, 471, 474, 474
Nakahama H (abst) 481
Nakajima M (abst) 305
Nakamoto M (abst) 285
Nakamoto S (abst) 340, 400
Nakamura K (abst) 306
Nakamura T (abst) 219, 221
Nakamura Y (abst) 321
Nakanishi T (abst) 282
Nakashima Y *See* Iwamoto T et al 1466
Nakazato Y (abst) 349
Nambi P (abst) 210
Nammour TM (abst) 515
Nanbu M (abst) 306
Nanda NC (abst) 283
Nanni V (abst) 376
Napolitano B (abst) 309
Naranjo J (abst) 1586
Naranjo P (abst) 1595, 1616
Narasimhan PT (abst) 529
Naray-Fejes-Toth A (abst) 216, 360, 536
Narins RG (abst) 268
Narita I (abst) 221
Narita M (abst) 514, 515, 522
Naruse M (abst) 211, 362, 380
Nasini M (abst) 290, 594
Nasr LB *See* Drüeke T et al 1438
Nast C (abst) 511
Nast CC (abst) 508, 598, 606, 610
Nath KA (abst) 376
Natori Y (abst) 437, 527
Natov S (abst) 483
Navar LG (abst) 552
Navarro M (abst) 1604, 1604
Naveh-Many T (abst) 470
Naves ML (abst) 1611
Naya M (abst) 1589
Naya MT (abst) 1592, 1594, 1595, 1595
Naylor BR (abst) 224
Neal LA (abst) 455
Neale J (abst) 409, 443
Neaton J (abst) 285
Needleman P (abst) 339
Neer EJ (abst) 214
Neff J (abst) 444
Neiberger RE (abst) 474
Neiders ME (abst) 500
Neilson EG (abst) 204, 416, 430
Nelson P (abst) 408
Nelson PA (abst) 329
Nelson R (abst) 513
Nessi R (abst) 287
Nestler E (abst) 358
Netzer M (abst) 439, 443, 474, 474
Netzker R (abst) 202
Neugarten J (abst) 501, 506, 515, 519
Neuhaus G (abst) 1185
Neumann HPH (abst) 242
Neumann KH (abst) 1170, 1183
Neumann R (abst) 1164, 1177
Neumann TV (abst) 490
Neumayer H-H (abst) 260
Neumayer HH (abst) 368
Neuser D (abst) 574
Neuwirth R (abst) 285
Nevins T (abst) 612
Nevins TE (abst) 605
Newberg K (abst) 1381
Newman D (abst) 602

Newman GE (abst) 319
Newman KD (abst) 252
Newmark KJ (abst) 310
Newstead C (abst) 313
Newton L (abst) 445
Ney A (abst) 478
Neyer U (abst) 332
Neyro MT (abst) 1605
Ng CM (abst) 446, 500
Nguyen AT *See* Herbelin A et al 116
Nguyen L (abst) 240
Nhoung S (abst) 224
Niaudet P (abst) 260, 445
Nicastri A (abst) 259
Nick HS (abst) 229, 229
Nicolás JM (abst) 1602
Nicolls MR (abst) 224
Nie S (abst) 385
Niedermayer W (abst) 1183
Nielsen B (abst) 1383, 1386
Niemann J (abst) 1178, 1181
Nieto J (abst) 1609, 1609, 1609, 1610
Nigam SK (abst) 216
Nihei H (abst) 515
Niles JL (abst) 415, 444
Nilsen L (abst) 239, 1380
Nishi S (abst) 491, 519
Nishida A (abst) 515
Nishii Y (abst) 464
Nishimura N *See* Kanda S et al 875
Nissenson AR (abst) 313
Nissensson AR (abst) 499
Nissim I (abst) 529, 529, 530
Nivez M-P (abst) 344
Niwa H (abst) 420, 448
Nizze H (abst) 1186
Njoku N *See* Wiggins RC et al 1281
Noble B (abst) 236, 385, 395, 500
Noble B *See* Zamlauski-Tucker MJ et al 1536
Noël J (abst) 525, 529
Noël LH (abst) 444
Noguchi T (abst) 524, 532
Noguera ML (abst) 284
Nol L-H (abst) 442
Nolan CR (abst) 281, 449, 474
Nolla H (abst) 595
Nolph K (abst) 332
Nomata K *See* Kanda S et al 875
Nomura K (abst) 491
Nonaka T (abst) 568
Nonnast-Daniel B (abst) 296
Nonoguchi H (abst) 343, 379, 586, 587
Noonan K (abst) 455
Nooyen YA (abst) 523
Nord EP (abst) 205, 213, 534, 536, 538, 543
Nordén G (abst) 1383
Noris M (abst) 376
Norman DJ (abst) 604, 610
Norman J (abst) 196
Norman JT (abst) 198, 201
Norris KC (abst) 314
Norton-Reel DJ (abst) 224
Nosadini R (abst) 394
Notkins AL (abst) 601
Nouwen EJ (abst) 496
Novarini A (abst) 402, 557
Nowack A (abst) 1170
Nowotny P (abst) 384
Nozawa K (abst) 395
Ntoso KA (abst) 297
Nusbaum P (abst) 442, 444
Nussberger J (abst) 337
Nüssberger J (abst) 574
Nussenzveig DR (abst) 341
Nuyts GD (abst) 187, 496
Nyberg G (abst) 236, 1383
Nye JP (abst) 227
Nyländen P (abst) 1384
Nylander W (abst) 614
Oates PJ (abst) 554
Oberle GP (abst) 425
Oberleithner H (abst) 228, 1163, 1163
O'Brien E (abst) 220
O'Brien M (abst) 335
O'Brien PC (abst) 276
O'Bryan-Tear G (abst) 421
Obst G (abst) 327, 333
Ochi S (abst) 193, 376
Ochs T (abst) 575
O'Connell N (abst) 469
O'Connor DT (abst) 382, 394, 469
O'Connor DT *See* Hsiao RJ et al 955
O'Connor DT *See* Ziegler MG et al 1357
O'Connor S (abst) 407
Oda T (abst) 420, 448
Odar-Cedarlof I (abst) 314
Odar-Cederlof I (abst) 304
Odar-Cederlöf I (abst) 1380
Odenthal HJ (abst) 1176
Odigie P (abst) 1165, 1171
O'Donnell MP (abst) 391, 509, 509, 520, 556
O'Donnell MP, Kasiske BL, Schmitz PG, Keane WF, Daniels F: High protein intake accelerates glomerulosclerosis independent of effects on glomerular hemodynamics 1263
O'Donnell MP *See* Kasiske BL et al 880
O'Donoghue D (abst) 438
O'Donovan R (abst) 469
Oe PL (abst) 184, 186, 327
Oegema TR (abst) 220, 421
Oelkers W (abst) 1172
Oemar BS (abst) 201
Oetliker OH (abst) 1169
Oettinger CW (abst) 298
of the Registry of Renal Patie Committee (abst) 1588
Offord KP (abst) 247
Ogata E (abst) 197, 211, 362, 380, 467, 468
Ogata K: Clinicopathological study of kidneys from patients on chronic dialysis 1333
Ogawa A (abst) 564, 568
Ogawa M *See* Yoshida H et al 1286
Ogborn MR (abst) 425, 502
Ogihara T (abst) 221
Ogino S (abst) 519
Ogunc S (abst) 368
Oh JH (abst) 598
Oh MS (abst) 282
Oh Y (abst) 285, 302
Ohi H (abst) 243
Ohneda M (abst) 321
Ohno AK (abst) 238
Ohrisch G (abst) 1180, 1182

Ohshima S (abst) 420, 448
Oishi R (abst) 587
Oite T (abst) 418
Ojeda JL, Ros MAA, Icardo JM, García-Porrero JA: Basement membrane alterations during development and regression of tubular cysts 1270
Okada K (abst) 337
Okazaki R (abst) 468
Okolicany J (abst) 342
Okubo M (abst) 417, 418
Okuda S (abst) 221, 222
Okuda S *See* Border WA et al 689
Okuda T (abst) 211
Okusa MD (abst) 568
Olaizola I (abst) 1611, 1611, 1611
Olbricht CJ (abst) 1185
Olbricht CJ, Gutjahr E, Cannon JK, Irmler H, Tisher CC: Effect of low molecular weight proteins and dextran on renal cathepsin B and L activity 918
Oldrizzi L (abst) 242, 243
Olea Baza I (abst) 598
Olgaard K (abst) 451
Oliet A (abst) 1587, 1606, 1606, 1614
Olivan P (abst) 1595
Olivari MT (abst) 610
Oliveira VC (abst) 1168, 1168
Oliver A (abst) 1589, 1590, 1590
Oliver J (abst) 1602
Oliver JC (abst) 298
Olivera A (abst) 337
Olmos A (abst) 1605
Olsen BR (abst) 222
Olsen OB (abst) 1385
Olsen S (abst) 491, 495
Olson RA (abst) 598
Olsson CA (abst) 476, 479
Oldrusek B (abst) 291
Onishi O (abst) 485
Ono J (abst) 463
Ono K (abst) 516
Onoyama K (abst) 285, 300, 302
Onsgard M (abst) 465
Oowada A (abst) 586
Opelz G (abst) 251
Oppenheimer F (abst) 1587, 1615, 1615, 1615
Oppermann M (abst) 1179
Opsahl JA (abst) 352, 358
Ordi J (abst) 1595
Ordonez JD (abst) 243
Oreopoulos DG (abst) 326
Ori Y (abst) 475
Orikasa M (abst) 418
Orita Y (abst) 193, 376, 481, 524, 532
Orkin SH (abst) 373
Orofino L (abst) 1589, 1589, 1589, 1592, 1593, 1595, 1595, 1597
Orte L (abst) 1592, 1595, 1597
Ortega O (abst) 1590, 1590
Ortiz S (abst) 1609, 1610
Ortiz-Interian C (abst) 303, 314
Ortuño F (abst) 1593
Ortuño J (abst) 1589, 1589, 1589, 1592, 1592, 1593, 1594, 1594, 1595, 1595, 1595, 1597, 1597
Ortuño T (abst) 1607, 1607, 1608
Os I (abst) 362
Osanai T (abst) 211
Osato S (abst) 302
Osborn M (abst) 482
Osborne JM *See* Emmerson BT et al 36
Oschowitzer B (abst) 1180
Oshima A (abst) 440
Osmundson PO (abst) 303
Ostedgaard LS (abst) 224, 227
Østensen J (abst) 572
Østensen J *See* Stokke ES et al 28:S-71
Oster JR (abst) 265, 266, 267
Osterode R (abst) 1177, 1185
O'Sullivan MJ (abst) 267
Otero A (abst) 1596
Otero R (abst) 1591
Oviasu E (abst) 447
Owada A (abst) 354
Owens D (abst) 245
Ownby D (abst) 596
Oxton L (abst) 335
Oyler A (abst) 569
Ozaki I (abst) 426
Ozono Y (abst) 438
P-Conde C (abst) 1594, 1613
P-Diaz V (abst) 1594, 1613
Pabico RC (abst) 282
Padilha RM (abst) 498, 506, 519
Padovese P (abst) 287, 289
Paganini E (abst) 340, 400
Pahira JJ (abst) 284
Pahlavan P (abst) 371
Paillard F (abst) 242
Paillard M (abst) 464, 537, 541
Painter P (abst) 311, 609
Pak CYC (abst) 282
Palaia T (abst) 583
Palaia TA (abst) 589
Palant CE (abst) 192, 567
Palevsky P (abst) 233
Palla K (abst) 229
Paller MS (abst) 490, 610
Palmer RMJ (abst) 379
Palmer SJ (abst) 193
Palomares L (abst) 1602
Palop L (abst) 1594, 1599, 1599, 1599, 1600
Pang I-H (abst) 215
Paniagua R (abst) 314
Pankewycz O (abst) 426, 593, 598
Panus L (abst) 491
Panus P (abst) 491
Panzica F (abst) 289
Papapoulos SE *See* Kok DJ et al 51
Pape JF (abst) 516
Papendick R (abst) 478
Papiha S *See* Moore RH et al 991
Pappas C (abst) 569
Paraiso V (abst) 1588, 1609, 1609
Pardo A (abst) 1595
Parekh N *See* Fretschner M et al 1227
Parfrey NA (abst) 421
Parfrey PS (abst) 250, 251
Parham P (abst) 596
Parivar F (abst) 461, 529
Park CS (abst) 442
Park MS (abst) 442
Park YS *See* Lee HY et al 727
Parker C (abst) 291

Parker CJ *See* Cheung AK et al 1055
Parker D *See* Atherton JC et al 28:S-36
Parker M (abst) 504
Parks D (abst) 491
Parlongo S (abst) 405, 456
Parmer RJ (abst) 469
Parra G (abst) 426
Parris CJ (abst) 606
Parris M (abst) 366
Parsons JT (abst) 191
Parthasarathy S (abst) 477
Parton R (abst) 228
Parvez Z (abst) 492
Parving H-H (abst) 243
Pascual J (abst) 1592, 1592, 1594, 1594, 1595, 1595, 1595
Pascual S (abst) 1598
Pasini M (abst) 350
Pasini M *See* Zoja C et al 934
Pasque CB (abst) 257, 260, 271
Pasquier R (abst) 435
Passlick-Deetjen J (abst) 1182
Pasternack A (abst) 1379, 1381, 1387
Pastoriza E (abst) 211, 535
Patek E (abst) 400
Patel B (abst) 273
Patel NB (abst) 492
Patel S (abst) 422, 467, 528
Patel S *See* Hsu CH 44
Patenaude CR (abst) 213
Paternina ER (abst) 1608
Patterson T (abst) 606, 609
Patz S (abst) 556
Paul LC (abst) 594
Paul SH (abst) 534
Paulais M (abst) 559
Paulmichl M (abst) 209, 377, 1162, 1165
Paulmichl M *See* Jungwirth A et al 1477
Paulmichl R (abst) 377
Paulus CP (abst) 472
Paunier L (abst) 1169
Pavón I (abst) 1591, 1591, 1591
Pawlowski I (abst) 427
Paz E (abst) 1608
Paz-Martinez V (abst) 334, 463
Pazderka F (abst) 609
Peach MJ (abst) 354
Pearce D (abst) 233, 540
Peces R (abst) 391, 1597, 1598
Peces R *See* Batlle DC et al 21
Pedersen RS (abst) 1389
Pederson JA (abst) 33
Pedraza-Chaverri J (abst) 355
Peer G (abst) 238
Pehrsson SK (abst) 1382
Pei Y (abst) 255, 449, 451
Peinado MS (abst) 1616
Peitzman SJ: Thomas Addis (1881–1949): Mixing patients, rats, and politics 833
Pejler G (abst) 1386
Pelayo JC (abst) 551, 554
Pelletier L (abst) 415, 435
Pemberton R (abst) 326
Pempkowiak L *See* Atherton JC et al 28:S-36
Peña JC (abst) 284, 355
Peñalva A (abst) 1602
Penniston JT (abst) 454
Peppler R (abst) 421
Pequinot E (abst) 378
Peral B (abst) 1615
Peral V (abst) 1604
Pèrez A (abst) 1585
Pérez A (abst) 1585, 1585, 1585
Perez A (abst) 1586
Pérez A (abst) 1586
Pérez AJ (abst) 1602
Pérez Bañasco V (abst) 1591
Pérez Fontán M (abst) 1602, 1616
Perez Fontan M (abst) 1596
Perez G (abst) 266, 303, 314, 514
Perez García R (abst) 1610, 1610
Perez Garcia R (abst) 1610
Perez J (abst) 363, 1616
Pérez MC (abst) 358
Perez R (abst) 1615
Perez-Castillo A (abst) 358
Perez-Garcia R (abst) 1596
Pérez-Grovas H (abst) 314, 397
Pérez-Mijares R (abst) 1598
Perico N (abst) 339, 345, 350, 377, 377, 424, 479, 485
Perico N *See* Zoja C et al 927
Perico N *See* Zoja C et al 934
Perkins JD (abst) 615
Perna AF (abst) 470
Pernalete N (abst) 463
Perrella R (abst) 616
Perret F (abst) 337
Perrone RD (abst) 227, 547
Persan L (abst) 388
Persson AEG (abst) 549
Persuad JW (abst) 524
Perticucci E (abst) 519
Perusek M (abst) 261
Pesek I (abst) 504
Pesko L (abst) 471
Peter HH (abst) 288
Petering D (abst) 477
Peterman JH (abst) 261
Peters J (abst) 245
Petersburg T (abst) 486
Petersen J (abst) 297, 304, 315
Petersen KG (abst) 1171
Peterson DR (abst) 353
Peterson JC (abst) 606
Peterson LN, Borzecki JS: Inhibition of tobramycin reabsorption in nephron segments by metabolic alkalosis 1492
Peterson OW (abst) 517, 555
Peterson PK (abst) 478
Petrillo RJ (abst) 598
Pettersson E (abst) 1383
Pettinger WA (abst) 370
Petzel D (abst) 358
Petzoldt R (abst) 1169
Peuschel B (abst) 1183
Pewen WF (abst) 333
Pfaff WW (abst) 606
Pfaller W (abst) 1162, 1163
Pfeilschifter J (abst) 209, 377, 1162, 1165
Pham P (abst) 335, 337, 354, 460
Phan S (abst) 422
Phan SH (abst) 426
Phillips F *See* Kasiske BL et al 880

Phillips J (abst) 509
Phillips LG (abst) 488
Phillips M (abst) 447
Phillips MI (abst) 580
Phillips TM (abst) 330
Piccinelli A (abst) 345, 377
Piccinelli A *See* Zoja C et al 927
Piccione J (abst) 259, 259
Piccoli G (abst) 273, 407 444
Pickard LL (abst) 601
Picus D (abst) 324
Pieke SA (abst) 249
Piera C (abst) 1588, 1588
Piera L (abst) 1595, 1599, 1602, 1605
Pierce C (abst) 484
Piering WF (abst) 282
Pierratos A (abst) 312
Pileggi F (abst) 237
Pindur G (abst) 1180
Pineda AA (abst) 276
Pinilla JM (abst) 358
Pinto JR (abst) 510, 516
Pinzani M (abst) 414
Piraino B (abst) 326, 328, 329
Piraino Beth (abst) 333
Pisetsky DS (abst) 351, 434
Pitts TO *See* Klinger M et al 1543
Pizzonia JH (abst) 427
Planelles G (abst) 559
Platt JL (abst) 421, 599, 601
Plaza C (abst) 1594, 1599, 1599, 1599, 1600
Plaza JJ (abst) 1592
Plennevaux F (abst) 552
Pleuss JA (abst) 459
Ploth DW (abst) 390
Plum J (abst) 1174, 1174, 1187, 1188
Pluvio M (abst) 500
Poch E (abst) 1602
Pocino M (abst) 1588
Podjarny E (abst) 392, 569
Podjarny E *See* Rosen S et al 1067
Poelstra K (abst) 407, 427
Poelstra K, Hardonk MJ, Koudstaal J, Bakker WW: Intraglomerular platelet aggregation and experimental glomerulonephritis 1500
Poggioli J (abst) 537, 541
Polinsky M (abst) 329, 611
Pollock AS (abst) 202
Pollok M (abst) 271, 396, 1178, 1178
Polo O (abst) 1387
Pomeranz A (abst) 392
Pomrantz A (abst) 256
Pons JM (abst) 1588
Ponz E (abst) 1588, 1588, 1602
Popovtzer MM (abst) 265, 296, 352, 451, 571
Popovtzer MM *See* Scherzer P et al 870
Pordy WT (abst) 320
Port FK (abst) 239, 270, 283, 324
Portale AA (abst) 469
Portale AA *See* Sebastian A et al 1341
Porter G (abst) 555
Portilla D (abst) 204, 492
Porush J (abst) 286
Porush JG (abst) 366
Porush JG *See* Chou S-Y et al 1
Posen G (abst) 293
Postiglione A (abst) 295
Poston L (abst) 392, 396
Postorino M (abst) 272, 315, 405
Potier M (abst) 230
Pou JM (abst) 1606
Pouysségur J (abst) 233, 539
Pouyssegur J (abst) 540
Poveda R (abst) 1600
Pozza G (abst) 513
Pradelles P (abst) 207
Praga M (abst) 261, 403, 610, 1587, 1587, 1607, 1607
Prager S (abst) 463
Prasad A (abst) 473
Prasthofer E (abst) 606
Pratt L (abst) 479
Predel H-G (abst) 342
Predel HG (abst) 372, 1172
Preisig PA (abst) 543
Prentis J (abst) 333
Preston AS (abst) 584
Preuss HG (abst) 405
Price PM *See* Safirstein R et al 1515
Prie D (abst) 201
Prieto C (abst) 610, 1604, 1607, 1607, 1607, 1608, 1608
Primack W (abst) 277
Printz MP (abst) 394
Prior J (abst) 378
Probst W (abst) 1177
Pruzanski W (abst) 312
Prydz K (abst) 228
Przechera M (abst) 1167, 1180
Przekwas J (abst) 380
Przekwas J *See* Granot Y et al 1301
Pscheidt R (abst) 540
Pugliese F (abst) 201, 210, 366
Pullen M (abst) 210
Pullig O (abst) 446
Pun KK, Ho PWM, Lau P: Effects of aluminum on the parathyroid hormone receptors of bone and kidney 72
Puntorieri S (abst) 518
Purcell H (abst) 532
Purroy A (abst) 1612, 1613
Purvis ML (abst) 333
Puschett JB (abst) 469, 482
Pusineri F (abst) 516
Pyke-Grimm K (abst) 329, 616
Quaggins S (abst) 266
Qualheim RE (abst) 244
Quamme GA (abst) 460
Quarles LD (abst) 450
Quass P (abst) 1187
Quattrocchio G (abst) 273
Quattrochhio G (abst) 407
Quellhorst E (abst) 331
Queluz T (abst) 427
Quentin E (abst) 1179, 1181
Quereda C (abst) 1589, 1589, 1589, 1592, 1593, 1595, 1595, 1597, 1597
Querin F *See* Cecchin E et al 943
Quesada T (abst) 358
Quiza C (abst) 427, 445
Qunibi W (abst) 298
Quraishi H (abst) 227
R-Carmona A (abst) 1594, 1613
Raab R (abst) 1173

Raatz SK (abst) 612
Rabelink AJ (abst) 184, 185, 283
Rabelink TJ, Koomans HA, van de Stolpe A, Bijlsma JA, Dorhout Mees EJ: Effects of atrial natriuretic peptide on distal tubule function in humans 996
Rabinowitz L (abst) 569
Rabito C (abst) 228
Rabkin R (abst) 530
Rachmel A (abst) 266
Racine N (abst) 288
Racusen L (abst) 517, 594
Racusen LC (abst) 495
Radda GK (abst) 517
Radeke H *See* Floege J et al 859
Radeke HH, Meier B, Topley N, Flöge J, Habermehl GG, Resch K: Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells 767
Radin MJ (abst) 342
Radin NS (abst) 212
Radnik RA (abst) 220
Radounikli A (abst) 1166
Ragni G (abst) 402, 557
Rahman M (abst) 334
Rahman MA (abst) 428
Rahn K-H (abst) 391
Raij L (abst) 203, 245, 379, 552
Raine AEG (abst) 384, 517
Rainfray M (abst) 242
Raja R (abst) 304
Raja RM (abst) 264, 315
Rajani K *See* Atherton JC et al 28:S-36
Rajaraman S (abst) 256, 428
Rajpoot D (abst) 256
Rakela J (abst) 252
Rakhit A (abst) 604
Rakowski TA (abst) 284
Rama H (abst) 1600, 1600
Ramachandran C (abst) 461, 464
Ramassar V (abst) 411, 421
Rambaldi A (abst) 205
Rambausek M (abst) 251, 253
Ramírez MD (abst) 284
Ramos Díaz M (abst) 1591
Ramos E (abst) 1587
Ramos Frendo B (abst) 1598
Ramos M (abst) 1598
Rampt ER (abst) 220
Ramsammy L (abst) 190, 213, 350, 351, 486
Ramsammy LS (abst) 205
Randall D (abst) 593
Randazzo R (abst) 314
Ranero R (abst) 1596
Ranieri E (abst) 445
Rantala I (abst) 1387
Rao KV (abst) 608, 611, 611
Rao R (abst) 602
Rapado A (abst) 1606
Rapp N (abst) 466
Rasch R (abst) 501, 517, 522, 555
Raselli A (abst) 1173
Rasenas L (abst) 405
Raskin P (abst) 246
Rasmussen H (abst) 385
Rassier ME (abst) 377, 460
Rater M (abst) 231
Rathaus M (abst) 392, 569
Rathaus M *See* Rosen S et al 1067
Rauterberg EW *See* Deppisch R et al 696
Ravenscraft MD (abst) 599
Ray PE (abst) 569
Raymond JR (abst) 202, 453, 456, 567
Reams GP (abst) 402
Reaven GM *See* Fuh MMT et al 1295
Reckelhoff JF (abst) 347, 517, 558
Rector F (abst) 563
Rector FC (abst) 233
Rector FC Jr. (abst) 540
Reddy P (abst) 292
Reddy S (abst) 392
Redfield MM (abst) 267
Redha R (abst) 582
Reeders S (abst) 250, 251
Reeders ST (abst) 248, 384, 521
Reeves WB (abst) 570
Regueiro JL (abst) 1608
Rehwald W (abst) 1162
Reichel H (abst) 475
Reid MH *See* Gordon SM et al 110
Reif MC (abst) 366
Reilly RF (abst) 233, 539
Reinhardt B (abst) 1181
Reisin E (abst) 392
Reiss R (abst) 492
Reithmeier R (abst) 234
Rekola S (abst) 1380, 1388
Remuzzi A (abst) 377, 485, 518, 519
Remuzzi G (abst) 205, 339, 345, 350, 367, 376, 377, 377, 424, 428, 479, 485, 516, 518, 519, 523
Remuzzi G *See* Zoja C et al 927
Remuzzi G *See* Zoja C et al 934
Renaud K (abst) 231
Rengel M (abst) 1610, 1615
Rennke HG (abst) 414, 423, 428, 498, 514
Renzi D (abst) 377
Renzi D *See* Zoja C et al 927
Requejo R (abst) 1608
Resch K (abst) 204
Resch K *See* Floege J et al 859
Resch K *See* Radeke HH et al 767
Reshkin SJ (abst) 586, 587
Reudelhuber T (abst) 540
Reudelhuber TL (abst) 233
Reuter M (abst) 1174
Revert L (abst) 1588, 1588, 1588, 1602, 1605, 1605
Revert LL (abst) 1616
Revuelta KL (abst) 1593
Reyes AA (abst) 570
Reyna A (abst) 273
Rezzo CT (abst) 501
Rholl JC (abst) 503
Ribeiro MO (abst) 519
Ribot S (abst) 315, 439
Ribstein J (abst) 401, 523, 574
Ricart MJ (abst) 1587, 1615, 1615, 1615
Ricci A (abst) 341
Ricci J (abst) 267
Rice J (abst) 240
Rich A (abst) 544
Richards GK (abst) 327, 333
Richards NT (abst) 392
Richards NT *See* Moore RH et al 991

Richie RE (abst) 614
Richter D (abst) 329
Rick M (abst) 210
Rickenbacher U (abst) 594
Ricker D (abst) 444
Ridocci F (abst) 1586
Ridolfi-Lüthy A (abst) 1169
Riedel E (abst) 300
Riegel W (abst) 274, 492, 1175
Riese R (abst) 222
Riesen W (abst) 1170, 1172
Rietberg B (abst) 267, 514
Rietra PJGM (abst) 186
Rifai A (abst) 424, 429
Rifici V (abst) 502
Riley D (abst) 540
Riley LJ Jr. (abst) 268
Rimmer JM (abst) 518
Rincon B (abst) 1588, 1609, 1609
Ringoir S (abst) 322, 322, 322
Rios AR *See* Schwartzman ML et al 94
Risler T (abst) 518, 1167, 1172, 1180, 1186
Ritter C (abst) 464, 469
Ritter C *See* Sugimoto T et al 1522
Ritz E (abst) 238, 251, 253, 253, 289, 303, 391, 420, 470, 475, 513, 1165, 1167, 1168, 1169, 1171
Ritz E *See* Deppisch R et al 696
Rivarola G (abst) 313, 313
Rivera C (abst) 1605
Rivera CF (abst) 1616
Rivera J (abst) 588
Rivera M (abst) 1589, 1592, 1594, 1595, 1597, 1597
Robbins C (abst) 305
Robert D (abst) 316
Roberts AFC (abst) 517
Roberts M (abst) 316, 318
Robey PG (abst) 220
Robillard J (abst) 572
Robillard JE (abst) 570
Robinette JB (abst) 479, 493
Robishaw JD (abst) 213
Roca Marsinyach F (abst) 1598
Roccatello D (abst) 273, 407, 444
Roch-Ramel F (abst) 467
Rocha AS *See* Kudo LH et al 1248
Rocher LL (abst) 489
Rodá M (abst) 1590
Rodby RA (abst) 605
Rodeheaver DP (abst) 493, 525
Rodel PV (abst) 278, 402
Rodemann HP (abst) 518
Rodicio JL (abst) 261, 403, 403, 610, 1587, 1587, 1604, 1606, 1606, 1606, 1607, 1607, 1607, 1608, 1608
Rodrigo A (abst) 1592, 1592
Rodriguez C (abst) 1184
Rodríguez C (abst) 1604
Rodriguez E (abst) 314
Rodriguez JC (abst) 1594
Rodríguez JC (abst) 1599
Rodriguez JC (abst) 1599
Rodríguez JC (abst) 1599, 1600
Rodriguez Jornet A (abst) 1598
Rodriguez M (abst) 257, 260, 271, 294, 295, 473, 518
Rodriguez M *See* Allon M et al 14
Rodríguez-Iturbe B (abst) 426
Rodriguez-Paternina E (abst) 1607, 1607, 1607
Rodriguez-Puyol D (abst) 316, 378
Rodriguez-Puyol M (abst) 316, 378
Roecker E (abst) 335
Roels F (abst) 187
Roessner A (abst) 1186
Roh D (abst) 526
Rohde R (abst) 444
Rollino C (abst) 273
Romano G (abst) 338
Rombola G (abst) 544
Rombolà G *See* Colussi G et al 28:S-63
Rombouts RFM (abst) 429
Rome L (abst) 573
Romero C (abst) 403
Romero E (abst) 595
Romero JC (abst) 261, 358, 364, 403, 403, 552, 553, 610
Romero L (abst) 498
Romero MF (abst) 350
Romero R (abst) 1597
Ron O (abst) 314, 397
Ronco C (abst) 316, 317, 317, 317
Ronco P (abst) 201, 260, 354, 445
Rondeau E (abst) 195, 219, 597, 611
Ros MAA *See* Ojeda JL et al 1270
Rosado M (abst) 1591, 1591, 1591
Rosales M (abst) 1616
Rosansky SJ (abst) 317
Roscoe JM (abst) 247, 251
Rose BD (abst) 283
Rose CE Jr. (abst) 587
Rosello J (abst) 1587
Rosen M (abst) 596
Rosen O (abst) 533
Rosen S (abst) 480, 493
Rosen S, Greenfeld Z, Bernheim J, Rathaus M, Podjarny E, Brezis M: Hypercalcemic nephropathy: Chronic disease with predominant medullary inner stripe injury 1067
Rosenberg ME (abst) 358
Rosenblum ND (abst) 222
Rosenfeld JB (abst) 312, 349
Rosenzweig SA (abst) 201
Rosman J (abst) 1171
Ross B (abst) 529
Ross BD (abst) 461
Ross D (abst) 301
Ross M (abst) 192
Ross WR (abst) 233
Rossi F (abst) 441
Rossi R (abst) 289
Rossier B (abst) 564
Rossier BC (abst) 563
Rossini M (abst) 516
Rossiter KA (abst) 216
Rostand SG (abst) 244, 283
Roszek B (abst) 185
Rotellar C (abst) 284
Roth DA (abst) 282
Röther E (abst) 288
Rother K (abst) 416, 431
Rother K *See* Torbohm I et al 1098
Rother U (abst) 1173
Rothrock J (abst) 216, 456, 458
Rothrock JK (abst) 207
Rothstein D (abst) 429
Roullet J-B (abst) 321

Rousaud F (abst) 1590, 1590
Rouse D (abst) 211
Rovin BH (abst) 429
Rovin BH, Wurst E, Kohan DE: Production of reactive oxygen species by tubular epithelial cells in culture 1509
Roxe DM (abst) 587
Roy A (abst) 318
Roy BA (abst) 333
Rubba P (abst) 295
Rubin A (abst) 449
Rubin J (abst) 333, 448
Rubin R (abst) 515, 519
Rubinek T *See* Levy D et al 1310
Rubinger D (abst) 296, 352, 451
Rubinoff M (abst) 279
Ruble D (abst) 203
Ruegg CE (abst) 529
Ruggenenti P (abst) 519
Rugiu C (abst) 242
Ruilope L (abst) 1606
Ruilope LM (abst) 403, 403, 1587, 1606, 1606
Ruiz de Alegría P (abst) 1611
Ruiz Fernandez A (abst) 1598
Ruiz LM (abst) 1587, 1588
Ruiz O (abst) 544
Ruiz P (abst) 351, 434
Ruley EJ (abst) 569
Rumberger JA (abst) 553
Rummel J (abst) 1181
Rumrich G (abst) 591
Ruoslahti E (abst) 221, 222
Ruoslahti E *See* Border WA et al 689
Rush DN (abst) 310, 600
Rush J (abst) 283
Rutledge L (abst) 555
Rutsky EA (abst) 244, 283
Ryan C (abst) 313
Ryan U (abst) 194
Ryba D (abst) 274
Rybczyńska A (abst) 454, 458
Ryffel B (abst) 1184, 1184
Ryu JH (abst) 281
Saad T (abst) 430
Saavedra J (abst) 1602, 1605, 1616
Saavedra M (abst) 315
Sabaté I (abst) 1601
Sabate I (abst) 1601
Sabaté I (abst) 1603
Sabater J (abst) 1589, 1589, 1593
Sabater R (abst) 1600, 1601, 1601, 1601
Sabatini S (abst) 228, 534, 572
Sabatini S, Kurtzman NA: Enzyme activity in obstructive uropathy: Basis for salt wastage and the acidification defect 79
Sabbatini M (abst) 599
Sablay L (abst) 515, 519
Sabra R (abst) 493
Sacksick T *See* Drüeke T et al 1438
Sacktor B (abst) 202
Sadjadi SA (abst) 265, 318
Sadler JH (abst) 404
Saenz A (abst) 1587
Safar ME *See* London GM et al 137
Safirstein R (abst) 490
Safirstein R, Price PM, Saggi SJ, Harris RC: Changes in gene expression after temporary renal ischemia 1515
Saggi SJ *See* Safirstein R et al 1515
Saha PK *See* Kanda S et al 875
Sahai A (abst) 211, 530
Sahler LG (abst) 282
Saijonmaa O (abst) 1383
Saiphoo C (abst) 449, 451
Saito T (abst) 321, 519
Saito T, Atkins RC: Contribution of mononuclear leucocytes to the progression of experimental focal glomerular sclerosis 1076
Saito T *See* Ishikawa S 1060
Saito Y (abst) 198
Saito Y *See* Kanda S et al 875
Saitoh M (abst) 471
Saka S (abst) 471
Sakai O (abst) 244, 330, 432, 568, 590
Sakai S (abst) 244
Sakai T (abst) 306
Sakamoto H (abst) 202
Sakamoto M (abst) 514, 515, 522
Sakamoto N (abst) 413, 426, 436, 440
Saklayen MG (abst) 488
Salahudeen AK (abst) 612
Salaita K (abst) 404
Salant DJ (abst) 410, 437
Salazar FJ (abst) 358
Saleh A (abst) 393, 544
Salido E (abst) 508, 511
Salinas-Madrigal L (abst) 375
Salit M (abst) 290
Salmon RF (abst) 530
Salmona M (abst) 523
Salnitro F (abst) 405
Salom MG (abst) 552
Salomon DR (abst) 601, 606
Salusky IB (abst) 328, 329, 451
Salvati P, Ferrario RG, Bianchi G: Diuretic effect of bumetanide in isolated perfused kidneys of Milan hypertensive rats 1084
Salvatierra J (abst) 1608
Sampson C (abst) 297
Samsell LJ (abst) 517, 555
San-Millán JL (abst) 1615
Sánchez G (abst) 314
Sanchez Guisande D (abst) 1596
Sanchez IO (abst) 485
Sánchez L (abst) 1603, 1611
Sanchez L (abst) 1614
Sanchez M (abst) 1585, 1609, 1609, 1609, 1610
Sánchez M (abst) 1611
Sánchez Peinado C (abst) 1604
Sanchez Sicilia L (abst) 1593, 1614, 1614
Sánchis J (abst) 1585
Sanchis J (abst) 1585, 1585
Sancho J (abst) 403, 1606
Sanders C (abst) 283
Sanders PW (abst) 494
Sandhagen B (abst) 373
Sandler R (abst) 211
Sandoval G (abst) 397
Sands JM (abst) 578, 588
Sandzen B (abst) 1385
Sanfelice NFT (abst) 519
Sang Y (abst) 321
Sansom SC (abst) 570
Santella RN (abst) 545

Santiago A (abst) 378, 424, 430
Santina CD (abst) 240
Santos Barajas J (abst) 1598
Santos MM (abst) 498, 506, 519
Sanz A (abst) 1593
Sanz-Guajardo D (abst) 1586, 1586, 1587
Sanz-Guajrado D (abst) 1586
Sanz-Moreno C (abst) 1586, 1586, 1586, 1587
Sardet C (abst) 233, 539
Sargent JA (abst) 318
Saric J (abst) 396, 1178
Sarrias X (abst) 1600, 1600
Saruta T (abst) 370
Sasaki S (abst) 540, 545, 547
Satlin LM (abst) 542, 545
Sato A (abst) 527
Sato K (abst) 596
Sato N (abst) 418
Sato Y (abst) 491
Satriano J (abst) 424, 430
Sauer H (abst) 369
Saure B (abst) 1181
Sauter DA (abst) 428
Sauter E (abst) 612
Sautner T (abst) 602
Savin V (abst) 285
Savin VJ (abst) 226, 430, 505
Savino D (abst) 257
Savory J (abst) 471
Sawanishi K (abst) 246
Sawaya B (abst) 596
Sawaya BP (abst) 494
Sawczuk IS (abst) 476, 479
Sawelson S (abst) 244
Sawyer N (abst) 455
Saxenhofer H (abst) 1173
Sayegh MH (abst) 599
Scaduto RC Jr. (abst) 213
Scalise R (abst) 236
Scanferla F (abst) 403
Scarborough B (abst) 342
Schabel T (abst) 381, 497
Schaefer K (abst) 294, 318, 1187
Schaefer R (abst) 492
Schaefer RM (abst) 520
Schafer JA (abst) 366, 574, 588
Schafer Z *See* Kagan A et al 971
Schafer Z *See* Kagan A et al 980
Schaffer AV (abst) 604
Schalling M (abst) 368
Schambelan M (abst) 465
Schärer K *See* Tönshoff B et al 1134
Schattenfroh S (abst) 393, 1172, 1172
Scheinman JI (abst) 222
Scheinman SJ (abst) 365, 367
Scheler F (abst) 1170, 1178, 1181
Schelling J (abst) 268
Schelotto C (abst) 290, 594
Schena FP (abst) 445
Schepers T (abst) 215
Scherberich JE (abst) 1170
Scherer S (abst) 251
Scherzer P (abst) 352, 571
Scherzer P, Wald H, Popovtzer MM: Reduced Na-K-ATPase in distal nephron in glycerol-induced acute tubular necrosis 870
Scheuermann EH (abst) 1185
Scheutz E (abst) 360
Scheutz J (abst) 360
Schieppati A (abst) 367
Schiff E (abst) 303
Schiff ER (abst) 314
Schifferdecker E (abst) 1170
Schiffl H (abst) 1182
Schild L (abst) 571
Schilling WP (abst) 584, 584
Schindler R (abst) 319
Schindler R, Lonnemann G, Shaldon S, Koch K-M, Dinarello CA: Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement 85
Schlatter E (abst) 562, 571, 1162, 1162
Schlenker A (abst) 369
Schlessinger F (abst) 266
Schlessinger FB (abst) 265
Schlessinger J (abst) 194, 200
Schleyerbach R (abst) 1184
Schloeder (abst) 539
Schlondorff D (abst) 218, 223, 371, 378, 424, 430, 501, 502
Schlossman SF (abst) 429
Schmid H (abst) 1185
Schmid M (abst) 1161
Schmidt B *See* Ward RA et al 776
Schmidt DF (abst) 319
Schmidt H (abst) 1170, 1185
Schmidt-Gayk H (abst) 475
Schmiedeke T (abst) 430, 434
Schmitt GW (abst) 449
Schmitt H (abst) 1182, 1185
Schmitt V *See* Deppisch R et al 696
Schmitz PG (abst) 391, 520, 556
Schmitz PG *See* Kasiske BL et al 880
Schmitz PG *See* O'Donnell MP et al 1263
Schnack S (abst) 1182
Schneeberger E (abst) 228
Schneider GL (abst) 235, 507
Schnellmann RG (abst) 493, 525
Schnermann J (abst) 357, 381, 494, 556, 560
Schobersberger W (abst) 1165
Schoenfeld PY *See* Mazbar SA et al 1325
Schoeppe W (abst) 195, 378, 1166, 1166, 1170, 1185
Schofield K (abst) 361
Schollmeyer P (abst) 274, 299, 323, 347, 1167, 1167, 1174, 1175, 1179
Schollmeyer PJ (abst) 288, 1171
Scholtz W (abst) 1174
Scholz H (abst) 1164, 1177
Schönermark M (abst) 416, 431
Schönermark M *See* Torbohm I et al 1098
Schoolwerth A (abst) 357
Schoolwerth AC (abst) 206, 537
Schrader DC (abst) 588
Schrama E (abst) 186
Schreiner G (abst) 431, 465, 484
Schreiner GF (abst) 339, 352
Schreyer NK (abst) 381
Schrier RW (abst) 194, 251, 269, 275, 337, 361, 380, 397, 453, 478, 486, 509, 525
Schrier RW *See* Granot Y et al 1301
Schrijver G (abst) 183, 551
Schroeder U (abst) 294
Schubert C (abst) 497
Schulak JA (abst) 607

Schulman G (abst) 494
Schulman S (abst) 329, 611
Schulte HD (abst) 1183
Schulte K-L (abst) 1172
Schultz H (abst) 210
Schulz W (abst) 1170, 1176, 1180, 1182
Schulze M (abst) 309, 1180
Schulze-Lohoff E (abst) 202
Schuppan D (abst) 258
Schurek HJ (abst) 1164
Schuster VL (abst) 224, 227
Schwab A (abst) 228
Schwab SJ (abst) 319, 484
Schwab TR (abst) 342
Schwartz AB (abst) 378
Schwartz GJ (abst) 533, 536, 542, 545
Schwartz JH (abst) 487, 546
Schwartz MM (abst) 431, 433
Schwartz P (abst) 482
Schwartzberg M (abst) 203, 347
Schwartzman ML (abst) 344
Schwartzman ML, Martasek P, Rios AR, Levere RD, Solangi K, Goodman AI, Abraham NG: Cytochrome P450-dependent arachidonic acid metabolism in human kidney 94
Schweer H *See* Tönshoff B et al 1134
Schwegler JS (abst) 1161
Schweitzer S (abst) 313
Schweitzer SU (abst) 240
Schwenk MH (abst) 478
Schwenk S (abst) 1173
Schwiebert E (abst) 216
Schwietzer GKW (abst) 393
Schwobel B (abst) 289
Scigalla P (abst) 244, 299, 300, 396
Scivittaro V (abst) 445
Scoble JE (abst) 612
Scoltock AB (abst) 554
Scott G (abst) 280
Sebastian A (abst) 465
Sebastian A, Hernandez RE, Portale AA, Colman J, Tatsuno J, Morris RC Jr: Dietary potassium influences kidney maintenance of serum phosphorus concentration 1341
Sebert JL (abst) 452
Seddighi S (abst) 368
Sedmak D (abst) 444
Sedor JR (abst) 349, 431
Sedor JR *See* Wiggins RC et al 1281
Segal J (abst) 312
Segal JH (abst) 202
Segerer W (abst) 1182
Segre G (abst) 451
Segre GV (abst) 449
Sehajpal P (abst) 599, 600
Seidel A (abst) 470
Seidel D *See* Gröne H-J et al 1449
Seidler AJ (abst) 404
Seifter JL (abst) 460, 588
Seikaly MG (abst) 359, 555
Seki G (abst) 1161
Seki M (abst) 243
Selak M (abst) 514
Selgas R (abst) 1594, 1594, 1613, 1613, 1613, 1614, 1614, 1614, 1614
Sella M (abst) 286, 472
Sella M *See* Abreo K et al 677
Sellinger M (abst) 1174
Sellitti D (abst) 336
Sellmayer A (abst) 350
Selvanayagam P (abst) 428
Semple PF (abst) 550
Semplicini A (abst) 394
Seney FD Jr. (abst) 359
Seniw C (abst) 297
Seow F, Chrisp JS, Lawrence JR, Field MJ: Analysis of magnesium in tubular fluid using flameless atomic absorption spectrophotometry (Technical Note) 818
Sepe V (abst) 506
Ser YL (abst) 258
Serhan CN (abst) 346, 347, 351
Serna C (abst) 1616
Serón D (abst) 1600, 1601
Seron D (abst) 1601, 1601
Serón D (abst) 1601, 1601
Seron D *See* Alexopoulos E et al 100
Serra A (abst) 1597
Serrallach (abst) 1600
Serrano S (abst) 1603, 1603
Sertl K (abst) 400, 602
Serventi M (abst) 402, 557
Servitge O (abst) 1601
Severson CD (abst) 224
Seyberth HW *See* Tönshoff B et al 1134
Seyfert UT (abst) 1179, 1180, 1180
Seymour A-ML (abst) 517
Seymour AA (abst) 337
Sezai Y (abst) 485
Sfakianakis GN (abst) 398
Sgoutas DS (abst) 598
Shade R (abst) 317
Shah RM (abst) 265, 318
Shah SV (abst) 407, 432, 483, 496
Shahawy M (abst) 482
Shai S-Y (abst) 355, 359
Shainkin-Kestenbaum R (abst) 471
Shaldon S (abst) 296, 307, 319, 320
Shaldon S *See* Schindler R et al 85
Shanley P *See* Anger MS et al 1211
Shanley PF (abst) 494
Shany S *See* Levy D et al 1310
Shao J (abst) 432
Shapira J (abst) 392, 569
Shapira Z *See* Yussim A et al 812
Shapiro JI (abst) 280, 509, 525, 545, 585
Shapiro RJ (abst) 520
Shapiro W (abst) 286
Sharma AM (abst) 393, 1172, 1172
Sharma R (abst) 226
Sharma V (abst) 599, 600
Sharp GH (abst) 518
Shaw E (abst) 407
Shaw S (abst) 1172, 1173
Shaw SG (abst) 1173, 1173, 1175, 1175
Shayman J (abst) 211, 413
Shayman JA (abst) 212, 532
Sheikh-Hamad D (abst) 359
Sheingold SH (abst) 520
Shelat H (abst) 388
Shen D-C *See* Fuh MMT et al 1295
Shen S (abst) 595
Shen ST (abst) 368

Shen XP (abst) 409, 432
Shenolikar S (abst) 234
Sheridan A (abst) 495
Sherman RA (abst) 319
Sherrard D (abst) 451
Sherrard DJ (abst) 235, 314, 449
Sherwood A (abst) 229
Sherwood GK (abst) 254
Sheth KJ (abst) 438
Shi J (abst) 530
Shi L-B (abst) 588
Shibasaki T (abst) 432
Shibata T (abst) 433
Shibuya H (abst) 463
Shichiri M (abst) 282
Shieh S-M *See* Fuh MMT et al 1295
Shiigai T (abst) 239
Shimada T (abst) 425
Shimada Y (abst) 485
Shimamura T (abst) 433, 436
Shimatsu A *See* Hattori N et al 951
Shimizu A (abst) 450
Shimizu F (abst) 418
Shimizu T (abst) 461
Shin SH (abst) 376
Shinowara N (abst) 583
Shinowara NL (abst) 589
Shioyama K (abst) 463
Shippee R (abst) 290
Shirato I (abst) 219
Shmueli D *See* Yussim A et al 812
Shoemaker MO *See* Lipman JJ et al 892
Shoker A (abst) 446, 500
Shopp GM (abst) 595
Shore I (abst) 447
Short CD (abst) 437, 438
Shube S (abst) 571
Shull GE (abst) 232
Shulman RG (abst) 476
Shultz P (abst) 203, 245
Shvil Y (abst) 470
Sial S (abst) 530
Sibley R (abst) 507
Sicolo M (abst) 327
Sicuso C (abst) 456
Siddiqui F (abst) 587
Sidhu A (abst) 388
Sieberth H-G (abst) 1180
Sieberth HG (abst) 472, 1175, 1177, 1182
Siegel NJ (abst) 476, 481
Sierra-Amor RI (abst) 284
Sikorski I (abst) 552
Silberberg J (abst) 288
Silbernagl S (abst) 1161, 1163
Silbiger S (abst) 223
Silva FG (abst) 257
Silva HB (abst) 237
Silva P (abst) 336, 364, 480
Silveira A (abst) 560
Silver J (abst) 296, 470
Silver SM (abst) 268
Silverman M (abst) 247, 251, 408, 585, 589
Simon EE (abst) 223, 543
Simon NR (abst) 320
Simon P (abst) 247, 252
Simon S (abst) 262
Simons K (abst) 224, 228
Simonsen S (abst) 607
Simonson MS (abst) 211, 349, 351
Simpson DP *See* Miskell CA 758
Singh AB (abst) 422, 433, 434
Singh AK (abst) 198, 433
Singh M (abst) 250, 251, 422, 433, 434
Singh S (abst) 238
Singhal P (abst) 218
Singhal PC (abst) 269, 378
Sinkey CA (abst) 401
Sirmon MD (abst) 449
Sirota R (abst) 325
Sirota RA (abst) 325
Skaarup P (abst) 1388
Sklar A (abst) 274
Skolnick M (abst) 248
Skolnik E (abst) 599, 600
Skopec J (abst) 387, 550
Skorecki K (abst) 194, 214, 215, 234, 341, 341, 365, 553
Skott H (abst) 1385
Skøtt P (abst) 243
Skröder R (abst) 320
Slatopolsky E (abst) 309, 314, 451, 464, 465, 466, 469
Slatopolsky E *See* Sugimoto T et al 1522
Slaughter D (abst) 301
Slayman C (abst) 233
Slayman CW (abst) 539
Sloan EA (abst) 522
Sloand JA (abst) 280
Slomowitz LA (abst) 245
Slotki IN (abst) 546
Sluiter HE (abst) 183, 551
Sluiter WJ (abst) 614
Smallwood JI (abst) 385
Smeby LC (abst) 320
Smith BA (abst) 572
Smith BE (abst) 558
Smith D (abst) 600
Smith FG (abst) 570, 572
Smith J (abst) 411
Smith J *See* Atherton JC et al 28:S-36
Smith JB (abst) 514
Smith M (abst) 263
Smith MV (abst) 33
Smith SR (abst) 604
Smith-Sivertsen C (abst) 1386, 1387
Smitherman R (abst) 313
Smits JFM (abst) 183, 524
Smogorzewski M (abst) 470, 521
Smolka A (abst) 560
Smollich BP (abst) 183
Snajdar RM (abst) 203
Sniderman A (abst) 288
Snipes E (abst) 325
Snipes ER (abst) 224, 325, 521
Snow ML (abst) 193
Snyder HM (abst) 589
So SKS (abst) 605, 612
Sobrero MI (abst) 393
Solá R (abst) 1606
Solangi K (abst) 309, 344, 600
Solangi K *See* Schwartzman ML et al 94
Solé M (abst) 1615
Soleimani M (abst) 533, 546
Soler Amigó J (abst) 1598

Solez K (abst) 495
Solf A (abst) 331
Soliman AR *See* Akmal M et al 854
Solini A (abst) 521
Solis C (abst) 1594
Solomon AK (abst) 593
Solomon J (abst) 524
Sombolos K (abst) 326
Somlo S (abst) 248, 250, 251, 521
Somodi Z (abst) 391
Sone M (abst) 321
Sonn F (abst) 351
Sonnenberg A (abst) 407
Sonnenberg H (abst) 562
Sonnenfeld G (abst) 215
Soper B (abst) 215
Sorenson GB (abst) 459
Sosa AM (abst) 1585, 1585, 1585, 1586
Sotelo JE (abst) 401
Souness G (abst) 357
Spector D (abst) 552, 589
Speight P (abst) 589
Spencer AJ (abst) 487, 495
Spiegel AM (abst) 216
Spies K-P (abst) 1172
Spindler E (abst) 296, 320
Spital A (abst) 558, 613
Spitzer A (abst) 453, 455, 553
Spohn M (abst) 228, 572
Spokes K (abst) 336, 364, 480
Spors L (abst) 318
Sprague SM (abst) 452
Spring K (abst) 583
Spring KR (abst) 580
Springate JE (abst) 236
Spurney RF (abst) 351, 434
Squiers EC (abst) 606
Squillace D (abst) 310
Sraer J-D (abst) 195, 219, 597, 611
Sredni B (abst) 600, 606, 608
Srinivasan R (abst) 611
St. John P (abst) 217
Stablein D (abst) 614
Stahl RAK (abst) 195, 378, 425, 1166, 1166
Stall S (abst) 405
Stalla K (abst) 596
Stanchfield WR (abst) 352
Stanson AW (abst) 404, 405
Stanton B (abst) 199, 216, 217
Stanton RC (abst) 203
Stapleton FB: Idiopathic hypercalciuria: Association with isolated hematuria and risk for urolithiasis in children 807
Star RA (abst) 590
Starosta R (abst) 463
States B (abst) 529
Stauffer JW *See* MacKay K et al 741
Stears JC (abst) 249
Steele TH (abst) 393
Stefanski E (abst) 312
Steffen HM (abst) 271, 396, 1178, 1178
Steffes MW (abst) 241
Steffes MW *See* Mauer SM et al 909
Steffgen J (abst) 1163
Steger G (abst) 613
Stegmayr B (abst) 1381, 1385, 1385, 1386, 1388, 1389
Steigner W (abst) 1163, 1163
Stein H (abst) 325, 325
Stein JH (abst) 512
Steinbach K (abst) 311, 397
Steiner A (abst) 238
Steinhardt GF (abst) 375
Steinhart C (abst) 274
Steinhauer HB (abst) 347, 1167, 1179
Steinhausen M *See* Fretschner M et al 1227
Steininger R (abst) 602
Stelkens H (abst) 342, 372
Stelwagen T (abst) 508
Stenman S *See* Groop L et al 1120
Stenver D (abst) 1383
Stenzel KH (abst) 600
Stephanz GB (abst) 229, 229
Stephens VM (abst) 316, 318
Stephenson JL (abst) 572
Stephenson RL (abst) 546
Stern N (abst) 395
Sterner G (abst) 1388
Sterns RH (abst) 268
Sternweis PC (abst) 215
Sterzel RB (abst) 197, 202, 223, 410
Sterzel RB *See* Unwin RJ et al 1031
Stevens C (abst) 436
Stevenson F (abst) 227
Stevenson V (abst) 413
Stewart-Phillips JL (abst) 212
Stier CT Jr. (abst) 394
Still W (abst) 522
Still WPT (abst) 526
Stinebaugh BJ (abst) 539
Stivelman JC (abst) 473
Stockenhuber F (abst) ... 235, 298, 300, 307, 311, 379, 400, 602
Stockenhuber F, Kurz RW, Geissler K, Jahn C, Hinterberger W, Balcke P, Lechner K: Recombinant human erythropoietin activates a broad spectrum of progenitor cells 150
Stoeckl F (abst) 423, 430, 434
Stokes JB (abst) 536, 563, 568
Stokke ES (abst) 572
Stokke ES, Østensen J, Kiil F: Effects of bumetanide and ouabain on lithium transport in the distal nephron of dogs 28:S-71
Stolte H (abst) 1169
Stone DK (abst) 234
Stone W (abst) 299, 325
Stopp M (abst) 546
Storch RL (abst) 320
Storch S (abst) 320
Storm T (abst) 451
Stote RM (abst) 583
Strandgaard S (abst) 1388
Strandhoy JW (abst) 551
Strange K (abst) 573, 586
Stranix B (abst) 212
Strasheim A (abst) 203
Straub S (abst) 575
Straus N (abst) 265
Strauss A (abst) 232
Strauss J (abst) 262, 463, 466
Straw J (abst) 307
Stray-Gundersen J (abst) 311
Strazzullo P (abst) 235
Strewler GJ (abst) 465

Striker G (abst) 504
Striker GE *See* MacKay K et al 741
Striker L (abst) 429, 504
Striker LJ *See* MacKay K et al 741
Stroemsaeter CE (abst) 1386
Strom TB (abst) 426, 436, 593, 598, 599, 601
Stromski ME (abst) 281, 556
Strong CJ (abst) 324
Struijk DG (abst) 186, 326
Struyker-Boudier HAJ (abst) 183, 524
Stuart FP (abst) 608
Stuart J (abst) 608
Stuart M (abst) 602
Stubenbord W (abst) 449
Stylianou E, Jenner LA, Davies M, Coles GA, Williams JD: Isolation, culture and characterization of human peritoneal mesothelial cells 1563
Subramaniam S (abst) 590
Sudhof TC (abst) 234
Sueishi K *See* Iwamoto T et al 1466
Sugimoto T, Ritter C, Morrissey J, Hayes C, Slatopolsky E: Effects of high concentrations of glucose on PTH secretion in parathyroid cells 1522
Sugimura K (abst) 471
Sugino N (abst) 515, 527
Sugisaki Y (abst) 434
Sugiura M (abst) 372, 486
Sugiura M *See* Kon V et al 1487
Suguira M (abst) 203, 375
Suki W (abst) 211
Suki WN (abst) 584, 584
Sullivan J (abst) 449
Sullivan L (abst) 573
Sulser D *See* Lipman JJ et al 892
Summer SN (abst) 361
Sumrani N (abst) 605, 613
Sun A (abst) 583
Sun AM (abst) 547
Sun L (abst) 370
Sun MJ (abst) 430
Sundal E (abst) 1383
Sunder-Plassmann G, Wagner L, Hruby K, Balcke P, Worman CP: Upregulation of a lymphoid serine protease in kidney allograft recipients 1350
Sunder-Plassmann G (abst) 613
Sundqvist T (abst) 1389
Suranyi MG (abst) 445
Surian M *See* Colussi G et al 28:S-63
Susic D (abst) 390
Susin M (abst) 254
Suthanthiran M (abst) 436, 599, 600
Suzuki M (abst) 244, 305, 330, 564, 568, 590
Suzuki N (abst) 413
Suzuki T (abst) 450
Suzuki Y (abst) 420
Svarnas A (abst) 520
Swainson CP (abst) 522, 550
Swan SK (abst) 495
Swanson JP (abst) 346
Swanson P (abst) 314
Swarts HGP (abst) 185
Sweeney WE (abst) 190
Sweet J *See* Cole EH et al 29
Sweny P (abst) 498, 612
Swift LL (abst) 382
Sybertz EJ (abst) 337
Szallasi T (abst) 523
Szczebanik J (abst) 1380
Szerlip H (abst) 233
Szukics B (abst) 1169
Tabei K (abst) 568, 573
Tachibana K (abst) 321
Tagouri Y (abst) 193
Taher S (abst) 298
Takahashi K (abst) 321, 351, 352, 375, 484, 493
Takaichi K (abst) 547
Takama T (abst) 193, 376
Takeda M (abst) 531
Takeda S (abst) 362, 447
Takei F (abst) 437
Takemoto F (abst) 379
Takemura K (abst) 514, 515, 522
Takenawa T (abst) 208
Takeuchi A (abst) 257
Takeuchi E (abst) 425
Takeuchi Y (abst) 418
Takeyasu K (abst) 231
Takiyyuddin MA (abst) 394
Talartschik J (abst) 1170
Talseth T (abst) 1384
Tamaki T (abst) 556, 582
Tamayo JA (abst) 284
Tamura T (abst) 202
Tan D (abst) 334
Tan E (abst) 410
Tan S (abst) 470
Tanaka H (abst) 222
Tanaka T (abst) 524, 532
Tang WW (abst) 434
Taniguchi J (abst) 567
Tannen R (abst) 211, 530
Tannenbaum J (abst) 298
Tanner GA (abst) 566
Tanuma Y (abst) 243
Tanzi R (abst) 250
Tapia E (abst) 498
Tapia L (abst) 449
Tappeiner G (abst) 238
Tarkowski A (abst) 1387
Tatsuno J *See* Sebastian A et al 1341
Taub M, Laurie GW, Martin GR, Kleinman HK: Altered basement membrane protein biosynthesis by primary cultures of cpk/cpk mouse kidney 1090
Tay M (abst) 479
Tayeb J (abst) 334
Taylor AJ (abst) 505
Taylor AL (abst) 265
Taylor C (abst) 236, 239
Taylor CA (abst) 488, 488
Taylor PH (abst) 602
Teger-Nilsson A-C (abst) 399
Tegzess AM (abst) 557, 614
Teitelbaum I (abst) 203, 576
Teixeira da Silva JC Jr. (abst) 547
Teixidó J (abst) 1597
Tejani A (abst) 256, 257, 614
Tejedor A (abst) 215, 525, 529, 539
Tejuca F (abst) 1591
Telenti A (abst) 252
Tell GS (abst) 236, 239
Tellier M (abst) 467
Tempesti C (abst) 549

ten Dam MAGJ (abst) 185, 590, 591
ten Kate RW (abst) 185, 590, 591
Tennenhouse HS *See* Boneh A 682
Teno C (abst) 1608
Teppo A-M (abst) 1382, 1386
Teppo A-M *See* Groop L et al 1120
ter Wee PM (abst) 557
Terada Y (abst) 573
Termine JD (abst) 220
Terranova V (abst) 410
Terrell RS (abst) 441
Teruel JL (abst) 1594, 1595, 1595
Tervaert JWC, Goldschmeding R, Elema JD, van der Giessen M, Huitema MG, van der Hem GK, The TH, von dem Borne AEGKr, Kallenberg CGM: Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis 799
Terzi F (abst) 549
Terzian L (abst) 378
Teschan PE *See* Lipman JJ et al 892
Teschner M (abst) 520
Tesio F *See* Cecchin E et al 943
Tessler F (abst) 616
Tetta C (abst) 410
Teulon J (abst) 559
Textor S (abst) 403
Textor SC (abst) 373
Textorius O *See* Mårtensson J et al 143
Thaiss F (abst) 195, 378, 425, 1166, 1166
The TH *See* Tervaert JWC et al 799
Thebaud HE (abst) 252
Theodorson E (abst) 314, 1380
Thiel G (abst) 353, 1165, 1184, 1186
Thistlethwaite JR Jr. (abst) 608
Thliveris JA (abst) 600
Thoenes GH (abst) 1184
Thomas D (abst) 255, 268
Thomas D *See* Horton JK et al 717
Thomas DM (abst) 245, 261
Thomas L (abst) 603
Thomas SR (abst) 559
Thomas TJ (abst) 433, 434
Thomasset M *See* Drüeke T et al 1438
Thompson J (abst) 360
Thompson JR (abst) 302
Thompson ME (abst) 482
Thomsen K: Lithium clearance as a measure of sodium and water delivery from the proximal tubules 28:S-10
Thomson SC (abst) 557
Thorens B (abst) 230, 582
Thorn W (abst) 1176
Thornton MA (abst) 496
Thulin G (abst) 476, 481
Thurau K *See* Beck F-X et al 1423
Thylen P (abst) 314
Thylén P (abst) 1380
Tidgren B (abst) 279, 314, 1380
Tien R (abst) 262
Tietjen DP (abst) 284
Tiggeler RGWL (abst) 326
Tikkanen I (abst) 1382
Tillotson DL (abst) 213
Timmermans JAH (abst) 454
Timpl R (abst) 446
Tini ML (abst) 205
Tippett P (abst) 384
Tirelli S (abst) 549
Tisher CC (abst) 229, 229, 560
Tisher CC *See* Olbricht CJ et al 918
Tkacenko V (abst) 506
Tobe S (abst) 234
Tobian L (abst) 387, 389, 394
Tobies A (abst) 347
Tobvin D (abst) 392
Todd KM (abst) 560
Tolbert E (abst) 504, 511
Tolchard S *See* Lipman JJ et al 892
Tolins JP (abst) 379
Tomino Y (abst) 219
Tomita K (abst) 282, 343, 379, 586, 587
Tomosugi N (abst) 435, 447
Tomura S (abst) 282, 321
Tönshoff B, Momper R, Kühl PG, Schweer H, Schärer K, Seyberth HW: Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome 1134
Topley N (abst) 204
Topley N *See* Floege J et al 859
Topley N *See* Horton JK et al 717
Topley N *See* Radeke HH et al 767
Torabi E (abst) 413
Toraya S (abst) 491
Torbohm I, Schönermark M, Wingen A-M, Berger B, Rother K, Hänsch GM: C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells 1098
Torffvit O (abst) 1381, 1388
Tormo MG (abst) 1586
Tornatore KM (abst) 614
Tornero F (abst) 1590, 1595, 1616
Törnroth T (abst) 1384
Torrano F (abst) 227
Torras A (abst) 1588, 1588, 1602, 1616
Torrente J (abst) 1590, 1595, 1616
Torres A (abst) 1594
Torres G (abst) 1598
Torres V (abst) 247
Torres VE (abst) 247, 252, 252, 281
Tortorice KL (abst) 608
Totsune K (abst) 321
Toupance O (abst) 290
Tournade H (abst) 415, 435
Tovar J (abst) 1606
Tovar JL (abst) 1595, 1602
Tovbin D (abst) 569
Trach P (abst) 468
Trachtman H (abst) 591
Traindl O (abst) 245, 1178, 1184
Tranæus A (abst) 1384
Trautmann M (abst) 347
Traver JA (abst) 1588, 1609, 1609
Travis LB (abst) 256
Trevisan R (abst) 199, 394
Trimble ME (abst) 591
Trinh-Trang-Tan M-M (abst) 462
Trott M (abst) 318
Trott MA (abst) 316
Troutman SL (abst) 574
Troy JL (abst) 371, 511
Troyer DA (abst) 212
Trudel M (abst) 412
Truong L (abst) 482
Tryggvason K (abst) 510

Tsai P (abst) 337
Tsao T (abst) 530
Tschernko E (abst) 209
Tschesche H (abst) 595
Tschopp M (abst) 251, 397
Tseng YC (abst) 336
Tsuchiya K (abst) 547
Tsukamoto Y (abst) 471
Tsuyoshi S (abst) 485
Tuck ML (abst) 395, 499, 502
Tucker BJ (abst) 370, 501, 517, 522, 551, 555, 557
Tucker DC (abst) 217
Tur-Kaspa I (abst) 265
Turello E (abst) 410
Turguet P (abst) 1597
Turitzin SN (abst) 284
Turman MA (abst) 601
Turner C (abst) 516
Tuso P (abst) 196
Tuttle K (abst) 261
Twardowski Z (abst) 332
Tyce GM (abst) 343
Tyrrell DLJ (abst) 327
Ucci AA (abst) 227
Uchida M (abst) 418
Uchida S (abst) 197, 362, 380
Ueda N (abst) 193, 376
Ueda S *See* Yoshida H et al 1286
Ueki K (abst) 221
Ujiie K (abst) 282, 343
Ulan RA (abst) 327
Uldall R (abst) 321
Ulecia N (abst) 1590
Ullian ME (abst) 359
Ullrich KJ (abst) 591
Ulrich W (abst) 238
Umans JG (abst) 395
Umeda M (abst) 515
Unwin R (abst) 534, 548, 568, 581
Unwin RJ, Ganz MD, Sterzel RB: Brain-gut peptides, renal function and cell growth (Editorial Review) 1031
Urbaitis BK (abst) 595
Ureña P (abst) 321
Ureña P (abst) 308
Ureña P *See* Herbelin A et al 116
Ureña V (abst) 1594
Uribarri J (abst) 282
Uriu K (abst) 257, 258, 276
Urmson J (abst) 421
Uslenghi C (abst) 287
Uyehara CFT (abst) 369, 579
V Tol A (abst) 185
v Wowern N (abst) 451
Vaamonde CA (abst) 265, 267, 303, 475, 478, 496
Vachon V (abst) 462
Vadas P (abst) 312
Vadgama J (abst) 278
Val J (abst) 1608, 1608
Valaitis D (abst) 371
Valderrabano F (abst) 1596, 1596, 1596
Valderrábano F (abst) 1610, 1610
Valderrabano F (abst) 1610, 1615
Valdes Cañedo F (abst) 1596
Valdés F (abst) 1602, 1605, 1616
Valdivieso A (abst) 268
Valencia SH (abst) 395, 483
Valente U (abst) 594
Valentin JP (abst) 523, 574
Valera A (abst) 1614
Valera Cortes A (abst) 1598
Vallastro V (abst) 338
Vallés M (abst) 1595
Valles M (abst) 1599
Vallès M (abst) 1602
Vallisa D (abst) 402, 557
Valoti N (abst) 345
Valtin H (abst) 362
Valvo E (abst) 235
Valvo F (abst) 404
van Acker BAC (abst) 253
van Adelsberg J (abst) 234
van Baak AA *See* Kudo LH et al 1248
van Bronswijk H (abst) 184
van Brummelen P (abst) 523
Van Buren DH (abst) 614
van de Stolpe A *See* Rabelink TJ et al 996
Van de Vyver FL (abst) 186
van den Born J (abst) 445
van den Heuvel LPWJ (abst) 445
van den Wall Bake AWL (abst) 446
van der Giessen M *See* Tervaert JWC et al 799
van der Hem GK (abst) 184
van der Hem GK *See* Tervaert JWC et al 799
van der Meulen J (abst) 184, 186, 327
van der Ploeg I (abst) 217
Van der vorst P (abst) 406
van der Woude FJ (abst) 186, 187
Van Dop C (abst) 607, 615
van Dorp WT (abst) 187
van Eendenburg JDH (abst) 407
van Eps RS (abst) 186
van Es LA (abst) 186, 187, 446
van Gemmeren D (abst) 1172
Van Haecke E (abst) 322
van Kamp GJ (abst) 590, 591
Van Landschoot N (abst) 322
Van Liew J (abst) 395
Van Liew JB (abst) 236, 385
Van Liew JB *See* Zamlauski-Tucker MJ et al 1536
van Os CH (abst) 454
Van Putten V (abst) 194, 380
Van Putten V *See* Granot Y et al 1301
van Rijn HJM (abst) 577
Van Scoy RE (abst) 252
Van Sickler JT (abst) 601, 606
van Waarde A (abst) 476
Van Wyck D (abst) 473
van Zyl-Smit R (abst) 446
VanBenthuysen KM (abst) 284
Vandenabeele P (abst) 414
Vander Molen M (abst) 213
Vanderson R (abst) 324
Vandewalle A (abst) 201
Vandorpe D (abst) 541, 548
Vanholder R (abst) 322, 322, 322
Vanhoutte PM (abst) 364
Vanke J (abst) 204
VanRollins M (abst) 345
VanWhy S (abst) 285
Vara J (abst) 1616
Vargas JC (abst) 1598
Varghese Z (abst) 498, 524, 612

Vari RC (abst) 395, 483
Varis J (abst) 1387
Vary JE (abst) 399
Vasdev S (abst) 297
Vassiliou P (abst) 479
Vaughan ED Jr. (abst) 339
Vaughn DA (abst) 561, 566, 566
Vaz O (abst) 1612, 1613
Vázquez Martul M (abst) 1616, 1616
Veerkamp JH (abst) 445
Vega J (abst) 341
Vega N (abst) 1594, 1599, 1599, 1599, 1600
Veis J (abst) 576
Velasquez MT (abst) 523
Velázquez H (abst) 562
Velly J *See* Barthelmebs M et al 1414
Veiosa JA (abst) 615
Venezia RA (abst) 331
Veniero P (abst) 338
Veninga A (abst) 407
Venkataseshan VS (abst) 246, 252
Venkatesan J (abst) 259, 259, 269
Venning MC *See* Moore RH et al 991
Venuto RC (abst) 346
Vera G (abst) 502, 615
Verbalis JG (abst) 269
Verbrugh HA (abst) 184, 327
Vercellotti GM (abst) 599, 601
Vergetis W (abst) 289
Verhoef J (abst) 184, 327
Verkman AS (abst) 225, 226, 559, 588
Verlander JW (abst) 229
Verpooten GA (abst) 187, 292, 496
Verpooten GF (abst) 187, 496
Verroust P (abst) 201, 354, 445
Vesell ES (abst) 399
Vetter H (abst) 348
Veys N (abst) 322
Vial MC (abst) 435
Viberti G (abst) 519
Viberti GC (abst) 199, 394, 510, 513, 516
Vicario JL (abst) 1608
Vidal L (abst) 1596
Vidal MT (abst) 1605
Vidaur JI (abst) 1587
Viegas MM (abst) 194
Vienken J (abst) 309
Vierhapper H (abst) 384
Viganò G (abst) 516, 523
Vigderman B (abst) 329
Viikari J (abst) 1382
Vilá N (abst) 313, 313
Vilardell J (abst) 1587, 1615, 1615
Villafruela JJ (abst) 1589, 1589, 1589, 1593
Villaro J (abst) 1585, 1585, 1586
Vinay P (abst) 525, 529
Vincenzi FF (abst) 390
Virgós MJ (abst) 1611, 1611
Visaya C (abst) 598
Visser J (abst) 187, 527
Vladutiu A (abst) 410, 427
Vlahakos DV (abst) 435, 604
Vlassara H (abst) 600
Vlasses P (abst) 236, 237
Vocino V (abst) 293
Vogel H (abst) 305
Vogt A (abst) 423, 430, 434
Vogt B (abst) 574
Vogt P (abst) 1183
Voigt A (abst) 1178
Voirol M (abst) 316
Völker K (abst) 1163
Völkl H (abst) 1162
Vollmer E (abst) 1186
Volpe M (abst) 383
von Albertini B (abst) 287, 297
von Bonsdorff M (abst) 1387, 1387
von dem Borne AEGKr *See* Tervaert JWC et al 799
von Herrath D (abst) 294, 318, 1187
Von Holst P (abst) 457
von Hungen K (abst) 499
Von Oeyen P (abst) 263
Von Sperling V (abst) 438
Voorheis J (abst) 489
Vora J (abst) 245
Vos PF (abst) 592
Vosburgh E (abst) 322
Wade JB (abst) 592
Wadhwa NK (abst) 323
Waeber B (abst) 337
Wagner HP (abst) 1169
Wagner L (abst) 613
Wagner L *See* Sunder-Plassmann G et al 1350
Wakabayashi Y (abst) 417
Wakashin M *See* Yoshida H et al 1286
Wakashin Y *See* Yoshida H et al 1286
Wald H (abst) 352, 571
Wald H *See* Scherzer P et al 870
Waldhaeusl W (abst) 384
Waldherr R (abst) 251, 253, 1167, 1168
Waldo FB (abst) 435, 439
Walker C (abst) 439
Walker J (abst) 436
Walker JD (abst) 199, 516
Walker JV (abst) 333
Walker P (abst) 408
Walker PD (abst) 496
Walker WG (abst) 285
Wall SM (abst) 536
Wallace D (abst) 573
Walli AK *See* Gröne H-J et al 1449
Walls J (abst) 531, 531, 597
Walser M: Progression of chronic renal failure in man (Editorial Review) 1195
Walshe J (abst) 292
Walshe JJ (abst) 614
Walter EA (abst) 548
Walters I (abst) 401, 506
Walz C (abst) 1172
Walz G (abst) 436, 599, 601
Wandel E (abst) 258, 1181
Wang D (abst) 547
Wang W (abst) 574
Wang W-G (abst) 487
Wang X (abst) 548
Wang YN (abst) 389
Wang Z-Q (abst) 225
Waniewski J (abst) 1384
Wanner C (abst) 302, 323, 492
Wanning C (abst) 396
Wanscher M (abst) 1386, 1387
Ward DM (abst) 323

Ward H (abst) 609, 615
Ward RA (abst) 323
Ward RA, Schmidt B, Blumenstein M, Gurland HJ: Evaluation of phagocytic cell function in an ex vivo model of hemodialysis 776
Ward TD (abst) 399
Warden DH (abst) 568
Warneboldt D (abst) 1170
Warneke G (abst) 482
Warnock DG (abst) 196, 232, 547
Warram J (abst) 241, 404, 510
Wartofsky L (abst) 336
Washio M (abst) 285
Watanabe M (abst) 224, 521
Watanabe MA (abst) 380
Watanabe N (abst) 432
Watanabe Y (abst) 436
Waterloos M (abst) 322
Watkins P (abst) 250
Watlington C (abst) 357, 360
Watson ML (abst) 250
Watson RL (abst) 400, 400
Webb RL (abst) 241
Weber (abst) 1169
Weber A (abst) 1167
Weber M (abst) 446
Weber MH (abst) 1179, 1181
Weber PC (abst) 350, 488
Weber RG (abst) 380
Webster SK (abst) 328, 334
Weeks B (abst) 223
Weening JJ (abst) 183, 407, 523, 524
Wehle B (abst) 1386
Wehrmann M (abst) 1167, 1168, 1168, 1185
Wei LJ (abst) 285
Wei SH (abst) 423
Weidmann P (abst) ... 1170, 1172, 1173, 1173, 1173, 1175, 1175
Weihprecht H (abst) 357, 381
Weiner ID (abst) 538, 549
Weiner MH (abst) 269
Weinman EJ (abst) 234
Weinstat DL (abst) 248, 521
Weinstein AM (abst) 581
Weinstein MJ (abst) 322
Weinstein RS (abst) 465
Weinstein T (abst) 436
Weir MR (abst) 277, 421, 497
Weisberg LS (abst) 340, 343
Weise WJ (abst) 437
Weisinger JR (abst) 334, 463
Weiss H (abst) 209, 377, 1165
Weiss M (abst) 345
Weiss RH (abst) 200, 204
Weisser B (abst) 348
Weissgarten J (abst) 326, 446, 500
Welch WJ (abst) 557
Welchel JD (abst) 598
Welling DJ (abst) 575
Welling LW (abst) 226, 575
Welling PA (abst) 575
Wendel G (abst) 300
Wenning A (abst) 260
Wens R (abst) 293, 324
Wenzel E (abst) 1179, 1180, 1180
Wertheim SJ *See* Cohen JJ et al 1219
Werynski A (abst) 1384
Wessel K *See* Floege J et al 859
Westberg G (abst) 1387
Westeel PF (abst) 354, 452
Westenend PJ (abst) 183, 523, 524
Westenfeder C (abst) 343
Westenfelder C (abst) 336, 477
Westlie L (abst) 1384
Westphale H-J (abst) 228, 1163
Wetzels JFM (abst) 183, 185, 187, 262, 551
Whalen M (abst) 545
Wheeler D (abst) 245
Wheeler DC (abst) 524
Whelton P (abst) 283
Whelton PK (abst) 404
Whitescarver SA (abst) 384
Whiteside C (abst) 360, 411, 488
Whitfield CF (abst) 213
Whitman G (abst) 284
Whittle J (abst) 404
Whorton AR (abst) 567
Wide L (abst) 468
Widhalm K (abst) 613
Widnell C (abst) 469
Widstam-Attoros U (abst) 1381
Wiechmann HW (abst) 1176
Wieder KJ (abst) 598, 599, 601
Wiegmann T (abst) 285
Wiegmann TB (abst) 505
Wieland H (abst) 323
Wiemeyer A (abst) 1166
Wienholtz G (abst) 1385, 1386, 1387
Wiesenfeld L (abst) 333
Wieslander J (abst) 249, 1388
Wiesner R (abst) 373, 403
Wiessner J (abst) 222
Wiggins R (abst) 422, 426
Wiggins RC (abst) 230, 416
Wiggins RC, Njoku N, Sedor JR: Tissue factor production by cultured rat mesangial cells. Stimulation by TNFα and lipopolysaccharide 1281
Wikdahl A-M (abst) 1385
Wikstad I (abst) 276, 512
Wikström B (abst) 274, 286, 373
Wilcox CS (abst) 270, 557
Wilcox LA *See* Cheung AK et al 1055
Wilkes B (abst) 309, 524
Wilkins M (abst) 339
Wilkinson A (abst) 606, 610, 616
Wilkowski MJ (abst) 281
Willekes-Koolschijn N (abst) 185
Willert J (abst) 1174
Williams B (abst) 531, 531
Williams DG (abst) 438, 447
Williams JC Jr. (abst) 592
Williams JD (abst) 245, 255, 261, 366, 381
Williams JD *See* Horton JK et al 717
Williams JD *See* Mackenzie RK et al 1316
Williams JD *See* Stylianou E et al 1563
Williams P (abst) 515
Williams RD (abst) 224
Williams SK (abst) 366, 588
Willis L (abst) 412
Willis LR (abst) 575
Wilson CB (abst) 413, 434, 477
Wilson D (abst) 403
Wilson DJ (abst) 404, 405

Wilson PD (abst) 225, 229, 229
Wilson PV (abst) 453
Winaver J (abst) 343
Winaver JM (abst) 337
Winberg J (abst) 276, 279
Wincett B (abst) 612
Winchester JF (abst) 284
Winde G (abst) 1186
Windebank AJ (abst) 306
Windus D (abst) 303, 324
Wingen A-M *See* Torbohm I et al 1098
Wingo CS (abst) 560, 575
Winslow J (abst) 411
Winters CJ (abst) 570
Wirta O (abst) 1381
Wiseman M (abst) 510
Wit LC (abst) 473
Witchell S (abst) 251
Woell E (abst) 209, 377
Woitas RP (abst) 1171
Wolcott DL (abst) 313
Wolf CJ (abst) 297
Wolf G (abst) 204, 1170
Wolfe RA (abst) 239, 241, 324
Wolfson M (abst) 324, 495
Wolfson RG (abst) 392
Wolgast M *See* Hellberg POA et al 1240
Wöll E (abst) 1162, 1165
Woloszczuk W (abst) 1184
Wong C (abst) 288, 312
Wong EFC (abst) 340, 344
Wong NLM (abst) 340, 344
Wong PY-K (abst) 368
Wong V (abst) 328
Woo DDL (abst) 200, 253
Woo JS *See* Lee HY et al 727
Wood PJ (abst) 469
Woodrow D (abst) 447
Woods LL (abst) 558
Woolfson RG (abst) 396
Worcester EM (abst) 462
Worgal S (abst) 513
Worgall S (abst) 240
Work J (abst) 396
Worman CP *See* Sunder-Plassmann G et al 1350
Wozniak M (abst) 580
Wright AF (abst) 250
Wright FS (abst) 562, 568
Wright PA (abst) 531
Wu CG (abst) 424, 429
Wu D (abst) 532
Wu HL (abst) 210
Wu L-T (abst) 407
Würmeli W (abst) 1179
Wurst E (abst) 349, 429
Wurst E *See* Rovin BH et al 1509
Wuthrich RP (abst) 409, 417, 437
Wuthrich RP, Glimcher LH, Yui MA, Jevnikar AM, Dumas SE, Kelley VE: MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells 783
Wutzl W (abst) 1168
Wyatt RJ (abst) 257
Wybo I (abst) 187
Wynn JJ (abst) 602
Xi X-P (abst) 540
Xie XS (abst) 234
Y-Ng P (abst) 476
Yaacoub A (abst) 363
Yadin O (abst) 329, 616
Yagil Y (abst) 381, 497
Yamada J *See* Kanda S et al 875
Yamada Y (abst) 196, 218
Yamaguchi DT (abst) 467
Yamaji Y (abst) 370
Yamakawa K, Kawamura J: Oxalate:OH exchange across rat renal cortical brush border membrane 1105
Yamaki M (abst) 592
Yamamoto S (abst) 524, 532
Yamamoto S *See* Yoshida H et al 1286
Yamamoto T (abst) 219, 230, 344
Yamasaki F (abst) 461
Yamauchi A (abst) 584
Yanagawa N (abst) 196, 359, 500, 526
Yanagihara T (abst) 303
Yanagisawa H (abst) 352, 484
Yanagisawa H, Morrissey J, Morrison AR, Klahr S: Eicosanoid production by isolated glomeruli of rats with unilateral ureteral obstruction 1528
Yanagisawa M (abst) 380
Yang X (abst) 572
Yankiver B (abst) 273
Yano F (abst) 524, 532
Yaoita E (abst) 230, 344
Yared A (abst) 360, 382, 497, 532
Yashiro M (abst) 246, 425
Yasushima K *See* Imai M et al 28:S-31
Yatscoff RW (abst) 600
Yeh I (abst) 297, 315
Yelamarty RV (abst) 213
Yip K-P (abst) 558
Ylinen K (abst) 1379
Yoita E (abst) 219
Yokota S (abst) 558
Yokoyama H (abst) 435, 447
Yokoyama K (abst) 193, 376
Yonemura K (abst) 455
Yoneshima H (abst) 450
Yosef I (abst) 392, 569
Yoshida F (abst) 440
Yoshida H (abst) 246, 425
Yoshida H, Wakashin Y, Ueda S, Azemoto R, Iesato K, Yamamoto S, Mori T, Ogawa M, Mori Y, Wakashin M: Detection of nephritogenic antigen from the Lewis rat renal tubular basement 1286
Yoshida K (abst) 221
Yoshida M (abst) 447
Yoshimoto M (abst) 230
Yoshimura A (abst) 417
Yoshinaga K (abst) 321
Yoshioka T (abst) 419, 497, 532
Yoshitomi K (abst) 461, 576
Yoshitomi K *See* Imai M et al 28:S-31
Yoshizawa N (abst) 420, 448
Young EW (abst) 388, 390, 405, 603
Young MF (abst) 220
Yu A (abst) 334, 582
Yudis M (abst) 325, 325
Yudkoff M (abst) 529
Yui MA (abst) 409
Yui MA *See* Wuthrich RP et al 783
Yumura W (abst) 527

Yussim A, Shapira Z, Shmueli D, Lustig S, Braslavsky D, Ben-Bassat M: Use of modified fine needle aspiration for study of glomerular pathology in human kidneys ... 812
Zabetakis PM (abst) ... 264, 405
Zabko-Potapovich B (abst) ... 210
Zabludowski J (abst) ... 312
Zachariah PK (abst) ... 404, 405
Zager RA (abst) ... 482, 496, 497
Zaharowitz H (abst) ... 287
Zahniser DJ (abst) ... 227
Zalups RK (abst) ... 525
Zamlauski-Tucker M (abst) ... 236, 385
Zamlauski-Tucker MJ, Van Liew JB, Goldinger J, Noble B: Persistent proximal tubular dysfunction late in Heymann nephritis ... 1536
Zamorano A (abst) ... 1593
Zamparo O (abst) ... 593
Zanglis A *See* Lianos EA ... 736
Zanker B (abst) ... 436, 599, 601
Zaoui P (abst) ... 299, 325
Zapata A (abst) ... 1613
Zara AC (abst) ... 288, 325
Zasuwa G (abst) ... 294, 334
Zatz R (abst) ... 498, 506, 512, 519
Zavilowitz BJ (abst) ... 533
Zeidel ML (abst) ... 361, 483, 540, 547, 562, 583, 593
Zeier M (abst) ... 253, 289, 1169
Zelikovic I (abst) ... 578, 593
Zeller KR (abst) ... 246
Zeng W (abst) ... 215
Zerbini G (abst) ... 513
Zerres K (abst) ... 253
Zevin D (abst) ... 420, 475
Zhao J (abst) ... 302
Zhon JH (abst) ... 389
Zhou F (abst) ... 334
Zhou HZ (abst) ... 509, 525
Zhou T (abst) ... 196
Zhou X-J (abst) ... 462, 505
Zhu JM (abst) ... 452
Zidek W (abst) ... 391
Ziegler MG, Kennedy B, Morrissey E, O'Connor DT: Norepinephrine clearance, chromogranin A and dopamine β hydroxylase in renal failure ... 1357
Zikos D (abst) ... 353
Zilberstein A (abst) ... 200
Zilio P (abst) ... 428
Zilleruelo G (abst) ... 262, 463, 466
Zimmerman SW (abst) ... 335
Zincke H (abst) ... 247
Zingg H (abst) ... 266
Zingraff J (abst) ... 321
Zingraff J *See* Herbelin A et al ... 116
Zinman B (abst) ... 341
Ziyadeh FN (abst) ... 224, 380, 521, 579
Zlotnik M (abst) ... 488
Zoccali C (abst) ... 315, 405
Zoja C (abst) ... 205, 377, 424, 428, 516, 523
Zoja C, Benigni A, Renzi D, Piccinelli A, Perico N, Remuzzi G: Endothelin and eicosanoid synthesis in cultured mesangial cells ... 927
Zoja C, Perico N, Bergamelli A, Pasini M, Morigi M, Dadan J, Belloni A, Bertani T, Remuzzi G: Ticlopidine prevents renal disease progression in rats with reduced renal mass ... 934
zum Büschenfelde K-HM (abst) ... 1181
zum Büschenfelde KHM (abst) ... 1179
Zurayk SH (abst) ... 316, 318
Zurlo J (abst) ... 427

Subject Index For Volume 37

ACE inhibition
renal functional reserve in diabetics (abst) 1170
ADPKD
genetic study of families (abst)..... 1615
ADPase (abst)..... 407
AIDS
(abst)..... 325
kidney and HIV 1571
nephropathy (abst) 254
renal involvement with HIV..... 1325
ATP (adenosine triphosphate)
intracellular (abst)..... 530
metabolism (abst) 529
pathophysiology (abst) 487
pharmacology (abst) 481, 584
physiology (abst) 209, 460, 461, 487, 525, 560, 565
therapeutic use (abst) 476
ATPase
Ca^{++} (abst)..... 460
H^+, antibody to (abst) 225
H^+, genetics (abst)..... 232, 234
H^+, metabolism (abst) 529
H^+, physiology (abst) 226, 227, 532, 537, 559
H^+,K^+, drug effects (abst)..... 575
H^+,K^+, genetics (abst)..... 568
H^+,K^+, physiology (abst) 560
Na^+,K^+, drug effects (abst)..... 368
Na^+,K^+, genetics (abst)..... 231, 561
Na^+,K^+, hormone effects (abst) 190, 571
Na^+,K^+, physiology (abst) .. 487, 528, 560, 565, 567, 568, 574, 575
Na^+,K^+, regulation (abst)..... 193, 349, 368, 481, 525
obstructive uropathy 79
ATPase inhibitors
(abst)..... 210, 297
physiology (abst)..... 386, 396
Acanthocyturia, diagnosis (abst) 255
Acetaminophen toxicity (abst)..... 235
Acetate
free biofiltration (abst) 1586
high efficiency HD (abst) 1590
Acetazolamide
carbonic anhydrase inhibition (abst) 1161
lithium clearance..... S-63
pharmacology (abst) 454, 542
Acetylcholine
antagonists and inhibitors (abst)..... 552
physiology (abst)..... 379, 550, 570
Acid solochrome azurine, staining bone for Al..... 1142
Acid-base
dietary K influence on phosphorus concentration.... 1341
disorders, HIV and the kidney..... 1571
imbalance (abst) 265, 532
regulation (abst)..... 263, 282, 393, 539, 544
Acidification by lithium S-75
Acidosis
calcitriol metabolism in RF 44
vascular smooth muscle cells (abst)..... 1597
Acidosis, metabolic
complications (abst) 269
etiology (abst)..... 298
pathophysiology (abst) .. 266, 268, 274, 448, 453, 464, 468, 505, 531, 534, 540, 543, 545, 573
therapy (abst) 267
tobramycin 1492
Acidosis, renal tubular
etiology (abst)..... 262
pathophysiology (abst) 264, 534
Acidosis, respiratory
diagnosis (abst)..... 265
pathophysiology (abst) 448, 540, 545, 547
Actin
(abst)..... 224, 225
drug effects (abst)..... 226, 227, 229
physiology (abst)..... 228
Acute renal failure
catecholamine abnormalities (abst) 1175
changes in gene expression after ischemia..... 1515
complications (abst) 270, 517
drug therapy (abst)..... 478
epidemiology (abst)..... 273, 277, 284
etiology (abst) 238, 259, 282
hantavirus and hemorrhagic fever (abst) 1169
hemofiltration (abst) 1175
kidney and HIV 1571
mortality (abst)..... 273
pathology (abst) 493
pathophysiology (abst) .. 278, 350, 475, 476, 477, 479, 480, 481, 482, 483, 484, 485, 486, 488, 489, 490, 491, 492, 496, 497
post-cardiac surgery (abst)..... 1596
post-infection survival (abst) 1388
red cell trapping, ischemia, hematocrit 1240
rhabdomyolysis (abst)..... 1388
therapy (abst)..... 273, 286, 313, 318, 321, 325
thromboxane in HUS 1134
Acute tubular necrosis
diagnosis (abst)..... 258, 280
drug therapy (abst)..... 235
early prognosis (abst)..... 1592
pathology (abst) 491, 495
pathophysiology (abst) 478, 480, 487, 488, 496
prediction for by PTH levels (abst) 1184
prevention and control (abst)..... 480
reduced Na-K-ATPase..... 870
severity index (abst)..... 1592
utility of pulsed Doppler (abst)..... 1615
Addis, Thomas..... 833
Adenosine
pharmacology (abst)..... 477
physiology (abst)..... 364, 381, 556, 612
receptors (abst)..... 380, 381
transport (abst)..... 476
Adenosine triphosphate
regulation of K channels (abst) 1162

Adenyl cyclase
antagonists and inhibitors (abst) 207
isolation and purification (abst) 215
physiology (abst) 361, 364, 388, 463, 574, 592
Adrenal glands (abst) 369
Adrenergic agonists, alpha 2 (abst) 579
Adrenergic blockers, alpha
pharmacology (abst) 206, 211, 369
Adrenergic receptors, alpha
analysis (abst) 370
pharmacology (abst) 211
physiology (abst) 382, 551, 557
Adriamycin toxicity (abst) 423, 488
Age
(abst) 272, 340, 498, 517
blood pressure levels (abst) 1598
factors (abst) 390
Agglomeration of crystals in stone formation 44
Alanine
(abst) 530, 577
in Henle's loops (abst) 1162
Albumins
adverse effects (abst) 417
analysis by immunofixation in ultrathin gels 1002
biosynthesis (abst) 503, 509
excretion (abst) 245, 285, 347
genetics (abst) 503
metabolism (abst) 527
transport (abst) 430
Alcohol abuse (abst) 485
Aldose reductase
diagnostic use (abst) 580
physiology (abst) 356, 588, 590
Aldosterone
antagonists and inhibitors (abst) 353
pharmacology (abst) 353
physiology (abst) 227, 233, 264, 358, 359, 548, 562, 563, 564, 575
regulation (abst) 205, 356
Alkaline phosphatase (abst) 465
in S3 segment (abst) 187
Alkalosis, metabolic
etiology (abst) 265
pathophysiology (abst) 534, 548
prevention and control (abst) 318
Alkalosis, respiratory
pathophysiology (abst) 545
Allograft
membranous nephropathy recurs (abst) 187
Allopurinol (abst) 525
mannitol in kidney preservation (abst) 1601
Alport's syndrome
genetics (abst) 248
immunology (abst) 441
pathology (abst) 252
pathophysiology (abst) 249
Aluminum
analysis (abst) 449
body burden (abst) 1611
bone and kidney PTH receptors 72
diagnositic use (abst) 315
erythroleukemia cells 677
hyperparathyroidism (abst) 1616
intoxication (abst) 1611
iron deficiency (abst) 1612
metabolism (abst) 307
monitoring in dialysis (abst) 186
osteomalacia (abst) 1389
overload, Fe absorption (abst) 1612
physiology (abst) 294, 449, 450, 451, 452, 471, 472
staining bone for 1142
steroids and chloroquine (abst) 1177
toxicity (abst) 286, 289, 291, 292, 295, 296, 299, 301, 305, 308, 309, 328, 449, 456, 472, 473, 474
uptake and transport (abst) 1611
Aluminum hydroxide
adverse effects (abst) 328
therapeutic use (abst) 451
Ambulatory blood pressure monitoring (abst) 398
Amiloride
analogs and derivatives (abst) 196
distal tubule function 996
pharmacology (abst) 577
Amino acid
analogs and derivatives (abst) 511
branched chain (abst) 509
physiology (abst) 371, 374, 500, 515, 521, 549
regulation (abst) 529
sulfur, cystinuria 143
therapeutic use (abst) 273
transport (abst) 230, 593
Amino acid sequence (abst) 382
Aminoglycoside antibiotic drugs (abst) 1174
tobramycin 1492
Aminoguanidine (abst) 506
Aminophylline (abst) 335
Ammonia
biosynthesis (abst) 212, 526, 530
metabolism (abst) 500, 527
physiology (abst) 543
regulation (abst) 529, 562
transport (abst) 264, 535, 536, 540, 542, 543, 547, 562, 583
Ammoniagenesis
antagonists and inhibitors (abst) 212
Ammonium chloride (abst) 530
Amphotericin B (abst) 285, 493
Amphotericin nephropathy (abst) 484, 493, 494
Amylases (abst) 615
Amyloid
associated hemodialysis (abst) 1604
Amyloid A
concentrations in HD (abst) 1386
Amyloidosis
complications (abst) 254, 287
diagnosis (abst) 296
etiology (abst) 290, 304
survival of patients in dialysis (abst) 1379
visceral (abst) 1605
Analbuminemia (abst) 356
Analgesic nephropathy (abst) 235
Anaphylatoxins
terminal complement complex an index to bioincompatibility 696
Ancrod, survival in lupus erythematosus 29
Anemia
Al in Friend erythroleukemia cells 677
changes in adrenergic system during EPO therapy (abst) 1178
diagnosis (abst) 289
dialysis, cysts, EPO levels (abst) 1599

drug therapy (abst) . 236, 237, 240, 244, 245, 271, 288, 293, 298, 299, 312, 313, 332, 378, 520
etiology (abst) . 240, 316, 507, 604
hematocrit effect in high efficiency hemodialysis. 1557
hematology with rHuEPO . 1599
hemorheological changes post-EPO treatment (abst) . 1178
increases 5′-nucleotidase in fibroblasts (abst) . 1164
pathophysiology (abst) . 286, 308, 473, 511
r-HuEPO in humans . 131
rHuEPO (abst) . 1585, 1593, 1609
surgery (abst) . 321
Angioplasty, renovascular hypertension (abst) . 1600
Angiotensin II
eicosanoid production, ureteral obstruction. 1528
Angiotensin converting enzyme
eicosanoid production, ureteral obstruction . 1528
Angiotensins
antagonists and inhibitors (abst) . 354, 359, 382, 557
metabolism (abst) . 354
pharmacology (abst) . 355, 358, 479, 592
physiology (abst) . 211, 213, 346, 350, 353, 354, 356, 359, 360, 378, 537, 541, 543, 548, 550, 552, 555, 556, 557, 571
receptors (abst) . 204, 359, 360, 476
Animal models
abnormalities of epithelium in SHR . 1438
osmotic diuresis and PT lithium reabsorption in dog. S-67
Anion gap (abst) . 265, 267, 268
Anipamil (abst) . 509
Anisotrophy (abst) . 225
Anoxia (abst) . 482, 490, 492, 493, 495, 529
Anti-GBM antibody (abst) . 252, 415
Anti-neutrophil cytoplasmic antibodies (ANCA)
analysis (abst) . 256
classification (abst) . 441, 442, 444
diagnostic use (abst) . 440, 443
immunology (abst) . 441, 444
physiology (abst) . 441, 442
Antibodies
biochemistry of IF-antineutrophil-cytoplasm (abst) . 1167
formation (abst) . 438, 607
neutrophil cytoplasm IgA (abst) . 1167
proximal tubule dysfunction in Heymann nephritis . 1536
reversal of rejection by OKT3 (abst) . 1607
role in immune complex formation . 1429
Anticoagulants (abst) . 318, 323, SPA24
Antidepressants, tricyclic toxicity (abst) . 272
Antigen-antibody load (abst) . 422
Antigenic determinants (abst) . 426
Antigens
classification (abst) . 441
diagnostic use (abst) . 433
genetics (abst) . 430
graft survival, HLA-dose II (abst) . 1608
hepatitis B infection . 663
isolation and purification (abst) . 441, 444
mercury induced anti-GBM disease . 64
MHC class II, TNF in epithelial cells . 783
nephritogenic, detection in TBM . 1286
receptors (abst) . 208
Antihypertensive agents (abst) . 519
Antineoplastic agents (abst) . 489
Antioxidants (abst) . 419, 477
Antiparasitic agents, toxicity (abst) . 478
Antiport
subcellular distribution of Na^+/H^+ in cortex . 707
Antiport, Ca^{++}/H^+ (abst) . 226
Antiport, Cl^-/HCO_3^- (abst) . 214, 388, 534, 536, 549, 579
Antiport, Na^+/Ca^{++} (abst) . 207, 210, 396, 461, 584
Antiport, Na^+/H^+ exchange
analysis (abst) . 196, 232
antagonists and inhibitors (abst) . 191, 343
genetics (abst) . 233, 384, 539, 540
pathophysiology (abst) . 199, 200, 394
physiology (abst) . 199, 226
regulation (abst) . 214, 228, 234, 353, 361, 371, 539, 560, 578
Antiport, Na^+/H^+ exchange (abst) . 193, 396, 533, 535, 537, 538, 540, 543, 547, 559
Antiport, Na^+/HCO_3^- (abst) . 529
Antiport, Na^+/K^+ (abst) . 510, 591
Aorta, injuries (abst) . 436
Aplastic osteodystrophy (abst) . 294, 449
Apo B, apo E rich lipoproteins . 1449
Apolipoproteins (abst) . 287
Arachidonic acids
biosynthesis (abst) . 350, 351
eicosanoid synthesis, *S. epidermidis* . 1316
mesangial cell proliferation . 1256
metabolism (abst) . 206, 344, 350, 351
metabolism in human kidney . 94
pharmacology (abst) . 348, 492
regulation (abst) . 214
Arginine (abst) . 528
Arginine vasopressin
calcium in cellular action of . 1060
Arrhythmias (abst) . 237
Arterio-venous fistula
vascular access in HD (abst) . 1599
Arterioles
(abst) . 367, 373
juxtamedullary afferent, TGF . 1402
Artery
compliance in ESRD . 137
Arthropathy, transplantation (abst) . 1615
Aspartic acid (abst) . 486
Aspirin (abst) . 348, 605
Atherosclerosis
complications (abst) . 242, 505
epidemiology (abst) . 318
pathophysiology (abst) . 212, 280, 287, 512
prevention and control (abst) . 609
Atomic absorption spectroscopy (abst) . 575
Atrial natriuretic factor
analogs and derivatives (abst) . 335, 337
biosynthesis (abst) . 339, 344
blood (abst) . 342
diagnostic use (abst) . 400
distal tubule function (abst) . 184
drug effects (abst) . 338, 342, 343
hormone effects (abst) . 336
pharmacology (abst) . 481, 586, 596
physiology (abst) . 199, 251, 267, 314, 335, 336, 337, 338, 339, 340, 341, 343, 375, 378, 503, 522, 523, 553, 574
receptors (abst) . 335, 337, 339, 341, 342, 344, 382
regulation (abst) . 217, 340, 362
secretion (abst) . 275, 284, 340, 343
suppression of prostaglandin production (abst) . 1175

therapeutic use (abst) 341, 495
urodilation (abst) 1173
Atrial natriuretic peptide
cardiac state in uremics (abst) 1382
effects on distal tubule function 996
hemodynamics, heart failure (abst) 1173
review in Nephrology Forum 1148
shifts Na to normal in hypertension (abst) 184
Attitude of health personnel (abst) 613
Autoantibodies
analysis (abst) 246, 447
anti-neutrophil cytoplasmic, Wegener's GN 186
immunology (abst) 445
isolation and purification (abst) 429
to myeloid lysosomal enzymes in CGN 799
Autoantigens (abst) 418
Autoimmune diseases (abst) 432
Autoimmune injury
drug therapy (abst) 477
genetics (abst) 422
pathology (abst) 422
pathophysiology (abst) .. 222, 377, 406, 409, 413, 414, 415, 421, 423, 424, 425, 428, 428, 429, 432, 434, 435, 437
regulation (abst) 406
Autoimmunity (abst) 351, 410, 445
Autonomic nervous system
drug effects (abst) 368
Autoregulation
in pancreatectomized and streptozotocin diabetic rats 909
in rat jAA 1402
Azathioprine
therapeutic use (abst) 406

β2 microglobulin
biosynthesis (abst) 303, 320, 325
blood (abst) 290
diagnostic use (abst) 296, 602
physiology (abst) 297, 304, 315
Bacterial infections
diagnosis (abst) 252
Bactobolin, therapeutic use (abst) 418
Band 3 proteins (abst) 224, 547
Baroreflex (abst) 392, 553
Basement membrane
anatomy and histology (abst) 246, 253
antibody to (abst) 415, 427, 435
drug effects (abst) 442
genetics (abst) 218, 219
immunology (abst) 437, 441, 446
pathophysiology (abst) 507
physiology (abst) 281, 592, 593
radionuclide imaging (abst) 408
ultrastructure (abst) 447
Basement membrane protein
altered biosynthesis by cpk/cpk mouse kidney 1090
Basolateral membrane
effect of diuretics on K transport 1423
organic bases transport (abst) 1161
Basque organ procurement center (abst) 1605
Benazepril
pharmacology (abst) 404
therapeutic use (abst) 235
Bence Jones proteins (abst) 494
Beta thromboglobulin levels in CAPD (abst) 133
Betadine, therapeutic use (abst) 307
Betaine, antagonists and inhibitors (abst) 585
Bicarbonate
correction of hypertriglyceridemia (abst) 1587
dependence of Cl−/base exchange (abst) 1161
tobramycin, metabolic alkalosis 1492
Bicarbonates
pharmacology (abst) 266
physiology (abst) 545
secretion (abst) 234, 536
transport (abst) 386, 467, 535, 536, 537, 538, 541, 542, 544, 545, 546, 548, 572
tubular acidification by Li S-75
Binding sites (abst) 201, 293
Biocompatibility of materials
(abst) 290, 308
immunology (abst) 288
pathophysiology (abst) 300, 316, 322, 325
Bioincompatibility
adequacy of dialysis 822
immune response in HD (abst) 1179
index, terminal complement complex 696
Biomaterials, central register (abst) 1180
Biopsy
immunofluorescence (abst) 1387
modified fine needle aspiration 812
techniques (abst) 279, 281
Biopty instrument (abst) 602
Bladder
cytology (abst) 572
irrigants (abst) 269
receptors (abst) 191
secretion (abst) 538, 544
Bleeding time (abst) 294, 322
Blood
aortic and large artery compliance in ESRD 137
interaction with artificial surfaces (abst) 1180
natural trace, and urine levels, Li S-58
recirculation, body temp. and hemodynamics (abst) .. 1589
total calcium in (abst) 1176
ultra-short purification (abst) 1586
Blood coagulation disorders, drugs (abst) 294
factors (abst) 381, 524
Blood coagulation physiology
drug effects (abst) 303, 523
hormone effects (abst) 516
pathophysiology (abst) 276
Blood flow
autoregulation in jAA, TGF 1402
autoregulation of in ischemic kidney (abst) 183
renal autoregulation in diabetic rats 909
renal medullary circulation 1
Blood membrane
terminal complement complex as index 696
Blood pressure
controls progression of renal insufficiency (abst) 1170
drug effects (abst) 303, 523
levels and age (abst) 1598
physiology (abst) 386, 389, 390, 405
regulation (abst) 339, 361, 386, 395
regulation during CsA therapy (abst) 1188
role of race and antihypertensive medications 1113
Blood transfusion
complications (abst) 320

immunology (abst) 600
pathophysiology (abst) 606
therapeutic use (abst) 598, 608
Blood viscosity (abst) 271
Blood volume (abst) 314, 354
Body fluid compartments
analysis (abst) 281
drug effects (abst) 304
pathophysiology (abst) 501
physiology (abst) 304, 314
Bone
(abst) 448, 452
loss of mass in transplant patients (abst) 1603
mineral content (abst) 451
resorption (abst) 271, 304, 334, 451, 454
staining for Al 1142
turnover (abst) 450
Bone disease
Al induced (abst) 452
Bone marrow
(abst) 290
transplant (abst) 285, 438
Bowman's capsule (abst) 219, 257
Bradykinin
physiology (abst) 209, 365, 373
receptors (abst) 348
Brain
adaptation (abst) 269
analysis (abst) 214
edema (abst) 268
gut peptides 1031
metabolism (abst) 521
natriuretic peptide (abst) 321
neoplasms (abst) 259
physiology (abst) 383, 389, 586, 591
secretion (abst) 321
treating hyponatremia 1006
Bright's disease, history of Thomas Addis 833
Brush border membrane
aminoglycoside antibiotic drugs (abst) 1174
Na+/H+ antiport activity 707
oxalate:OH exchange 1105
transport in cadmium intoxication 727
Buffers
(abst) 544
cause hypoxemia (abst) 1595
Bumetanide
(abst) 270, 567
diuretic effect in Milan hypertensive rats 1084
ouabain effect on Li transport S-71

CAPD
anemia by CEI (abst) 1614
arterial calcification (abst) 1594
beta thromboglobulin levels (abst) 1614
carpal tunnel syndrome (abst) 1594, 1613
cytotoxicity of fluids (abst) 184
eicosanoid synthesis, S. epidermidis 1316
experience with rHuEPO (abst) 1179
gemfibrozil (abst) 132
human peritoneal mesothelial cells 1563
lipoprotein leakage, lipid levels, protein loss 980
multicystic transformation (abst) 1385
peritoneal equilibration test (abst) 1385
peritoneal function (abst) 1182
peritoneal macrophage response to vitamin D 1310
protein loss during 971
psyllium seed husk (abst) 1385
rHuEPO (abst) 1592
regional treatment program (abst) 1591
ultrafiltration failure (abst) 1614
zero net UF (abst) 1591
CAVH
pharmacokinetics (abst) 1180
CGS 13080 (abst) 604
Ca2+
endothelin, eicosanoid in mesangial cells 927
Cadaveric transplantation
survival (abst) 1591
Cadmium
K conductance in MDCK cells 1477
intoxication, transport of organic compounds 727
toxicity (abst) 477
Calciphylaxix (abst) 280
Calcitonin
(abst) 473
gene related peptide (abst) 314
Calcitriol
adverse effects (abst) 452
analogs and derivatives (abst) 464
biosynthesis (abst) 465, 466, 470
metabolism (abst) 467, 469
metabolism in RF 44
physiology (abst) 271, 390, 420, 468, 470, 518, 594
receptors (abst) 200, 469
regulation (abst) 465, 466
therapeutic use (abst) 391, 451, 463, 464, 465, 468
Calcium
abnormalities of epithelium in SHR 1438
antagonists and inhibitors (abst) 452, 485
cytosolic, acidosis in VSMC (abst) 1597
diuretic action of antagonist (abst) 1166
effect of CsA in intracellular free (abst) 1187
entry blockers (abst) 1606
excretion (abst) 393
gluconate (abst) 403
hormone effects (abst) 387, 473, 518
idiopathic hypercalciuria in children 807
intracellular (abst) 205, 210, 211, 213, 362, 371, 487, 576, 594, 595
metabolism (abst) 390, 399, 405, 455, 475
optimal contration in collecting tubules 1060
pharmacokinetics (abst) 478
pharmacology (abst) 494
physiology (abst) 210, 283, 290, 293, 302, 324, 367, 388, 390, 391, 407, 454, 456, 460, 462, 468, 470, 505, 541, 546, 553, 561, 564, 567
regulation (abst) 206, 207, 208, 209, 211, 213, 216, 396, 458, 461, 470, 590
steroids and chloroquine (abst) 1177
therapeutic use (abst) 274, 296, 388, 402, 481
total in blood (abst) 1176
transport (abst) 337, 372, 393, 456, 457, 458, 460, 461, 464, 467, 468, 471, 486, 584
two antagonists, hemodynamics (abst) 1171
Calcium acetate (abst) 449
Calcium binding protein (abst) 471
Calcium carbonate
administration and dosage (abst) 304
adverse effects (abst) 450

pharmacology (abst) ... 456
therapeutic use (abst) ... 451, 452, 455
Calcium channel blockers (abst) ... 268
Calcium channels
genetics (abst) ... 232
hormone effects (abst) ... 367
physiology (abst) ... 205, 387, 454, 456, 458, 584
Calcium oxalate
(abst) ... 459, 462, 471
antagonists and inhibitors (abst) ... 462, 474
crystal agglomeration in stones ... 51
Calmodulin (abst) ... 370
dependent kinase (abst) ... 196
cAMP
cellular free calcium in AVP induced ... 1060
lithium effect in IMCT ... 1211
Campylobacter pylori incidence (abst) ... 1180
Cancer
transitional cell carcinoma in APKD (abst) ... 1181
Captopril
hypertension and proteinuria (abst) ... 1609
hypoprotein diet (abst) ... 1606
isotopic renography (abst) ... 1602
obesity and proteinuria (abst) ... 1607
pharmacology (abst) ... 271, 355, 390, 516, 523, 524
proteinuria (abst) ... 1587
renography (abst) ... 398, 404, 405
test vs. sequential scintigraphy, hypertension (abst) ... 1172
therapeutic use (abst) ... 242, 261, 551
therapy in GS (abst) ... 1170
Carbohydrate, metabolism, metyrapone (abst) ... 1175
Carbon dioxide (abst) ... 535, 541
Carbonic anhydrase
(abst) ... 533, 540
inhibition with acetazolamide (abst) ... 1161
inhibitors (abst) ... 545
Cardiac
function during HD (abst) ... 1176
instability after short dialysis (abst) ... 1610
output (abst) ... 283, 517
surgery, ARF after (abst) ... 1596
tamponade (abst) ... 284, 312
Cardiology
hemodynamics and ANP (abst) ... 1173
Cardiopulmonary resuscitation in dialysis patients
(abst) ... 1183
Cardiovascular diseases, mortality (abst) ... 241, 283
Carnitine
deficiency (abst) ... 492
Carpal tunnel syndrome (abst) ... 305
in CAPD (abst) ... 1594, 1613
Carrier proteins (abst) ... 454
Catecholamines
abnormalities in ARF (abst) ... 1175
(abst) ... 362, 383, 396, 398, 479
in hypertension (abst) ... 1379
Cathepsin B and L activity, LMWP and dextran ... 918
Cathepsins (abst) ... 229, 407, 486
Catheter
ciprofloxacine (abst) ... 1613
infections (abst) ... 327, 328, 329, 335
insertion of Tenckhoff (abst) ... 1385
intravascular types (abst) ... 307
prophylactic filling with heparin or urokinase (abst) ... 1181
thrombosis after HD (abst) ... 1386
Cell
accessory functions in PBMC cultures from uremics ... 126
adhesion (abst) ... 219, 223, 308
culture techniques (abst) ... 194, 200, 201, 217, 221, 228, 231, 416
differentiation (abst) ... '94, 197, 198, 222
division (abst) ... 335, 367
epithelial, growth in vitro ... 1048
fusion (abst) ... 228
growth, brain-gut peptides ... 1031
human peritoneal mesothelial ... 1563
intracellular communication (abst) ... 228
migration (abst) ... 408
Cell kinetics & growth
drug effects (abst) ... 190
hormone effects (abst) ... 198
pathophysiology (abst) ... 199
regulation (abst) ... 191, 198, 204, 217, 500
Cell membrane permeability
(abst) ... 543, 547, 581, 592
drug effects (abst) ... 304
pathophysiology (abst) ... 495, 502
regulation (abst) ... 211, 583, 585, 593
transport (abst) ... 226
Cell membranes (abst) ... 201, 408, 426
Cell membranes (apical)
hormone effects (abst) ... 205, 227
immunology (abst) ... 415
metabolism (abst) ... 490
physiology (abst) ... 216, 217, 227, 458, 533, 534, 560, 583, 585, 590, 592
transport (abst) ... 225, 230, 559
Cell membranes (basolateral)
(abst) ... 214, 215, 217, 458, 533, 534, 538, 543, 545, 546, 563, 584, 590, 591
Cell membranes (brush border)
anatomy and histology (abst) ... 232
drug effects (abst) ... 578
immunology (abst) ... 445
isolation and purification (abst) ... 527
metabolism (abst) ... 529
physiology (abst) ... 207, 215, 225, 343, 455, 457, 460, 462, 465, 585, 589, 593
transport (abst) ... 234
Cell polarity
orientation (abst) ... 215, 222, 229, 533, 538
orientation, physiology (abst) ... 209, 216, 224, 586, 587
Cell proliferation
(abst) ... 192, 195, 203, 509, 516
regulation (abst) ... 197, 199, 201, 202, 204, 350, 408, 410, 412, 414, 417, 426, 436, 490
Cell volume
(abst) ... 226, 560, 571, 573
regulation (abst) ... 216, 564, 567, 573, 576, 579, 580, 581, 586, 590
Cellular electrophysiology (abst) ... 232, 369, 439, 563, 564, 565, 570, 576
Cellular immunity (abst) ... 423, 428, 443, 599
Cellular transport mechanisms
(abst) ... 487, 533, 573, 593
hormone effects (abst) ... 534, 573
regulation (abst) ... 229, 372, 383, 459, 538, 559, 568, 569
Central pontine myelinolysis (abst) ... 262
Cerebral
aneurysm (abst) ... 249

blood flow (abst) 295, 303
hemmorrhage (abst) 295
infarction (abst) 394
Chemistry, Henry Bence Jones 1019
Children
development (abst) 605
early detection of renal disease, infection (abst) 1168
hemolytic uremic syndrome, thromboxane 1134
idiopathic hypercalciuria 807
Chlorides
(abst) 396, 570, 579
antagonists and inhibitors (abst) 365
channels (abst) 211, 215, 216, 564, 570, 571
physiology (abst) 544, 569
response to Ang II, salt sensitivity (abst) 1172
secretion (abst) 566, 581
transport (abst) 363, 377, 380, 386, 389, 396, 539, 559, 563, 566, 567, 575, 586
Cholera toxin (abst) 561
Cholesterol
(abst) 207, 280, 324
biosynthesis (abst) 520
blood (abst) 499, 502, 512
oxidase (abst) 207
physiology (abst) 371, 514, 515
renal injury of diet induced 880
Cholestyramine (abst) 520
Choline
(abst) 212
transport in IMCD cells (abst) 1164
Chondroitin (abst) 221, 415
Chromagranin A
in renal failure 1357
in uremia 955
Chromatography (abst) 233, 234, 459
Chromogranins (abst) 382, 394, 469
Chronic renal disease
role of race and antihypertensive medications 1113
Chronic renal failure
arterial hypertension (abst) 1603
clinicopathological study, dialysis 1333
complications (abst) . 237, 238, 240, 245, 464, 507, 516, 551
diagnosis (abst) 255
diet therapy (abst) 239, 243, 499
drug effects (abst) 401
drug therapy (abst) 242, 399, 424, 498
erythropoietin (abst) 1383
evolution of APKD (abst) 1596
excess PTH, lipid metabolism 854
expression of IL-2 receptors (abst) 1179
fenoldopam (abst) 1606
genetics (abst) 253, 420
high-density lipoprotein kinetics 1295
human T cell activation 1543
immunology (abst) 438, 439, 443
management of hyperlipidemia 847
mortality (abst) 241
outcome (abst) 399
pathophysiology (abst) .. 235, 257, 285, 312, 384, 467, 470, 499, 504, 505, 521, 531
piretanide effect (abst) 1176
progression, review 1195
regional treatment program (abst) 1591
response of GH and LH (abst) 1602
therapy (abst) 330
tumor markers (abst) 1605
Chronic renal insufficiency
predialysis, EPO therapy (abst) 1178
tumor markers (abst) 1590
Ciprofloxacin (abst) 259
kinetics in ARF (abst) 1180
peritonitis treatment (abst) 1616
skin infections (abst) 1613
Circadian rhythm (abst) 253, 258
Circulation, renal medullary 1
Cirrhosis (abst) 341
hepatitis B 663
Cisplatin
chronic magnesium loss in childhood (abst) 1169
pharmacology (abst) 457
toxicity (abst) 480
Cisplatin nephropathy
diagnosis (abst) 481
pathophysiology (abst) 483
Citrates
adverse effects (abst) 318
anticoagulation in HD (abst) 186
physiology (abst) 305, 471
therapeutic use (abst) 323
urine (abst) 282, 284
Clearance
acetazolamide and furosemide, Li S-63
cathepsin B and L activity, LMWP and dextran 918
effect of diuretic, antidiuretic agents on Li S-22
furosemide effect during volume expansion S-45
lithium as measure of Na and H_2O delivery in PT ... S-10
lithium reabsorption beyond proximal tubules S-39
lithium, history S-2
natural trace blood and urine levels, Li S-58
osmotic diuresis, Li reabsorption in dog S-67
sites of Li transport in nephron S-26
sodium intake and diuretics, Li clearance S-36
substance P and SQ 12,225 effect on (abst) 1172
validity of lithium concept S-17
xipamide (abst) 1166
Clonidine (abst) 366
Cloning
complementary DNA to protein mRNA 1460
methods (abst) 191, 232, 233, 234
Clubbing, fingers (abst) 448
cDNA
(abst) 359, 584
isolation and purification (abst) 232, 233, 430
Colchicine (abst) 422
Collagen IV
carboxyterminal domain in diabetes (abst) 1388
Collagens
biosynthesis (abst) . 195, 218, 220, 221, 222, 344, 416, 426, 507, 508, 518
C5b-8 and C5b-9 modulate, epithelial cells 1098
diagnostic use (abst) 258
genetics (abst) 510
hormone effects (abst) 504
immunology (abst) 446
pathology (abst) 440, 447
physiology (abst) 447
secretion (abst) 416
Colon (abst) 227
Colony stimulating factors (abst) 205, 424
Coma (abst) 267

Complement
activation by HD membranes ... 1055
alternative pathway determined in plasma (abst) ... 1179
diagnostic use (abst) ... 243, 444
fixation texts (abst) ... 273
immunology (abst) ... 412, 429
interleukin-1, TNF ... 85
isolation and purification (abst) ... 443
phagocytic cell function in HD model ... 776
receptors (abst) ... 409, 432
regulation (abst) ... 431, 433
terminal complex, index to bioincompatibility ... 696
Complement activation
drug effects (abst) ... 291
immunology (abst) ... 438
pathophysiology (abst) ... 288, 299, 300, 302, 319, 599
physiology (abst) ... 308
regulation (abst) ... 430
Computers
diagnostic use (abst) ... 411
methods (abst) ... 283, 300
models (abst) ... 488
modulated profile hemodialysis (abst) ... 1181
Concentrating ability (abst) ... 572, 592
Congestive heart failure
diagnosis (abst) ... 489
drug therapy (abst) ... 338
pathophysiology (abst) ... 267, 269, 275, 337, 571
Connective tissue disorders, drugs (abst) ... 278, 402
Constipation (abst) ... 272
Contrast media (abst) ... 260, 282, 480, 483, 484, 489, 492
Converting enzyme inhibitors
anemia in CAPD (abst) ... 1614
growth hormone, rise in GFR (abst) ... 1171
post-glomerular resistance in GS mice (abst) ... 183
Converting enzyme, angiotensin (abst) ... 355, 356, 359
Coronary artery disease
(abst) ... 243
long-term complications of transplantation ... 1363
Cortex
subcellular distribution of Na+/H+ ... 707
Cortical cells
growth regulators of ... 875
Cortical collecting duct
basement membrane alterations, cysts ... 1270
furosemide effect ... 1248
modeled by MDCK cells (abst) ... 1163
potassium channels (abst) ... 1162
Cortical collecting tubule
reaction of MDCK cells to crystals ... 36
Cortisol (abst) ... 384
Costs, cost analysis (abst) ... 241, 520
Creatinine
blood (abst) ... 241, 248, 249
clearance (abst) ... 241, 272, 496
long-term complications of transplantation ... 1363
metabolism (abst) ... 531
renal extraction (abst) ... 185
Crescent
mononuclear cell activation, IgAN ... 1552
plasminogen activator secretion ... 1466
Crescentic glomerulonephritis
autoantibodies to myeloid lysosomal enzymes ... 799
idiopathic form (abst) ... 1187
Critical care (abst) ... 286
Cromakalim (abst) ... 582
Cryoglobulinemia (abst) ... 444
Cryoprecipitate, uremic thrombopathy (abst) ... 1605
Crystal
calcium oxalate stone formation ... 44
uric acid and monosodium urate monohydrate ... 36
Culture
human peritoneal mesothelial cells ... 1563
Cuprophan
activation of complement by HD membranes ... 1055
Cyclic AMP
(abst) ... 362, 365, 379, 460, 576
physiology (abst) ... 202, 206, 209, 216, 226, 464, 464, 536, 586
receptors (abst) ... 367
Cyclic GMP (abst) ... 335, 336, 338, 343, 360
Cyclo-oxygenase (prostaglandin synthase)
antagonists and inhibitors (abst) ... 345, 346, 348, 365
physiology (abst) ... 192, 347, 351, 375
Cyclophilin, cloning of cDNA to mRNA ... 1460
Cyclophosphamide
(abst) ... 238, 256
treatment of lupus nephritis (abst) ... 1595, 1605
Cyclosporin A
bad response to steroid (abst) ... 1610
cadaver renal transplant (abst) ... 1601, 1614
childhood INS (abst) ... 1616
compensatory kidney growth (abst) ... 1598
dosage (abst) ... 1184
effect on intracellular free Ca (abst) ... 1187
induced tubular atrophy (abst) ... 1185
initial nonfunction of allograft (abst) ... 1602
kidney growth, function in rat ... 21
lack of NAG activity correlation (abst) ... 1185
measuring in blood (abst) ... 1593
monitoring of prostaglandins (abst) ... 1587
regulation of BP and hANP (abst) ... 1188
relapse after discontinuation (abst) ... 1167
renal changes in transplants (abst) ... 1384
renal function during therapy (abst) ... 1188
triple drug therapy (abst) ... 1613
Cyclosporine
circadian rhythms (abst) ... 1603
cytochemical detection of toxicity (abst) ... 187
elderly patients (abst) ... 1607
endothelin role in glomerular dysfunction ... 1487
osteodystrophy in transplants (abst) ... 1603
Cyclosporine nephropathy
diagnosis (abst) ... 260, 482, 496, 610
epidemiology (abst) ... 482
pathology (abst) ... 493, 600
pathophysiology (abst) ... 190, 477, 479, 483, 485, 486, 495, 497, 594, 599, 607, 610
therapy (abst) ... 350
Cyclosporines
adverse effects (abst) ... 266, 391, 392, 403, 475, 598, 605, 608, 613
immunology (abst) ... 601
metabolism (abst) ... 600
pharmacology (abst) ... 193, 365, 391, 595, 597, 598, 602, 607
therapeutic use (abst) ... 255, 442, 482, 483, 489, 603, 606, 613
toxicity (abst) ... 190, 234, 260, 285, 493, 594, 595, 597, 607, 610, 612
Cystatin (abst) ... 500

Cysteine
mercapturic acid formation in kidney (abst) 1161
Cystic kidney disease, acquired..... 505
Cystinosis (abst)..... 517, 530
Cystinuria
sulfur amino acid metabolism..... 143
Cysts
analysis in PKD (abst)..... 20
anemia, dialysis, EPO (abst) 1599
basement membrane alterations during development . 1270
decompression surgery (abst)..... 247
development/formation (abst)..... 190, 225, 412, 581
glucocorticoid induced PKD 901
volume, cystic puncture (abst)..... 1588
intra- and extracellular proteins in PKD 1301
multicystic transformation in CAPD (abst) 1385
prognosis of APKD (abst)..... 1597
volume, cystic puncture (abst) 1588
Cytochrome P450, AA metabolism in human kidney..... 94
Cytochromes (abst)..... 344, 345, 350, 360, 376, 600
Cytokine
(abst)..... 594
oxygen radical production 767
uremia and HD influence on IL-1 and TNFa 116
Cytomegalovirus infection (abst) 607, 608, 610, 611
MHC class I expression (abst)..... 187
Cytoplasmic viscosity (abst) 225
Cytoskeletal proteins (abst)..... 226, 531
Cytoskeleton (abst)..... 224, 226, 230
Cytotoxicity
histidine (abst)..... 1183
lymphoid serine protease, allografts..... 1350

DFMO (difluoromethylornithine) (abst)..... 433, 434
DNA
antagonists and inhibitors (abst)..... 415
biosynthesis (abst) 420
drug effects (abst)..... 483
markers and PKD diagnosis (abst)..... 1597
repair (abst)..... 420
DOPA decarboxylase (abst)..... 363
Decay accelerating factor (abst)..... 431, 433
Decidua basalis (abst) 597
Decision analysis (abst) 482
Deferoxamine
(abst) 273, 289, 292, 309, 451
Dehydration (abst) 549
Delayed graft function (abst) 606, 611
Denervation (abst) 454
15-Deoxyspergualin (abst) 417
Deoxiurdine test (abst)..... 1590
Desferrioxamine
in Al overload (abst)..... 1611
Desmin (abst)..... 230
Dexamethasone (abst) 563, 601
Dextran effect on cathepsin B and L activity 918
Diabetes
antihypertension therapy (abst) 1170
arterial calcification (abst) 1594
concentrations of glucose affect PTH secretion..... 1522
glucose-6-phosphate in IM (abst)..... 1169
microalbuminuria and exercise (abst)..... 1381
pantethine treats hyperlipidemia (abst) 1616
proteinuria, hypertension, captopril (abst)..... 1609
steroid therapy, insulin (abst)..... 1384
streptozotocin, pancreatectomized rats,
autoregulation 909
Diabetes insipidus
(abst) 246, 250, 362, 499, 592
Diabetes mellitus
Immunology (abst) 426
and ESRF, smoking (abst) 1381
carboxyterminal domain (abst)..... 1388
complications (abst) 241, 243, 245, 263, 280, 282, 301, 329, 398, 506, 610
diet therapy (abst)..... 236
drug therapy (abst) 401, 475, 483
excretion of laminin, fibronectin and THP (abst) 1169
kappa light chain excretion..... 1120
pathology (abst) 436
pathophysiology (abst) .. 263, 274, 285, 339, 341, 347, 350, 501, 505, 509, 511, 512, 513, 522, 524, 528, 550, 553, 554, 555
pattern of urinary protein excretion (abst)..... 1381
Diabetes, insulin dependent
prevalence of microalbuminuria (abst)..... 1381
smoking and hyperfiltration (abst) 1381
Diabetes, type 1
hemodynamics and segmental tubular reabsorption .. 1126
renal functional reserve (abst) 1170
Diabetes, type 2
newly diagnosed (abst)..... 1381
Diabetic nephropathy
complications (abst) 236, 239
diagnosis (abst)..... 241, 259
diet therapy (abst)..... 246
drug therapy (abst) 236, 239, 245, 506, 516, 519
epidemiology (abst)..... 272
genetics (abst)..... 510
hormone effects (abst) 261
mortality (abst)..... 241
pathology (abst) 440, 447
pathophysiology (abst) .. 199, 221, 224, 236, 248, 285, 345, 360, 404, 502, 506, 507, 508, 510, 512, 513, 517, 519, 520, 521, 522, 523, 585, 588
therapy (abst) 282
Diacylglycerol kinase (abst)..... 208
Diacylglycerols (abst) 212, 206, 421, 431, 559
Dialysate
acetate free biofiltration (abst) 1586
glucose concentration (abst)..... 1385
sterile, effect on fever (abst)..... 1187
uremic encephalopathy..... 892
Dialysis
Al in Friend erythroleukemia cells..... 677
(abst)..... 239, 282, 309, 310, 315, 420, 448, 449, 451
adequacy..... 822
adrenergic modulation of K in uremia..... 793
amyloidosis patient survival (abst)..... 1379
antiproteinase activity (abst) 1597
arthropathy (abst)..... 1615
cardiopulmonary resuscitation (abst)..... 1183
census, Galician (abst) 1596
changing patient population (abst)..... 1386
clinicopathological study 1333
comparative study, HD and CAPD (abst) 1591

complications (abst) 235, 237, 244, 283, 287, 289, 290, 291, 294, 298, 305, 309, 311, 312, 314, 316, 318, 320, 323, 325, 331, 334, 400, 403, 449, 450, 473, 492
cultured PBMC, cell function 126
drug therapy (abst) . 237, 289, 304, 307, 311, 319, 322, 324, 373
efficiency of techniques, rHuEPO (abst) 1586
epidemic hypotension caused by sodium azide 110
erythropoietin production (abst) 1383
exercise capability post-EPO treatment (abst) 1178
immunology (abst) 299, 302, 310, 322, 323, 436
lipoprotein leakage in CAPD 980
methods (abst). 273, 290, 292, 293, 297, 302, 306, 313, 315, 379
mortality (abst) 291, 301, 313, 324, 325
outcome (abst). 297, 300, 315, 318, 321, 322, 330, 333, 362, 368, 608
pathophysiology (abst)... 288, 290, 294, 295, 297, 306, 312
physiology (abst) 304, 311, 314, 317, 324, 340
protein loss during CAPD 971
rHuEPO (abst) 1591
rapid high-efficiency (abst) 1615
slow (abst) 313, 316, 320
staining bone for Al 1142
surgery (abst) 303
therapeutic use (abst) 325
tidal peritoneal (abst) 332
ultra-short blood purification (abst) 1586
ultrafast (abst) 320
value of serum Al monitoring (abst) 186
venovenous (abst) 321
visceral amyloidosis (abst) 1605
Dialysis catheters, complications (abst) 326
Dialysis membranes
adverse effects (abst) 494
complications (abst) 288, 293, 295
methods (abst). 287, 288, 290, 291, 294, 297, 298, 299, 300, 302, 306, 307, 308, 309, 320, 322
therapeutic use (abst) 316
Dialysis membranes, cuprophane
adverse effects (abst) 301, 325
complications (abst) 303, 315
immunology (abst) 299, 308
physiology (abst) 287
Dialysis solutions
adverse effects (abst) 298
complications (abst) 331
immunology (abst) 329
methods (abst) . 292, 293, 302, 316, 318, 322, 324, 332, 334
Dialysis units, epidemiology (abst) 310
Dialysis, CAPD
complications (abst) 132, 244, 279, 309, 326, 327, 328, 329, 331, 332, 333, 334
drug therapy (abst) 326, 330
epidemiology (abst) 330
immunology (abst) 327, 329, 330, 436
methods (abst) 332, 379, 455
mortality (abst) 324, 330
outcome (abst) 277, 326, 330, 333
physiology (abst) 334
rehabilitation (abst) 333
Dialysis, high efficiency
complications (abst) 298, 324
methods (abst) 292, 319
outcome (abst) 296, 319
physiology (abst) 295, 310, 317
Dialysis, high flux
complications (abst) 286, 295, 298, 301, 322
methods (abst) 306
pathophysiology (abst) 288
physiology (abst) 317
Dialysis, pediatric complications (abst) 326
Dialysis, peritoneal
(abst) 329, 331, 335
drug therapy (abst) 331
outcome (abst) 327, 332, 399
pathophysiology (abst) 328
Dialysis, short
cardiovascular instability (abst) 1610
Dialyzers
activation of complement by HD membranes 1055
antiproteinase activity (abst) 1597
blood interaction with artificial surfaces (abst) 1180
central register for side effects of (abst) 1180
phagocytic cell function in HD model 776
plasma IL-1 levels (abst) 1588
study of Hemophan and cellulose acetate membrane (abst) 1386
terminal complement complex, index of bioincompatibility 696
Diet
hypoprotein, captopril (abst) 1606
induced hypercholesterolemia, renal injury 880
influence of K on phosphorus concentration 1341
influence of, Henry Bence Jones 1019
intestinal permeability in uremics (abst) 1389
management of hyperlipidemia 847
phosphate restriction, protine kinase C 682
restriction of phosphate, insulin 14
sodium intake and diuretics, Li clearance S-36
Dietary carbohydrates (abst) 523
Dietary fats
physiology (abst) 360, 382, 395, 524, 532
therapeutic use (abst) 556
Dietary intake (abst) 384, 388, 589
of sodium (abst) 400, 411
Dietary modification (abst) 609
Dietary proteins
adverse effects (abst) 501
pharmacology (abst) 357, 591
physiology (abst) ... 376, 501, 502, 503, 510, 528, 558, 615
Digoxin-like factor (abst) 1173
Dihydrophyridines (abst) 456
24,25 Dihydroxyvitamin D_3 (abst) 451
Diltiazem (abst) 245, 596
Dimethylaminoethanol (abst) 585
Dimethylthiourea (abst) 423
Disinfection methods (abst) 287
Distal convoluted tubules
diuretics effect on K transport 1423
Distal tubule
atrial natriuretic peptide 996
bumetanide and ouabain effect on Li transport S-71
function, ANP (abst) 184
Diuresis
(abst) 339, 341, 381
drug effects (abst) 271, 338, 528, 583, 587
physiology (abst) 270, 284
regulation (abst) 369, 577, 580, 587, 592

Diuretics
(abst) ... 561, 577
action of calcium antagonist (abst) ... 1166
acetazolamide, furosemide, Li clearance ... S-63
agents affect on Li clearance ... S-22
atrial natriuretic peptide, reviewed ... 1148
bumetanide in Milan hypertensive rats ... 1084
effect on K transport ... 1423
sodium intake and lithium clearance ... S-36
validity of lithium clearance ... S-17
Dopamine
gamma-L-glutamyl-L-dopa ... 1414
metabolism (abst) ... 1185
pharmacology (abst) ... 343, 370, 481
physiology (abst) ... 359, 363, 378, 455, 522
receptors (abst) ... 341, 368, 374, 379, 388
therapeutic use (abst) ... 555
Dopamine B hydroxylase
in renal failure ... 1357
Doppler ultrasound (abst) ... 242, 616
Dosage
lithium ... S-78
Dosage forms (abst) ... 304
Drug delivery systems (abst) ... 527
discontinuation (abst) ... 604
induced nephropathies (abst) ... 259, 487
interactions (abst) ... 333
overdose (abst) ... 272, 302
targeting, LMWP (abst) ... 187
Duplex-echography in hemodialysis (abst) ... 1587
Dyslipidemia management in renal disease ... 847
Dyslipoproteinemia, renal insufficiency (abst) ... 1382

Erythropoietin
models for patient selection (abst) ... 1383
Early graft function (abst) ... 611
Early growth response, ischemia ... 1515
Edema, treating hyponatremia ... 1006
Education (abst) ... 283
Efferent arteriole
hyderonephrotic rat kidney ... 1227
Eicosanoids
(abst) ... 345, 524
endothelin synthesis in mesangial cells ... 927
excretion (abst) ... 594
potassium conductance in proximal tubules (abst) ... 1162
production, ureteral obstruction ... 1528
prostaglandins and mesangial cell proliferation ... 1256
synthesis, S. epidermidis ... 1316
Electroencephalography (abst) ... 289
Electrolytes
abnormality, hyponatremia ... 1006
acid-base disorders, HIVN ... 1571
Electron microscopy (abst) ... 447
Electrophysiology of Triturus nephron ... 157
Enalapril
adverse effects (abst) ... 604
in IgAN (abst) ... 1380
low protein in puromycin aminonucleoside nephropathy ... 749
pharmacology (abst) ... 245, 347, 385, 498, 504, 508, 509, 511, 516, 518, 519, 520
therapeutic use (abst) ... 236, 261, 278, 391, 401, 402
Encephalopathy in CRF
dialysable solutes ... 892
drug effects (abst) ... 293, 298
etiology (abst) ... 289, 313, 320
pathophysiology (abst) ... 306
End-stage renal disease
adequacy of dialysis ... 822
clinical issues with APKD (abst) ... 1588
complications (abst) ... 236, 237, 240, 307, 312, 323, 449
epidemiology (abst) ... 239, 241, 244, 252, 257, 270, 285, 404
erythropoietin therapy (abst) ... 1178
etiology (abst) ... 236, 248, 251, 257, 276
gene polymorphism in IgAN ... 991
mortality (abst) ... 239, 283, 325
peritoneal function in CAPD (abst) ... 1182
peritonitis, vitamin D_3 ... 1310
progression of CRF, review ... 1195
protein loss in CAPD ... 971
renal involvement with HIV ... 1325
structural adaptation of nephrons (abst) ... 1170
End-stage renal failure
aortic compliance in ... 137
children and rHuEPO (abst) ... 1604
human T cell activation and PTH ... 1543
intra- and extracellular proteins in PKD ... 1301
long-term complications of transplantation ... 1363
Endephalopathy in CRF
diagnosis (abst) ... 305
Endocrine
abnormalities in CRF (abst) ... 1602
Endocytosis
hormone effects (abst) ... 530
physiology (abst) ... 415, 417, 589
regulation (abst) ... 227, 341
Endoplasmic reticulum (abst) ... 216, 578
Endosomes (abst) ... 228
Endothelial cells
(abst) ... 365, 385
cyclosporine-induced glomerular dysfunction ... 1487
injury (abst) ... 595, 599
isolation and purification (abst) ... 194
thromboxane biosynthesis in HUS ... 1134
Endothelin
(abst) ... 190, 365, 367, 372, 373, 380, 385, 479, 587
cyclosporine-induced glomerular dysfunction ... 1487
eicosanoid synthesis, mesangial cells ... 927
physiology (abst) ... 211, 282, 366, 369, 372, 373, 380, 385, 479, 587
receptors (abst) ... 203, 210, 363, 374
response to, PAF-acether (abst) ... 1603
Endothelium-derived relaxing factor (EDRF)
antagonists and inhibitors (abst) ... 387, 395
physiology (abst) ... 203, 364, 371, 373, 379
Endotoxins (abst) ... 203, 364, 371, 373, 379
effects on kidney function ... 1219
Energy metabolism (abst) ... 515
ischemic (abst) ... 1174
Enisoprost (abst) ... 421
Enteral feeding (abst) ... 329
Enzymes
cytochrome P450, AA metabolism ... 94
myeloid lysosomal, autoantibodies in CGN ... 799
physiological role of kallikrein (abst) ... 1165
proteolytic, CsA-induced tubular atrophy (abst) ... 1185
Enzymuria (abst) ... 495

Epidermal growth factor
physiology (abst)... 190, 191, 194, 195, 196, 200, 214, 348, 416, 568
receptors (abst)... 194, 374
therapeutic use (abst)... 478
urine (abst)... 375
Epinephrine (abst)... 377
Epithelial cells
abnormalities of, in SHR... 1438
(abst)... 200, 230, 427, 572, 578
alpha-adrenergic hyperpolarization (abst)... 1165
changes in gene expression after ischemia... 1515
collagen release, C5b-8 and C5b-9... 1098
control of growth in vitro... 1048
intra- and extracellular proteins in PKD... 1301
plasminogen activator secretion... 1466
MHC class II antigen, TNF... 783
reactive oxygen species... 1509
uptake of apo B, apo E rich lipoproteins... 1449
Epoxyeicosatrienoic acid (abst)... 348
Erythrocyte
abnormalities (abst)... 258, 373, 488
anatomy and histology (abst)... 284
deformability (abst)... 499
drug effects (abst)... 300
immunology (abst)... 409, 422, 432
morphology in segmental necrotizing glomerulitis (abst)... 1597
pathophysiology (abst)... 316, 390, 499
transport (abst)... 502
volume and morphology, hematuria (abst)... 1585
Erythrocyte function
drug effects (abst)... 378
pathophysiology (abst)... 373, 409
Erythropoiesis
drug effects (abst)... 236, 330, 507
pathophysiology (abst)... 290
Erythropoietin
administration and dosage (abst)... 235, 236, 240, 289, 311, 326, 330, 331, 379
adrenergic system changes (abst)... 1178
adverse effects (abst)... 237, 244, 278, 381, 396
biosynthesis (abst)... 374
during predialysis period (abst)... 1178
exercise capability in dialysis patients (abst)... 1178
experience in CAPD (abst)... 1179
hemorheological changes post-therapy (abst)... 1178
hormone effects (abst)... 285, 301
in PKD (abst)... 1177
metabolism (abst)... 366, 526
open dose-range trial (abst)... 1383
oxygen-dependent formation (abst)... 1164
pharmacokinetics (abst)... 237, 331
pharmacology (abst)... 213, 271, 290, 293, 300, 303, 304, 307, 321, 322, 507
physiology (abst)... 292, 308, 321, 322, 507, 1383
prevalence and costs (abst)... 1383
production in dialysis patients (abst)... 1383
regulation (abst)... 213
therapeutic use (abst)... 237, 240, 244, 245, 278, 279, 288, 293, 298, 299, 312, 313, 332, 368, 373, 378, 520, 551, 1178
Essential hypertension
follow-up of glucose and cholesterol (abst)... 1606
Estrogens
physiology (abst)... 475, 516, 555
receptors (abst)... 516, 523
therapeutic use (abst)... 294
Ethanol (abst)... 450
Ethnic groups (abst)... 257, 603, 614
Evoked potentials (abst)... 293, 320
Excretion
kappa light chains in diabetes mellitus... 1120
phosphate restriction, insulin... 14
Exercise
adverse effects (abst)... 265, 275, 284
ANP, cGMP and RAA-system (abst)... 1174
drug effects (abst)... 278
during HD (abst)... 1182
outcome (abst)... 333, 609
physiology (abst)... 265, 279, 311, 515
predialytic uremic patients (abst)... 1382
Extracellular matrix
analysis (abst)... 409
anatomy and histology (abst)... 223
biosynthesis (abst)... 195, 197
growth and development (abst)... 217, 218
hormone effects (abst)... 192, 219
pathophysiology (abst)... 440, 507
physiology (abst)... 218, 221, 222, 223
receptors (abst)... 223
Extracellular space (abst)... 539
Extracorporeal regional complexing, HD (abst)... 292
Eye diseases (abst)... 315

Fatty acids
deficiency (abst)... 352, 431
drug effects (abst)... 297
physiology (abst)... 504
Fenoldopam in CRF (abst)... 1606
Fetal renal function (abst)... 570, 572
Fibrin
tissue factor production, TNFα... 1281
Fibrin (abst)... 428
Fibrinolysis
antagonists and inhibitors (abst)... 254
hormone effects (abst)... 195
plasminogen activator secretion... 1466
Fibroblasts
growth and development (abst)... 199, 518
pathophysiology (abst)... 514
Fibronectins
biosynthesis (abst)... 220
receptors (abst)... 218
regulation (abst)... 221
Fibrosis (abst)... 328
Fine needle aspiration
modified... 812
Fish oil
diet, renal growth and function... 57
physiology (abst)... 524
therapeutic use (abst)... 255, 437, 499, 614
Flameless atomic absorption spectrophotometry, $MgCl_2$... 818
Flow cytometry (abst)... 287, 439, 527, 572
Fluorescent microscopy
methods (abst)... 252, 361
Fluorides (abst)... 216
Fluroescent probes (abst)... 206, 228, 390, 563

fMLP, formyl peptide (abst) 215, 346
Focal glomerulosclerosis
enalapril and low protein 749
mononuclear leucocytes and progression of 1076
Focal segmental glomerulosclerosis
renal involvement in HIV 1325
Folic acid nephropathy (abst) 436
Follicular cells (abst) 547
Fosinopril (abst) 397
Free radicals
adverse effects (abst) 230, 428, 475, 476, 485, 496, 497
biosynthesis (abst) . 294, 301, 306, 334, 407, 427, 429, 441, 498
pharmacology (abst) 479
physiology (abst) 363, 425, 490, 515, 522
Friend erythroleukemia cells, AI 677
Frozen sections (abst) 602, 606
Fructose-1,6-diphosphate (abst) 487
Furosemide
(abst) 338, 550, 561
acetazolamide, lithium clearance S-63
effect during volume expansion S-45
effect on water, urea transport in collecting duct 1248

G proteins
isolation and purification (abst) 214, 215
pharmacology (abst) 214, 590
physiology (abst) ... 202, 213, 214, 215, 216, 217, 453, 561
Gadolinium-DTPA (abst) 275
Galactosamine (abst) 419
Gamma-L-glutamyl-L-dopa 1414
Ganciclovir (abst) 611
Gastroenteritis (abst) 266
Gastrointestinal
bleeding (abst) 244
motility (abst) 279
tract, brain-gut peptides 1031
Gemfibrozil
in CAPD (abst) 1613
lovastatin in nephrology (abst) 1177
Gene
analysis (abst) 253, 355, 359, 484
cloning of cDNA to cyclophilin-like mRNA ..... Iwai
expression (abst) 380, 411, 428, 560, 561, 566
expression after renal ischemia 1515
isolation and purification (abst) 191
mapping (abst) 218, 521
polymorphism in IgAN 991
regulation (abst) ... 215, 219, 223, 229, 350, 354, 358, 370, 373, 580, 584
transfer (abst) 193, 202
Genetic
counseling (abst) 250
linkage (abst) 247, 248, 249, 250, 253, 384
mapping (abst) 248
markers (abst) 250
polymorphism (abst) 510
Gentamicin
pharmacology (abst) 475, 495
receptors (abst) 487
toxicity (abst) 578
Gentamicin nephropathy (abst) .. 476, 481, 486, 487, 488, 490
Gentamycin
antagonists and inhibitors (abst) 486
Glioma cells (abst) 586

Glomerular basement membrane
alterations during cyst development 1270
anti-, mercury-induced disease 64
autoantibodies to, progressive GN 965
Glomerular epithelial cells
growth and development (abst) 416
immunology (abst) 410, 413, 423, 430, 431, 432
pathophysiology (abst) 491
Glomerular filtration rate
analysis (abst) 241, 270, 277, 615
autoregulation in rat jAA 1402
dietary fish oil 57
drug effects (abst) .. 345, 377, 425, 484, 489, 493, 497, 558, 599
hemodynamics, segmental tubular reabsorption in diabetics 1126
high post-transplantation (abst) 1608
hormone effects (abst) 238
hormone levels, hyperfiltration, ACE inhibition (abst) 1171
hyperplasia in remnant kidney 758
measured with Cr51 EDTA (abst) 1388
progression of CRF, review 1195
regulation (abst) 340, 378, 501, 510, 551, 593
renal autoregulation in diabetic rats 909
Glomerular filtration reserve, autotransplantation (abst) . 1183
Glomerular hemodynamics
drug effects (abst) 382, 498, 520, 524, 594
hormone effects (abst) 371, 550, 555
pathophysiology (abst) 498, 500, 506, 514
regulation (abst) ... 370, 372, 375, 379, 382, 517, 550, 554, 557
Glomerular hypertrophy
drug effects (abst) 504
hormone effects (abst) 503, 504
pathophysiology (abst) 242, 506, 508, 511, 523
Glomerular injury
drug therapy (abst) 391
immunology (abst) 406
pathophysiology (abst) .. 378, 382, 384, 418, 430, 433, 436, 483, 498, 507, 515, 517
prevention and control (abst) 417, 504, 511, 518, 519
therapy (abst) 556
Glomerular permeability (abst) 448, 507, 510
Glomerular sclerosis
complications (abst) 257
diagnosis (abst) 242
drug effects (abst) 524
enalapril and low protein 749
hormone effects (abst) 504
outcome (abst) 257
pathology (abst) 409
pathophysiology (abst) 504, 506, 512, 518, 524
prevention and control (abst) 508, 516, 523
therapy (abst) 244, 332
Glomeruli
measurement of renin secretion (abst) 1165
modified fine needle aspiration 812
Glomerulocystic kidney disease (abst) 257
Glomerulonephritis
ANCA-associated (abst) 256, 275, 441
ancrod, survival, lupus erythematosus 29
biphasic, $HgCl_2$ 64
chronic (abst) 242, 392, 522
collagen release, C5b-8 and C5b-9 1098

crescentic (abst) 249, 407
crescentic, autoantibodies vs. myeloid lysosomal enzymes 799
diagnosis (abst) 258
genetics (abst) 191
idiopathic form of crescentic (abst) 1187
immune complex (abst) 1165
immune complex mediated, antibodies 1429
immunology (abst) 443, 444, 445
long-term prognosis of mesangioproliferative (abst) .. 1167
mononuclear cell activation in IgAN 1552
oxygen radical production, IL-1α, TNFα 767
pathology (abst) 446, 447
pathophysiology (abst) 346, 352, 362, 498, 500
platelet aggregation 1500
postinfectious acute (abst) 1599
post-transplant (abst) 1615
progression of FGS and mononuclear leucocytes 1076
prostaglandins, mesangial cell proliferation 1256
Glomerulonephritis, experimental
(abst) 422, 423, 429
diet therapy (abst) 437, 506
drug therapy (abst) 418, 422, 427, 428, 519
etiology (abst) 410
immunology (abst) . 406, 408, 411, 412, 413, 414, 415, 416, 417, 418, 419, 423, 424, 425, 427, 428, 430, 432, 433, 434
pathophysiology (abst) .. 222, 410, 414, 415, 416, 418, 421, 422, 429, 434, 435, 500, 509, 515
platelet activating factor 736
Glomerulonephritis, fibrillary (abst) 440
Glomerulonephritis, immune complex (abst) 410
Glomerulonephritis, membrano-proliferative (abst) .. 243, 260
Glomerulonephritis, membranous
complications (abst) 261
drug therapy (abst) 262
immunology (abst) 437, 438, 445
Glomerulonephritis, mesangial proliferative
pathology (abst) 519
pathophysiology (abst) 195
Glomerulonephritis, rapidly progressive
diagnosis (abst) 275
drug therapy (abst) 280
immunology (abst) 444
therapy (abst) 280
Glomerulosclerosis
captopril therapy (abst) 1170
converting enzyme inhibitor (abst) 183
hepatitis B infection 663
high protein intake accelerates 1263
hypertrophy and sclerosis in SV40 transgenic mice ... 741
prognosis of ATN (abst) 1592
proteoglycans, growth factor-beta 689
uptake of apo B and apo E rich lipoproteins 1449
Glomerulus
anatomy and histology (abst) 238, 241
antibody to (abst) 429
drug effects (abst) 379
growth and development (abst) 218, 338
immunology (abst) 416, 422
metabolism (abst) 376
pathology (abst) 408, 410, 411, 418, 419, 435, 447
pathophysiology (abst) 332, 440, 501
physiology (abst) 374, 426
transport (abst) 258
ultrastructure (abst) 519
Glucagon
physiology (abst) 515, 556
Glucocorticoids
(abst) 353, 548, 559
induced PKD 901
receptors (abst) 425
therapeutic use (abst) 419
Glucose
adverse effects (abst) 223
biosynthesis (abst) 526
blood (abst) 510
concentrations affect PTH secretion 1522
metabolism (abst) 462, 513, 521, 559, 1385
physiology (abst) 221, 263, 381, 555
transport (abst) 225, 230, 582
Glucose-6-phosphate
dehydrogenase (abst) 203
in IM (abst) 1169
Glutamate dehydrogenase (abst) 531
Glutamine (abst) 530
Glutathione (abst) 316, 525, 529
peroxidase (abst) 290
Glycation (abst) 506
Glycerol
(abst) 477
induced acute tubular necrosis, Na-K-ATPase 870
Glycerophosphorylcholine (abst) 582
regulation in IMCD (abst) 1164
Glycine
physiology (abst) 269, 453
therapeutic use (abst) 480, 587
Glycolipids (abst) 212
Glycolysis (abst) 530
Glycoprotein
(abst) 233, 418, 418
Tamm-Horsfall, inflammatory response of neutrophils 717
THP 1395
Glycosaminoglycans & proteoglycans (abst) .. 220, 222, 223, 495, 599
Glycosuria, cadmium intoxication 727
Glycosylation (abst) 200, 218
Gonadotropin (GnRH) releasing hormone (abst) 276
Goodpasture's syndrome (abst) 409, 427, 446
Graft, donors (abst) 1607
Graft vs. host disease (abst) 422, 429, 432, 433
Growth
(abst) 329, 616
compensatory kidney, CsA (abst) 1598
dietary fish oil, renal 57
disorders (abst) 240, 329
drug therapy (abst) 615
factors (abst) 198, 200
hormone effects (abst) 513
outcome (abst) 569, 607, 614
regulators of cortical tubular cells 875
Growth factor
monokines and platelet-derived, in mesangial cells 859
Growth factor beta
proteoglycans, mesangial cells 689
Growth hormone
and hormone binding protein 951
deficiency (abst) 504
hemodialysis (abst) 1608

in GFR and CEI (abst) 1171
pharmacology (abst) 238
physiology (abst) 460, 504, 513, 526
therapeutic use (abst) 240, 329, 615, 616
Guanidines (abst) 514
Guanidinoacetic acid (abst) 531
Guanyl cyclase (abst) 364
Guillain-Barre syndrome (abst) 297
Gut
brain peptides, cell growth 1031

HIV infection (abst) 254, 307, 315, 330, 439
HLA DQ gene in IgAN 991
HMG CoA reductase inhibition (abst) 185
HTLV infection (abst) 314
Hantavirus, hemorrhagic fever studies in Germany (abst) 1169
Health service accessibility (abst) 615
Heart (abst) 340, 343, 545
Heart diseases (abst) 280, 309, 517
Heart transplantation (abst) 482, 607
Hematocrit
(abst) 292, 296, 303, 390
effect on solute removal during HD 1557
influence in ischemia 1240
Hematuria (abst) 258, 284
idiopathic hypercalciuria in children 807
morphology (abst) 1585
pH, osmolality, temp. and incubation (abst) 1585
urine erythrocyte morphology (abst) 1585
Hemodiafiltration (abst) 287, 308, 309, 316, 317, 318, 323
Hemodialysis
activation of complement by membranes 1055
adequacy of 822
amyloid associated (abst) 1604
arterio-venous fistula (abst) 1599
bleeding time (abst) 1608
calculation of KT/V (abst) 1588
central vein thrombosis (abst) 1386
changing patient populations (abst) 1386
citrate (abst) 186
clinicopathological study 1333
compared to CAPD (abst) 1591
computer-modulated profile (abst) 1181
C-reactive protein serum levels (abst) 1180
deoxiurdine test (abst) 1590
dialysable solutes in uremic encephalopathy 892
duplex-echography (abst) 1587
effect of hematocrit on high efficiency 1557
elderly patients' quality of life (abst) 1182
glucose affects PTH secretion 1522
heparin for anticoagulation (abst) 1386
hypotension, bath temp.(abst) 1589
immune response, biocompatibility (abst) 1179
iron overload detection 943
kidney and HIV 1571
lactate (abst) 1590
left ventricular diastolic function (abst) 1176
pathogenesis (abst) 1380
phagocytic cell function 776
physical exercise during (abst) 1182
protein loss (abst) 1182
protein loss during CAPD 971
protenitor cells activated by r-HuEPO 150
quality of life (abst) 1593
rHuEPO (abst) 1585, 1586, 1593, 1594, 1595, 1598, 1608, 1609, 1615
rapid high-efficiency (abst) 1615
red cell oxidation (abst) 1586
serum amyloid A concentrations (abst) 1386
sterile dialysate affects fever (abst) 1187
study of membranes (abst) 1386
terminal complement complex an index of bioincompatibility 696
transcription, IL-1, TNF 85
ultrafiltration at different temps (abst) 1589
uremia, IL-1 and TNFa 116
venograms in patients with thrombosis (abst) 1387
Hemodynamics
analysis (abst) 403
atrial natriuretic peptide, review 1148
blood recirculation and body temp. (abst) 1589
calcium antagonists 1171
dietary K influence on potassium concentration 1341
drug effects (abst) 368, 484
effects of endotoxin 1219
efferent arteriole in hydronephrotic kidney 1227
high protein intake accelerates GS 1263
monokines, platelet-derived growth factor 859
oral calcium therapy, hypertension (abst) 1598
physiology (abst) 217, 317
r-HuEPO (abst) 183, 1594, 1600
renal autoregulation in diabetic rats 909
segmental butular reabsorption in type 1 diabetics 1126
thromboxane B_2 in GN (abst) 1166
Hemofilters (abst) 316
Hemofiltration (abst) 286, 309, 317, 318
Hemoglobins (abst) 373
Hemolytic uremic syndrome
children, thromboxane biosynthesis 1134
long term prognosis (abst) 1168
morphology (abst) 1168
Hemolytic-uremic syndrome (abst) 254, 438
Hemoperfusion (abst) 272, 273, 302
Hemorhagic fever
nephropathia epidemica (abst) 1387
Hemorrhage (abst) 550
Henoch-Schönlein purpura (abst) 439
Heparan sulfate
(abst) 194, 198, 421
Heparin
for anticoagulation in HD (abst) 1386
or urokinase filling in catheters (abst) 1181
Heparin (abst) 288, 291, 297, 308, 313, 323, 390, 434, 479, 508
Heparin sulfate
antibody to (abst) 445
Hepatectomy (abst) 252
Hepatic computed tomography
detects iron overload in HD 943
Hepatitis
(abst) 303, 447
B infection 663
B nephropathy (abst) 447
B vaccine (abst) 438, 442
non-A, non-B (abst) 298, 303, 320
Hepatocytes (abst) 514
Hepatotoxicity (abst) 472
Heredofamilial diseases (abst) 220
12-HETE, hydroxyeicosatrienoic acid (abst) 208

Heymann nephritis
proximal tubule dysfunction ... 1536
$HgCl_2$ nephropathy (abst) ... 407, 421, 432, 485, 491
High efficiency hemodialysis
acetate (abst) ... 1590
effect of hematocrit ... 1557
High salt diet (abst) ... 388, 394
Hippuran-I-131 (abst) ... 327
Histamine
antagonists (H2) (abst) ... 597
receptors (abst) ... 453
Histidine (abst) ... 360, 365
Histidine cytotoxicity (abst) ... 1183
Histocompatibility antigens (abst) ... 251, 406, 424, 438, 596
Histones (abst) ... 430
History
Henry Bence Jones ... 1019
Thomas Addis ... 833
Hollow fibers (abst) ... 297, 301, 316, 317, 323
Home care (abst) ... 240, 328, 333
Hormones
atrial natriuretic peptide, review ... 1148
brain-gut peptides ... 1031
chromogranin A in uremia ... 955
control of medullary circulation ... 1
glucocorticoid induced PKD ... 901
levels during hyperfiltration (abst) ... 1171
progenitor cells activated by r-HuEPO ... 150
Hospitalization (abst) ... 241, 292, 311, 328
Host vs. graft disease (abst) ... 406
Human
r-HuEPO and renal function ... 131
Human immunodeficiency virus
renal involvement, San Francisco General Hospital ... 1325
renal transplantation (abst) ... 184
type 1, renal complications in ... 1571
Hybridization (abst) ... 192, 193, 229, 230, 248, 253
Hydraulic conductivity (abst) ... 226, 505
Hydrocephalus (abst) ... 389
Hydrochlorothiazide (abst) ... 458
Hydrocortisone (abst) ... 193
Hydrogen ion
(abst) ... 529, 533, 541
concentration (abst) ... 467
transport (abst) ... 232, 234, 535, 536, 538, 546, 548, 568, 569, 593
Hydrogen peroxide (abst) ... 376
reactive oxygen species ... 1509
Hydronephrosis, efferent arteriole ... 1227
Hydrostatic pressure (abst) ... 558
Hydroxyapatites (abst) ... 472
Hyperaldosteronism (abst) ... 397, 465
Hypercalcemia
(abst) ... 265, 302, 450, 469, 473
associated with Walker 256 tumor (abst) ... 1606
post-transplantation (abst) ... 1185
Hypercalcemic nephropathy
predominant medullary inner stripe injury ... 1067
Hypercalciuria (abst) ... 271, 405
Hypercatabolism (abst) ... 263, 278
Hypercholesterolemia
diet therapy (abst) ... 609
epidemiology (abst) ... 603
injury in diet-induced ... 880
pathophysiology (abst) ... 502, 512, 519, 520
Hyperfiltration
(abst) ... 371, 397
pathophysiology (abst) ... 235, 245, 341, 374, 402, 501, 502, 503, 510, 512, 515, 524, 528, 552, 553
segmental tubular reabsorption in type 1 diabetics ... 1126
smoking effect on IDDM (abst) ... 1381
Hyperglycemia
complications (abst) ... 267
epidemiology (abst) ... 259
kappa light chains excretion in diabetes ... 1120
pathophysiology (abst) ... 341, 505
Hyperinsulinemia (abst) ... 398
Hyperkalemia
adrenergic modulation of K in uremia ... 793
etiology (abst) ... 264, 266
pathophysiology (abst) ... 264, 535
physiology (abst) ... 572
therapy (abst) ... 266
Hyperlipidemia
complications (abst) ... 274
drug therapy (abst) ... 323
etiology (abst) ... 613
management ... 847
panatethine in diabetics (abst) ... 1616
pathophysiology (abst) ... 287, 502, 503, 509, 512, 514
therapy (abst) ... 244
Hypermagnesemia (abst) ... 264, 267
Hypermetabolism
drug effects (abst) ... 274, 525
pathophysiology (abst) ... 527
Hypernatremia
mortality (abst) ... 263
pathophysiology (abst) ... 586, 591
Hyperosmolality
(abst) ... 269
induced protein (abst) ... 576
Hyperoxaluria (abst) ... 274
Hyperparathyroidism
after Al depletion (abst) ... 1616
calcitriol metabolism in RF ... 44
chromogranin A in uremia ... 955
complications (abst) ... 265
drug therapy (abst) ... 450, 465, 468
glucose concentrations affect PTH secretion ... 1522
human T cell activation and PTH ... 1543
lipid metabolism in CRF ... 854
pathophysiology (abst) ... 299, 448, 467
surgery (abst) ... 283, 296, 449
Hyperplasia, GFR in remnant kidney ... 758
Hyperpolarization, alpha-adrenergic (abst) ... 1165
Hypersulfatemia (abst) ... 267
Hypertension
abnormalities of epithelium in SHR ... 1438
angioplasty (abst) ... 1600
arterial, CRF (abst) ... 1603
autotransplantation (abst) ... 1600
bumetanide ... 1084
captopril test vs. sequential scintigraphy (abst) ... 1172
complications (abst) ... 236, 244, 285, 404
correlations between active, inactive renin (abst) ... 1187
cytochrome P450, AA metabolism ... 94
diagnosis (abst) ... 398
digoxin-like factor (abst) ... 1173
drug effects (abst) ... 278
drug therapy (abst) ... 245, 278, 397, 398, 401, 402, 516

epidemiology (abst) ... 277, 603
etiology (abst) ... 237, 244, 251, 276, 279, 396, 401, 403
exercise, ANP, cGMP and RAA-system (abst) ... 1174
follow-up of glucose, cholesterol (abst) ... 1606
genetics (abst) ... 384
gout, lead, ARF (abst) ... 1588
insulin sensitivity (abst) ... 1172
ion-exchanging seaweed (abst) ... 1380
long-term complications of transplantation ... 1363
malignant (abst) ... 399
oral calcium therapy (abst) ... 1598
pathophysiology (abst) ... 209, 251, 271, 277, 283, 314, 340, 342, 384, 387, 390, 392, 393, 394, 397, 398, 399, 400, 401, 402, 403, 404, 405, 499, 514, 1171
prevention and control (abst) ... 400
protein phosphoylation in platelets (abst) ... 1187
renin mediated, catecholamines (abst) ... 1379
renin use in detection of (abst) ... 1380
renovascular (abst) ... 393, 395, 404, 405
role of race and medications ... 1113
shift in Na to normal by ANP (abst) ... 184
therapy (abst) ... 397, 402, 1170
vasodilator (CGRP) and ANP describe pathogenesis (abst) ... 1380

Hypertension, animal models
diagnosis (abst) ... 482
diet therapy (abst) ... 360, 411
drug effects (abst) ... 480
drug therapy (abst) ... 509, 582
Goldblatt kidney (abst) ... 389, 390, 428, 498, 558
immunology (abst) ... 431
Na-DOCA (abst) ... 389, 395
pathophysiology (abst) ... 359, 371, 372, 484, 420, 511

Hypertension, animal models (inbred strains)
diet therapy (abst) ... 387, 388
drug therapy (abst) ... 518, 520, 523
mortality (abst) ... 394
pathophysiology (abst) ... 336, 382, 383, 384, 385, 386, 387, 388, 389, 390, 391, 392, 393, 394, 395, 396

Hypertensive nephropathy (abst) ... 285
Hyperthermia (abst) ... 497

Hypertriglyceridemia
correction by dialysis (abst) ... 1587
effect of CRF on HDL kinetics ... 1295

Hypertrophy
and sclerosis ... 741
aortic compliance in ESRD ... 137
CsA, kidney growth, function ... 21
dietary fish oil ... 57
type 2 diabetics (abst) ... 1381

Hyperuricemia, sulfur amino acid metabolism, cystinuria ... 143

Hypoalbuminemia
(abst) ... 261
nephrotic proteinuria (abst) ... 1587

Hypocalcemia (abst) ... 264, 295
Hypochloremia (abst) ... 569
Hypogonadism (abst) ... 276
Hypokalemia (abst) ... 263, 265, 277, 562, 565

Hyponatremia
complications (abst) ... 262, 268
drug therapy (abst) ... 579
etiology (abst) ... 262, 265
pathophysiology (abst) ... 269, 569
treatment of ... 1006

Hypoparathyroidism (abst) ... 452
Hypophosphatemia (abst) ... 263, 526
Hypotension (abst) ... 558
in HD, bath temp. (abst) ... 1589
Hypothyroidism (abst) ... 257
Hypovolemia, pathogenesis in NS (abst) ... 1596
Hypoxemia, buffer causes (abst) ... 1595

Hypoxia
(abst) ... 478, 494
hypercalcemic nephropathy ... 1067

ICAM-1, intercellular adhesion molecule-1 (abst) ... 437, 506
IVIG, i.v. immunoglobulin preparations (abst) ... 280, 441
Ibuprofen (abst) ... 271
Idiopathic hypercalciuria in children ... 807
IgA deficiency (abst) ... 410

IgA nephropathy
complications (abst) ... 257
diagnosis (abst) ... 254, 273
diet therapy (abst) ... 255
enalapril (abst) ... 1380
etiology (abst) ... 261
gene polymorphism ... 991
genetics (abst) ... 251, 445
immunology (abst) ... 246, 251, 261, 435, 438, 439, 445, 446
measure GFR with CR51 EDTA (abst) ... 1388
mononuclear cell activation ... 1552
neutrophil cytoplasm antibodies (abst) ... 1167
pathology (abst) ... 519

Image analysis ... 246
Imipenem/cilastin during CAVH ... 1180

Immune complex glomerulonephritis
cellular glomerular infiltrates (abst) ... 1166

Immune complexes
adverse effects (abst) ... 378
analysis (abst) ... 413, 437
formation, antibodies ... 1429
pathophysiology (abst) ... 406, 414
physiology (abst) ... 409, 413, 432, 433, 439, 440

Immune response (abst) ... 436, 438, 442, 444, 446
Immune tolerance (abst) ... 593, 597, 601
Immunoadsorption (abst) ... 605
Immunofixation in ultrathin gels ... 1002

Immunofluorescence
in glomeruli post-mortem (abst) ... 1387

Immunoglobulin excretion (abst) ... 513

Immunoglobulins
adverse effects (abst) ... 432
analysis (abst) ... 446
biosynthesis (abst) ... 445, 500
blood (abst) ... 261
deficiency (abst) ... 410
physiology (abst) ... 435
therapeutic use (abst) ... 478

Immunohistochemical techniques (abst) ... 445, 454, 474

Immunologic cytotoxicity
drug effects (abst) ... 420
pathophysiology (abst) ... 414, 596, 598, 613
regulation (abst) ... 363

Immunologic receptors (abst) ... 218, 424, 430

Immunosuppression
(abst) ... 596, 609
agents (abst) ... 609

alterations in Langerhans cells (abst) ... 1601
endothelin role in CsA-induced glomerular dysfunction ... 1487
leflunomide (abst) ... 1184
liver disease and CsA (abst) ... 1604
outcome (abst) ... 406, 420, 421, 433, 434, 483, 599, 608
pathophysiology (abst) ... 606
sandimmun (abst) ... 1184
therapeutic use (abst) ... 604, 614
transplantation (abst) ... 1383
Immunotherapy (abst) ... 435, 478
In vitro control of epithelial cells ... 1048
Indomethacin (abst) ... 348, 352, 577
adverse effects (abst) ... 398, 497
pharmacology (abst) ... 437, 503, 558
Infection
control (abst) ... 331
cytomegalovirus, MHC class I (abst) ... 187
early detection in children (abst) ... 1168
eicosanoid synthesis, S. epidermidis ... 1316
endotoxin ... 1219
hepatitis B ... 663
human peritoneal mesothelial cells ... 1563
phagocytic cell function in HD ... 776
post-transplant CMV (abst) ... 1186
renal involvement with HIV ... 1325
urinary tract (abst) ... 1388
Inflammation
(abst) ... 416, 417, 428
control of epithelial cell growth in vitro ... 1048
cytokines in uremic and HD patients ... 116
drugs induce, in TIN (abst) ... 1594
monokines and platelet-derived growth factor ... 859
nephrotoxicity and NSAID (abst) ... 1600
platelet aggregation and GN ... 1500
progression of FGS, mononuclear leucocytes ... 1076
Influenza vaccine (abst) ... 446
Injury
changes in gene expression post-ischemia ... 1515
control of epithelial cell growth in vitro ... 1048
epithelial cells, MHC class II and TNF ... 783
hematocrit influence ... 1240
high protein intake accelerates GS ... 1263
hypercalcemic nephropathy ... 1067
hypercholesterolemia ... 880
interstitial monocytes in chronic ... 100
mononuclear cell activation in IgAN ... 1552
platelet activating factor in GN ... 736
prevention of ischemic in transplantation ... 171
proximal tubule dysfunction in Heymann nephritis ... 1536
reactive oxygen species ... 1509
ticlopidine, progression of renal ... 934
tissue factor production ... 1281
Inner medullary collecting duct
choline transport (abst) ... 1164
extracellular osmolality, ion concentration (abst) ... 1163
furosemide effect ... 1248
glycerophosphorylcholine (abst) ... 1164
Inner medullary collecting tubule cells
lithium effect on cAMP ... 1211
Inositol
(abst) ... 532, 576, 586, 588
sodium dependent transport (abst) ... 588
Inositol phosphates
antibody to (abst) ... 208
biosynthesis (abst) ... 199, 204, 532
physiology (abst) ... 212, 413
Insulin
administration and dosage (abst) ... 261
diabetes secondary to steroid therapy (abst) ... 1384
dietary phosphate restriction ... 14
glucose affects PTH secretion ... 1522
kappa light chains excretion in diabetes ... 1120
metabolism (abst) ... 530
physiology (abst) ... 190, 195, 380, 381, 452, 505, 508, 521, 573
receptors (abst) ... 201
resistance (abst) ... 381, 386
reversal of steroid-induced resistance (abst) ... 1389
secretion (abst) ... 462, 466, 505, 513
sensitivity in hypertension (abst) ... 1172
Insulin-like growth factor
physiology (abst) ... 201, 370, 380, 504, 513
receptors (abst) ... 522, 526
urine (abst) ... 376
Integrins, receptors (abst) ... 223
Intercalated cells
(abst) ... 231, 540
physiology (abst) ... 227, 234, 536, 545
Interferons (abst) ... 334, 445
Interleukin 1-α
oxygen radical production ... 767
Interleukin-1
complement, TNF ... 85
membranes in HD (abst) ... 1588
Interleukin-2
mononuclear cell cultures from uremics ... 126
receptor expression in CRF (abst) ... 1179
toxin (abst) ... 593
Interleukins
biosynthesis (abst) ... 288, 301, 319, 330, 408, 436
diagnostic use (abst) ... 602, 609
immunology (abst) ... 409, 601
pathophysiology (abst) ... 406
physiology (abst) ... 193, 204, 205, 307, 349, 364, 369, 418, 426, 436, 445, 606
receptors (abst) ... 299, 407, 431, 438, 439, 500, 599, 601
secretion (abst) ... 411, 422, 608
Interstitial cells
glomerular function, lupus nephritis ... 100
Interstitial fibrosis (abst) ... 518, 521
Interstitial infiltrates in lupus nephritis ... 100
Interstitial nephritis
idiopathic (abst) ... 255
Intestinal absorption
(abst) ... 353, 399, 457, 471, 472, 473, 474, 546
Intoxication
aluminum (abst) ... 124, 1611, 1611
aluminum, PTH receptors ... 72
exogenous (abst) ... 1389
Intracellular pH
(abst) ... 385, 393, 540, 560, 574
regulation (abst) ... 191, 199, 361, 388, 391, 530, 535, 537, 540, 541, 544, 562, 569
Intradialytic hypotension (abst) ... 319, 325
Ion
lithium transport across membranes ... S-4
permeability of thin loop segments, Li transport ... S-31
tubular acidification by Li ... S-75
Ion channels (abst) ... 192, 199, 561

Iothalamate (abst) 270
Iron
  absorption in Al overload (abst) 1612
  aluminum uptake and transport (abst) 1611
  deficiency (abst) 1612
  detection of overload in HD 943
  excretion (abst) 248
  metabolism (abst) 293
  physiology (abst) 273, 286, 376, 450, 473, 498
  renal handling in nephrotic syndrome 1409
  therapeutic use (abst) 299
  toxicity (abst) 292
  uptake, Al in Friend erythroleukemia cells 677
Ischemia
  autoregulation of RBF (abst) 183
  changes in gene expression 1515
  energy metabolism in cortex and medulla (abst) 1174
  prevention of injury in transplantation 171
  red cell trapping, hematocrit 1240
Islets of Langerhans (abst) 466
Isoproterenol (abst) 396

Joint diseases (abst) 287, 296, 519
Juxtamedullary afferent arterioles, TGF 1402

KT/V calculation (abst) 1588
Kallikrein
  antagonists and inhibitors (abst) 369
  pathophysiology (abst) 1171
  physiological role (abst) 1165
  urine (abst) 399
Kaluresis
  atrial natriuretic peptide, dis[illegible]e function 996
Kappa light chains
  excretion of, in diabetes mellitus 1120
Ketanserin (abst) 523
Keto acids (abst) 549
Ketoacidosis (abst) 539
Kidney
  function tests (abst) 270, 277
  growth and development (abst) ... 358, 388, 533, 542, 546, 559
Kinetics, HDL 1295
Knee joint (abst) 287

L-dopa .....
  gamma-L-glutamyl-L-dopa 1414
LLC-PK1 cells (abst) 220, 454
Lactate in HD concentrates (abst) 1590
Lactates (abst) 292, 332
Lactoferrin (abst) 442
Laminin (abst) 223, 407, 440
Langerhans cells, transplant patients (abst) 1601
Latex photometric immunoassay (abst) 276
Lead
  hypertension, gout, ARF (abst) 1588
Lectin
  binding, MDCK cell differentiation (abst) 1163
  dolichos biflorus agglutinin (abst) 1163
Lectins
  (abst) 234, 407, 413, 440
  monoclonal antibodies (abst) 1388
Leflunomide, new immunosuppressive drug (abst) 1184
Left ventricular hypertrophy (abst) 228
Lesions
  history of Thomas Addis 833
  lupus nephritis 100
  rheumatoid arthritis (abst) 1379
  treating hyponatremia 1006
Leukemia (abst) 260
Leukocytes (abst) 278
Leukotriene B_4
  nephrotoxic serum nephritis (abst) 1166
Leukotrienes
  biosynthesis (abst) 329, 346, 352, 421
  inflammatory response of neutrophils by THG 717
  immunology (abst) 434
  physiology (abst) 346, 347, 350, 355, 368
  receptors (abst) 351
Licorice (abst) 357
Lipases (abst) 212
Lipid
  deposition (abst) 436
  excess PTH in CRF 854
  lipoprotein leakage, protein loss during CAPD 980
  management of hyperlipidemia in renal disease 847
Lipoproteins
  apheresis (abst) 244
  apo B and apo E rich 1449
  drug effects (abst) 323
  high-density kinetics, CRF 1295
  leakage, lipid levels in CAPD 980
  lipase (abst) 613
  physiology (abst) 501, 502, 509, 514, 608
Lipoxins (abst) 347, 351
Lipoxygenase
  antagonists and inhibitors (abst) 395, 421
  physiology (abst) 368
Lisinopril
  (abst) 239, 503, 508
  diabetic nephropathy (abst) 1380
Lithiasis, microhematuria (abst) 1610
Lithium
  acetazolamide and furosemide administration S-63
  adverse effects (abst) 534, 592
  analysis (abst) 575
  bumetanide and ouabain effect on transport of S-71
  clearance (abst) 235, 577, 592
  clearance, Na and H_2O delivery in PT S-10
  diuretic agents effect on clearance S-22
  effects of cAMP generation in IMCT 1211
  furosemide effect during volume expansion S-45
  history of concept S-2
  impairment of tubular acidification by S-75
  in renal physiology S-78
  natural trace blood and urine levels S-58
  osmotic diuresis, reabsorption in dog S-67
  permeability of transport in tALH S-31
  pharmacology (abst) 534
  physiology (abst) 369, 577
  reabsorption beyond the proximal tubules S-39
  renal tubular effects of S-52
  sites of transport S-26
  sodium intake (abst) 185
  sodium intake and diuretics S-36
  transport (abst) 259, 572
  transport across biological membranes S-4
  validity of clearance concept S-17
Lithotripsy (abst) 284, 412

Liver
biopsy (abst) ... 611
cysts (abst) ... 252
diseases (abst) ... 270, 341, 487, 496
growth regulators of cortical tubular cells ... 875
physiology (abst) ... 198
transplantation (abst) ... 373, 403
Loop of Henle
alanine handling (abst) ... 1163
drug effects (abst) ... 207
furosemide effect during volume expansion ... S-45
injuries (abst) ... 494
pathophysiology (abst) ... 517
permeability of Li clearance ... S-31
physiology (abst) ... 380, 461, 472, 474, 536, 542, 572, 577, 586
Lovastatin
(abst) ... 323, 391, 519
gemfibrozil in nephrology (abst) ... 1177
Low molecular weight proteins
drug targeting (abst) ... 187
protein loss during CAPD ... 971
Low-density lipoprotein cholesterol (abst) ... 185
Lung
antibody to (abst) ... 409
diseases (abst) ... 427
Lupus anticoagulant, transplantation (abst) ... 1595
Lupus erythematosus
ancrod, survival ... 29
Lupus erythematosus, systemic
complications (abst) ... 437
diagnosis (abst) ... 444
drug therapy (abst) ... 406
immunology (abst) ... 409, 435, 444
pathology (abst) ... 430
pathophysiology (abst) ... 434, 437
Lupus nephritis
cyclophosphamide (abst) ... 1595
diagnosis (abst) ... 256
drug therapy (abst) ... 238, 256, 442
immunology (abst) ... 411, 444, 447
interstitial cells correlate with function ... 100
pathology (abst) ... 419, 437
pathophysiology (abst) ... 351, 414, 424
treatment (abst) ... 1605
Lymphocyte activation (abst) ... 410, 435, 436
Lymphocytes (abst) ... 281, 303, 393, 434
human T cell activation and PTH ... 1543
Lymphocytes, B (abst) ... 410, 446
Lymphocytes, T
analysis (abst) ... 439
antibody to (abst) ... 427
classification (abst) ... 606
drug effects (abst) ... 597
genetics (abst) ... 599
immunology (abst) ... 419, 420, 423, 426, 428, 429, 599, 600
pathophysiology (abst) ... 435, 439, 596, 598, 606
physiology (abst) ... 208, 436, 595, 596, 601
Lymphokines (abst) ... 600
Lysosomes (abst) ... 527

MAC-1 glycoprotein (abst) ... 308, 438
MAUP glycoprotein (abst) ... 601
MDCK cells
differentiation in (abst) ... 1163
model cortical collecting duct (abst) ... 1163
MHC class II antigen
and TNF in epithelial cells ... 783
Macrophages (abst) ... 327, 330, 385, 387, 465, 504
Macula densa (abst) ... 357, 381, 561, 565
Madin-Darby canine kidney
(abst) ... 228, 377, 454, 532, 565, 582
cadmium, K conductance ... 1477
Magnesium
analysis using flameless atomic absorption spectrophotometry ... 818
cisplatin in childhood (abst) ... 1169
intracellular (abst) ... 461
metabolism (abst) ... 344
physiology (abst) ... 460, 564
therapeutic use (abst) ... 296
urine (abst) ... 612
Magnesium chloride (abst) ... 476
Magnesium citrate (abst) ... 459
Magnesium oxide (abst) ... 459
Magnetic resonance imaging, MRI (abst) ... 275, 281, 282, 492, 556
Magnetic resonance spectroscopy (abst) ... 280, 461
Malignancy
long-term complications of transplantation ... 1363
urate production ... 36
Malnutrition (abst) ... 263
Malondialdehyde (abst) ... 248
Mannitol (abst) ... 340, 495
kidney preservation (abst) ... 1601
Mannose (abst) ... 585
Mean corpuscular volume (abst) ... 289
Medullary collecting tubule cells
lithium effect on cAMP ... 1211
Medullary inner stripe injury, hypercalcemic nephropathy ... 1067
Membrane fluidity (abst) ... 207, 209, 225, 457, 499, 580
Membrane potentials (abst) ... 281, 366, 468, 533
Membrane proteins
biosynthesis (abst) ... 218, 219, 221
genetics (abst) ... 539
immunology (abst) ... 429, 445
isolation and purification (abst) ... 214, 227, 231, 233, 234
Membranous glomerulonephritis
therapy (abst) ... 1167
Membranous nephropathy
in allografts (abst) ... 187
Mercapturic acid formation localization (abst) ... 1161
Mercury
anti-GBM disease and renal antigens ... 64
compounds (abst) ... 421, 488
toxicity (abst) ... 292, 491
transport (abst) ... 190, 202, 457
Mesangial cells
(abst) ... 192, 229, 378, 507
anatomy and histology (abst) ... 218, 227
drug effects (abst) ... 434, 508
endothelin and eicosanoid synthesis ... 927
growth and development (abst) ... 190, 193, 194, 197, 201, 202, 203, 204, 223, 244, 335, 509, 516
hormone effects (abst) ... 197, 201, 204
immunology (abst) ... 407, 418, 430, 431, 433
metabolism (abst) ... 219, 220, 221, 222, 223
monokines and platelet-derived growth factor ... 859

oxygen radical production, TNFα, IL-1α 767
pathophysiology (abst) 420, 431, 502
physiology (abst)... 195, 210, 214, 215, 217, 363, 368, 376, 385, 387, 408, 426, 472, 506, 514, 551, 563, 567
proliferation, prostaglandins..... 1256
tissue factor production 1281
Mesangial glomerulonephritis
rheumatoid arthritis (abst) 1379
Mesangial hyperplasia
renal involvement in HIV..... 1325
Mesangioproliferative glomerulonephritis
long-term prognosis (abst) 1167
Mesenteric arteries (abst)..... 387
Metabolic acidosis
tobramycin 1492
Metal nephropathy (abst)..... 477, 478, 485
Metalloproteinases (abst)..... 595
Metals (abst)..... 582
Methicillin, cephalosporins, CAPD peritonitis (abst) 186
Methylguanidine (abst)..... 515, 522
Methyltransferases (abst)..... 198
Metolazone (abst)..... 566
Metyrapone (abst) 274
effect on carbohydrate metabolism (abst) 1175
Mice
Hyp mutation, phosphate deprivation, protein kinase C 682
SV40 transgenic, hypertrophy and sclerosis 741
Microalbuminuria
exercise, BP in diabetics (abst) 1381
in ADPKD 1609
prevalence in Swedish diabetics (abst)..... 1381
single kidney patients (abst) 1609
Microfilaments (abst) 226, 228, 482
Microhematuria (abst) 1610
Microscopy in vivo (abst) 549
Microsomal membrane extraction factor (abst)..... 350, 351
Microsomes
(abst)..... 360, 477
liver (abst)..... 515
Middle molecules and uremic peptides (abst)..... 1176
Migration inhibition factor (abst)..... 426
Mineralocorticoids (abst) 342, 357, 403, 588
Minimal change disease
(abst) 242, 260, 281, 448, 507
Misoprostol (abst) 497
Mitochondria
anatomy and histology (abst) 224, 227
metabolism (abst) 487, 528
pathology (abst) 206
Mitogens (abst)..... 204, 251, 442
Mitomycin C nephrotoxicity (abst) 1602
Mixed function oxidases (abst) 515
Modelling of Na measurements verified (abst) 1181
Monoclonal antibodies
adverse effects (abst) 414
analysis (abst)..... 407, 445
diagnostic use (abst)..... 225, 344
immunology (abst) 418
isolation and purification (abst) 196, 406, 408
lectins, characterization (abst) 1388
physiology (abst)..... 425, 536
therapeutic use (abst)..... 427
Monoclonal proteins (abst) 247
Monocytes (abst) 310, 424, 426
Monokines
platelet-derived growth factor in mesangial cells..... 859
Mononuclear cells
in IgA nephropathy with crescents 1552
Mononuclear inflammatory cells, lupus nephritis 100
Mononuclear leucocytes
progression of FGS..... 1076
Monosodium urate monohydrate crystals, MDCK cells... 36
Morphogenesis (abst)..... 194, 217
Morphometry (abst) 241, 246, 411, 419, 491
Mortality, transplantation (abst) 1384
mRNA (abst)..... 201, 220, 229, 470, 532, 580 581
Multiple myeloma (abst)..... 247, 276
Multiple organ system failure (abst) 318
Mupirocin (abst)..... 289
Murine systemic lupus erythematosus, ancrod..... 29
Muscle
(abst)..... 265, 531, 569
contraction (abst)..... 385
skeletal (abst)..... 510
Myeloid lysosomal enzymes, autoantibodies in CGN.... 799
Myeloma cast nephropathy (abst) 276, 494
Myocardium (abst)..... 510, 516
Myocytes (abst)..... 505
Myopia in nephropathia epidemica (abst) 1387
Myosin (abst)..... 230

N-Ethylmaleimide (abst)..... 228
N-Methyl arginine (abst) 371, 395, 552
Na^+/H^+ antiport
subcellular distribution in cortex 707
$Na^+/K^+/Cl^-$ cotransport
bumetanide in Milan hypertensive rats 1084
Na-K-ATPase
acute tubular necrosis..... 870
Naproxen (abst)..... 527
Natriuresis
calcium entry blockers (abst)..... 1606
drug effects (abst) 268, 271, 337, 341, 355, 390
hormone effects (abst)..... 381, 383, 403
pathophysiology (abst) 384, 389
physiology (abst)..... 284, 341, 342, 565, 574
regulation (abst) ... 337, 339, 342, 349, 350, 352, 356, 357, 358, 363, 375
Neoplasms (abst)..... 254
Neopterin (abst)..... 443, 602
Nephrectomy
age and renal reserve (abst)..... 1388
clinicopathological study 1333
complications (abst)..... 401
effect of vitamin D in renal growth (abst) 1165
glomerular hypertrophy and sclerosis in SV40 mice... 741
growth regulators of cortical tubular cells..... 875
high protein accelerates GS 1263
hyperplasia and GFR 758
outcome (abst)..... 277, 383, 420, 574
pathophysiology (abst)..... 200
ticlopidine prevents progression of renal disease 934
Nephrocalcin
diagnostic use (abst)..... 439, 443
physiology (abst)..... 471, 474
Nephron
(abst)..... 275, 421, 510, 560
cable properties and electogenic transport systems ... 157

renal tubular effects of Li S-52
sites of Li transport S-26
structural adaptation to ESRD (abst) 1170
superficial (abst) 232
tobramycin reabsorption, metabolic alkalosis 1492
Nephropathia epidemica
in rural people (abst) 1387
transient myopia (abst) 1387
Nephrotic syndrome
apo B and apo E rich lipoproteins in epithelial cells .. 1449
bad response to CsA (abst) 1610
childhood idiopathic, CsA (abst) 1616
complications (abst) 243, 256, 283
congenital (abst) 277
diet therapy (abst) 243
dietary protein (abst) 1598
drug therapy (abst) 255, 261, 262, 451, 503
etiology (abst) 254, 256, 260
immunology (abst) 439, 445
management of hyperlipidemia 847
natural anticoagulants (abst) 1589
outcome (abst) 257
pathogenesis (abst) 1596
pathophysiology (abst) .. 253, 260, 342, 345, 356, 417, 503, 507, 509, 512, 524, 527, 574
plasminogen activator inhibitor (abst) 1590
relapse, discontinuation of CsA and prednisolone (abst) 1167
renal iron handling 1409
steroid-dependent, CsA (abst) 1604
therapy (abst) 277
therapy of idiopathic MGN (abst) 1167
Nephrotoxic serum nephritis, leukotriene B4 1166
Nephrotoxicity
changes in gene expression post-ischemia 1515
correlation of NAG in PT and urine during CsA (abst) 1185
diagnosis (abst) 481, 486, 496, 610
drug therapy (abst) 478
drugs (abst) 1594, 1600
endotoxin 1219
etiology (abst) 259, 260
genetics (abst) 476
hormone effects (abst) 491
mitomycin C (abst) 1602
outcome (abst) 610
pathology (abst) 487
pathophysiology (abst) .. 190, 376, 420, 475, 477, 478, 480, 483, 484, 485, 488, 489, 492, 493, 494, 495, 497
platelet activating factor in GN 736
prostanoids role in Sandimmun (abst) 1184
renal function during CsA therapy (abst) 1188
renal iron handling 1409
tobramycin, metabolic alkalosis 1492
urine cytology (abst) 1186
Nerve growth factor (abst) 198
5′-nucleotidase, anemia in fibroblasts (abst) 1164
Neurologic syndrome, hyponatremia 1006
Neurotoxin, uremic encephalopathy 892
Neutotransmitters, brain-gut peptides 1031
Neutrophil activating factor (abst) 362
Neutrophil function
drug effects (abst) 322, 595
hormone effects (abst) 407
pathophysiology (abst) 299, 301, 322, 329, 441, 476
physiology (abst) 334, 413, 551
regulation (abst) 346, 413, 494
Neutrophils
cytoplasm in rapidly progressive GN 965
immunology (abst) 413, 442
pathophysiology (abst) 255, 302, 308, 323
Nicotinic acid derivative, insulin resistance (abst) 1389
Nifedipine
lisinopril in diabetic nephropathy (abst) 1380
pharmacology (abst) 299, 504, 595
therapeutic use (abst) 239, 242, 402, 597
Nitrendipine (abst) 260
Nitroglycerine (abst) 375
Nitroprusside (abst) 555
Nonsteroidal anti-inflammatory drugs (NSAID)
nephrotoxicity (abst) 1600
Norepinephrine
in renal failure 1357
metabolism (abst) 521
physiology (abst) 302, 367, 396, 534, 552, 559
secretion (abst) 269
Normotension, salt sensitivity (abst) 1172
Nucleoproteins (abst) 423, 430, 434
Nucleotides
mechanism of activation of K channels (abst) 1162

OKT3 immunotherapy
adverse effects (abst) 414, 606
antibody to (abst) 607
physiology (abst) 595
therapeutic use (abst) 608
Obstruction
altered basement membrane protein biosynthesis 1090
enzyme activity in urinary 79
ureteral, eicosanoid production 1528
Obstructive arterial diseases (abst) 318
Olfactory neuroblastoma (abst) 266
Oncogenes (abst) 191, 197, 204
Oocytes (abst) 547
Opportunistic infections (abst) 607
Oral thrush, HIV and the kidney 1571
Organ preservation (abst) 596, 609
Organ procurement (abst) 613, 615
Ornithine decarboxylase
antagonists and inhibitors (abst) 472
genetics (abst) 202
regulation (abst) 489
Osmolar gap (abst) 268
Osmolarity (abst) . 196, 274, 279, 284, 537, 572, 576, 585, 586
Osteitis fibrosa (abst) 450, 465
Osteoblasts (abst) 449, 456, 467
Osteoclasts (abst) 451
Osteomalacia, regression of Al-induced (abst) 1389
Osteonectin (abst) 220
Osteoporosis (abst) 448, 451
Ouabain
bumetanide effect on Li transport S-71
Ouabain-like factor (abst) 210
Ovarian carcinoma (abst) 489
Oxalate:OH exchange across BBM 1105
Oxalates (abst) 274, 284, 291, 516, 577, 587
Oxidative burst (abst) 305, 323, 413, 432
Oxidative injury (stress)
pathology (abst) 497

pathophysiology (abst) .. 230, 305, 306, 316, 427, 428, 429, 475, 483, 488, 490, 491, 493, 501, 502, 514, 522, 525
prevention and control (abst) 525
Oxygen
consumption (abst) 476, 527, 528
dependent erythropoietin formation (abst) 1164
reactive species, epithelial cells 1509
Oxygen free radical
interleukin 1-α, TNFα 767
platelet aggregation and GN 1500
Oxytocin (abst) 203, 580

P-glycoprotein (abst) 234
PAF-acether, endothelin (abst) 1603
PAH, p-aminohippurate (abst) 581, 591
Palmitate (abst) 591
Pancreas
pathophysiology (abst) 505
physiology (abst) 466
renal transplantation (abst) 615
ultrastructure (abst) 216
Pancreatectomized diabetic rats, renal autoregulation ... 909
Papillary collecting duct
lectin DBA in isolation of (abst) 1163
Paraplegia (abst) 325
Paraproteinemias (abst) 254, 257
Parathyroid cells (abst) 469
Parathyroid glands (abst) 436, 450
Parathyroid hormones
(abst) 293, 314, 450, 466
antagonists and inhibitors (abst) 464
bone and kidney receptors of 72
concentration post-HD, vitamin D (abst) 1177
glucose concentrations 1522
human T cell activation 1543
levels predict ATN post-transplantation (abst) 1184
lipid metabolism in CRF 854
pharmacology (abst) 481, 587
physiology (abst) ... 196, 202, 205, 210, 211, 285, 294, 295, 301, 302, 304, 324, 380, 454, 458, 459, 460, 463, 464, 473, 500, 518, 547, 557, 603
Parathyroid hyperplasia (abst) 463
Parathyroidectomy
outcome (abst) 283, 285, 296, 302, 321, 448, 449
pathophysiology (abst) 196
Parenteral nutrition (abst) 273
Pathology
graft, 500 transplantations (abst) 1186
modified FNA 812
Pentamidine nephropathy (abst) 478
Pepsinogen (abst) 590, 591
Peptic ulcer (abst) 316
Peptidases
antagonists and inhibitors (abst) 337
Peptide receptors
(abst) 342
hormone effects (abst) 336
isolation and purification (abst) 335, 337, 344
pathophysiology (abst) 339, 342
physiology (abst) 340, 341, 359
Peptides
atrial natriuretic, review 1148
brain-gut 1031
chromogranin A in uremia 955
endothelin and eicosanoid synthesis 927
uremic and middle molecules (abst) 1176
Percutaneous transluminal angioplasty (abst) 319, 397
Perfusion
efferent arteriole in hydronephrotic kidney 1227
Pericardial effusion (abst) 331
Pericardiocentesis (abst) 284
Perindopril (abst) 498
Peritoneal equilibration test (abst) 1385
Peritoneal mesothelial cells 1563
Peritoneal sclerosis (abst) 326
Peritoneum, pathology (abst) 328
Peritonitis
(abst) 327, 328
complications (abst) 326, 332
eicosanoid synthesis, S. epidermidis 1316
epidemiology (abst) 256, 326, 329, 330, 330
methicillin, cephalosporins (abst) 186
prevention and control (abst) 331, 335
protein pattern (abst) 1182
response to vitamin D3 1310
treatment (abst) 1616
Permeability
human peritoneal mesothelial cells 1563
Permselectivity
(abst) 506, 513, 612
drug effects (abst) 261, 508, 516, 519
Pertussis toxin (abst) 463, 561
Phagocytic cell function in hemodialysis 776
Phlorizin (abst) 585, 589
Phorbol esters (abst) 192, 212, 349, 470
Phosphatases
(abst) 496
antagonists and inhibitors 368
Phosphate binders
(abst) 296, 449, 450, 455, 584
adverse effects (abst) 305, 328
physiology (abst) 462, 474
Phosphate restriction
(abst) 246, 453, 457, 460, 463, 469, 552
sodium dependent (abst) 456
Phosphate transport
sodium dependent (abst) . 190, 202, 231, 367, 377, 453, 456
Phosphates
deficiency (abst) 231
dietary restriction, insulin 14
mediation of uremic encephalopathy 892
metabolism (abst) 526
physiology (abst) ... 302, 449, 453, 454, 458, 459, 461, 462, 469, 518, 568
protein kinase C, Hyp mutation 682
transport (abst) 452, 453, 455, 456, 457, 459, 460, 465, 586, 587
Phosphatidylcholine (abst) 213
Phosphodiesterase
(abst) 207
isolation and purification (abst) 362
Phospholipase A2 (abst) 194, 206, 312, 472, 488
Phospholipase C
hormone effects (abst) 199, 203
metabolism (abst) 200
physiology (abst) 193, 202, 213, 336, 364
Phospholipase D (abst) 208
Phospholipases (abst) 478, 492
Phospholipids (abst) 213, 486, 490, 333

Phosphonoformic acid (abst) 455, 459
Phosphorus, concentration, dietary K 1341
Phosphorylation (abst) 194, 209, 230, 560
Piretanide effect on Ca, phosphate excretion (abst) 1176
Piroxicam (abst) 347
Pituitary hormones (abst) 491
Placental decidua (abst) 597
Plasma
  alternative pathways of complement (abst) 1179
  cells (abst) 254
  clearance (abst) 327
  exchange (abst) 605
Plasma membrane
  cadmium intoxication, transport 727
Plasmapheresis (abst) 288, 297, 325
Plasminogen
  activator inhibitors (abst) 219, 254, 435, 1590
  activators (abst) 195, 286, 428
Plasminogen activator secretion 1466
Platelet activating factor
  antagonists and inhibitors (abst) 378
  in experimental glomerulonephritis 736
  physiology (abst) 208, 363, 367, 372, 377, 551, 579
  receptors (abst) 378
Platelet adhesion (abst) 424
Platelet aggregation (abst) 287, 321, 512
Platelet-derived growth factor
  (abst) 192, 194, 199, 200, 203, 204, 408, 414
  monokines, mesangial cells 859
Platelets
  (abst) 209, 367, 412, 417
  aggregation and GN 1500
  physiology (abst) 194, 250, 385
  therapeutic use (abst) 598
Podocytes (abst) 426
  lipoproteins 1449
Poly-L-lysine (abst) 201
Polyacrylonitrile
  complement activation by HD membranes 1055
Polyamines (abst) 240, 433, 434
Polycystic kidney disease
  (abst) 200, 247, 250, 425, 566, 605
  analysis of cysts (abst) 1588
  basement membrane alterations during cyst development 1270
  clinical issues (abst) 1588
  complications (abst) 249, 251, 252, 253, 397, 502
  cystic puncture (abst) 1588
  diagnosis (abst) 247, 249, 251, 1597
  erythropoietin (abst) 1177
  evolution of CRF (abst) 1596
  genetic study of families (abst) 1615
  genetics (abst) 247, 248, 249, 250, 253, 521
  glucocorticoid-induced 901
  intra-and extracellular proteins in 1301
  microalbuminuria (abst) 1609
  outcome (abst) 238, 248, 251, 252
  pathophysiology (abst) .. 196, 225, 229, 247, 253, 292, 380, 412
  prognosis (abst) 1597
  transitional cell carcinoma (abst) 1181
Polycythemia (abst) 612
Polymerase chain reaction (abst) 314, 560
Polymorphonuclear leukocytes
  Tamm-Horsfall glycoprotein 717
Polyuria (abst) 522
Porphyrins (abst) 306, 309
Postinfectious acute glomerulonephritis (abst) 1599
Posture (abst) 317
Potassium
  adrenergic modulation of, in uremia 793
  conductance, cadmium 1477
  diuretics effect on transport of 1423
  drug effects (abst) 268, 558
  eicosanoids and conductance in proximal tubules (abst) 1162
  influence of dietary, on concentration of phosphorus . 1341
  mechanisms of ATP and bradykinin induced channels (abst) 1162
  physiology (abst) 379, 459, 562, 569, 571
  role by proximal tubular cell volume regulation (abst) 1162
  therapeutic use (abst) 384, 387
  transport (abst) 363, 560, 563, 564, 568, 573, 574, 575
Potassium channels
  physiology (abst) ... 562, 563, 564, 565, 566, 567, 568, 570, 571, 573, 574, 576, 1162
Potassium/bicarbonate symport (abst) 541
Prazosin (abst) 608
Prednisone (abst) 262, 240, 451, 603, 604, 614
  therapy in transplantation (abst) 1592
Pregnancy
  (abst) 354, 550, 571
  complications (abst) 263, 277, 392, 558
  renal transplantation (abst) 1612
Principal cells (abst) 540, 548
Procoagulant activity (abst) 446
Procollagen
  (abst) 508, 511
  biosynthesis (abst) 224, 521, 598
Progenitor cells, r-HuEPO 150
Progression
  controlled by BP in renal insufficiency (abst) 1170
  mononuclear leucocytes in FGS 1076
  of CRF, review 1195
  of Wegener's granulomatosis (abst) 1168
  role of race and antihypertensive medications 1113
  ticlopidine prevents renal 934
Progression of renal disease
  diagnosis (abst) 241, 242, 249, 255
  drug effects (abst) 279, 402
  pathophysiology (abst) 424, 499
  prevention and control (abst) 239
Progressive glomerular disease
  growth factor β, proteoglycans 689
Progressive glomerulonephritis
  autoantibodies to GBM 965
Proline (abst) 344, 416
Propranolol (abst) 458
Prostacyclin (abst) 366, 552
Prostaglandins
  biosynthesis (abst) . 195, 345, 348, 349, 351, 352, 365, 371, 376, 377, 503, 595
  dietary fish oil 57
  drug effects (abst) 558, 594
  eicosanoid production, ureteral obstruction 1528
  mesangial cell proliferation 1256
  pharmacology (abst) 398, 579
  physiology (abst) ... 209, 211, 212, 225, 344, 349, 366, 403, 411, 555, 582, 591

suppression by ANF (abst) 1175
Prostanoids, Sandimmun nephrotoxicity (abst) 1184
Prostatectomy (abst) 269
Protease
lymphoid serine in allograft recipients 1350
plasminogen activator secretion 1466
Protein
basement membrane biosynthesis, cpk/cpk mouse kidney 1090
chromogranin A 955
cloning of cDNA to mRNA 1460
C-reactive serum levels during HD (abst) 1180
growth hormone in urine 951
high intake accelerates GS 1263
immunofixation in ultrathin gels 1002
loss during CAPD 971
loss during HD (abst) 1182
low molecular weight, dextran, cathepsin B and L 918
nephrotic syndrome (abst) 1598
new diagnostic analysis of urinary (abst) 1168
pattern of patients with peritonitis (abst) 1182
pattern of urinary excretion in diabetic children (abst) 1381
phosphorylation in platelets (abst) 1187
structure (abst) 232
synthesis (abst) 477, 490, 521, 583
Protein C
(abst) 381
deficiency (abst) 280
Protein S (abst) 381
Protein catabolism
analysis (abst) 334
pathophysiology (abst) 294, 505
Protein kinase C
effect of Hyp mutation and phosphate deprivation 682
Protein kinases
hormone effects (abst) 199, 385
intra-and extracellular in PKD 1301
low molecular weight (abst) 527
pharmacology (abst) 209, 576, 582, 589
physiology (abst) 190, 192, 199, 202, 205, 207, 216, 234, 453, 456, 527, 541, 544, 560, 567
Protein restriction
(abst) 246, 511
outcome (abst) 239, 243, 271, 357, 531
physiology (abst) 272, 500, 506
therapeutic use (abst) 549, 612
Proteinases (abst) 520
Proteinuria
(abst) 503, 523, 574
cadmium, K conductance in MDCK cells 1477
captopril (abst) 1587
drug effects (abst) 235, 236, 239, 261, 262, 397, 498, 503, 508
drug therapy (abst) 255, 395, 509
enalapril and low protein in PAN 749
etiology (abst) 243, 428, 433, 512
hypoalbuminemia (abst) 1587
long-term complications of transplantation 1363
obesity (abst) 1607
one functioning kidney (abst) 1609
pathophysiology (abst) 377, 385, 392, 404, 408, 412, 418, 419, 448, 497, 501, 507, 519
renal involvement with HIV 1325
Proteoglycans
transforming growth factor-Beta 689
Proteolipids (abst) 462
Proteolysis (abst) 528
Proximal tubule
bicarbonate, Cl^-/base exchange in S3 (abst) 1161
diuretic, antidiuretic agents effect on Li clearance S-22
dysfunction late in Heymann nephritis 1536
lithium clearance as measure of Na and H_2O delivery S-10
lithium reabsorption S-39
medullary circulation, hormones 1
osmotic diuresis, Li reabsorption S-67
renal physiology and Li S-78
sites of transport of Li S-26
validity of lithium clearance S-17
Psoriasis (abst) 489
Psudomonas aeruginosa (abst) 295
Psyllium seed husk effect in CAPD (abst) 1385
Pulmonary fibrosis (abst) 281
Purinergic receptors (abst) 202, 584
Puromycin aminonucleoside
analogs and derivatives (abst) 198
nephrosis (abst) 218, 219, 412, 431, 466, 488, 491, 498, 504, 522
Puromycin aminonucleoside nephropathy
enalapril and low protein 749
Puromycin nephrosis
reactive oxygen species 1509
Pyelonephritis (abst) 512
Pyrazinoylguanidine (abst) 399
Pyruvate kinase (abst) 532

Quality of life 278
(abst) 278
donors in Norway (abst) 1384
elderly patients on HD (abst) 1182

Race, role of in antihypertensive medications 1113
Radioimmunoassay (abst) 466
Radionuclide imaging (abst) 225, 242, 296
Ramped hypertonic sodium dialysis (abst) 306
Ranitidine (abst) 316, 456
Recirculation (abst) 297
Recombinant human erythropoietin
activates progenitor cells 150
anemia (abst) 1593, 1608, 1609
bleeding time (abst) 1608
children with ESRF (abst) 1604
efficiency of dialysis techniques (abst) 1586
erythrocytic age-related compounds (abst) 1594
hematocrit effect on hemodialysis 1557
hematology (abst) 1599
hemodynamics (abst) 1586, 1594, 1600
in CAPD (abst) 1614
in anemic HD patients (abst) 1585
physical activity (abst) 1593
physiology (abst) 1585
quality of life (abst) 1593
renal function in humans 131
short dialysis (abst) 183, 1591
strategy for HD (abst) 1609
treatment (abst) 1592, 1598
urea kinetics (abst) 1595
Red blood cells, ischemia, hematocrit 1240

Reflux nephropathy (abst) 276, 279
Rehabilitation (abst) 333
Rejection
  acute, vascular (abst) 606
  complications (abst) 312
  diagnosis (abst) 597, 601, 602, 609, 610, 613, 616
  diet therapy (abst) 612
  drug therapy (abst) 1594
  early detection (abst) 1186
  epidemiology (abst) 603, 609
  genetics (abst) 192
  lymphoid serine protease 1350
  outcome (abst) 614
  pathology in late (abst) 1600
  pathophysiology (abst) 346, 608
  prevention and control (abst) 604, 606, 608
  prognosis (abst) 1601
  reversal by OKT3 (abst) 1607
Remnant kidney function
  drug effects (abst) 424
  metabolism (abst) 527
  pathology (abst) 431
  pathophysiology (abst) 500, 518, 525, 554
  physiology (abst) 355
Renal adaptation (abst) 401, 569
Renal arteries (abst) 386, 550, 598
Renal artery stenosis
  complications (abst) 505
  diagnosis (abst) 398, 404, 405, 1172
  pathophysiology (abst) 554
  therapy (abst) 397
Renal blood flow
  drug effects (abst) 477, 484, 555, 582
  endotoxin 1219
  hormone effects (abst) 557
  pathophysiology (abst) 554
  regulation (abst) 346, 355, 550, 552, 558
Renal capillaries
  drug effects (abst) 485, 497
  injuries (abst) 406, 436
  physiology (abst) 353, 356, 551
Renal cortex
  genetics (abst) 528
  growth and development (abst) 372, 542, 561
  physiology (abst) 460, 553, 554
  ultrastructure (abst) 229
Renal disease
  tumor marker serum levels (abst) 1181
Renal failure
  aortic and large artery compliance 137
  calcitriol metabolism 44
  ciprofloxacin kinetics (abst) 1180
  dyslipoproteinemia (abst) 1382
  mediation of uremic encephalopathy 892
  norepinephrine clearance, chromogranin A, dopamine 1357
Renal growth
  hyperplasia and nephrectomy 758
Renal hypertrophy
  etiology (abst) 224, 553
  pathophysiology (abst) ... 193, 195, 201, 204, 511, 518, 522
Renal hypertrophy (abst)
  (abst) 196, 201, 261, 508
Renal injury (abst) 258, 376, 413
Renal insufficiency
  Campylobacter pylori (ital) (abst) 1180
Renal ischemia
  complications (abst) 505, 514
  diagnosis (abst) 242, 556
  diet therapy (abst) 532
  drug therapy (abst) 495, 497
  outcome (abst) 485, 496
  pathophysiology (abst) .. 476, 479, 480, 481, 482, 484, 488, 489, 492, 493, 494, 495, 497, 532, 549
Renal medulla
  genetics (abst) 584
  growth and development (abst) 542
  physiology (abst) 364, 411, 553, 586
Renal medulla, inner zone (abst) 343
Renal medulla, outer zone (abst) 476, 528, 588
Renal neoplasms
  diagnosis (abst) 443
  immunology (abst) 224, 406, 415
  pathology (abst) 242
  pathophysiology (abst) 344, 420
Renal nerves
  genetics (abst) 354
  pathophysiology (abst) 200
  physiology (abst) 454, 554, 570
Renal osteodystrophy
  diagnosis (abst) 309, 314, 451
  drug therapy (abst) 451
  etiology (abst) 334, 452
  outcome (abst) 448
  pathophysiology (abst) 295, 449, 450, 456
  prevention and control (abst) 296
  surgery (abst) 296
Renal papilla (abst) 336
Renal reserve (abst) 402, 404, 557, 614
Renal scars (abst) 276, 512
Renal transplantation
  cadaveric (abst) 603, 609, 611, 612
  complications (abst) 249, 266, 397, 398, 400, 401, 603, 604, 605, 607, 611, 612, 613
  drug therapy (abst) 495, 595, 604, 608, 614
  immunology (abst) 594
  mortality (abst) 239
  outcome (abst) 277, 282, 496, 557, 605, 613, 614
  pathology (abst) 606
  pediatric (abst) 602, 603, 604, 605, 607, 611, 612, 614, 615, 616
  physiology (abst) 615
  rehabilitation (abst) 609
  second (abst) 611
  therapeutic use (abst) 610
Renal tubules
  growth and development (abst) ... 198, 478, 484, 485, 490, 492
  physiology (abst) 259, 474, 575, 579
Renal tubules, collecting ducts
  genetics (abst) 580
  hormone effects (abst) 199
  pathophysiology (abst) 535, 574
  physiology (abst) ... 203, 206, 216, 217, 343, 361, 362, 536, 538, 541, 542, 548, 549, 562, 564, 576, 577, 578, 580, 581, 584, 585
Renal tubules, distal
  anatomy and histology (abst) 454
  immunology (abst) 424
  physiology (abst) 461, 464, 471

transport (abst) 559
Renal tubules, pars convoluta (abst) 224, 530
Renal tubules, pars recta (abst) 458
Renal tubules, proximal
anatomy and histology (abst) 527
drug effects (abst) 379
growth and development (abst) ... 192, 197, 199, 204, 368, 380
hormone effects (abst) 211, 469, 508, 537
immunology (abst) 416, 417, 423
injuries (abst) 500, 529
isolation and purification (abst) 525
metabolism (abst) 429, 526, 527, 528, 531
pathology (abst) 226
pathophysiology (abst) ..... 267, 511, 517, 5[illegible], 526, 571
physiology (abst) ... 214, 217, 371, 453, 456, 46[illegible] 462, 467, 471, 474, 525, 528, 531, 533, 536, 539, 540, 543, 559, 568, 576, 581, 591
ultrastructure (abst) 206, 487, 495
Renal vascular resistance, CsA in uninephrectomy 21
Renal veins (abst) 264
Renin
(abst) 352, 354, 355, 357, 358, 362, 383, 522
correlations during essential hypertension (abst) 1187
detection of hypertension (abst) 1380
measurement of secretion (abst) 1165
physiology (abst) 345, 353, 356, 357, 361, 381
Renin-angiotensin system
drug effects (abst) 338
efferent arteriole in hydronephrotic kidney 1227
pathophysiology (abst) 397, 428, 509
physiology (abst) 339, 353, 354, 355, 358, 360
regulation (abst) 352, 353, 354, 355, 358, 360
Renin-angiotensin-aldosterone system
post-transplantation (abst) 1174
Renography
captopril isotopic (abst) 1602
Reperfusion injury (abst) 479, 482, 496, 497
Resident education (abst) 613
Residual renal function (abst) 312
Resistance genes (abst) 234
Restriction fragment length polymorphisms (abst) 246
Retinoic acid (abst) 195
Rhabdomyolysis (abst) 269, 270, 275, 284
in ARF (abst) 1388
Rheumatoid arthritis
(abst) 519
lesions (abst) 1379
mesangial GN (abst) 1379
Ribonucleases (abst) 518
Rickets, vitamin D (abst) 1616
Rifampin (abst) 327, 333, 335
Risk factors (abst) 311, 404, 448
Ritodrine (abst) 263
Rubidium
diuretics effect on K transport 1423
transport (abst) 575

S-nitroso-N-acetyl penicillamine (abst) 203
S. epidermidis
stimulates eicosanoid synthesis 1316
S3, intestinal alkaline phosphatase (abst) 187
S6 kinase (abst) 195
Salt
appetite (abst) 356
wastage, acidification defect 79
Sandimmun, immunosuppressant (abst) 1184
SCH 28080 (abst) 575
SCH 34826 (abst) 337
Schizophrenia (abst) 262
School performance (abst) 605
Seaweed preparation, hypertension (abst) 1380
Segmental necrotizing glomerulitis, morphology (abst) .. 1597
Seizures (abst) 594
Selenium, deficiency (abst) 290, 472, 473
Sepsis (abst) 263, 278, 305, 307, 476, 487
Serine esterases (abst) 443, 444, 598, 613
Serotonin, receptors (abst) 202, 567
Serum sickness
(abst) 500
hepatitis B infection 663
Serum total protein, diagnostic use (abst) 301
Severity index used in ATN (abst) 1592
Sex differences (abst) 268, 269, 347
Shock (abst) 485
endotoxemia 1219
Shunt stenosis (abst) 311, 319, 324
Shunt thrombosis (abst) 278, 286, 305, 308, 324
SIADH (abst) 266, 589
Sicca-like syndrome (abst) 315
Signal transduction
atrial natriuretic peptide 1148
intracellular (abst) .. 198, 202, 203, 205, 208, 210, 213, 214, 215, 216, 431, 442, 468
Sin[illegible]an virus (abst) 201
Single channel recordings from TAL (abst) 1162
SKF 105494 (abst) 583, 587
Sleep apnea (abst) 323
Sleep restlessness in uremics (abst) 1387
Sodium
(abst) 266, 529, 575, 589
adverse effects (abst) 369, 384
atrial natriuretic peptide, distal tubule 996
azide, epidemic hypotension 110
cloning of cDNA to mRNA 1460
diagnostic use (abst) 267
distal tubule function, ANP 996
fractional excretion of (abst) 400, 522, 610
intake and diuretics, Li transport S-36
intake, lithium excretion (abst) 185
intracellular (abst) 525
lithium clearance as measure of S-10
modelling computation verified (abst) 1181
physiology (abst) ... 337, 383, 388, 393, 397, 403, 458, 571, 572
reabsorption after endotoxin administration 1219
regulation (abst) 217, 356, 453
restriction (abst) 395, 511, 561, 565
retention (abst) 270, 277, 571, 574
transport (abst) 229, 260, 263, 337, 353, 358, 359, 366, 372, 452, 453, 456, 458, 460, 464, 465, 499, 502, 529, 533, 535, 563, 573, 575
Sodium bicarbonate (abst) 267
Sodium channels
(abst) 208, 209, 213, 217, 233, 561, 563, 564, 565, 574
Sodium chloride
(abst) 338, 370, 392, 393, 411, 562, 586
changes Ang II levels (abst) 1172
Sodium citrate
in salt-sensitive normotensive men (abst) 1172

Sodium inositol symport (abst) 584
Sodium/D-mannose symport (abst) 585
Sodium/amino acid symport (abst)..... 209, 477, 593
Sodium/bicarbonate symport (abst) .. 211, 533, 537, 543, 544
Sodium/carbonate/bicarbonate cotransport (abst)..... 546
Sodium/chloride symport (abst)..... 559
Sodium/glucose symport (abst) 477, 589
Sodium/phosphate symport (abst)... 452, 453, 455, 459, 586, 587
Sodium/potassium/chloride cotransport (abst).. 196, 370, 565
Sodium/taurine symport (abst)..... 578, 583, 591
Solute removal (abst) 253, 296, 328, 334, 399
Somatostatin (abst)..... 378
Sonography
  color coded duplex, renal artery stenosis (abst) 1172
Sorbitol (abst)..... 588, 590
Spectrophotometry, analysis of magnesium 818
Sphingosine (abst) 210
Spinal artery occlusion (abst) 325
Splenectomy (abst)..... 488
Spontaneously hypertensive rat
  abnormalities of epithelium 1438
SQ-29852 (abst) 394
Staphylococcus
  (abst) 289, 327, 328, 331, 333
Statistical analysis (abst) 249, 265
Steroids
  triple therapy in transplantation (abst)..... 1595
Stones
  calcium oxalate urinary formation..... 51
  oxalate:OH exchange across BBM 1105
  sulfur amino acid metabolism in cystinuria..... 143
Streptococci type 1 M1
  survival of ARF patients (abst) 1388
Stroke (abst)..... 388, 394
Structure-activity relationship (abst)..... 231
Substance P
  SQ 14,225 effect on concentration and clearance (abst) 1172
Substance abuse (abst)..... 235
Sucrose (abst)..... 405
Sulfamyl diuretics, antibody to (abst) 566
Sulfates (abst)..... 474
Sulfhydryl compounds (abst)..... 539
Sulindac (abst) 552
Superoxide anion, reactive oxygen species..... 1509
Superoxide dismutase (abst) 490
Suppressor function (abst)..... 596, 601
Survival
  ancrod, lupus erythematosus..... 29
  prognosis in HUS (abst)..... 1168
Sympathetic tone/activity (abst)..... 317, 383, 398, 405, 553
Synaptosomes (abst) 470

T cell
  activation, PTH..... 1543
  mononuclear cell culture from uremic patients..... 126
Takayasu syndrome (abst)..... 443
Tamm-Horsfall glycoprotein (abst) 255, 427, 462
  excretion of laminin and fibronectin in diabetes (abst) 1169
  inflammatory response of neutrophils 717
  uromodulin 1395
Taurine (abst)..... 578, 591
Technetium-DTPA (99m) superscript (abst) 327
Tenckhoff catheter insertion (abst) 1385
Terbutaline (abst)..... 263
Testicular isozyme (abst)..... 355
Theophylline (abst)..... 302
Thiazide receptors (abst) 562, 566
Thiazides (abst) 516, 566
Thick ascending limb of Henle
  single channel recordings (abst)..... 1162
Thin basement membrane disease (abst)..... 246, 252
Thin limb of Henle, lithium transport S-31
Threshold trait, PKD..... 901
Thrombin (abst) 195, 365
Thrombomodulin (abst) 595
Thrombosis
  (abst)..... 605
  repeat venograms after HD (abst) 1387
Thrombospondin (abst) 416
Thrombotic thrombocytopenic purpura (abst)..... 325, 1168
Thromboxane synthetase
  antagonists and inhibitors (abst)..... 415, 501
Thromboxanes
  (abst) 347, 351, 424, 484, 604
  β_2 mediates hemodynamics (abst) 1166
  biosynthesis (abst)..... 195, 348, 349, 352, 377, 415, 484
  hemolytic uremic syndrome in children..... 1134
  metabolism (abst)..... 346
  pharmacology (abst)..... 479
  physiology (abst) 346, 350, 366, 371, 501, 557
  receptors (abst)..... 524
  urine (abst) 345
Thrombus formation, platelet aggregation, GN..... 1500
Thy-1 antigen (abst)..... 232
Thyroid hormones (abst) 336, 377, 485, 489
Ticlopidine
  (abst)..... 424
  progression of renal failure..... 934
Tight junctions (abst)..... 457
Tobramycin reabsorption, metabolic alkalosis 1492
Tomography, computed (abst)..... 553
Toxicity
  cadmium and K conductance in MDCK cells 1477
  commercial CAPD fluids (abst) 184
  dosage of CsA (abst)..... 1184
  endotoxin 1219
  exogenous intoxications (abst)..... 1389
  iron uptake, Al in Friend erythroleukemia cells 677
  renal iron handling in nephrotic syndrome 1409
  tobramycin, metabolic alkalosis..... 1492
Transcription
  genetic (abst) 197, 201, 220, 222, 319, 521
  interleukin, TNF, complement..... 85
Transferrin (abst) 449
Transforming growth factor (abst)... 191, 192, 197, 221, 222, 426, 484, 492
Translation, genetic (abst) 231
Transplantation
  adequacy of dialysis 822
  age and renal reserve (abst)..... 1388
  allogene renal, ANP, cGMP and RAA-system (abst) . 1174
  bone mass loss (abst) 1603
  census, Galician (abst) 1596
  circadian rhythms of CsA (abst)..... 1603
  clinicopathological study of dialysis..... 1333
  CsA (abst)..... 187, 1384, 1593, 1603, 1604, 1607, 1614
  donors (abst)..... 1607

dopamine metabolism (abst) 1185
drug therapy (abst) 1592, 1601, 1602
early detection of rejection (abst) 1186
glomerular diseases (abst) 1615
glomerular filtration rate high (abst) 1608
HIV infection (abst) 184
hypercalcemia (abst) 1185
immunosuppressants (abst) 1383
late failure (abst) 1600
levels of PTH determine ATN development (abst) ... 1184
long-term complications 1363
loss of glomerular filtration reserve (abst) 1183
lupus anticoagulant, vascular thrombosis (abst) 1595
monitoring of PGE2, TXB2 and 6-keto-PGF1a (abst) . 1587
mortality and morbidity (abst) 1384
organ procurement (abst) 1605
pathology (abst) 1186
post-, CMV infection (abst) 1186
pregnancy (abst) 1612
prevention of ischemic injury 171
prognosis in failure of (abst) 1601
pulsed Doppler (abst) 1615
quality of life (abst) 1384
renovascular hypertension (abst) 1600
serum lipids post- (abst) 1382
survival (abst) 1591, 1608
triple drug therapy (abst) 1595, 1613
upregulation of lymphoid serine protease 1350
vasculopathy (abst) 1186
Transport
bumetanide in Milan hypertensive rats 1084
cadmium, K conductance in MDCK cells 1477
diuretics effect on K 1423
electrophysiology of Triturus nephron 157
furosemide effect in IMCD and CCD 1248
organic bases across basolateral membrane (abst) ... 1161
organic compounds, cadmium intoxication 727
oxalate:OH across BBM 1105
permeability of Li in tLH S-31
protein and solute, ultrafiltration (abst) 1384
subcellular distribution of Na+/H+ 707
Transport inhibitors, experimental (abst) 460
Transport, lithium
across biological membranes S-4
bumetanide and ouabain effect on S-71
history S-2
renal tubular effects S-52
sites of, in nephron S-26
Transtubular K^+ gradient (abst) 264
Triglycerides (abst) 288, 324
Triturus nephron electrophysiology 157
TRPM-2 (abst) 476, 479
Tuberculosis (abst) 607
Tubular excretion of creatinine (abst) 185
Tubular basement membrane
nephritogenic antigen detection 1286
Tubular defects (abst) 526
Tubular epithelial cells (abst) 380
Tubular reabsorption (abst) 235, 263, 355, 363, 458, 460, 517, 522, 537, 541, 542, 545, 548, 572, 573, 575, 579, 590, 592
Tubular secretion (abst) 541, 543, 546, 577
Tubules, collecting
cellular free Ca^{2+} in AVP-induced cAMP 1060
Tubuloglomerular feedback
autoregulation in juxtamedullary afferent arterioles .. 1402
drug effects (abst) 245, 494
physioiogy (abst) 549, 554, 555, 557
Tubulointerstitial diseases
(abst) 198, 254, 412, 498
damage, lupus nephritis 100
Tubulointerstitial nephritis
detection of nephritogenic antigen in TBM 1286
drugs induce inflammatory infiltrate (abst) 1594
renal iron handling 1409
Tumor
markers in CRF (abst) 1590, 1605
markers in renal disease (abst) 439, 443, 1181
Tumor necrosis factor
(abst) 363, 409
biosynthesis (abst) . 288, 301, 310, 315, 319, 329, 417, 597, 600
complement, IL-1 85
diagnostic use (abst) 597
epithelial cells, MHC class II antigen 783
physiology (abst) ... 205, 215, 307, 345, 414, 422, 435, 445, 606
receptors (abst) 407
Tumor necrosis factor α
oxygen radical production 767
uremia and hemodialysis 116
Tyrosine kinases (abst) 194, 374

Ultrafiltration
different temps. (abst) 1589
epidemic hypotension caused by sodium azide 110
loss of, protein and solute transport (abst) 1384
reasons for failure in CAPD (abst) 1614
zero net in CAPD (abst) 1591
Ultrasound imaging (abst) 251, 326, 450
Ultrathin gels, analysis of albumin 1002
Ultraviolet light (abst) 331
Uninephrectomy
CsA effect on renal growth, function 21
dietary fish oil 57
Up regulation (abst) 459
Urea kinetics
(abst) 300, 399
analysis (abst) 295, 315, 332, 334
diagnostic use (abst) 326
physiology (abst) 304, 579
Uremia
(abst) 463, 511, 513
accessory cell functions 126
adrenergic modulation of K 793
calcitriol metabolism in RF 44
chromogranin A 955
clinicopathological study of kidneys, dialysis 1333
complications (abst) . 240, 244, 276, 306, 315, 318, 502, 517
detection of iron overload 943
drug therapy (abst) 274, 509, 523
encephalopathy in the rat 892
exercise in predialytic (abst) 1382
growth hormone (abst) 1608
immunology (abst) 322, 442, 446
influence on Il-1 and TNFα 116
intestinal permeability (abst) 1389
level of ANP, cardiac state (abst) 1382
nocturnal restlessness (abst) 1387
pathophysiology (abst) .. 212, 280, 470, 500, 502, 505, 510, 513, 515, 516, 520, 526, 600

red cell oxidation (abst) 1586
Uremic encephalopathy, dialysable solutes..... 892
Uremic thrombopathy (abst) 1605
Uric acid
(abst) 259, 400, 475
MDCK cell reaction to crystals..... 36
Urinary acidification (abst)..... 226, 228, 264, 266, 464, 494
Urinary enzymes (abst) 258, 276
Urinary tract infections (abst) 272, 1388
Urinary tract obstruction
(abst)..... 262, 490
pathophysiology (abst) 339, 352, 375, 461, 484
Urine
composition, Henry Bence Jones..... 1019
cystinuria 143
concentration, medullary circulation..... 1
cytology, toxicity (abst) 1186
growth hormone, binding protein in..... 951
kappa light chains in diabetes mellitus..... 1120
natural trace levels, Li clearance..... S-58
new diagnostic analysis of urinary proteins (abst).... 1168
Tamm-Horsfall glycoprotein..... 1395
Urodilation (abst)..... 1173
Urolithiasis
drug therapy (abst)..... 587
in children, idiopathic hypercalciuria..... 807
pathophysiology (abst).. 222, 274, 282, 284, 462, 468, 471, 472
prevention and control (abst)..... 459
therapy (abst)..... 412
Urologic surgery (abst) 490
Uromodulin, THP..... 1395
Uropathy
obstructive, enzyme activity 79

Vaccines (abst)..... 438
Vagotomy (abst)..... 570
Vanadate (abst) 528
Vascular access (abst) 303, 310
Vascular resistance
hormone effects (abst) 556
pathophysiology (abst)..... 392
physiology (abst)..... 396
regulation (abst) 360, 554, 555
Vascular smooth muscle
embryology (abst)..... 220
growth and development (abst) 200, 204
physiology (abst)... 337, 359, 364, 374, 385, 386, 387, 388, 391, 396
Vascular tone, autoregulation in diabetic rats..... 909
Vasculitis
autoantibodies to GBM in progressive GN 965
diagnosis (abst)..... 281, 440, 443
hepatitis B virus 663
immunology (abst)..... 441, 442, 444
pathology (abst) 437
systemic necrotizing, antibodies (abst) 1167
Vasculopathy post-transplantation (abst)..... 1186
Vasoconstriction
drug effects (abst)..... 375, 391, 598
endothelin, CsA-induced glomerular dysfunction 1487
hormone effects (abst)..... 366, 367, 372, 386, 551
regulation (abst)..... 347, 351, 354, 479, 552
Vasodilation
(abst)..... 347
gamma-L-glutamyl-L-dopa..... 1414
Vasopressins
antagonists and inhibitors (abst) .. 348, 367, 579, 583, 587, 589
genetics (abst)..... 266
isolation and purification (abst) 361
pharmacology (abst).... 207, 225, 362, 581, 583, 586, 588, 592, 593
physiology (abst)... 191, 203, 204, 205, 206, 212, 231, 262, 274, 279, 317, 338, 476, 499, 574, 576, 579, 580, 582, 584, 585, 587, 589, 592
receptors (abst) 191, 194, 201, 250, 361, 362, 367
Vasoreactivity (abst) 369, 493
Venous pressure (abst)..... 311
Verapamil
immunology (abst) 421
pharmacology (abst) 486, 521, 558
therapeutic use (abst)..... 319, 401
Vesicoureteral reflux (abst) 262, 271, 276
Virus
hepatitis B..... 663
Viscosity (abst)..... 271
Vitamin B6 (abst)..... 291, 324
Vitamin D
analogs and derivatives (abst) 463, 467
concentration of PTH after HD (abst)..... 1177
familial rickets (abst)..... 1616
hypercalcemic nephropathy 1067
metabolism (abst) 391, 466
phosphate deprivation, protein kinase C..... 682
physiology (abst)..... 456, 468, 469, 473
renal growth post-nephrectomy (abst)..... 1165
therapeutic use (abst)..... 463
Vitamin D_3
peritoneal macrophage response to CAPD 1310
Voiding dysfunction (abst)..... 272
Volume
furosemide effect during expansion S-45
osmolality, ion concentration in IMCD (abst)..... 1163
role of potassium in regulation (abst)..... 1162
Volume expansion
hormone effects (abst) 400
pathophysiology (abst)..... 267
physiology (abst) 336, 358, 550, 565, 570, 571
therapeutic use (abst)..... 341
von Hippel-Lindau syndrome (abst) 242
von Willebrand factor (abst)..... 322, 361, 602

Walker 256 tumor (abst) 1606
Water
(abst) 209, 336, 580, 581, 588, 589
effect of Li on transport S-52
fractional excretion of (abst) 401
immersion (abst)..... 401
intake (abst) 265
lithium clearance as a measure of S-10
Water channels
hormone effects (abst) 589
physiology (abst)..... 226, 231, 593
regulation (abst) 582, 583, 588
Water treatment systems, sodium azide and dialysis 110
Water-electrolyte regulation
(abst) 209, 257, 260, 265, 268, 269, 310, 348, 403, 517, 570, 578, 579, 581, 583, 588

Wegener's granulomatosis
(abst) 440, 444
anti-neutrophil cytoplasmic autoantibodies (abst) 186
with kidney involvement (abst) 1168
Weight loss (abst) 392
Wilms' tumor (abst) 439
Wound healing (abst) 433

Xanthine oxidase (abst) 479, 480, 482, 491
Xenoreactive antibodies (abst) 601
Xenotransplantation (abst) 601
Xipamide
characterization (abst) 1166

Yersinia enterocolitica (abst) 423

Zeranol (abst) 523
Zidovudine (abst) 307
Zinc
deficiency (abst) 330
metabolism (abst) 473
Zymosan
reactive oxygen species 1509

KIDNEY INTERNATIONAL

Volume 37, Number 1, January 1990

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Renal medullary circulation: Hormonal control. *Shyan-Yih Chou, Jerome G. Porush, and Pierre F. Faubert* 1

LABORATORY INVESTIGATION

Insulin in the acute renal adaptation to dietary phosphate restriction in the rat. *Michael Allon, Mariano Rodriguez, and Francisco Llach* 14

Effect of cyclosporin A on renal function and kidney growth in the uninephrectomized rat. *Daniel C. Batlle, Cory Gutterman, Taha Keilani, Ramon Peces, and Michael LaPointe* 21

Ancrod improves survival in murine systemic lupus erythematosus. *Edward H. Cole, Michael F.X. Glynn, Carl A. Laskin, Joan Sweet, Nancy Mason, and Gary A. Levy* 29

Reaction of MDCK cells to crystals of monosodium urate monohydrate and uric acid. *Bryan T. Emmerson, Michael Cross, Julie M. Osborne, and Roy A. Axelsen* 36

Factors influencing calcitriol metabolism in renal failure. *Chen H. Hsu and Sanjeev Patel* 44

Crystal agglomeration is a major element in calcium oxalate urinary stone formation. *Dik J. Kok, Socrates E. Papapoulos, and Olav L.M. Bijvoet* 51

Effects of dietary fish oil on renal growth and function in uninephrectomized rats. *Joy L. Logan, Ulrich F. Michael, and Bryant Benson* 57

Renal antigens in mercuric chloride induced, anti-GBM autoantibody glomerular disease. *Sudesh P. Makker and John J. Kanalas* 64

Effects of aluminum on the parathyroid hormone receptors of bone and kidney. *K.K. Pun, P.W.M. Ho, and P. Lau* 72

Enzyme activity in obstructive uropathy: Basis for salt wastage and the acidification defect. *Sandra Sabatini and Neil A. Kurtzman, with the technical assistance of Bei-Lei Yang* 79

Transcription, not synthesis, of interleukin-1 and tumor necrosis factor by complement. *Ralf Schindler, Gerhard Lonnemann, Stanley Shaldon, Karl-M. Koch, and Charles A. Dinarello* 85

Cytochrome P450-dependent arachidonic acid metabolism in human kidney. *Michal L. Schwartzman, Pavel Martasek, Amelia R. Rios, Richard D. Levere, Karim Solangi, Alvin I. Goodman, and Nader G. Abraham* 94

CLINICAL INVESTIGATION

Lupus nephritis: Correlation of interstitial cells with glomerular function. *Efstathios Alexopoulos, Daniel Seron, R. Barrie Hartley, and J. Stewart Cameron* 100

Epidemic hypotension in a dialysis center caused by sodium azide. *Steven M. Gordon, Jonathan Drachman, Lee A. Bland, Marie H. Reid, Martin Favero, and William R. Jarvis* 110

Influence of uremia and hemodialysis on circulating interleukin-1 and tumor necrosis factor α. *Andre Herbelin, Anh Thu Nguyen, Johanna Zingraff, Pablo Ureña, and Beatrice Descamps-Latscha* 116

Accessory cell functions in mononuclear cell cultures from uremic patients. *J. Ladefoged and E. Langhoff* 126

Effect of recombinant human erythropoietin in renal function in humans. *Victoria S. Lim, Jerry Fangman, Michael J. Flanigan, Richard L. DeGowin, and Robert T. Abels* 131

Contents continued on next page

Aortic and large artery compliance in end-stage renal failure. *Gerard M. London, Sylvain J. Marchais, Michel E. Safar, Albert F. Genest, Alain P. Guerin, Fabien Metivier, Khalil Chedid, and Alena M. London* 137

Sulfur amino acid metabolism in cystinuria: A biochemical and clinical study of patients. *Johannes Mårtensson, Torsten Denneberg, Åke Lindell, and Ola Textorius* 143

Recombinant human erythropoietin activates a broad spectrum of progenitor cells. *Felix Stockenhuber, Robert W. Kurz, Klaus Geissler, Christian Jahn, Wolfgang Hinterberger, Peter Balcke, and Klaus Lechner* 150

ROBERT F. PITTS MEMORIAL LECTURE

Electrophysiology of *Triturus* nephron: Cable properties and electrogenic transport systems. *Takeshi Hoshi* 157

NEPHROLOGY FORUM

Prevention of ischemic injury in renal transplantation. *William F. Finn* 171

ABSTRACTS

Dutch Society of Nephrology 183

American Society of Nephrology 189

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 658

Awards and Grants 660

Instructions for Authors on pages xxiii–xxv

KIDNEY INTERNATIONAL

Volume 37, Number 2, February 1990

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Hepatitis B infection and renal disease: Clinical, immunopathogenetic and therapeutic considerations. *Richard J. Johnson and William G. Couser* 663

LABORATORY INVESTIGATION

Aluminum inhibits hemoglobin synthesis but enhances iron uptake in Friend erythroleukemia cells. *Kenneth Abreo, Jonathan Glass, and M'Liss Sella* 677

Protein kinase C in mouse kidney: Effect of the *Hyp* mutation and phosphate deprivation. *Avihu Boneh and Harriet S. Tennenhouse* 682

Transforming growth factor-β regulates production of proteoglycans by mesangial cells. *Wayne A. Border, Seiya Okuda, Lucia R. Languino, and Erkki Ruoslahti* 689

Fluid phase generation of terminal complement complex as a novel index of bioincompatibility. *Reinhold Deppisch, Vera Schmitt, Jürgen Bommer, Gertrud M. Hänsch, Eberhard Ritz, and Ernst Wilhard Rauterberg* 696

Subcellular distribution of Na^+/H^+ antiport activity in rat renal cortex. *Charles B. Hensley, Michael E. Bradley, and Austin K. Mircheff* 707

Activation of the inflammatory response of neutrophils by Tamm-Horsfall glycoprotein. *Jeffrey K. Horton, Malcolm Davies, Nicholas Topley, David Thomas, and John D. Williams* 717

Transport of organic compounds in renal plasma membrane vesicles of cadmium intoxicated rats. *Hye Young Lee, Kyoung Ryong Kim, Jae Suk Woo, Yong Keun Kim, and Yang Saeng Park* ... 727

Glomerular platelet-activating factor levels and origin in experimental glomerulonephritis. *Elias A. Lianos and Anthony Zanglis* 736

Relationship of glomerular hypertrophy and sclerosis: Studies in SV40 transgenic mice. *Karen MacKay, Liliane J. Striker, Joseph W. Stauffer, Lawrence Y. Agodoa, and Gary E. Striker*..... 741

Enalapril and low protein reverse chronic puromycin aminonucleoside nephropathy. *George N. Marinides, Gerald C. Groggel, Arthur H. Cohen, and Wayne A. Border* 749

Hyperplasia precedes increased glomerular filtration rate in rat remnant kidney. *Carol A. Miskell and David P. Simpson*..... 758

Interleukin 1-α and tumor necrosis factor-α induce oxygen radical production in mesangial cells. *Heinfried H. Radeke, Beate Meier, Nicholas Topley, Jürgen Flöge, Gerhard G. Habermehl, and Klaus Resch*..... 767

Evaluation of phagocytic cell function in an ex vivo model of hemodialysis. *Richard A. Ward, Bärbel Schmidt, Matthias Blumenstein, and Hans J. Gurland*..... 776

MHC class II, antigen presentation and tumor necrosis factor in renal tubular epithelial cells. *Rudolf P. Wuthrich, Laurie H. Glimcher, Mary A. Yui, Anthony M. Jevnikar, Stephanie E. Dumas, and Vicki E. Kelley* 783

CLINICAL INVESTIGATION

Adrenergic modulation of potassium metabolism in uremia. *Pietro Castellino, Margaret J. Bia, and Ralph A. DeFronzo* 793

Contents continued on next page

Autoantibodies against myeloid lysosomal enzymes in crescentic glomerulonephritis. *J.W. Cohen Tervaert, R. Goldschmeding, J.D. Elema, M. van der Giessen, M.G. Huitema, G.K. van der Hem, T.H. The, A.E.G.Kr. von dem Borne, and C.G.M. Kallenberg* 799

Idiopathic hypercalciuria: Association with isolated hematuria and risk for urolithiasis in children. *A report of the Southwest Pediatric Nephrology Study Group, prepared by F. Bruder Stapleton.* 807

Use of modified fine needle aspiration for study of glomerular pathology in human kidneys. *Alexander Yussim, Zaki Shapira, Dan Shmueli, Shamir Lustig, Diana Braslavsky, and Mina Ben-Bassat* 812

TECHNICAL NOTE

Analysis of magnesium in tubular fluid using flameless atomic absorption spectrophotometry. *Francis Seow, Jeremy S. Chrisp, James R. Lawrence, and Michael J. Field* 818

NEPHROLOGY FORUM

Assessing the adequacy of dialysis. *Raymond M. Hakim* 822

HISTORICAL ARCHIVE

Thomas Addis (1881–1949): Mixing patients, rats, and politics. *Steven J. Peitzman* 833

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 842

Awards and Grants 844

Instructions for Authors on page xviii

KIDNEY INTERNATIONAL

Volume 37, Number 3, March 1990

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Management of hyperlipidemia of kidney disease. *Scott M. Grundy* 847

LABORATORY INVESTIGATION

Excess parathyroid hormone adversely affects lipid metabolism in chronic renal failure. *Mohammad Akmal, Sidika E. Kasim, Amin R. Soliman, and Shaul G. Massry* 854

Monokines and platelet-derived growth factor modulate prostanoid production in growth arrested, human mesangial cells. *Jürgen Floege, Nicholas Topley, Klaus Wessel, Volkhard Kaever, Heinfried Radeke, Jürgen Hoppe, Tadamitsu Kishimoto, and Klaus Resch* 859

Reduced Na-K-ATPase in distal nephron in glycerol-induced acute tubular necrosis. *Pnina Scherzer, Hanna Wald, and Mordecai M. Popovtzer* 870

A study of growth regulators of renal cortical tubular cells in the rabbit liver. *Shigeru Kanda, Koichiro Nomata, Pabitra K. Saha, Naoki Nishimura, Jun Yamada, Hiroshi Kanetake, and Yutaka Saito* 875

Renal injury of diet-induced hypercholesterolemia in rats. *Bertram L. Kasiske, Michael P. O'Donnell, Paul G. Schmitz, Youngki Kim, and William F. Keane, with the technical assistance of Fred Phillips, Frank Daniels, and Gregory Holden* 880

Role of dialysable solutes in the mediation of uremic encephalopathy in the rat. *Jonathan J. Lipman, Patricia L. Lawrence, David K. DeBoer, Michael O. Shoemaker, Daniel Sulser, Stephen Tolchard, and Paul E. Teschan* 892

Glucocorticoid-induced polycystic kidney disease—A threshold trait. *Alan T.J. McDonald, John F.S. Crocker, Sharon C. Digout, Susanna C. McCarthy, Stan R. Blecher, and David E.C. Cole* 901

Studies of renal autoregulation in pancreatectomized and streptozotocin diabetic rats. *S. Michael Mauer, David M. Brown, Michael W. Steffes, and Sylvia Azar* 909

Effect of low molecular weight proteins and dextran on renal cathepsin B and L activity. *Christoph J. Olbricht, Elisabeth Gutjahr, James K. Cannon, Holger Irmler, and C. Craig Tisher* 918

Endothelin and eicosanoid synthesis in cultured mesangial cells. *Carla Zoja, Ariela Benigni, Daniela Renzi, Antonella Piccinelli, Norberto Perico, and Giuseppe Remuzzi* 927

Ticlopidine prevents renal disease progression in rats with reduced renal mass. *Carla Zoja, Norberto Perico, Alice Bergamelli, Marzia Pasini, Marina Morigi, Jacek Dadan, Aldo Belloni, Tullio Bertani, and Giuseppe Remuzzi* 934

CLINICAL INVESTIGATION

Efficacy of hepatic computed tomography to detect iron overload in chronic hemodialysis. *Emanuela Cecchin, Sergio De Marchi, Francesco Querin, Mauro G. Marin, Renzo Fiorentino, and Franco Tesio* 943

Growth hormone and growth hormone binding protein in human urine. *Naoki Hattori, Akira Shimatsu, Yuzuru Kato, and Hiroo Imura* 951

Contents continued on next page

Chromogranin A in uremia: Progressive retention of immunoreactive fragments. *Ray J. Hsiao, Matthew S. Mezger, and Daniel T. O'Connor* 955

Autoantibodies to GBM and neutrophil cytoplasm in rapidly progressive glomerulonephritis. *David R.W. Jayne, Philip D. Marshall, Sally J. Jones, and C. Martin Lockwood* 965

Kinetics of peritoneal protein loss during CAPD: I. Different characteristics for low and high molecular weight proteins. *Alexander Kagan, Yaacov Bar-Khayim, Zehava Schafer, and Menahem Fainaru* 971

Kinetics of peritoneal protein loss during CAPD: II. Lipoprotein leakage and its impact on plasma lipid levels. *Alexander Kagan, Yaacov Bar-Khayim, Zehava Schafer, and Menahem Fainaru* .. 980

HLA DQ region gene polymorphism associated with primary IgA nephropathy. *Richard H. Moore, Graham A. Hitman, Ekundayo Y. Lucas, Nicholas T. Richards, Michael C. Venning, Surinder Papiha, Timothy H.J. Goodship, Andrew Fidler, Juliette Awad, Hilliard Festenstein, John Cunningham, and Frank P. Marsh* 991

Effects of atrial natriuretic peptide on distal tubule function in humans. *Ton J. Rabelink, Hein A. Koomans, Anja van de Stolpe, Joost A. Bijlsma, and Evert J. Dorhout Mees* 996

TECHNICAL NOTE

Analysis of albumin charge by direct immunofixation in ultrathin gels. *Giovanni Candiano, Fabrizio Ginevri, Silvia Acerbo, Alessandro Garberi, Rosanna Gusmano, and Gian Marco Ghiggeri* 1002

NEPHROLOGY FORUM

Treating hyponatremia: Damned if we do and damned if we don't. *Tomas Berl* 1006

HISTORICAL ARCHIVES

Henry Bence Jones (1813–1873): On the influence of diet on urine composition. *Leon G. Fine* .. 1019

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 1027

Awards and Grants 1029

KIDNEY INTERNATIONAL

Volume 37, Supplement 28

Lithium in Renal Physiology

Utrecht, The Netherlands

April 26–27, 1989

Table of contents

Introduction. *Evert J. Dorhout Mees and Hein A. Koomans* S-1

History of the "lithium concept." *Evert J. Dorhout Mees* S-2

Lithium transport across biological membranes. *N.-H. Holstein-Rathlou* S-4

Lithium clearance as a measure of sodium and water delivery from the proximal tubules. *Klaus Thomsen* S-10

Validity of the lithium clearance concept assessed with micropuncture studies. *Paul P. Leyssac* ... S-17

Effect of diuretic and antidiuretic agents on lithium clearance as a marker for proximal delivery. *Kent A. Kirchner* S-22

Possible sites of lithium transport in the nephron. *Rainer Greger* S-26

Permeability characteristics and probability of lithium transport in the thin limbs of Henle's loop. *Masashi Imai, Taisuke Isozaki, Koichi Yasoshima, and Koji Yoshitomi* S-31

Lithium clearance in healthy humans: Effects of sodium intake and diuretics. *J.C. Atherton, R. Green, A. Higgins, A. Large, C. McNicholas, D. Parker, L. Pempkowiak, K. Rajani, and J. Smith* S-36

Lithium clearance in healthy humans suggesting lithium reabsorption beyond the proximal tubules. *Walther H. Boer, Hein A. Koomans, and Evert J. Dorhout Mees* S-39

Furosemide effect during volume expansion: Evidence against lithium transport in the loop. *Sten Christensen* S-45

Renal tubular effects of lithium. *Mary Jo Godinich and Daniel C. Batlle* S-52

Lithium clearance derived from the natural trace blood and urine lithium levels. *Jacques A. Durr, Nancy L. Miller, and Allen C. Alfrey* S-58

Lithium clearance in humans: Effects of acute administration of acetazolamide and furosemide. *Giacomo Colussi, Giuseppe Rombolà, Maurizio Surian, Maria Elisabetta De Ferrari, Cristina Airaghi, Elisabetta Benazzi, Fabio Malberti, and Luigi Minetti* S-63

Osmotic diuresis and proximal tubular lithium reabsorption in the dog. *John Brown* S-67

Effects of bumetanide and ouabain on lithium transport in the distal nephron of dogs. *Eirik S. Stokke, Jonny Østensen, and Fredrik Kiil* S-71

Impairment of renal tubular acidification by lithium: A microperfusion study in the rat. *Myriam MacLaughlin and Margarida de Mello Aires* S-75

Lithium in renal physiology: Post-conference discussion and consensus. *Hein A. Koomans and Evert J. Dorhout Mees* S-78

KIDNEY INTERNATIONAL

Volume 37, Number 4, April 1990

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Brain-gut peptides, renal function and cell growth. *Robert J. Unwin, M.D. Ganz, and R.B. Sterzel* 1031

LABORATORY INVESTIGATION

Control of rat glomerular epithelial cell growth in vitro. *Stephen Adler, X. Chen, and B. Eng* .. 1048

Activation of complement by hemodialysis membranes: Polyacrylonitrile binds more C3a than cuprophan. *Alfred K. Cheung, Charles J. Parker, Linda A. Wilcox, and Jarmila Janatova* 1055

Optimal concentration of cellular free calcium for AVP-induced cAMP in collecting tubules. *San-e Ishikawa and Toshikazu Saito* 1060

Hypercalcemic nephropathy: Chronic disease with predominant medullary inner stripe injury. *Seymour Rosen, Zev Greenfeld, Jacques Bernheim, Mauro Rathaus, Eduardo Podjarny, and Mayer Brezis* 1067

Contribution of mononuclear leucocytes to the progression of experimental focal glomerular sclerosis. *Takao Saito and Robert C. Atkins* 1076

Diuretic effect of bumetanide in isolated perfused kidneys of Milan hypertensive rats. *Patricia Salvati, Romana G. Ferrario, and Giuseppe Bianchi* 1084

Altered basement membrane protein biosynthesis by primary cultures of cpk/cpk mouse kidney. *Mary Taub, Gordon W. Laurie, George R. Martin, and Hynda K. Kleinman* 1090

C5b-8 and C5b-9 modulate the collagen release of human glomerular epithelial cells. *Ingo Torbohm, Matthias Schönermark, Anne-Margarete Wingen, Beate Berger, Klaus Rother, and Gertrud M. Hänsch* 1098

Oxalate:OH exchange across rat renal cortical brush border membrane. *Kensuke Yamakawa and Juichi Kawamura* 1105

CLINICAL INVESTIGATION

Progressive renal disease: Role of race and antihypertensive medications. *Peter C. Brazy and James F. Fitzwilliam* 1113

Urinary excretion of kappa light chains in patients with diabetes mellitus. *Leif Groop, Anne Mäkipernaa, Svante Stenman, Ralph A. DeFronzo, and Anna-Maija Teppo* 1120

Renal hemodynamics and segmental tubular reabsorption in early type 1 diabetes. *Thierry P. Hannedouche, Alvimar G. Delgado, Daze A. Gnionsahe, Christian Boitard, Bernard Lacour, and Jean-Pierre Grünfeld* 1126

Increased thromboxane biosynthesis in childhood hemolytic uremic syndrome. *Burkhard Tönshoff, Rita Momper, P. Gonne Kühl, Horst Schweer, Karl Schärer, and Hannsjörg W. Seyberth* 1134

TECHNICAL NOTE

Staining of bone for aluminum: Use of acid solochrome azurine. *Michael Kaye, Anthony B. Hodsman, and Lydia Malynowsky* 1142

NEPHROLOGY FORUM

Atrial natriuretic peptide. *Martin G. Cogan* 1148

Contents continued on next page

Contents continued

ABSTRACTS
20th Congress of the Gesellschaft für Nephrologie 1161
INTERNATIONAL SOCIETY OF NEPHROLOGY
Meetings 1190
Awards and Grants 1193

KIDNEY INTERNATIONAL

Volume 37, Number 5, May 1990

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Progression of chronic renal failure in man. *Mackenzie Walser* 1195

LABORATORY INVESTIGATION

Effects of lithium on cAMP generation in cultured rat inner medullary collecting tubule cells. *Michael S. Anger, Paul Shanley, Julie Mansour, and Tomas Berl* 1211

Direct effects of endotoxin on the function of the isolated perfused rat kidney. *Julius J. Cohen, Altamese J. Black, and Steven J. Wertheim* 1219

A narrow segment of the efferent arteriole controls efferent resistance in the hydronephrotic rat kidney. *Matthias Fretschner, Karlhans Endlich, Coloma Fester, Niranjan Parekh, and Michael Steinhausen* 1227

Red cell trapping after ischemia and long-term kidney damage. Influence of hematocrit. *P. Olof A. Hellberg, Alfred Bayati, Örjan Källskog, and Mats Wolgast* 1240

Effect of furosemide on water and urea transport in cortical and inner medullary collecting duct. *Lúcia H. Kudo, Alfred A. van Baak, and Antonino S. Rocha* 1248

Prostaglandins and rat glomerular mesangial cell proliferation. *Paolo Menè and Michael J. Dunn* .. 1256

High protein intake accelerates glomerulosclerosis independent of effects on glomerular hemodynamics. *Michael P. O'Donnell, Bertram L. Kasiske, Paul G. Schmitz, and William F. Keane, with the technical assistance of Frank Daniels* 1263

Basement membrane alterations during development and regression of tubular cysts. *José L. Ojeda, MA Angeles Ros, José M. Icardo, and Juan A. García-Porrero* 1270

Tissue factor production by cultured rat mesangial cells. Stimulation by TNFα and lipopolysaccharide. *Roger C. Wiggins, Nnennaya Njoku, and John R. Sedor* 1281

Detection of nephritogenic antigen from the Lewis rat renal tubular basement membrane. *Hiromichi Yoshida, Yoko Wakashin, Shiro Ueda, Ryosaku Azemoto, Kenji Iesato, Shunichi Yamamoto, Teruo Mori, Makoto Ogawa, Yoshio Mori, and Masafumi Wakashin* 1286

CLINICAL INVESTIGATION

Effect of chronic renal failure on high-density lipoprotein kinetics. *Martin M.T. Fuh, C-Ming Lee, Chii-Y Jeng, Der-Chung Shen, Shyh-Ming Shieh, Gerald M. Reaven, and Y-D. Ida Chen* 1295

Intra- and extracellular proteins in human normal and polycystic kidney epithelial cells. *Yosef Granot, Vicki Van Putten, Julie Przekwas, Patricia A. Gabow, and Robert W. Schrier* 1301

Diversity in peritoneal macrophage response of CAPD patients to 1,25-dihydroxyvitamin D_3. *Rachel Levy, Joseph Klein, Tamar Rubinek, Michael Alkan, Shraga Shany, and Cidio Chaimovitz* 1310

Eicosanoid synthesis in human peritoneal macrophages stimulated with *S. epidermidis*. *Ruth K. Mackenzie, Gerald A. Coles, and John D. Williams* 1316

Renal involvement in patients infected with HIV: Experience at San Francisco General Hospital. *Sami A. Mazbar, Patricia Y. Schoenfeld, and Michael H. Humphreys* 1325

Contents continued on next page

Clinicopathological study of kidneys from patients on chronic dialysis. *Kentaro Ogata* 1333

Dietary potassium influences kidney maintenance of serum phosphorus concentration. *Anthony Sebastian, Rosemary E. Hernandez, Anthony A. Portale, Joan Colman, Jessie Tatsuno, and R. Curtis Morris, Jr.* 1341

Upregulation of a lymphoid serine protease in kidney allograft recipients. *Gere Sunder-Plassmann, Ludwig Wagner, Karl Hruby, Peter Balcke, and Colin P. Worman* 1350

Norepinephrine clearance, chromogranin A and dopamine β hydroxylase in renal failure. *Michael G. Ziegler, Brian Kennedy, Ellen Morrissey, and Daniel T. O'Connor* 1357

NEPHROLOGY FORUM

Long-term complications of renal transplantation. *William E. Braun* 1363

ABSTRACTS

Scandinavian Society of Nephrology 1379

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 1391

Awards and Grants 1394

Instructions for Authors on inside back cover

KIDNEY INTERNATIONAL

Volume 37, Number 6, June 1990

Official Journal of the International Society of Nephrology

Le Journal de la Société Internationale de Néphrologie

Table of contents

EDITORIAL REVIEW

Tamm-Horsfall protein—uromodulin (1950–1990). *Satish Kumar and Andrew Muchmore* 1395

RAPID COMMUNICATIONS

Tubuloglomerular feedback dependence of autoregulation in rat juxtamedullary afferent arterioles. *Leon C. Moore and Daniel Casellas* 1402

LABORATORY INVESTIGATION

Renal iron handling in the nephrotic syndrome. *Allen C. Alfrey and William S. Hammond* 1409

Metabolism and vascular effects of gamma-L-glutamyl-L-dopa on the isolated rat kidney. *Mariette Barthelmebs, Agnès Caillette, Jean-Daniel Ehrhardt, Jeanne Velly, and Jean-Louis Imbs* 1414

Effect of diuretics on cell potassium transport: An electron microprobe study. *Franz-X. Beck, Adolf Dörge, Gerhard Giebisch, and Klaus Thurau* 1423

Role of precipitating and nonprecipitating antibodies in glomerular immune complex formation. *Fernando G. Cosio, Alan P. Bakaletz, and John D. Mahan* 1429

Ultrastructural and functional abnormalities of intestinal and renal epithelium in the SHR. *Tilman Drüeke, Uta Hennessen, Bernadette Nabarra, Leila Ben Nasr, Philip A. Lucas, Patricia Dang, Monique Thomasset, Bernard Lacour, Evelyne Coudrier, and David A. McCarron with the technical assistance of P. Duchambon, L. Berthet, I. Andrianarison, T. Sacksick, and M. Eb* .. 1438

Receptor mediated uptake of apo B and apo E rich lipoproteins by human glomerular epithelial cells. *Hermann-Josef Gröne, Autar K. Walli, Elisabeth Gröne, Annette Krämer, Michael R. Clemens, and Dietrich Seidel* 1449

Molecular cloning of a complementary DNA to rat cyclophilin-like protein mRNA. *Naoharu Iwai and Tadashi Inagami* 1460

Secretion of plasminogen activator and its inhibitor by glomerular epithelial cells. *Taketo Iwamoto, Yutaka Nakashima, and Katsuo Sueishi* 1466

Cadmium enhances potassium conductance in cultured renal epitheloid (MDCK) cells. *A. Jungwirth, M. Paulmichl, and F. Lang* 1477

Role of endothelin in cyclosporine-induced glomerular dysfunction. *Valentina Kon, Masanori Sugiura, Tadashi Inagami, Bradley R. Harvie, Iekuni Ichikawa, and Richard L. Hoover* 1487

Inhibition of tobramycin reabsorption in nephron segments by metabolic alkalosis. *Linda N. Peterson, with the technical assistance of Janet S. Borzecki* 1492

Intraglomerular platelet aggregation and experimental glomerulonephritis. *Klaas Poelstra, Machiel J. Hardonk, Jan Koudstaal, and Winston W. Bakker* 1500

Production of reactive oxygen species by tubular epithelial cells in culture. *Brad H. Rovin, Eric Wurst, and Donald E. Kohan* 1509

Changes in gene expression after temporary renal ischemia. *Robert Safirstein, Peter M. Price, Subodh J. Saggi, and Raymond C. Harris* 1515

Effects of high concentrations of glucose on PTH secretion in parathyroid cells. *Toshitsugu Sugimoto, Cynthia Ritter, Jeremiah Morrissey, Catalina Hayes, and Eduardo Slatopolsky* 1522

Contents continued on next page

Eicosanoid production by isolated glomeruli of rats with unilateral ureteral obstruction. *Hiroyuki Yanagisawa, Jeremiah Morrissey, Aubrey R. Morrison, and Saulo Klahr* 1528

Persistent proximal tubule dysfunction late in Heymann nephritis. *Marianna J. Zamlauski-Tucker, Judith B. Van Liew, James Goldinger, and Bernice Noble* 1536

CLINICAL INVESTIGATION

Effect of parathyroid hormone on human T cell activation. *Marian Klinger, Jadwiga M. Alexiewicz, Mariana Linker-Israeli, Thomas O. Pitts, Zbigniew Gaciong, George Z. Fadda, and Shaul G. Massry* 1543

Mononuclear cell activation and decreased renal function in IgA nephropathy with crescents. *Hai-Ling Li, Wayne W. Hancock, David H. Hooke, John P. Dowling, and Robert C. Atkins* ... 1552

Effect of hematocrit on solute removal during high efficiency hemodialysis. *Victoria S. Lim, Michael J. Flanigan, and Jerry Fangman* 1557

Isolation, culture and characterization of human peritoneal mesothelial cells. *Eleni Stylianou, Lucy A. Jenner, Malcolm Davies, Gerald A. Coles, and John D. Williams* 1563

NEPHROLOGY FORUM

Renal complications of human immunodeficiency virus type 1. *Jacques J. Bourgoignie* 1571

ABSTRACTS

Spanish Society of Nephrology 1585

INTERNATIONAL SOCIETY OF NEPHROLOGY

Meetings 1618

Awards and Grants 1622

ACKNOWLEDGMENT OF REFEREES 1625

INDEX TO VOLUME 37 1631

Instructions for Authors on page 1630